StudyFinder
Search Results
Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
Search all categories
477 Study Matches
The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART) (AID-HEART)
Benjamin VanTassell - bvantassell@vcu.edu
NCT06062966
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Primary diagnosis for the clinic visit is stage D heart failure being on chronic stable dose of inotrope therapy (dobutamine or milrinone for the previous 28 days)
* Prior documentation of impaired left ventricular systolic function (ejection fraction \<50%) at most recent assessment by any imaging modality (within 12 months)
* Stable dose of inotrope treatment without a recent hospitalization within the previous month
* Age ≥21 years and willing/able to provide written informed consent
* The patient is willing and able to comply with the protocol (i.e. self administration of the treatment, and exercise protocol).
* Screening plasma C-reactive protein levels \>2 mg/L
Exclusion Criteria:
* Concomitant clinically significant comorbidities including (but not limited to) acute coronary syndromes, uncontrolled hypertension or orthostatic hypotension, tachy- or brady-arrhythmias, acute or chronic pulmonary disease or neuromuscular disorders affecting respiration that would interfere with the execution, interpretation, or completion of the study
* Recent (previous 3 months) or planned resynchronization therapy (CRT), or valve surgeries
* Previous or planned implantation of left ventricular assist devices or heart transplant within the next 3 months
* Recent (\<14 days) use of immunosuppressive or anti-inflammatory drugs (including oral corticosteroids at a dose of prednisone equivalent of 0.5 mg/kg/day but not including inhaled or low dose oral corticosteroids or non-steroidal anti-inflammatory drugs)
* Chronic inflammatory disorder (including but not limited to rheumatoid arthritis, systemic lupus erythematosus)
* Active infection (of any type), including chronic/recurrent infectious disease (including HBV, HCV, and HIV/AIDS) - but excluding HCV+ with undetectable plasma RNA
* Prior (within the past 5 years) or current malignancy on targeted treatment - excluding carcinoma in situ \[any location\] or localized non-melanoma skin cancer
* Stage V kidney disease or on renal-replacement therapy
* Neutropenia (\<1,500/mm3 or \<1,000/mm3 in African-American patients)
* Pregnancy or breastfeeding
* Angina, hypertension, arrhythmias, electrocardiograph (ECG) changes, or other non-cardiac limitations that limit 6MWD obtained during the baseline testing
* Hypersensitivity to anakinra or to E. coli derived products DRUG: Anakinra
Heart Failure
Inotrope sensitivity, IL-1 Blockade, Subcutaneous (SC), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV, 6 Minute Walk Test (6MWT)
I'm interested
Share via email
Show 1 location
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Virginia Commonwealth University Richmond, Virginia | Azita Talasazah - (talasazah@vcu.edu) Benjamin Van Tassell - (bvantassell@vcu.edu) |
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack (ARTEMIS)
Novo Nordisk - clinicaltrials@novonordisk.com
NCT06118281
Show full eligibility criteria
Hide eligibility criteria
Key inclusion:
* Age 18 years or above at the time of signing the informed consent.
* Hospitalisation for acute myocardial infarction with evidence of type 1 myocardial infarction (MI) by invasive angiography performed at site with percutaneous coronary intervention (PCI) capabilities.
* ST-segment elevation myocardial infarction (STEMI) with all the following: a) Relevant onset of symptoms suggestive of cardiac ischaemia within 12 hours before hospitalisation, at the investigator's discretion.
b) Electrocardiogram (ECG)-changes (in the absence of left ventricular hypertrophy or left bundle branch block): ST-segment elevation at the J point in at least two contiguous leads greater than or equal 0.25 (millivolt) mV in men less than 40 years, greater than or equal 0.2 mV in men greater than or equal 40 years, or greater than or equal 0.15 mV in women in leads V2-V3; and/or greater than or equal 0.1 mV in all other leads.
OR
* Non-ST-segment myocardial infarction with all the following: a) Relevant onset of symptoms suggestive of cardiac ischaemia within 24 hours before hospitalisation, at the investigator's discretion. b) Rise and/or fall in car-diac troponin I or T with at least one value above the 99th percentile upper reference limit.
* Possibility for both randomisation and administration of the loading dose of study intervention as early as possible after invasive procedure, and latest within 36 hours of hospitalisation (time 0) for STEMI, and latest within 72 hours of hospitalisation (time 0) for NSTEMI.
* Presence of at least one of the following criteria confirmed based on the participant's medical records and/or medical history interview: a) Any prior MI. b) Prior coronary revascularisation. c) Diabetes mellitus treated with ongoing glucose-lowering agent(s). d)Known chronic kidney disease (CKD) (estimated glomerular filtration rate (eGFR) greater than or equal to 15 and less than 60 milliliter per minute per 1.73 square meter (mL/min/1.73 m\^2). e) Prior ischaemic stroke. f) Known carotid disease or peripheral artery disease in the lower extremities. g) Multivessel coronary artery disease (current/prior). h) For STEMI patients only: anterior MI at index acute myocardial infarction (AMI)
Key exclusion:
* Use of fibrinolytic therapy for treatment of the current AMI.
* Chronic heart failure classified as being in New York Heart Association (NYHA) Class IV.
* Ongoing haemodynamic instability defined as any of the following: a) Killip Class III or IV. b) Sustained and/or symptomatic hypotension (systolic blood pressure less than 90 millimeters of mercury (mmHg)).
* Severe kidney impairment defined as any of the following: a) eGFR less than 15 mililitre per minute per 1.73 m\^2. b) Chronic haemodialysis or peritoneal dialysis.
* Known alanine aminotransferase (ALT) greater than 8 x upper limit of normal (reference range) (ULN).
* Severe hepatic disease defined as at least one of the following: a) Previously known or current hepatic encephalopathy (clinical evaluation). b) Previously known or current ascites (clinical eval-uation). c) Jaundice (clinical evaluation). d) Previous oesophageal/gastric variceal bleeding. c) Known hepatic cirrhosis.
* Major cardiac surgical (including but not restricted to coronary artery bypass graft surgery (CABG)), non-cardiac surgical, or major endoscopic procedure (thoracoscopic or laparoscopic) within the past 60 days or any major surgical procedure planned at the time of randomisation or as treatment for the current AMI (CABG). Deferred (staged)percutaneous coronary intervention for a non-culprit vessel identified during the current AMI is allowed.
* Clinical evidence of, or suspicion of, active infection at the discretion of the investigator.
* Known (acute or chronic) hepatitis B or hepatitis C.
* History or evidence of untreated latent tuberculosis (TB) such as (but not limited to): a) History of a positive TB test or chest X-ray compatible with latent TB; and TB treatment initiated less than 28 days prior to randomisation. b) Participants with TB risk factors but unwilling to undergo TB treatment if confirmed positive for latent TB based on central laboratory test at baseline (visit 2).
DRUG: Ziltivekimab, DRUG: Placebo
Cardiovascular Risk, Acute Myocardial Infarction (AMI)
I'm interested
Share via email
Show 970 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| "AHEPA" University General Hospital of Thessaloniki Thessaloniki, | |
| "AHEPA" University General Hospital of Thessaloniki Thessaloniki, | |
| "Hygeia" General Hospital of Athens Athens, | |
| "Sotiria" Thoracic Diseases Hospital of Athens Athens, | |
| "UMHAT "Sveta Anna" Sofia" AD, Clinic of Cardiology Sofia, | |
| 'G. Gennimatas' General Hospital of Athens Athens, | |
| 'G. Gennimatas' General Hospital of Athens - Cardiology Department Athens, | |
| 1 Wojskowy Szpital Kliniczny z Polikliniką SPZOZ Lublin, | |
| 10 Wojskowy Szpital Kliniczny z Poliklinika - Samodzielny Publiczny Zaklad Opieki Zdrowotnej w Bydgoszczy Bydgoszcz, | |
| 4 Wojskowy Szpital Kliniczny Z Poliklinika Samodzielny Publiczny Zaklad Opieki Zdrowotnej We Wroclawiu Wroclaw, Lower Silesian Voivodeship | |
| A.O.U Città della Salute e della Scienza di Torino Torino, | |
| A.O.U Città della Salute e della Scienza di Torino Torino, | |
| A.O.U. Ferrara, Sant'Anna Cona (Ferrara), Fe | |
| AORN "Sant'Anna e San Sebastiano" Caserta, Ce | |
| AOU Maggiore della Carità di Novara - Dipartimento Toraco-Cardio-Vascolare - SCDU Cardiologia Novara, | |
| AOUI Verona Verona, Vr | |
| AOUI Verona Verona, Vr | |
| ASSOCIAÇÃO LAR SÃO FRANCISCO DE ASSIS NA PROVIDÊNCIA DE DEUS - Hospital Regional de Presidente Prudente Presidente Prudente, São Paulo | |
| AUSL Romagna - Distretto Rimini - Ospedale Infermi Rimini, | |
| AUSL Toscana Sud Est - Ospedale Misericordia Grosseto Grosseto, | |
| Aakash Healthcare Super Speciality Hospital New Delhi, | |
| Aalborg Universitetshospital Hjertemedicinsk Afdeling Gistrup, | |
| Aalborg Universitetshospital Kardiologisk Afdeling Aalborg, | |
| Aarhus Universitetshospital, Hjertesygdomme Aarhus N, | |
| Abbott Northwestern Hospital Minneapolis, Minnesota | |
| Acibadem City Clinic UMHAT EOOD, Cardiology Sofia, | |
| Acibadem City Clinic UMHAT Tokuda EAD, Cardiology Sofia, | |
| Adana Şehir Eğitim ve Araştırma Hastanesi Adana, | |
| Adrian Costa Clinical Trials Centre Geelong, Victoria | |
| Advanced Cardiovascular, LLC Alexander City, Alabama | |
| Advanced Heart & Vein Center Thornton, Colorado | |
| Advanced Heart Care LLC Bridgewater, New Jersey | |
| Adventist Healthcare Shady Grove Medical Center Rockville, Maryland | |
| Afyonkarahisar Sağlık Bilimleri Üniversitesi Sağlık Uygulama Ve Araştırma Merkezi- Kardiyoloji Afyonkarahisar, | |
| Ajou University Hospital Suwon, Gyeonggi-do | |
| Akdeniz Üniversitesi Hastanesi-Kardiyoloji Antalya, | |
| Alexandra General Hospital, Therapeutic Clinic Athens, Attica | |
| All India Institute of Medical Sciences (AIIMS) New Delhi, National Capital Territory of Delhi | |
| All India Institute of Medical Sciences (AIIMS) New Delhi, National Capital Territory of Delhi | |
| All India Institute of Medical Sciences (AIIMS), Bhubaneswar Bhubaneswar, Odisha | |
| All India Institute of Medical Sciences (AIIMS), Nagpur Nagpur, Maharashtra | |
| American Heart of Poland S.A. Tychy, | |
| American Heart of Poland S.A. Tychy, | |
| American Heart of Poland S.A. Tychy, | |
| American Heart of Poland S.A. Tychy, | |
| American Heart of Poland S.A. Tychy, | |
| American Heart of Poland S.A. Tychy, | |
| American Heart of Poland S.A. Tychy, | |
| American Heart of Poland S.A. Tychy, | |
| Amper Kliniken AG - Helios Amper-Klinikum Dachau - Kardiologie Dachau, | |
| Amphia Ziekenhuis Breda, | |
| AnMed Health Clinical Research Anderson, South Carolina | |
| Ankara Bilkent Şehir Hastanesi-Kardiyoloji Ankara, | |
| Ankara Sehir Hastanesi Cardiology Ankara, | |
| Ankara Üniversitesi Tıp Fakültesi İbni Sina Hastanesi- Kardiyoloji Ankara, Altindag | |
| Antalya Eğitim ve Araştırma Hastanesi- Kardiyoloji Muratpasa/ Antalya, | |
| Ap-Hp-Hopital Bichat-Claude Bernard Paris, | |
| Ap-Hp-Hopital Europeen Georges Pompidou Paris, | |
| Aphp-Hopital La Pitie Salpetriere Paris, | |
| Apollo Multispeciality Hospital, Kolkata Kolkata, West Bengal | |
| Apollo Multispeciality Hospital, Kolkata Kolkata, West Bengal | |
| Arcispedale S Maria Nuova Azienda ULSS-IRCCS Reggio Emilia, | |
| Arkansas Cardiology Clinic Little Rock, Arkansas | |
| Arneja Heart & Multispeciality Hospital Nagpur, Maharashtra | |
| Asahi General Hospital＿Cardiology Chiba, | |
| Asan Medical Center Seoul, | |
| Ascension Sacred Heart Pensacola, Florida | |
| Ascension St. Mary's Research Institute - Michigan Southfield, Michigan | |
| Asklepieion General Hospital - Cardiology Clinic Athens/Voula, | |
| Asklepios Klinik Langen - Medizinische Klinik I Langen, | |
| Assistance Publique Hopitaux de Marseille-Hopital de La Timone Marseille, | |
| Associação Lar São Francisco de Assis na Providência de Deus - Bragança Paulista Bragança Paulista, São Paulo | |
| Atal Bihari Vajpayee Institute of Medical Sciences and Dr. Ram Manohar Lohia Hospital New Delhi, National Capital Territory of Delhi | |
| Atlanta VAMC Decatur, Georgia | |
| AtlantiCare Regional Medical Center Pomona, New Jersey | |
| Augusta University Augusta, Georgia | |
| Augusta University Augusta, Georgia | |
| Aultman Hospital Canton, Ohio | |
| Aurora St. Luke's Medi Ctr Milwaukee, Wisconsin | |
| Austin Heart San Marcos, Texas | |
| Austin Hospital Heidelberg, Victoria | |
| Azienda Ospedaliera Santa Maria Degli Angeli Pordenone, PN | |
| Azienda Ospedaliera Universitaria Careggi Florence, Tuscany | |
| Azienda Ospedaliera Universitaria Federico II di Napoli Naples, | |
| Azienda Ospedaliera di Parma Parma, | |
| Azienda Ospedaliera di Parma Parma, | |
| Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli Naples, | |
| Azienda Ospedaliero - Universitaria Sant'Andrea Rome, | |
| Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara Novara, | |
| Azienda Ospedaliero-Universitaria Renato Dulbecco Catanzaro, Cz | |
| Azienda Ospedaliero-Universitaria SS Antonio e Biagio e Cesare Arrigo Alessandria, | |
| Azienda Sanitaria Friuli Occidentale - Azienda Ospedaliera Santa Maria Degli Angeli - SC Cardiologia Pordenone Pordenone, PN | |
| Azienda Sanitaria Ospedaliera Ordine Mauriziano SC Cardiologia Torino, To | |
| Azienda Sanitaria Ospedaliera Ordine Mauriziano SC Cardiologia Torino, To | |
| Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII Bergamo, | |
| Azienda Unità Sanitaria Locale Di Piacenza - Cardiologia Piacenza, | |
| B M Birla Heart Research Centre Kolkata, West Bengal | |
| B M Birla Heart Research Centre Kolkata, West Bengal | |
| BG Klinikum Unfallkrankenhaus Berlin GmbH - Klinik für Kardiologie Berlin, | |
| Baptist Clin Res Institute Memphis, Tennessee | |
| Baptist Heart Specialists Jacksonville, Florida | |
| Baptist Hospital Cardiology Pensacola, Florida | |
| Barts Heart Centre London, | |
| Batra Hospital and Medical Research Center New Delhi, National Capital Territory of Delhi | |
| Batra Hospital and Medical Research Center New Delhi, National Capital Territory of Delhi | |
| Baylor Scott & White Res Inst Plano, Texas | |
| Beijing Anzhen Hospital, Capital Medical University Beijing, Beijing Municipality | |
| Beijing Anzhen Hospital, Capital Medical University Beijing, Beijing Municipality | |
| Bellvitge Universitary Hospital L' Hospitalet Del Llobregat, | |
| Birmingham VA Medical Center Birmingham, Alabama | |
| Blackpool Victoria Hospital Blackpool, | |
| Bon Secours St. Mary's Hospital of Richmond, LLC Richmond, Virginia | |
| Bravis Zkh Roosendaal Roosendaal, | |
| Bremer Institut für Herz- und Kreislaufforschung (BIHKF) Bremen, | |
| Bridgeport Hospital Bridgeport, Connecticut | |
| Brigham & Women's Hospital Boston, Massachusetts | |
| Bursa Yüksek İhtisas Eğitim ve Araştırma Merkezi-Kardiyoloji Bursa, | |
| Bursa Şehir Hastanesi- Kardiyoloji Bursa, | |
| CHU de Quebec-Universite-Laval,HDQ Québec, | |
| CHUM Centre de Recherch Hotel-Dieu Montreal, Quebec | |
| CHUM Centre de Recherch Hotel-Dieu Montreal, Quebec | |
| CIP Centro Integrado de Pesquisas do Hospital de Base São José do Rio Preto, São Paulo | |
| CIP Centro Integrado de Pesquisas do Hospital de Base São José do Rio Preto, São Paulo | |
| CISSS de Lanaudiere - Centre hospitalier De Lanaudiere Saint-Charles-Borromée, Quebec | |
| CISSSL Hôsp Pierre-Le Gardeur Terrebonne, Quebec | |
| CIUSS Hopit de Chicoutimi Chicoutimi, Quebec | |
| CV Research of Knoxville Powell, Tennessee | |
| Cairns Base Hospital Cairns, Queensland | |
| Cangzhou Central Hospital Cangzhou Shi, Hebei | |
| Cangzhou Central Hospital Cangzhou Shi, Hebei | |
| Canisius-Wilhelmina ziekenhuis Nijmegen, | |
| Cardio. Consult. of S. GA Thomasville, Georgia | |
| Cardiolg Assoc Rsch LLC_Tupelo Tupelo, Mississippi | |
| Cardiolg Assoc Rsch LLC_Tupelo Tupelo, Mississippi | |
| Cardiology Associates of Fairfield County Stamford, Connecticut | |
| Cardiology Associates_Asheville Asheville, North Carolina | |
| Cardiología Hospital J. M. Ramos Mejia Buenos Aires, | |
| Cardiovascular Associates of the Delaware Valley Sewell, New Jersey | |
| Catharina Zkh Eindhoven - Cardiologie Eindhoven, | |
| Cellitinnen-Krankenhaus St. Vinzenz Köln - Kardiologie Cologne, | |
| Central Arkansas Veteran's Healthcare System Little Rock, Arkansas | |
| Central India Cardiology Hospital and Research Institute Nagpur, Maharashtra | |
| Centre Hospitalier Regional Universitaire de Tours-Hopital Trousseau Chambray-lès-Tours, | |
| Centre Hospitalier Saint Joseph Saint Luc Lyon, | |
| Centre Hospitalier Sud Francilien Corbeil-Essonnes, | |
| Centre Hospitalier Universitaire Grenoble Alpes-Site Nord Michallon La Tronche, | |
| Centre Hospitalier Universitaire de Besancon-Hopital Jean Minjoz Besançon, | |
| Centre Hospitalier Universitaire de Bordeaux-Hopital Haut Leveque Pessac, | |
| Centre Hospitalier Universitaire de Caen Normandie- Cote de Nacre Caen, | |
| Centre Hospitalier Universitaire de Lille-Institut Coeur Poumon Lille, | |
| Centre Hospitalier Universitaire de Nice-Hopital Pasteur Nice, | |
| Centre Hospitalier Universitaire de Poitiers Poitiers, | |
| Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil Toulouse, | |
| Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil-1 Toulouse, | |
| Centre hosp affilié univ rég Trois-Rivières, Quebec | |
| Centro Médico Nacional Siglo XXI Mexico City, | |
| Centro Privado de Cardiología San Miguel de Tucuimán, Tucumán Province | |
| Centro de Atención e Investigación Cardiovascular del Potosi (CICAP) San Luis Potosí City, | |
| Centro de Estudios Clinicos de Querétaro S.C. Santiago de Querétaro, Qro., Querétaro | |
| Centro de Estudios Clinicos de Querétaro S.C. Santiago de Querétaro, Qro., Querétaro | |
| Centro de Imagen y Tecnologia en Intervención Cardiovascular México, | |
| Centro de Investigación C.I.C.E 9 de Julio - Sanatorio 9 de Julio San Miguel de Tucumán, Tucumán Province | |
| Centro de Pesquisa Clínica do Hospital de Clínicas da Universidade Federal de Uberlândia Uberlândia, Minas Gerais | |
| Centro de atención e investigación cardiovascular del Potosí San Luis Potosí City, San Luis Potosí | |
| Cerrahpaşa Kardiyoloji Enstitüsü Istanbul, | |
| Chambersburg Hospital Chambersburg, Pennsylvania | |
| Chambersburg Hospital Chambersburg, Pennsylvania | |
| Charité - Campus Benjamin Franklin - Klinik für Kardiologie Berlin, | |
| Chattanooga Heart Institute Chattanooga, Tennessee | |
| Chattanooga Heart Institute Chattanooga, Tennessee | |
| China-Japan Friendship Hospital Beijing, | |
| China-Japan Friendship Hospital Beijing, | |
| China-Japan Union Hospital of Jilin University Changchun, Jilin | |
| China-Japan Union Hospital of Jilin University-Cardiology Changchun, Jilin | |
| Chinese Academy of Medical Sciences Fuwai Hospital Beijing, Beijing Municipality | |
| Chippenham Medical Center Richmond, Virginia | |
| Chonnam National University Hospital Gwangju, Kwangju-kwangyǒkshi | |
| Chopda Medicare and Research Centre Pvt. Ltd. Nashik, Maharashtra | |
| Christiana Care Health Services, Inc. Newark, Delaware | |
| Christus Heart and Vascular Institute Tyler, Texas | |
| Chru de Nancy - Hopital Brabois Vandœuvre-lès-Nancy, | |
| Chungbuk National University Hospital Cheongju-si, | |
| Chungnam National University Hospital Daejeon, | |
| Chungnam National University Hospital Daejeon, | |
| Chungnam National University Sejong Hospital Sejong-si, | |
| Cleveland Clinic_Cleveland Cleveland, Ohio | |
| Clínica Privada Velez Sarsfield Córdoba, | |
| Clínica Privada Velez Sarsfield Córdoba, | |
| Colorado Heart and Vascular PC Golden, Colorado | |
| Complejo Hospitalario Universitario A Coruna A Coruña, | |
| Complejo Hospitalario Universitario A Coruna A Coruña, | |
| Concord Repatriation General Hospital - Cardiology Department Concord, New South Wales | |
| Copernicus Podmiot Leczniczy Sp. z o.o. Gdansk, | |
| Corewell Health Grand Rapids, Michigan | |
| Dallas VA Medical Center Dallas, Texas | |
| Danbury Hospital - Cardiology Department Danbury, Connecticut | |
| Dartmouth-Hitchcock Med Ctr Lebanon, New Hampshire | |
| Dayanand Medical College & Hospital Ludhiana, Punjab | |
| Dayanand Medical College & Hospital Ludhiana, Punjab | |
| Deenanath Mangeshkar Hospital & Research Centre Pune, | |
| Deenanath Mangeshkar Hospital & Research Centre Pune, | |
| Denver Health Medical Center Denver, Colorado | |
| Derriford Hospital - Plymouth Plymouth, | |
| Deutsches Herzzentrum TU München - Klinik für Herz- und Kreislauferkrankungen München, | |
| Dolnoslaski Szpital Specjalistyczny Im. T.Marciniaka-Centrum Medycyny Ratunkowej Wroclaw, | |
| Dr. Ram Manohar Lohia Institute of Medical Sciences Lucknow, Uttar Pradesh | |
| Dr. Ram Manohar Lohia Institute of Medical Sciences Lucknow, Uttar Pradesh | |
| Dr. Siyami Ersek Göğüs Kalp ve Damar Cerrahisi EAH- Kardiyoloji Istanbul, | |
| Duke University Medical Center Durham, North Carolina | |
| ESIC Medical College and Hospital, Hyderabad Hyderabad, Telangana | |
| Eastern Shore Rsrch Inst, LLC Fairhope, Alabama | |
| Ehime Prefectural Central Hosp Ehime, | |
| Elisabeth-TweeSteden Ziekenhuis Tilburg, | |
| Emory University Hospital Atlanta, Georgia | |
| Endeavor Health Glenbook Hosp Evanston, Illinois | |
| Ente Ecclesiastico Ospedale Generale Regionale Miulli - Cardiologia e UTIC Acquaviva delle Fonti, | |
| Erciyes University Cardiology Kayseri, | |
| Erciyes Üniversitesi Hastanesi- Kardiyoloji Kayseri, | |
| Eskişehir Osmangazi Üniversitesi Hastanesi- Kardiyoloji Eskişehir, Odunpazari | |
| Eskişehir Şehir Hastanesi- Kardiyoloji Eskişehir, | |
| Essentia Health Duluth, Minnesota | |
| Evangelismos Hospital Athens, | |
| Ewha Womans University Seoul Hospital Seoul, | |
| FN u Sv. Anny Brno, | |
| FN u Sv. Anny Brno, | |
| Fairview Health Services Maplewood, Minnesota | |
| Fairview Health Services Maplewood, Minnesota | |
| Fakultni nemocnice Brno Brno-Bohunice, | |
| Fakultni nemocnice Kralovske Vinohrady Prague, | |
| Fakultni nemocnice Olomouc Olomouc, | |
| Fakultni nemocnice Plzen - Lochotin Plzen - Lochotín, | |
| Flinders Medical Centre Bedford Park, | |
| Fondazione IRCCS Policlinico San Matteo Pavia, | |
| Fondazione IRCCS San Gerardo dei Tintori Monza, Monza and Brianza | |
| Fondazione Policlinico Universitario Agostino Gemelli IRCS Roma, | |
| Fondazione Policlinico Universitario Agostino Gemelli Irccs Rome, | |
| Fortis Escorts Heart Institute, New Delhi New Delhi, National Capital Territory of Delhi | |
| Fortis Hospital, Mohali Mohali, | |
| Fortis Hospital, Mohali Mohali, | |
| Freeman Hospital, Newcastle Newcastle upon Tyne, | |
| Fujita Health University Hospital_Cardiology Aichi, | |
| Fujita Health University Hospital_Cardiology Aichi, | |
| Fukuoka University Hospital_Cardiology Fukuoka-shi, Fukuoka, | |
| Fukuoka University Hospital_Cardiology Fukuoka-shi, Fukuoka, | |
| Fundacion Favaloro CABA, | |
| Fundación Nuestra Señora del Rosario - Estudios Clínicos los Arroyos San Nicolás de los Arroyos, Buenos Aires | |
| G B Pant Institute of Postgraduate Medical Education and Research New Delhi, National Capital Territory of Delhi | |
| G. Kuppuswamy Naidu Memorial Hospital Coimbatore, Tamil Nadu | |
| G. Kuppuswamy Naidu Memorial Hospital Coimbatore, Tamil Nadu | |
| G.H. of Athens "Evaggelismos" Athens, | |
| Gachon University Gil Medical Center Incheon, Namdong-gu | |
| Ganesh Shankar Vidyarthe Memorial (GSVM) Medical College Kanpur, Uttar Pradesh | |
| Geisinger Medical Center Danville, Pennsylvania | |
| Gen Hospital of Thessaloniki G.Papanikolaou,Cardiology Dpt Thessaloniki, | |
| General Hospital Of Eleusina Thriasio - Cardiology Clinic Eleusina, | |
| General Hospital Of Patras Agios Andreas - Cardiology Department Pátrai, | |
| General Hospital of Athens "Elpis" - Cardiology Department Ampelokipoi/Athens, | |
| General Hospital of Athens "Laiko" Athens, Attikí | |
| General Hospital of Chios "Skilitsio" - Cardiology Clinic Chios, | |
| General Hospital of Imathia Monada Veria Véroia, | |
| General Hospital of Imathia Monada Veria - Cardiology Department Véroia, | |
| General Hospital of Thessaloniki PAPAGEORGIOU Nea Efkarpia, Thessaloniki | |
| General Hospital of Tianjin Medical University-Endocrinology Tianjin, Tianjin Municipality | |
| Genesis Health Care System Zanesville, Ohio | |
| Geniko Nosokomeio Peiraia Tzaneio - Cardiology department Piraeus, | |
| Glenfield Hospital Leicester, | |
| Gold Coast University Hospital - Cardiology Department Southport, Queensland | |
| Gold Coast University Hosptial Southport, Queensland | |
| Golden Jubilee University National Hospital Glasgow, | |
| Grande Ospedale Metropolitano Niguarda Milan, | |
| Grandview Medical Center Birmingham, Alabama | |
| Grey Nuns Community Hospital Edmonton, Alberta | |
| Groene Hart Zkh Gouda - Cardiologie Gouda, | |
| Group Euroclinic - Athens Euroclinic - Cardiology Department Athens, | |
| Guangdong Provincial People's Hospital Guangzhou, | |
| Guangdong Provincial People's Hospital Guangzhou, | |
| H. Clinico Univ. Virgen de la Victoria, Malaga Málaga, | |
| HCA Research Institute McAllen, Texas | |
| HMC, locatie Westeinde - Cardiologie The Hague, | |
| Hackensack Meridian Health Hackensack, New Jersey | |
| Hadassah Ein Karam MC - Cardio Department Jerusalem, | |
| Hadassah Mount Scorpus MC - Cardiology department Jerusalem, | |
| Hamilton Health Sciences Corp, Ontario Hamilton, Ontario | |
| Hanaoka Seishu Memorial Hosp._Cardiovascular Medicine Sapporo-shi, Hokkaido, | |
| Hanaoka Seishu Memorial Hospital Hokkaido, | |
| Hanyang University Seoul Hospital Seoul, | |
| Harefield Hospital Harefield, Middlesex | |
| Health Sciences North Rsrch Inst Greater Sudbury, Ontario | |
| Heart & Vascular Inst._Titus Mount Pleasant, Texas | |
| Heart Center Rsrch_Hunstville Huntsville, Alabama | |
| Hebei General Hospital Shijiazhuang, Hebei | |
| Helios Klinikum Erfurt GmbH - 3. Med. Klinik - Kardiologie Erfurt, | |
| Henry Dunant Hospital Center Athens, | |
| Heritage Medical Research Clinic Calgary, | |
| Herlev og Gentofte Hospital Herlev, | |
| Hermosillo Heart Team Hermosillo, Sonora | |
| Hillel Yaffe MC - Cardiology Department Hadera, | |
| Hippokration Hospital Athens, | |
| Holy Cross Hospital Silver Spring, Maryland | |
| Holy Name Medical Center Teaneck, New Jersey | |
| Honor Health Scottsdale, Arizona | |
| Hopital Sacre-Coeur de Montreal Montreal, Quebec | |
| Hospices Civils de Lyon- Hopital Louis Pradel Bron, | |
| Hospital Agamenon Magalhães Recife, Pernambuco | |
| Hospital Agamenon Magalhães Recife, Pernambuco | |
| Hospital Alvaro Cunqueiro de Vigo Vigo, | |
| Hospital Angeles de Culiacan Culiacán, Sinaloa | |
| Hospital Angeles de Xalapa Xalapa, Veracruz | |
| Hospital Angeles de las Lomas México, State of Mexico | |
| Hospital Canselor Tuanku Muhriz UKM Cheras, | |
| Hospital Cardiologica Aguascalientes Aguascalientes, Aguascalientes | |
| Hospital Civil De Guadalajara Fray Antonio Alcalde Guadalajara, Jalisco | |
| Hospital Clinic i Provincial Barcelona, | |
| Hospital Clinico San Carlos Madrid, | |
| Hospital Clinico Universitario de Valencia Valencia, | |
| Hospital Clinico Universitario de Valladolid Valladolid, | |
| Hospital Clinico de Santiago Santiago de Compostela, | |
| Hospital Clinico de Santiago Santiago de Compostela, | |
| Hospital De La Santa Creu I Sant Pau Barcelona, | |
| Hospital De La Santa Creu I Sant Pau Barcelona, | |
| Hospital Del Mar Barcelona, | |
| Hospital Del Mar Barcelona, | |
| Hospital Dr. Jose Maria Cullen Santa Fe, | |
| Hospital Espanol De Mendoza Godoy Cruz, Mendoza Province | |
| Hospital Espanol De Mendoza Godoy Cruz, Mendoza Province | |
| Hospital General Universitario Dr. Balmis Alicante, | |
| Hospital General de Mexico (HGM) Cuauhtémoc, Mexico City | |
| Hospital Germans Trias I Pujol Badalona, | |
| Hospital Germans Trias I Pujol Badalona, | |
| Hospital Gral Alicante Dr. Balmis Alicante, | |
| Hospital Gregorio Maranon Madrid, | |
| Hospital Gregorio Maranon Madrid, | |
| Hospital Israelita Albert Einstein Morumbi, São Paulo | |
| Hospital Italiano Buenos Aires, | |
| Hospital Italiano de la Plata La Plata, Buenos Aires | |
| Hospital Juárez de Mexico Ciudad de México, D.F., | |
| Hospital Juárez de Mexico Ciudad de México, D.F., | |
| Hospital Maternidade e Pronto Socorro Santa Lucia Poços de Caldas, Minas Gerais | |
| Hospital Mãe de Deus - Porto Alegre Porto Alegre/RS, | |
| Hospital Pulau Pinang George Town, | |
| Hospital Queen Elizabeth II Kota Kinabalu, | |
| Hospital Raja Perempuan Zainab II Kota Bharu, Kelantan, | |
| Hospital Raja Permaisuri Bainun Ipoh Ipoh, Perak | |
| Hospital Ramon Y Cajal Madrid, | |
| Hospital Ruy Azeredo Ltda Goiânia, Goiás | |
| Hospital Serdang Kajang, Selangor | |
| Hospital Serdang Kajang, Selangor | |
| Hospital Sultanah Aminah Johor Bahru, | |
| Hospital Sultanah Bahiyah Alor Star, Kedah | |
| Hospital São Lucas - PUC/RS Porto Alegre, Rio Grande do Sul | |
| Hospital Tengku Ampuan Afzan Kuantan, Pahang | |
| Hospital Univ. Virgen de la Arrixaca El Palmar, | |
| Hospital Universitari Joan XXIII Tarragona, | |
| Hospital Universitari Joan XXIII Tarragona, | |
| Hospital Universitario Austral Pilar, | |
| Hospital Universitario Austral - Instituto de Cardiologia Pilar, Buenos Aires | |
| Hospital Universitario Dr. Jose Eleuterio Gonzalez Monterrey, | |
| Hospital Universitario La Paz Madrid, | |
| Hospital Universitario Marqués de Valdecilla Santander, | |
| Hospital Universitario Virgen del Rocio Seville, | |
| Hospital Universitario de La Princesa Madrid, | |
| Hospital Universiti Kebangsaan Malaysia Cheras, Kuala Lumpur | |
| Hospital Universiti Sains Malaysia_Kota Bharu, Kelantan Kota Bharu, Kelantan | |
| Hospital Virgen de la Arrixaca El Palmar, Murcia | |
| Hospital das Clínicas da Universidade Federal do Triangulo Mineiro Uberaba, Minas Gerais | |
| Hospital de Lleida "Arnau de Vilanova" Lleida, | |
| Hospital del Centenario Rosario, Santa Fe, Santa Fe Province | |
| Hospital do Coração do Brasil Brasília, Federal District | |
| Houston Medical Center Houston, Texas | |
| Houston Medical Center Houston, Texas | |
| Houston Methodist Hospital Houston, Texas | |
| Huashan Hospital Fudan University Shanghai, | |
| Huashan Hospital Fudan University Shanghai, | |
| Hyogo Medical University Hospital_Cardiovascular Medicine Hyōgo, | |
| Hyogo Medical University Hospital_Cardiovascular Medicine Hyōgo, | |
| Hyogo Prefectural HarimaHimeji General Medical Center_Cardiology Himeji-shi, Hyogo, | |
| Hyogo Prefectural HarimaHimeji General Medical Center_Cardiology Himeji-shi, Hyogo, | |
| ICOT Istituto Marco Pasquali - UOC Cardiologia Latina, Lazio | |
| ICOT Istituto Marco Pasquali - UOC Cardiologia Latina, Lazio | |
| II. interni klinika VFN - Kardiologie a angiologie Prague, | |
| IKEM Prague, | |
| IRCCS Policlinico San Donato San Donato Milanese, MI | |
| Ikazia Ziekenhuis Rotterdam, | |
| Illawarra Heart Health Centre Wollongong, New South Wales | |
| Indiana University Health Methodist Hospital Indianapolis, Indiana | |
| Indraprastha Apollo Hospital, New Delhi New Delhi, National Capital Territory of Delhi | |
| Indraprastha Apollo Hospital, New Delhi New Delhi, National Capital Territory of Delhi | |
| Inha University Hospital Incheon, | |
| Inje University Haeundae Paik Hospital Busan, | |
| Inova Fairfax Medical Campus, Falls Church Fairfax, Virginia | |
| Ins Uni de Cardi et de PNA de Québec, | |
| Inspira Health - Cardiology Mullica Hill, New Jersey | |
| Instituto Cardiovascular Buenos Aires CABA, Buenos Aires | |
| Instituto Dante Pazzanese de Cardiologia São Paulo, | |
| Instituto Nacional de Cardiologia Ignacio Chavez Mexico City, | |
| Instituto Nacional de Ciencias Medicas y Nutricion Tlalpan, Mexico City | |
| Instituto Nacional de Ciencias Medicas y Nutricion Tlalpan, Mexico City | |
| Instituto de Cardiología de Corrientes Corrientes, | |
| Instituto de Pesquisa Clinica de Campinas Campinas, | |
| Integral Pesquisa e Ensino Votuporanga, São Paulo | |
| Integral Pesquisa e Ensino Votuporanga, São Paulo | |
| Interbalkan Medical Center of Thessaloniki Thessaloniki, | |
| Intercard Spolka z ograniczona odpowiedzialnoscia Krosno, | |
| Intercard Spolka z ograniczona odpowiedzialnoscia Krosno, | |
| Intercoastal Medical Group Sarasota, Florida | |
| Intercoastal Medical Group Sarasota, Florida | |
| Intermountain Medical Center Murray, Utah | |
| Interventional Cardiology Medical Group West Hills, California | |
| Irmandade Santa Casa de Misericórdia de Passos Passos, Minas Gerais | |
| Irmandade da Santa Casa de Misericordia de Porto Alegre Porto Alegre, | |
| Irmandade da Santa Casa de Misericórdia de Marília Marília, São Paulo | |
| Ishikawa Prefectural Central Hospital_Cardiology Ishikawa, | |
| Ishikawa Prefectural Central Hospital_Cardiology Ishikawa, | |
| Ishikiriseiki Hospital_Circulatory Medicine Osaka, | |
| Istanbul University Cerrahpasa Medical Faculty Istanbul, Bakirkoy | |
| Jackson Heart Clinic Jackson, Mississippi | |
| Jacobi Medical Center The Bronx, New York | |
| Jacobi Medical Center The Bronx, New York | |
| Jadestone Clinical Research, LLC Silver Spring, Maryland | |
| Japanese Red Cross Fukuoka Hospital_Cardiology Fukuoka, | |
| Japanese Red Cross Fukuoka Hospital_Cardiology Fukuoka, | |
| Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) Puducherry, Tamil Nadu | |
| Jawaharlal Nehru Medical College and Hospital Aligarh, Utter Pradesh | |
| Jawaharlal Nehru Medical College and Hospital Aligarh, Utter Pradesh | |
| Jeroen Bosch Zkh 's-Hertogenbosch, | |
| Jersey City Med Center Jersey City, New Jersey | |
| Jinan Central Hospital Jinan, | |
| Jmf Clínica Do Coração Ltda Aracaju, | |
| Juntendo University Shizuoka Hospital Shizuoka, Izunokuni, | |
| Juntendo University Shizuoka Hospital_Gastroenterology & Hepatology Izunokuni-shi, Shizuoka, | |
| Justice K S Hegde Charitable Hospital Mangaluru, Karnataka | |
| Kagawa Prefectural Central Hospital_Cardiovascular Medicine Takamatsu-shi, Kagawa, | |
| Kaiser Permanente Viewridge Medical Offices San Diego, California | |
| Kanto Rosai Hospital_Cardiology Kanagawa, | |
| Kanto Rosai Hospital_Cardiology Kanagawa, | |
| Kaplan MC - Cardiac Intensive Care Rehovot, | |
| Kartal Kosuyolu Yuksek Ihtisas EAH Istanbul, | |
| Kasturba Medical College and Hospital, Manipal Udupi, Karnataka | |
| Kat Attica General Hospital - Cardiology Department Kifissia, | |
| Kath. St. Paulus GmbH - St Johannes Hospital Dortmund - Kardiologie Dortmund, | |
| Kayseri City Hospital Kayseri, | |
| Kayseri Şehir Hastanesi-Kardiyoloji Kayseri, | |
| Keimyung University Dongsan Hospital Daegu, | |
| Kelowna Cardiology Res. Ltd. Kelowna, British Columbia | |
| Kettering General Hospital Kettering, | |
| Kettering Medical Center Kettering, Ohio | |
| King George Hospital Visakhapatnam, Andhra Pradesh | |
| King George's Medical University (KGMU) Lucknow, Uttar Pradesh | |
| King George's Medical University (KGMU) Lucknow, Uttar Pradesh | |
| King's College Hospital - Cardiology London, | |
| Kings College Hospital London, | |
| Kingston General Hospital Kingston, Ontario | |
| Kingston General Hospital Kingston, Ontario | |
| Kliniczny Szpital Wojewodzki nr 2 im. Sw. Jadwigi Krolowej w Rzeszowie Rzeszów, | |
| Klinikum Friedrichshafen GmbH - Klinik für Kardiologie, Angiologie, Pneumologie und internistische Intensivmedizin Friedrichshafen, | |
| Klinikum Fulda gAG - Med. Klinik I Fulda, | |
| Klinikum Leverkusen gGmbH - Med. Klinik 1 Leverkusen, | |
| Knoxville Heart Group Knoxville, Tennessee | |
| Kocaeli Üniversitesi Hastanesi- Kardiyoloji Kocaeli, | |
| Konstantopouleio G.H. of Athens, "Agia Olga" Athens, | |
| Korea University Anam Hospital Seoul, | |
| Korea University Guro Hospital Seoul, | |
| Koşuyolu Yüksek İhtisas EAH- Kardiyoloji Istanbul, | |
| Krajska zdravotni, a.s. - Masarykova nemocnice v Usti nad Labem, o.z. Ústní Nad Labem, Czechia | |
| Krajská nemocice Liberec, a.s Liberec, | |
| Krajská nemocnice T.Bati a.s. Zlín, | |
| Kyung Hee University Hospital at Gangdong Seoul, | |
| Kyunghee University Medical Center Seoul, | |
| Kyungpook National University Hospital Daegu, | |
| Kütahya Sağlık Bilimleri Üniversitesi Evliya Çelebi EAH- Kardiyoloji Merkez/Kütahya, | |
| Kütahya Şehir Hastanesi-Kardiyoloji Kütahya, | |
| LA BioMed Harbor UCLA Med Cenr Torrance, California | |
| Lakshmi Hospital Palakkad, | |
| Lalitha PVS Institute of Medical Sciences Guntur, Andhra Pradesh | |
| Les Hopitaux de Chartres-Hopital Louis Pasteur Le Coudray, | |
| Lincoln County Hospital Lincoln, | |
| Lincoln County Hospital Lincoln, | |
| Lindner Center,Christ Hospital Cincinnati, Ohio | |
| Lisie Hospital Kochi, | |
| Lister Hospital Stevenage, | |
| Lister Hospital Stevenage, | |
| Liver Ins@ Mthdist DTX Med Cen Dallas, Texas | |
| Liverpool Heart & Chest Hospital Liverpool, | |
| Liverpool Hospital Liverpool, New South Wales | |
| Liverpool Hospital Liverpool, New South Wales | |
| Loma Linda University Faculty Medical Clinics Loma Linda, California | |
| London Health Sciences Center Ontario London, Ontario | |
| Louis Stokes Clvlnd VA Med Ctr Cleveland, Ohio | |
| Lyell McEwin Hospital Elizabeth Vale, South Australia | |
| Lyell McEwin Hospital Elizabeth Vale, South Australia | |
| MHAT "Dr. Bratan Shukerov" Smolyan, | |
| MHAT - Cardiolife OOD - Lovech Lovech, | |
| MHAT - City Clinic - Sveti Georgi EOOD Montana, | |
| MHAT - Dr. Atanas Dafovski AD, Cardiology department Kardzhali, | |
| MHAT - Ivan Skenderov EOOD Gotse Delchev, | |
| MHAT - Pazardzhik AD Pazardzhik, | |
| MHAT Dr. Bratan Shukerov Smolyan, | |
| MHAT Dr. Tota Venkova AD Gabrovo, | |
| MHAT Hadzhi Dimitar OOD Sliven, | |
| MHAT Haskovo AD Haskovo, | |
| MHAT Heart and Brain EAD - Burgas, Cardiology Burgas, | |
| MHAT Heart and Brain EAD - Pleven, Cardiology Pleven, | |
| MHAT MC-Sv Ivan Rilski EOOD Plovdiv, | |
| MHAT National Cardiology Hospital EAD Sofia, | |
| MHAT Puls AD, Cardiology Department Blagoevgrad, | |
| MHAT Southwest Hospital OOD, Cardiology Department Sandanski, | |
| MHAT Sveta Karidad EAD Plovdiv, | |
| MVZ CCB Frankfurt Und Main-Taunus GbR Frankfurt, | |
| Maasstad Ziekenhuis - Cardiologie Rotterdam, | |
| Maine Medical Center Bramhall Scarborough, Maine | |
| Malla Reddy Narayana Multispeciality Hospital Hyderabad, Telangana | |
| Malla Reddy Narayana Multispeciality Hospital Hyderabad, Telangana | |
| Marengo CIMS Hospital Ahmedabad, Gujarat | |
| Marmara University Medical Faculty Istanbul, | |
| Marmara Üniversitesi Pendik EAH- Kardiyoloji Istanbul, | |
| Matsuyama Red Cross Hospital_Department of Cardiovascular Medicine Ehime, | |
| Max Super Speciality Hospital, Saket New Delhi, | |
| Mayo Clinic Arizona Phoenix, Arizona | |
| Mayo Clinic Jacksonville Jacksonville, Florida | |
| McGuire VA Medical Center Richmond, Virginia | |
| McLaren Bay Region Bay City, Michigan | |
| McLaren Greater Lansing Lansing, Michigan | |
| McLaren Macomb Health Care Mount Clemens, Michigan | |
| McLaren Northern MI Hosp Petoskey, Michigan | |
| Meander MC Amersfoort, | |
| MedStar Hlth Res Institute Clinton, Maryland | |
| MedStar Hlth Res Institute Clinton, Maryland | |
| Medical College & Hospital, Kolkata Kolkata, West Bengal | |
| Medical College & Hospital, Kolkata Kolkata, West Bengal | |
| Medicover Hospitals, Visakhapatnam MVP Visakhapatnam, Andhra Pradesh | |
| Medisch Spectrum Twente - Cardiologie Enschede, | |
| Medizinische Hochschule Hannover - Kardiologie und Angiologie Hanover, | |
| Meir MC - Cardiology department Kfar Saba, | |
| Memorial Healthcare Owosso, Michigan | |
| Mercy Gilbert Medical Center Gilbert, Arizona | |
| Mercy Health - St. Vincent Medical Center Toledo, Ohio | |
| Mercy Research Springfield, Missouri | |
| MercyOne NE Iowa Fam Med & Res Waterloo, Iowa | |
| Mersin Üniversitesi Hastanesi- Kardiyoloji Mersin, | |
| Mersin Şehir Eğitim Araştırma Hastanesi- Kardiyoloji Mersin, | |
| Methodist Healthcare System of San Antonio San Antonio, Texas | |
| Methodist Healthcare System of San Antonio San Antonio, Texas | |
| Methodist Physicians Clinic Omaha, Nebraska | |
| MetroHealth Medical Center Cleveland, Ohio | |
| Metropolitan General Hospital Healthcare Facilities Operation And Management Single Member S.A. - Cardiology Clinic Athens, | |
| MidMic Medical Cntr - Midland Midland, Michigan | |
| Midwest Cardiovascu Rsrch Foundation Davenport, Iowa | |
| Midwest Heart and Vascular Specialists Overland Park, Kansas | |
| Midwest Heart and Vascular Specialists Overland Park, Kansas | |
| Miedziowe Centrum Zdrowia s.a. Lubin, | |
| Missouri Cardiovascular Specialist Columbia, Missouri | |
| Mito Saiseikai General Hospital_Cardiology Ibaraki, | |
| Mito Saiseikai General Hospital_Cardiology Ibaraki, | |
| Miyazaki Medical Association Hospital Miyazaki, Miyazaki | |
| Miyazaki Medical Association Hospital_Cardiology Miyazaki, Miyazaki | |
| Mobile Heart USA Health Cardiology Clinic Mobile, Alabama | |
| Monument Health Clinical Rsrch Rapid City, South Dakota | |
| Morriston Hospital Swansea, | |
| Moses H. Cone Mem Hosp Greensboro, North Carolina | |
| Mount Sinai Morningside Manhattan, New York | |
| Multicare Health System Tacoma, Washington | |
| Multiprofile Hospital For Active Treatment Dr. Tota Venkova AD Gabrovo, | |
| Musgrove Park Hospital Taunton, | |
| Myongji Hospital Goyang-si, Gyeonggi-do | |
| NC Heart and Vascular Research Raleigh, North Carolina | |
| NHO Kure Medical Center and Chugoku Cancer Center Kure-shi, Hiroshima, | |
| NHO Kure Medical Center and Chugoku Cancer Center_Cardiology Kure-shi, Hiroshima, | |
| NIMTS Army Share Fund Hospital Athens, | |
| NUPEC Cardio Belo Horizonte, | |
| NYU Grossman School of Med New York, New York | |
| Nanfang Hospital, Southern Medical University Guangzhou, Guangdong | |
| Nanfang Hospital, Southern Medical University Guangzhou, Guangdong | |
| Nanjing Drum Tower Hospital Nanjing, | |
| Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy Warsaw, | |
| National Heart Institute Kuala Lumpur, | |
| National Heart Institute Kuala Lumpur, | |
| National Hospital Organization Kumamoto Medical Center_Cardiology Kumamoto, | |
| National Hospital Organization Kumamoto Medical Center_Cardiology Kumamoto, | |
| Necmettin Erbakan University Hospital Konya, | |
| Necmettin Erbakan Üniversitesi Tıp Fakültesi Hastanesi- Kardiyoloji Konya, | |
| Nemocnice AGEL Třinec-Podlesí a.s. Třinec, | |
| Nemocnice Na Homolce Prague, | |
| Nemocnice Pardubickeho kraje a.s. Pardubice, | |
| Nemocnice České Budějovice a.s. České Budějovice, | |
| Nepean Hospital Kingswood, New South Wales | |
| New Brunswick Heart Centre Saint John, New Brunswick | |
| New Brunswick Heart Centre Saint John, New Brunswick | |
| New Cross Hospital Wolverhampton, West Midlands | |
| Niagara Health System St. Catharines, Ontario | |
| Nil Ratan Sircar Medical College and Hospital Kolkata, West | |
| Nil Ratan Sircar Medical College and Hospital Kolkata, West | |
| Nishinomiya Watanabe Cardiovascular Cerebral Center_Cardiovascular Medicine Hyōgo, | |
| Noordwest Ziekenhuisgroep Alkmaar, | |
| Nordsjællands hospital - Kardiologisk Forskning Hillerød, | |
| North Kansas City Hospital Kansas City, Missouri | |
| North Mississippi Medical Center Tupelo, Mississippi | |
| Northeast Georgia Medical Ctr Gainesville, Georgia | |
| Northern General Hospital Sheffield, | |
| Northern General Hospital Sheffield, | |
| Northern Health Epping, Victoria | |
| Northern Light Eastern Maine Medical Center Bangor, Maine | |
| Novant Hlth Cardio - Kimel Park Winston-Salem, North Carolina | |
| Novant Hlth Vasc Ins Charlotte Charlotte, North Carolina | |
| Nuevo Hospital Civil "Dr. Juan I. Menchaca" Guadalajara, Jalisco | |
| Nuevo Hospital Civil "Dr. Juan I. Menchaca" Guadalajara, Jalisco | |
| OLVG Oost Amsterdam, | |
| OSF HealthCare_Cardiovasc Inst Peoria, Illinois | |
| Odense Universitetshospital, Kardiologisk afd. Odense C, | |
| Odense Universitetshospital, Kardiologisk afd. Odense C, | |
| Ondokuz Mayıs Üniversitesi Hastanesi- Kardiyoloji Samsun, | |
| Osaka General Medical Center_Cardiology Osaka, | |
| Osmania General Hospital Hyderabad, Telangana | |
| Osmania General Hospital Hyderabad, Telangana | |
| Ospedale Civile dell'Annunziata Cosenza, | |
| Ospedale Isola Tiberina Gemelli Isola Rome, | |
| Ospedale Maggiore Carlo Alberto Pizzardi Bologna, | |
| Ospedale Policlinico San Martino Genoa, Liguria | |
| Ospedale Sandro Pertini - UOC Cardiologia Rome, | |
| Ospedale Sant'Andrea - UOC Cardiologia La Spezia, | |
| Overton Brooks V.A. Medical Center Shreveport, Louisiana | |
| Overton Brooks V.A. Medical Center Shreveport, Louisiana | |
| PUCCAMP - Hospital e Maternidade Celso Pierro Campinas, São Paulo | |
| PUCCAMP - Hospital e Maternidade Celso Pierro Campinas, São Paulo | |
| Pan-Arcadian General Hospital of Tripoli Evangelistria - Cardiology Department Tripoli, | |
| Parkway Cardiology Associates, PC Oak Ridge, Tennessee | |
| Peking University First Hospital-Cardiology Beijing, Beijing Municipality | |
| Peking University First Hospital-Cardiology Beijing, Beijing Municipality | |
| Peking University Third Hospital Beijing, | |
| Peking University Third Hospital Beijing, | |
| Peninsula University Hospital - Cardiology Department Frankston, Victoria | |
| Penn State Hershey Medical Center Hershey, Pennsylvania | |
| Penn State Hlth Holy Spirit Med Ctr Camp Hill, Pennsylvania | |
| PharmaTex Research, LLC Amarillo, Texas | |
| Podhalanski Szpital Specjalistyczny Nowy Targ, | |
| Policlinico Casilino - Cardiologia e UTIC Rome, | |
| Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh Chandigarh, | |
| Prairie Cardiovascular Consultants, Ltd. Springfield, Illinois | |
| Presidio Ospedaliero di Rivoli Rivoli, To | |
| Prince of Wales Hospital - Sydney Randwick, New South Wales | |
| Princess Alexandra Hospital Woolloongabba, Queensland | |
| Princess Alexandra Hospital Woolloongabba, Queensland | |
| Prism Hlth Carolina Card Cons Greenville, South Carolina | |
| ProMedica Toledo, Ohio | |
| Prolato Clinical Research Cntr Houston, Texas | |
| Pusan National University Yangsan Hospital Yangsan, | |
| Pusan National University Yangsan Hospital Yangsan, | |
| QE II Health Sciences Centre Halifax, Nova Scotia | |
| QE II Health Sciences Centre Halifax, Nova Scotia | |
| Queen Alexandra Hospital Portsmouth, | |
| Queen Alexandra Hospital - Cardiology Portsmouth, | |
| Rabin MC -Beilinson - Cardiac intensive unit Petah Tikva, | |
| Radboudumc Nijmegen, | |
| Ramaiah Memorial Hospital Bengaluru, Karnataka | |
| Rambam MC - Cardiac Intensive Care Unit Haifa, | |
| Reading Hospital West Reading, Pennsylvania | |
| Regina General Hospital Regina, Saskatchewan | |
| Regions Hospital Saint Paul, Minnesota | |
| Reid Physician Associates Richmond, Indiana | |
| Renmin Hospital of Wuhan University-Cardiology Wuhan, Hubei | |
| Rhode Island Hospital Providence, Rhode Island | |
| Rhythm Heart Institute Vadodara, Gujarat | |
| Rhön-Klinikum AG - Zentralklinik Bad Berka - Kardiologie Bad Berka, | |
| Rigshospitalet - Kardiologisk Forskningsenhed København Ø, | |
| Rijnstate Ziekenhuis Arnhem, | |
| Robert Packer Hospital Sayre, Pennsylvania | |
| Robert-Bosch-Krankenhaus GmbH Stuttgart Stuttgart, | |
| Royal Adelaide Hospital - Cardiology Department Adelaide, South Australia | |
| Royal Adelaide Hospital Cardiovascular Clinical Trials Adelaide, South Australia | |
| Royal Alexandra Hospital Edmonton, Alberta | |
| Royal Bournemouth Hospital - Cardiology Bournemouth, Dorset | |
| Royal Brisbane and Women's Hospital Herston, Queensland | |
| Royal Brompton and Harefield Hospitals Harefield, Middlesex | |
| Royal Cornwall Hospital (Treliske) Truro, Cornwall | |
| Royal Infirmary of Edinburgh - Cardiology Edinburgh, | |
| Royal Perth Hospital Perth, Western Australia | |
| Royal University Hospital Saskatoon, Saskatchewan | |
| Royal Victoria Regional Health Centre Barrie, Ontario | |
| Royal Victoria Regional Health Centre Barrie, Ontario | |
| S Denver Cardiology Associates Littleton, Colorado | |
| S.P. Medical College & Associated Group of Hospitals Bikaner, Rajasthan | |
| S.P. Medical College & Associated Group of Hospitals Bikaner, Rajasthan | |
| SCANMED Spółka Akcyjna Kluczbork, | |
| SCANMED Spółka Akcyjna Kluczbork, | |
| SCANMED Spółka Akcyjna Kluczbork, | |
| SCANMED Spółka Akcyjna Kluczbork, | |
| SCANMED Spółka Akcyjna Kluczbork, | |
| SCANMED Spółka Akcyjna Kluczbork, | |
| SCB Medical College and Hospital Cuttack, Odisha | |
| SHATC - Cardiolife OOD - Varna Varna, | |
| SHATC - Medica Kor EAD Rousse, | |
| SHATC - Yambol EAD Yambol, | |
| SMC Heart Institute and IVF Research Centre Raipur, Chhattisgarh | |
| SMS Medical College & Attached Hospitals Jaipur, Rajasthan | |
| SMS Medical College & Attached Hospitals Jaipur, Rajasthan | |
| Sahyadri Super Speciality Hospital Pune, Maharashtra | |
| Saint Elizabeth Medical Center Edgewood, Kentucky | |
| Saint Joseph's Hospital Health Center Liverpool, New York | |
| Saint Paul's Hospital Vancouver, British Columbia | |
| Saint Thomas Hospital Nashville, Tennessee | |
| Saiseikai Yokohamashi Nanbu Hospital_Cardiology Yokohama-shi, Kanagawa, | |
| Saiseikai Yokohamashi Nanbu Hospital_Cardiology Yokohama-shi, Kanagawa, | |
| Saiseikai Yokohamashi Tobu Hospital_Cardiology Kanagawa, | |
| Saiseikai Yokohamashi Tobu Hospital_Cardiology Kanagawa, | |
| Samodzielny Publiczny Specjalistyczny Szpital Zachodni Im.Sw.Jana Pawla II Grodzisk Mazowiecki, | |
| Samodzielny Publiczny Specjalistyczny Szpital Zachodni Im.Sw.Jana Pawla II Grodzisk Mazowiecki, | |
| Samodzielny Publiczny Zaklad Opieki Zdrowotnej Ministerstwa Spraw Wewnetrznych i Administracji w Rzeszowie Rzeszów, | |
| Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie Krakow, | |
| Samodzielny Publiczny Zaklad Opieki Zdrowotnej W Pulawach Puławy, Lublin Voivodeship | |
| Samodzielny Publiczny Zaklad Opieki Zdrowotnej W Pulawach Puławy, Lublin Voivodeship | |
| Samodzielny Publiczny Zespol Opieki Zdrowotnej w Swidnicy Swidnica, | |
| Samodzielny Publiczny Zespol Opieki Zdrowotnej w Swidnicy Swidnica, | |
| Samodzielny Publiczny Zespół Zakładów Opieki Zdrowotnej w Ostrowi Mazowieckiej Ostrów Mazowiecka, | |
| San Diego Cardiac Center San Diego, California | |
| San Francisco V.A. Medical Center San Francisco, California | |
| San Francisco V.A. Medical Center San Francisco, California | |
| Sanatorio Finochietto CABA, Buenos Aires | |
| Sanatorio Finochietto CABA, Buenos Aires | |
| Sanatorio Güemes Ciudad de Buenos Aires, Buenos Aires | |
| Sanatorio Modelo Quilmes Quilmes, Buenos Aires | |
| Sanatorio Parque Rosario, Santa Fe Province | |
| Sanford Health - Fargo Fargo, North Dakota | |
| Sanford Health - Fargo Fargo, North Dakota | |
| Sanford Research Sioux Falls, South Dakota | |
| Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow, Uttar Pradesh | |
| Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow, Uttar Pradesh | |
| Sarawak Heart Centre Kota Samarahan, Sarawak | |
| Sardar Vallabhbhai Patel Institute of Medical Sciences and Research Ahmedabad, Gujarat | |
| Sentara Bayside Hospital Norfolk, Virginia | |
| Seoul National University Bundang Hospital Seongnam-si, | |
| Seoul National University Hospital Seoul, | |
| Servicios Integrales Nova de Monterrey San Nicolás de los Garza, | |
| Servicios Integrales Nova de Monterrey San Nicolás de los Garza, | |
| Seth GS Medical College & KEM Hospital Mumbai, Maharashtra | |
| Seth GS Medical College & KEM Hospital Mumbai, Maharashtra | |
| Severance Hospital, Yonsei University Health System Seoul, | |
| Shamir MC - Cardiology Department Beer Yaakov, | |
| Sheba MC - Cardiology Clinical Research Unit Tel Litwinsky, | |
| Shengjing Hospital of China Medical University Shenyang, | |
| Shengjing Hospital of China Medical University-Cardiology Shenyang, Liaoning | |
| Shiga University of Medical Science Hospital_Cardiology Shiga, | |
| Shri B. D. Mehta Mahavir Heart Institute Surat, Gujarat | |
| Shri Krishna Hrudayalaya & Critical Care Centre Nagpur, Maharashtra | |
| Shri Krishna Hrudayalaya & Critical Care Centre Nagpur, Maharashtra | |
| Shri Mahant Indiresh Hospital Dehradun, | |
| Sichuan Provincial People's Hospital-Cardiology Chengdu, Sichuan | |
| Sir Ganga Ram Hospital New Delhi, National Capital Territory of Delhi | |
| Sir Run Run Shaw Hospital, Zhejiang University School of Medicine Hangzhou, | |
| Sir Run Run Shaw Hospital, Zhejiang University School of Medicine Hangzhou, | |
| Sismanogleio General Hospital - Cardiology Department Marousi, | |
| Sourasky MC - Cardio Vascular Research Center Tel Aviv, | |
| South Oklahoma Heart Research, LLC Oklahoma City, Oklahoma | |
| South Oklahoma Heart Research, LLC Oklahoma City, Oklahoma | |
| Southlake Regional Hlth Centre Newmarket, Ontario | |
| Southlake Regional Hlth Centre Newmarket, Ontario | |
| Specialized Hospital For Active Cardiology Treatement Cardiolife OOD Varna, | |
| Specjalistyczny Szpital Im. E. Szczeklika W Tarnowie Tarnów, Lesser Poland Voivodeship | |
| Specjalistyczny Szpital Im. E. Szczeklika W Tarnowie Tarnów, Lesser Poland Voivodeship | |
| Specjalistyczny Szpital Miejski im. M.Kopernika w Toruniu Torun, | |
| Sri Jayadeva Institute of Cardiovascular Sciences & Research Bengaluru, Karnataka | |
| Sri Ramachandra Medical Centre Chennai, Tamil Nadu | |
| Sri Ramachandra Medical Centre Chennai, Tamil Nadu | |
| Ss. Annunziata Chieti, Abruzzo | |
| St Bartholomew's Hospital - Barts Heart Centre London, | |
| St Francis Hospital Lindner Research Center Roslyn, New York | |
| St Francis Hospital Lindner Research Center Roslyn, New York | |
| St. Boniface Hospital Winnipeg, Manitoba | |
| St. Boniface Hospital Winnipeg, Manitoba | |
| St. Luke's Idaho Cardiology Associates Meridian, Idaho | |
| St. Michael's Hospital Toronto, Ontario | |
| St. Michael's Hospital Toronto, Ontario | |
| St.Mary's Hospital_Cardiology Fukuoka, | |
| Sterling Hospitals, Race Course Road Vadodara, Gujarat | |
| Stony Brook University Hospital Stony Brook, New York | |
| Städt. Klinikum Dresden - 2. Medizinische Klinik Dresden, | |
| Sultan Ahmad Shah Medical Centre @IIUM Kuantan, Pahang | |
| Sunnybrook Health Sciences Centre Toronto, Ontario | |
| Sunnybrook Health Sciences Centre Toronto, Ontario | |
| Sunshine Coast University Hospital - Clinical Research Unit Birtinya, Queensland | |
| Sunshine Hospital - Western Centre for Health Research and Education St Albans, Victoria | |
| Svendborg Sygehus - Kardiologisk Svendborg, | |
| Swedish Medical Center_Seattle Seattle, Washington | |
| Szpital Grochowski im. dr med. Rafala Masztaka Sp. z o.o. Warsaw, | |
| Szpital Grochowski im. dr med. Rafała Masztaka Sp. z o.o. Warsaw, | |
| Szpital Miejski Nr 4 w Gliwicach Sp. z o.o., Oddzial Kardiologii Gliwice, Silesian Voivodeship | |
| Szpital Uniwersytecki Nr 2 im. Dr. Jana Biziela Bydgoszcz, | |
| Szpital Wolski im. dr Anny Gostyńskiej Sp. z o.o. Warsaw, | |
| Szpitale Pomorskie Sp. z o.o. Gdynia, | |
| TEDA International Cardiovascular Hospital-Cardiovascular Tianjin, Tianjin Municipality | |
| Teda International Cardiovascular Hospital Binhai, | |
| Teikyo University Hospital_Cardiology Tokyo, | |
| Tennova HC Turkey Creek MC Knoxville, Tennessee | |
| Tergooi, Hilversum Hilversum, | |
| Texas Heart Inst Medical Ctr Houston, Texas | |
| The 1st Affiliated Hospital of WMU-Cardiology Wenzhou, Zhejiang | |
| The Alfred - Endocrinology & Diabetes Department South Yarra, Victoria | |
| The Catholic University of Korea, Bucheon St. Mary's Hospital Bucheon-si, Gyeonggi-do | |
| The Catholic University of Korea, Seoul St. Mary's Hospital Seoul, | |
| The First Affiliated Hospital of Harbin Medical University Harbin, Heilongjiang | |
| The First Affiliated Hospital of Harbin Medical University Harbin, Heilongjiang | |
| The First Affiliated Hospital of WMU-Cardiology Wenzhou, Zhejiang | |
| The First Affiliated Hospital of Xi'an Jiaotong University-Cardiovascular Xi'an, Shaanxi | |
| The First Affiliated hospital of Fujian Medical University Fuzhou, | |
| The First Affiliated hospital of Fujian Medical University Fuzhou, | |
| The Heart House Haddon Heights Haddon Heights, New Jersey | |
| The James Cook University Hospital - Cardiology Middlesbrough, | |
| The Madras Medical Mission Chennai, Tamil Nadu | |
| The New York Hospital Brooklyn, New York | |
| The People's Hospital of Guangxi Zhuang Autonomous Region Nanning, Guangxi | |
| The People's Hospital of Liaoning Province Shenyang, Liaoning | |
| The People's Hospital of Liaoning Province-Cardiology Shenyang, Liaoning | |
| The Prince Charles Hospital Brisbane, Queensland | |
| The Prince Charles Hospital Brisbane, Queensland | |
| The Sakakibara Heart Institute of Okayama_Department of Cardiovascular Medicine Okayama, | |
| The Sakakibara Heart Institute of Okayama_Department of Cardiovascular Medicine Okayama, | |
| The Second Affiliated Hospital Of Chongqing Medical University Chongqing, Chongqing Municipality | |
| The Second Affiliated Hospital Of Chongqing Medical University Chongqing, Chongqing Municipality | |
| The Second Affiliated Hospital of Nanjing Medical university Nanjing, | |
| The Second Affiliated Hospital of Nanjing Medical university Nanjing, | |
| The Second Xiangya Hospital of Central South University Changsha, | |
| The Second Xiangya Hospital of Central South University Changsha, | |
| Thoracic General Hospital Of Athens I Sotiria - Cardiology Department Athens, | |
| Tianjin People's Hospital Tianjin, Tianjin Municipality | |
| Tianjin People's Hospital Tianjin, Tianjin Municipality | |
| Toho University Sakura Medical Center_Cardiology Chiba, | |
| Tohoku University Hospital, Cardiovascular Sendai-shi, Miyagi, | |
| Tokai University Hospital_Cardiology Kanagawa, | |
| Tokai University Hospital_Cardiology Kanagawa, | |
| Tokat Gaziosmanpaşa Üniversitesi Tıp Fakültesi Hastanesi- Kardiyoloji Tokat Province, | |
| Tokushima Prefectural Central Hospital_Cardiology Tokushima, | |
| Tokushima Prefectural Central Hospital_Cardiology Tokushima, | |
| Torbay Hospital - Cardiology Torquay, | |
| Torrance Memorial Medical Center Torrance, California | |
| Townsville University Hospital Douglas, Queensland | |
| Trakya Üniversitesi Tıp Fakültesi Hastanesi- Kardiyoloji Edirne, | |
| Trinity Health Michigan Heart Ypsilanti, Michigan | |
| Trinity Health Oakland Hospital Pontiac, Michigan | |
| Trinity Medical Group Minot, North Dakota | |
| Trinity Medical Group Minot, North Dakota | |
| Trinity Medical WNY, PC Buffalo, New York | |
| Tsuchiura Kyodo General Hospital_Internal Medicine Ibaraki, | |
| Tsuchiura Kyodo General Hospital_Internal Medicine Ibaraki, | |
| Tsukuba Medical Center Hospital_Department of Cardiology Tsukuba-shi, Ibaraki, | |
| U.G.H of Athens "Attikon" Chaidari, Athens, | |
| UCSD Medical Center San Diego, California | |
| UF Hlth Jacksonville Jacksonville, Florida | |
| UHN-Toronto General Hospital Toronto, Ontario | |
| UHN-Toronto General Hospital Toronto, Ontario | |
| UMAE Hospital IMSS Monterrey, Nuevo León | |
| UMC Groningen - Cardiologie Groningen, | |
| UMC of Southern Nevada Las Vegas, Nevada | |
| UMHAT "Sveta Marina" EAD Varna, | |
| UMHAT - Burgas AD Burgas, | |
| UMHAT Aleksandrovska EAD, Clinic of Cardiology Sofia, | |
| UMHAT Deva Maria EOOD Burgas, | |
| UMHAT Pulmed OOD - Plovdiv, Department of Cardiology Plovdiv, | |
| UMHAT Sofiamed EAD Sofia, | |
| UMHAT Sveta Anna Sofia AD, Clinic of Cardiology Sofia, | |
| UMHAT Sveta Ekaterina EAD Sofia, | |
| UMHAT Sveta Marina EAD, Second Clinic of Cardiology Varna, | |
| UMHAT Sveti Georgi EAD, Plovdiv, Clinic of Cardiology Plovdiv, | |
| UMHATEM N.I. Pirogov EAD Sofia, | |
| UNC Hospital HVC_Meadowmont Chapel Hill, North Carolina | |
| UT Health University of Texas Houston, Texas | |
| Unidad Medica de Alta Especialidad No. 71 IMSS Torreón, Coahuila | |
| Unidad Medica de Alta Especialidad No. 71 IMSS Torreón, Coahuila | |
| Uniklinik Klinikum Bielefeld - Kardiologie und Internist. Intensivmedizin Bielefeld, | |
| Uniklinik Regensburg - Innere Medizin II Regensburg, | |
| Uniklinik TU Dresden - Herzzentrum Dresden GmbH Dresden, | |
| Uniklinik Tübingen - Innere Med. III Kardiologie und Angiologie Tübingen, | |
| UniklinikHeidelberg - Innere Med. III - Kardiologie, Angiologie, Pneumologie Heidelberg, | |
| Union Hospital Tongji Medical College Huazhong University of Science and Technology-Cardiology Wuhan, Hubei | |
| Univ Gen Hospital Larisa, Cardiology Medicine Clinic Larissa, | |
| Univ of Alberta Hosp Edmonton Edmonton, Alberta | |
| Univ of Mississippi Med Center Jackson, Mississippi | |
| Universiti Teknologi MARA, Sungai Buloh Campus Sungai Buloh, Selangor | |
| University General Hospital of Ioannina,Internal Medicine Ioannina, | |
| University General Hospital of Ioannina,Internal Medicine Ioannina, | |
| University Hospitals of Cleveland Medical Center Elyria, Ohio | |
| University Malaya Medical Centre Kuala Lumpur, | |
| University Medical Center New Orleans New Orleans, Louisiana | |
| University Of Washington_Seattle Seattle, Washington | |
| University of CO - Division of Cardiology Aurora, Colorado | |
| University of Californ LA-UCLA Los Angeles, California | |
| University of California Irvine Irvine, California | |
| University of Cincinnati/UC Health Cincinnati, Ohio | |
| University of Florida Gainesville, Florida | |
| University of Kansas Hospital Fairway, Kansas | |
| University of Louisville Louisville, Kentucky | |
| University of Ottawa Heart Ins Ottawa, Ontario | |
| University of Rochester Rochester, New York | |
| University of Texas Medical Branch Galveston, Texas | |
| University of Texas Southwestern Medical Center Dallas, Texas | |
| University of Toledo Toledo, Ohio | |
| University of Virginia Charlottesville, Virginia | |
| Universitätsklinikum Düsseldorf - Klinik für Kardiologie, Pneumologie und Angiologie Düsseldorf, | |
| Universitätsklinikum Frankfurt aM - Kardiologie Frankfurt am Main, | |
| Universitätsklinikum Freiburg - Medical Center Freiburg im Breisgau, | |
| Universitätsklinikum Hamburg-Eppendorf - University Medical Center Hamburg-Eppendorf Hamburg, | |
| Universitätsklinikum Leipzig - Klinik und Poliklinik für Kardiologie Leipzig, | |
| Universitätsklinikum Mannheim - 1. Medizinische Klinik Mannheim, | |
| Uniwersytecki Szpital Kliniczny Nr 2 PUM W Szczecinie Szczecin, | |
| Uniwersytecki Szpital Kliniczny Nr 2 Uniwersytetu Medycznego w Lodzi Lodz, Łódź Voivodeship | |
| Uniwersytecki Szpital Kliniczny W Poznaniu Poznan, | |
| Uniwersytecki Szpital Kliniczny W Poznaniu Poznan, | |
| Uniwersytecki Szpital Kliniczny nr 2 Uniwersytetu Medycznego w Łodzi Lodz, | |
| Uniwersytecki Szpital Kliniczny w Bialymstoku Bialystok, Podlaskie Voivodeship | |
| Uniwersytecki Szpital Kliniczny w Opolu Opole, | |
| Uniwersytecki Szpital Kliniczny w Opolu Opole, | |
| Uniwersyteckie Centrum Kliniczne (UCK) Gdansk, | |
| Uniwersyteckie Centrum Kliniczne (UCK) Gdansk, | |
| Uniwersyteckie Centrum Kliniczne WUM Warsaw, | |
| Uniwersyteckie Centrum Kliniczne WUM Warsaw, | |
| VA Medical Center_Minneapolis Minneapolis, Minnesota | |
| VA Medical Center_Salem Salem, Virginia | |
| VAGrtrLosAngelesHlthcareSystem Los Angeles, California | |
| Valley Clinical Trials Northridge, California | |
| Valley Clinical Trials Northridge, California | |
| Valley Health Link Winchester, Virginia | |
| Vancouver General Hospital Vancouver, | |
| Vanderbilt University Medical Center Nashville, Tennessee | |
| Vanderbilt University Medical Center Nashville, Tennessee | |
| Vardhaman Mahavir Medical College & Safdarjung Hospital New Delhi, National Capital Territory of Delhi | |
| Vijan Hospital & Research Centre Nashik, Maharashtra | |
| Virginia Commonwealth University Health System Richmond, Virginia | |
| Virtua Health Camden, New Jersey | |
| WMU Homer Stryker MD School of Medicine Kalamazoo, Michigan | |
| Wake Forest Uni Hlth Sciences High Point, North Carolina | |
| Washington University School of Medicine_St. Louis St Louis, Missouri | |
| Wayne State University/University Health Center Detroit, Michigan | |
| West China Hospital Sichuan University-Cardiology Chengdu, Sichuan | |
| West China Hospital Sichuan University-Cardiology Chengdu, Sichuan | |
| Westchester Medical Center Valhalla, New York | |
| Westchester Medical Center Valhalla, New York | |
| William Harvey Hospital Ashford, Kent | |
| William Harvey Hospital Ashford, Kent | |
| William Osler Hel Bra Civic Hs Brampton, Ontario | |
| William Osler Hel Bra Civic Hs Brampton, Ontario | |
| Winter Haven Hospital Winter Haven, Florida | |
| Winter Haven Hospital Winter Haven, Florida | |
| Wojewodzki Szpital Im. Sw.Ojca Pio W Przemyslu Przemyśl, | |
| Wojewodzki Szpital Specjalistyczny W Bialej Podlaskiej Biała Podlaska, | |
| Wojewodzki Szpital Specjalistyczny We Wroclawiu Wroclaw, | |
| Wojewodzki Szpital Specjalistyczny We Wroclawiu Wroclaw, | |
| Wojewodzki Szpital Zespolony W Elblagu samodzielny publiczny zakład opieki zdrowotnej Elblag, | |
| Wojewodzki Szpital Zespolony W Elblagu samodzielny publiczny zakład opieki zdrowotnej Elblag, | |
| Wojewódzki Specjalistyczny Szpital im.Wl. Bieganskiego, Lodz, | |
| Wojewódzki Specjalistyczny Szpital im.Wl. Bieganskiego, Lodz, | |
| Wojewódzki Szpital Specjalistyczny im. NMP w Częstochowie Częstochowa, | |
| Wojewódzki Szpital Zespolony im. dr. Romana Ostrzyckiego w Koninie Konin, | |
| Wolfson MC - The Heart Institute Holon, | |
| Wonju Severance Christian Hospital Wŏnju, | |
| Wright State University Fairborn, Ohio | |
| Xiangya Hospital Central-South University Changsha, Hunan | |
| Xiangya Hospital Central-South University Changsha, Hunan | |
| Yale Ctr for Clin Invest New Haven, Connecticut | |
| Yokohama City University Hospital Yokohama, | |
| Yokohama City University Hospital Yokohama, | |
| Yokohama City University Medical Center_Cardiovascular Center Kanagawa, | |
| Yokohama City University Medical Center_Cardiovascular Center Kanagawa, | |
| Yokohama Municipal Citizen's Hospital_Cardiology Kanagawa, | |
| Zespol Zakladow Opieki Zdrowotnej w Ostrowie Wielkopolskim Ostrów Wielkopolski, Greater Poland Voivodeship | |
| Zespół Zakładów Opieki Zdrowotnej w Ostrowie Wielkopolskim Ostrów Wielkopolski, Greater Poland Voivodeship | |
| Zhejiang Hospital, Zhejiang University School of Medicine Hangzhou, | |
| Zhejiang Hospital-Cardiology Hangzhou, Zhejiang | |
| Zhongda Hospital Southeast University Nanjing, | |
| Zhongda Hospital, Southeast University Nanjing, | |
| Zhongshan Hospital, Fudan University-Cardiology Shanghai, Shanghai Municipality | |
| İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi Hastanesi- Prof. Dr. Murat Dilmener Yerleşkesi Istanbul, Bakirkoy | |
| İstanbul Üniversitesi-Cerrahpaşa Kardiyoloji Enstitüsü Istanbul, | |
| Śródmiejskie Centrum Kliniczne,II Oddział Kardiologii MSB, Klinika Chorób Serca CMKP Warsaw, |
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants (ESTHI)
Nichol Nunn - nichol.nunn@hsc.utah.edu
NCT04177914
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
• Corrected age \<104 weeks and 0 days, AND
• Child is ≥ 37 weeks post menstrual age, AND
• Child must have symptomatic hydrocephalus, defined as: Ventriculomegaly on MRI (frontal-occipital horn ratio (FOR) \>0.45, which approximates "moderate ventriculomegaly"), and at least one of the following: * Head circumference \>98th percentile for corrected age with either bulging fontanelle or splayed sutures * Upgaze paresis/palsy (sundowning) * CSF leak * Papilledema * Tense pseudomeningocele or tense fluid along a track * Vomiting or irritability, with no other attributable cause * Bradycardias or apneas, with no other attributable cause * Intracranial pressure (ICP) monitoring showing persistent elevation of pressure with or without plateau waves AND
• No prior history of shunt insertion or endoscopic third ventriculostomy (ETV) procedure (previous temporization devices and/or external ventricular drains permissible)
Exclusion Criteria:
• Hydrocephalus due to intraventricular hemorrhage in a child born before 37 weeks gestational age; OR
• Anatomy not suitable for ETV+CPC or anteriorly placed ventriculoperitoneal shunt defined as: * Moderate to severe prepontine adhesions on steady state free precession (SSFP) or T2 weighted fast (turbo) spin echo (FSE/TSE) MRI, which includes the following sequences: FIESTA, FIESTA-C, TrueFISP, CISS, Balanced FFE (bFFE), CUBE, SPACE, VISTA, IsoFSE, and 3D MVOX * Closure of one or both foramina of Monro * Thick floor of third ventricle (≥ 3mm) * Narrow third ventricle (\<5mm) * Presence of scalp, bone, or ventricular lesions that make placement of an anterior shunt impracticable; OR
• Underlying condition with a high chance of mortality within 12 months; OR
• Hydrocephalus with loculated CSF compartments; OR
• Peritoneal cavity not suitable for distal shunt placement; OR
• Active CSF infection; OR
• Hydranencephaly; OR
• Child requires an intraventricular procedure (e.g. endoscopic biopsy) in addition to the initial first-time permanent procedure for the treatment of hydrocephalus.
PROCEDURE: Endoscopic Third Ventriculostomy with Choroid Plexus Cauterization (ETV+CPC), DEVICE: Ventriculoperitoneal Shunt
Hydrocephalus
Hydrocephalus, Infants, Ventriculoperitoneal Shunt, ETV+CPC, endoscopic third ventriculostomy, choroid plexus cauterization
I'm interested
Share via email
Show 21 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Alberta Children's Hospital Calgary, Alberta | Ruksana Rashid, MBBS MPH MSc - (rsrashid@ucalgary.ca) |
| Arnold Palmer Hospital for Children Orlando, Florida | Richard Guerrero - (richard.guerrero@orlandohealth.com) |
| British Columbia Children's Hospital Vancouver, British Columbia | Annika Weirs - (annika.weir@cw.bc.ca) |
| Children's Hospital Colorado Aurora, Colorado | Susan Staulcup, 80045 - (SUSAN.STAULCUP@UCDENVER.EDU) |
| Children's Hospital of Los Angeles Glendale, California | Helen Berroya - (hberroya@chla.usc.edu) |
| Children's Hospital of Pittsburgh of UPMC Pittsburgh, Pennsylvania | Kimberly Diamond, BS, BA - (diamondkl@upmc.edu) |
| Children's Of Alabama Birmingham, Alabama | Anastasia Smith, MPH - (Anastasia.Smith@childrensal.org) |
| Johns Hopkins Children's Center Baltimore, Maryland | Sydney White - (swhit128@jh.edu) |
| Monroe Carell Jr. Children's Hospital at Vanderbilt Nashville, Tennessee | Julia Loes - (julia.loes@vumc.org) Stephen Gannon - (stephen.r.gannon@vumc.org) |
| Nationwide Children's Hospital Columbus, Ohio | Jared Haught - (Jared.Haught@nationwidechildrens.org) |
| Phoenix Children's Hospital Phoenix, Arizona | Bethany Norton - (bnorton1@phoenixchildrens.com) |
| Primary Children's Hospital Salt Lake City, Utah | Alli Ludwick - (allison.ludwick@hsc.utah.edu) |
| Seattle Children's Hospital Seattle, Washington | Jessica Becerra - (Jessica.Becerra@seattlechildrens.org) |
| St. Louis Children's Hospital St Louis, Missouri | Diego Morales, MS - (moralesd@wudosis.wustl.edu) Mary Goldschmidt - (goldschmidt@wustl.edu) |
| Texas Children's Hospital Houston, Texas | Edgardo Santisbon - (exsantis@texaschildrens.org) |
| The Hospital for Sick Children Toronto, Ontario | Homa Ashrafpour - (homa.ashrafpour@sickkids.ca) |
| The Pennsylvania State University University Park, Pennsylvania | |
| Trustees of Indiana University Indianapolis, Indiana | Mariah Shirrell - (mkillin@iu.edu) |
| Virginia Commonwealth University Richmond, Virginia | |
| Wolfson Children's Hospital Jacksonville, Florida | Asmaa Hatem - (Asmaa.Hatem@jax.ufl.edu) |
| Yale University New Haven, Connecticut |
ASSESS ALL ALS Study
ALL ALS Patient Navigator - info@all-als.org
NCT06578195
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria for ALS participants:
• Age 18 years or older
• Capable of providing informed consent
• Willing to follow study procedures
• Diagnosis of ALS by a physician
• Access to a smartphone, computer or tablet, and internet (need not be in the home - access to a public library or other available computer with internet connection is sufficient) Inclusion Criteria for control participants:
• Age 18 years or older
• Capable of providing informed consent
• Willing to follow study procedures
• No diagnosis of ALS , Progressive Muscular Atrophy (PMA) or Primary Lateral Sclerosis (PLS)
• No history of familial ALS/Frontotemporal Dementia (FTD) in a close family member\*\* unless the participant has previously tested negative for the known causative ALS genes. Participants with a family history of singleton ALS are permitted to enroll. * \*\* Defined by the presence of a known ALS causative gene such as C9orf72 in a family member or a family history suggestive of an inherited ALS/FTD syndrome defined by two family members with a history of ALS and/or FTD.
• Access to a smartphone, computer or tablet, and internet (need not be in the home - access to a public library or other available computer with internet connection is sufficient) Exclusion Criteria for all participants:
• Significant cognitive impairment, clinical dementia, or unstable psychiatric illness, including psychosis, active suicidal ideation, suicide attempt, or untreated major depression \<= 90 days of screening, that would interfere with the study procedure, according to Investigator's judgement.
• Clinically significant unstable medical condition (other than ALS) (e.g., cardiovascular instability, systemic infection, untreated thyroid dysfunction, malignant and potentially progressive cancer) that would render the participant unlikely to be able to complete 12 months of follow-up, according to Investigator's judgment. Exclusion Criteria for participants undergoing optional Lumbar Puncture
• Medically unable to undergo lumbar puncture (LP) as determined by the site investigator (i.e., bleeding disorder, a skin infection at or near the LP site, known or suspected intracranial or intraspinal tumor or other cause of increased intracranial pressure).
• Allergy to Lidocaine or other local anesthetic agents.
• Use of anticoagulant medication or antiplatelet medications (aside from aspirin 81 mg) that cannot be safely withheld prior to lumbar puncture.
• Blood dyscrasia, abnormal bleeding diathesis, or the use of dialysis for renal failure.
• Current pregnancy based on participant self-report
• Clinical judgement of the site investigator that the participant would be unable to undergo multiple lumbar punctures.
• Age 18 years or older
• Capable of providing informed consent
• Willing to follow study procedures
• Diagnosis of ALS by a physician
• Access to a smartphone, computer or tablet, and internet (need not be in the home - access to a public library or other available computer with internet connection is sufficient) Inclusion Criteria for control participants:
• Age 18 years or older
• Capable of providing informed consent
• Willing to follow study procedures
• No diagnosis of ALS , Progressive Muscular Atrophy (PMA) or Primary Lateral Sclerosis (PLS)
• No history of familial ALS/Frontotemporal Dementia (FTD) in a close family member\*\* unless the participant has previously tested negative for the known causative ALS genes. Participants with a family history of singleton ALS are permitted to enroll. * \*\* Defined by the presence of a known ALS causative gene such as C9orf72 in a family member or a family history suggestive of an inherited ALS/FTD syndrome defined by two family members with a history of ALS and/or FTD.
• Access to a smartphone, computer or tablet, and internet (need not be in the home - access to a public library or other available computer with internet connection is sufficient) Exclusion Criteria for all participants:
• Significant cognitive impairment, clinical dementia, or unstable psychiatric illness, including psychosis, active suicidal ideation, suicide attempt, or untreated major depression \<= 90 days of screening, that would interfere with the study procedure, according to Investigator's judgement.
• Clinically significant unstable medical condition (other than ALS) (e.g., cardiovascular instability, systemic infection, untreated thyroid dysfunction, malignant and potentially progressive cancer) that would render the participant unlikely to be able to complete 12 months of follow-up, according to Investigator's judgment. Exclusion Criteria for participants undergoing optional Lumbar Puncture
• Medically unable to undergo lumbar puncture (LP) as determined by the site investigator (i.e., bleeding disorder, a skin infection at or near the LP site, known or suspected intracranial or intraspinal tumor or other cause of increased intracranial pressure).
• Allergy to Lidocaine or other local anesthetic agents.
• Use of anticoagulant medication or antiplatelet medications (aside from aspirin 81 mg) that cannot be safely withheld prior to lumbar puncture.
• Blood dyscrasia, abnormal bleeding diathesis, or the use of dialysis for renal failure.
• Current pregnancy based on participant self-report
• Clinical judgement of the site investigator that the participant would be unable to undergo multiple lumbar punctures.
Amyotrophic Lateral Sclerosis
ALS, Amyotrophic Lateral Sclerosis, biomarker, observational
I'm interested
Share via email
Show 37 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Barrow Neurological Institute Phoenix, Arizona | Christopher Shiver - (fulton.research@dignityhealth.org) |
| CHALS-CCT, University of Puerto Rico, Medical Sciences Campus San Juan, Puerto Rico | Frances M Aponte - (frances.aponte2@upr.edu) |
| Columbia University New York, New York | Ben Hoover - (alsresearch@cumc.columbia.edu) |
| Dartmouth Hitchcock Medical Center Lebanon, New Hampshire | Gina Kersey - (DHALLALS@Hitchcock.org) |
| Duke University Durham, North Carolina | Duke Research Team - (alsresearch@dm.duke.edu) |
| Georgetown University Washington D.C., District of Columbia | Cassandra Holmes - (cassie.holmes@georgetown.edu) |
| Henry Ford Health Detroit, Michigan | Maria Stotland - (mstotla1@hfhs.org) |
| Hospital for Special Care New Britain, Connecticut | Sabine Lebel-Hardenac - (shardenack@hfsc.org) |
| Indiana University Indianapolis, Indiana | Lisa Grinstead - (lgrinste@iu.edu) Patti Hogan - (hoganpr@iu.edu) |
| John Hopkins University Baltimore, Maryland | Colleen Kane - (Ckane13@jh.edu) |
| Massachusetts General Brigham Boston, Massachusetts | Miranda Duncan - (mghassessallals@mgb.org) |
| Mayo Clinic Rochester, Minnesota | Jany Dagher - (dagher.jany@mayo.edu) Jeffery Gainer - (gainer.jeffery@mayo.edu) |
| Nih/Ninds Bethseda, Maryland | Katelyn Porter - (katelyn.porter@nih.gov) |
| Northwestern University Chicago, Illinois | Aeryn Hopwood - (aeryn.hopwood@northwestern.edu) |
| Nova Southeastern University Davie, Florida | Donovan Mott - (donovan.mott@nova.edu) |
| Ohio State University Columbus, Ohio | Alexander Michael - (alsresearch@osumc.edu) |
| Penn State Health Hershey, Pennsylvania | Michele Hare - (nervemuscle@pennstatehealth.psu.edu) |
| Providence ALS Center Portland, Oregon | Kimberly Perry - (kimberly.perry2@providence.org) |
| Saint Alphonsus Regional Medical Center Boise, Idaho | Helena Snider - (neuro.research@saintalphonsus.org) |
| Synapticure (Remote Participation Only) Chicago, Illinois | Lindsey Haddock - (lindsey@synapticure.com) |
| Temple University Philadelphia, Pennsylvania | John Furey - (tuf40109@temple.edu) |
| Texas Neurology Dallas, Texas | Haley Rucker - (hrucker@texasneurology.com) Reham Azab - (razab@texasneurology.com) |
| University of Alabama Birmingham Birmingham, Alabama | Melanie Benge - (melaniebenge@uabmc.edu) |
| University of California San Diego San Diego, California | Gil Gutierrez - (grg005@health.ucsd.edu) |
| University of California, Irvine Orange, California | Rosa Gonzalez - (rosaig1@hs.uci.edu) |
| University of California, Los Angeles Los Angeles, California | Elizabeth Cruz - (elizabethcruz@mednet.ucla.edu) |
| University of California, San Francisco San Francisco, California | Hannah George - (hannah.george@ucsf.edu) |
| University of Colorado Anschutz Medical Campus Aurora, Colorado | Alexis Shepardson - (neuroresearch@cuanschutz.edu) |
| University of Michigan Ann Arbor, Michigan | Caroline Piecuch - (carolinp@med.umich.edu) |
| University of Minnesota Minneapolis, Minnesota | Julia Munoz - (munoz156@umn.edu) |
| University of Nebraska Medical Center Omaha, Nebraska | Veronica Alonso - (valonso@unmc.edu) Nathan McKain - (nmckain@unmc.edu) |
| University of Pennsylvania Philadelphia, Pennsylvania | Matthew Burst - (matthew.burst@pennmedicine.upenn.edu) |
| University of Utah Salt Lake City, Utah | Scott Redlin - (scott.redlin@utah.edu) |
| University of Washington Seattle, Washington | Lila Brisk - (lbrisk@uw.edu) |
| Vanderbilt University Medical Center Nashville, Tennessee | Nicola Rutherford - (nicola.j.rutherford.1@vumc.org) |
| Virginia Commonwealth University Richmond, Virginia | Demetrius Carter - (demetrius.r.carter@vcuhealth.org) |
| Washington University St Louis, Missouri | Jesse Markway - (als@wustl.edu) |
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Mansoor Raza Mirza, MD - ACR-368-201ClinicalTrial@acrivon.com
NCT05548296
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
General
• Participant must be able to give signed, written informed consent.
• Participant must have histologically documented, high-grade endometrial cancer. Arms 1 and 2
• All high-grade epithelial endometrial histological subtypes are eligible including: endometrioid (all Grade 3), serous, carcinosarcomas, clear-cell carcinoma, and mixed histologies. Note: Subjects with p53 mutant Grade 2 endometrioid cancer are eligible Arms 3 and 4
• Serous carcinoma or mixed tumors with a majority component of serous carcinoma or carcinosarcoma where the carcinomatous component is serous carcinoma.
• Treatment History Requirements: Arms 1 and 2
• Subject must have received prior platinum-based chemotherapy
• Subject must have received prior anti-PD-(L)1 therapy
• Subject must not have received more than three lines of prior systemic therapy Arms 3 and 4
• Subject must have received prior platinum-based chemotherapy
• Subject must have received prior anti-PD-(L)1 therapy
• Subject must not have received more than two lines of prior systemic therapy
• Participant must have histologically confirmed metastatic cancer that has progressed during or after at least 1 prior therapeutic regimen.
• Participant must have at least 1 measurable lesion per RECIST v1.1 criteria (by local Investigator) in a baseline tumor imaging that has been obtained within 28 days of the treatment start. Participant must have radiographic evidence of disease progression based on RECIST v1.1 criteria following the most recent line of treatment.
• Arm 1 and 2 only: Participant must be willing to provide tissue from a newly obtained tumor biopsy from an accessible tumor lesion not previously irradiated after written informed consent. Newly obtained is defined as a specimen taken after written informed consent is obtained, during the 28-day Screening period. Note: Subjects at EU sites are not eligible for Arm 1 and Arm 2
• For all subjects participating in Arm 3 and 4, archival tumor tissue must be provided either during or after screening either as a tissue block or at least 20 unstained slides.
• Participant must have stabilized or recovered (Grade 1 or baseline) from all prior therapy related toxicities, except as follows:
• Alopecia is accepted.
• Endocrine events from prior immunotherapy stabilized at ≤ Grade 2 due to need for replacement therapy are accepted (including hypothyroidism, diabetes mellitus, or adrenal insufficiency).
• Neuropathy events from prior cytotoxic therapies stabilized at ≤ Grade 2 are accepted.
• Participant must have an Eastern Cooperative Oncology Group Performance Status 0 or 1.
• Participant must have an estimated life expectancy of longer than 3 months in the clinical judgment of the investigator.
• Participant must have adequate organ function at Screening, defined as:
• Absolute neutrophil count \> 1500 cells/µL without growth factor support within 2 weeks prior to obtaining the hematology values at Screening.
• Hemoglobin ≥ 9.0 g/dL.
• Platelets ≥ 150,000 cells/µL without transfusion within 1 week prior to obtaining the hematology values at Screening.
• Renal function is defined as Glomerular filtration rate (GFR) ≥ 50 mL/min/1.73m2. Note: GFR may be estimated using site standard methods (e.g., CKD-EPI, MDRD, or Cockcroft-Gault) or measured using 24-hour urine collection or Chrome-EDTA clearance, as per site standard practice.
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN); ≤ 5 × ULN if liver metastases are present.
• Total bilirubin ≤ 1.5 × ULN not associated with Gilbert's syndrome. If associated with Gilbert's syndrome ≤ 3 x ULN is acceptable.
• Serum albumin ≥ 3 g/dL.
• Participant must have adequate coagulation profile as defined below if not on anticoagulation. If subject is receiving anticoagulation therapy, then subject must be on a stable dose of anticoagulation for ≥ 1 month:
• Prothrombin time within 1.5 x ULN.
• Activated partial thromboplastin time within 1.5 x ULN.
Exclusion Criteria:
General
• Participant with known symptomatic brain metastases requiring \> 10 mg/day of prednisolone (or its equivalent). Participants with previously diagnosed brain metastases are eligible if they have completed their treatment, have recovered from the acute effects of radiation therapy or surgery prior to the start of ACR-368 treatment, fulfill the steroid requirement for these metastases, and are neurologically stable based on central nervous system imaging ≥ 4 weeks after treatment.
• Participant has mesenchymal tumors of the uterus.
• Participant has a history of clinically meaningful ascites, defined as history of paracentesis or thoracentesis with therapeutic intent, within 4 weeks of Screening. Subjects with planned therapeutic paracentesis or thoracentesis between Screening and Cycle 1 Day 1 dosing are excluded.
• Participant had systemic therapy or radiation therapy within 3 weeks prior to the first dose of study drug.
• Participants has known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection that is considered uncontrolled based on the criteria included in Appendix 2.
• Participant has a history of clinically meaningful coagulopathy, bleeding diathesis.
• Participant has cardiovascular disease, defined as:
• Uncontrolled hypertension defined as blood pressure \> 160/90 mmHg at Screening confirmed by repeat (medication permitted).
• History of torsades de pointes, significant Screening electrocardiogram (ECG) abnormalities, including ventricular rhythm disturbances, unstable cardiac arrhythmia requiring medication, pathologic symptomatic bradycardia, left bundle branch block, second degree atrioventricular (AV) block type II, third degree AV block, Grade ≥ 2 bradycardia, uncorrected hypokalemia not amenable to correction, congenital long QT syndrome, prolonged QT interval due to medications, corrected QT based on Fridericia's formula (QTcF) \> 450 msec (for men) or \> 470 msec (for women).
• Symptomatic heart failure (per New York Heart Association guidelines; (Caraballo, 2019), unstable angina, myocardial infarction, severe cardiovascular disease (ejection fraction \< 20%, transient ischemic attack, or cerebrovascular accident within 6 months of Day 1).
• Participant has a history of major surgery within 4 weeks of Screening.
• Participant has experienced bowel obstruction related to the current cancer within the last 4 weeks or signs or symptoms of intestinal obstruction, which include nausea, vomiting, or objective radiologic finding of bowel obstruction in the last 4 weeks before the start of the treatment.
• Participant has taken a prior cell cycle CHK1 inhibitor, including ACR-368
DRUG: ACR-368, DRUG: Gemcitabine, DIAGNOSTIC_TEST: OncoSignature
Endometrial Adenocarcinoma
Endometrial Cancer, Endometrial Neoplasm, Ultralow dose gemcitabine, ACR-368
I'm interested
Share via email
Show 90 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Alaska Women's Cancer Center Anchorage, Alaska | |
| American Oncology Partners of Maryland Pa Bethesda, Maryland | |
| Arizona Oncology Associate, PC- HOPE Tucson, Arizona | |
| Ascension St. Vicent Hospital, Inc. Indianapolis, Indiana | |
| CRO Aviano Aviano, | |
| Carle Cancer Center Urbana, Illinois | |
| Cedars Sinai Medical Center Los Angeles, California | |
| Centre Francois Baclesse Caen, | |
| Centre Leon Berard Lyon, | |
| City of Hope National Medical Center Duarte, California | |
| Cleveland Clinic Foundation Cleveland, Ohio | |
| Dana Farber Cancer Institute Boston, Massachusetts | |
| Emory University Atlanta, Georgia | |
| Firsthealth of The Carolinas Pinehurst, North Carolina | |
| Florida Gynecologic Oncology/Regional Cancer Center Fort Myers, Florida | |
| Fondazione Pascale Istituto Tumori Naples, | |
| Fox Chase Cancer Center Philadelphia, Pennsylvania | |
| Fred Hutchinson Cancer Center Seattle, Washington | |
| Froedtert and Medical College of Wisconsin Milwaukee, Wisconsin | |
| Fundación Instituto Valenciano de Oncologia (IVO) Valencia, | |
| Gabrail Cancer Center Canton, Ohio | |
| HCA Midwest Kansas City, Missouri | |
| Hoag Cancer Center Newport Beach, California | |
| Holy Cross Hospital Silver Spring, Maryland | |
| HonorHealth Phoenix, Arizona | |
| Hospital Clinic de Barcelona Barcelona, | |
| Hospital Universitario 12 de Octubre Madrid, | |
| Hospital Universitario La Paz Madrid, | |
| Hospital Universitario Puerta de Hierro Majadahonda, | |
| Hospital Universitario Ramon y Cajal Madrid, | |
| Humanitas University Pieve Emanuele, | |
| Huntsman Cancer Institute, University of Utah Salt Lake City, Utah | |
| Insitute de Cancérologie de l'Ouest Saint-Herblain, | |
| Institute Gustave Roussy Villejuif, | |
| Istituto Clinico Cannizzaro Catania Catania, | |
| Istituto Europeo Di Oncologia Milan, | |
| John Theurer Cancer Center at Hackensack University Medical Center Hackensack, New Jersey | |
| KEM | Evang. Kliniken Essen-Mitte Essen, | |
| Karmanos Cancer Institute Detroit, Michigan | |
| LSU Health Sciences New Orleans, Louisiana | |
| Laura & Isaac Perlmutter Cancer Center New York, New York | |
| Memorial Sloan-Kettering Cancer Center New York, New York | |
| Miami Valley Hospital South Centerville, Ohio | |
| Mount Sinai Comprehensive Cancer Center Miami Beach, Florida | |
| Mount Sinai Health System New York, New York | |
| National Institutes of Health, Clinical Center Bethesda, Maryland | |
| New York Presbyterian Hospital-Columbia University Medical Center New York, New York | |
| Northeast Georgia Medical Center Gainesville, Georgia | |
| Northwest Cancer Specialists, P.C. Vancouver, Washington | |
| Northwestern Medicine Chicago, Illinois | |
| Ohio State University Columbus, Ohio | |
| Oncology Associates of Oregon Eugene, Oregon | |
| Oregon Health & Sciences University Portland, Oregon | |
| Ospedale Mauriziano Torino Turin, | |
| Policlinico Gemelli Roma, | |
| Providence Sacred Heart Medical Center and Children's Hospital Spokane, Washington | |
| Rutgers Cancer Institute of Nj New Brunswick, New Jersey | |
| Sanford Health Sioux Falls, South Dakota | |
| Stanford Cancer Center Palo Alto, California | |
| Stephenson Cancer Center at OU Health Oklahoma City, Oklahoma | Ashley Willy - (phase1-referrals@ouhsc.edu) |
| Summit Cancer Center Spokane, Washington | |
| Swedish Cancer Center Seattle, Washington | |
| Texas Oncology Pearland, Texas | |
| Texas Oncology-Dallas Presbyterian Hospital Dallas, Texas | |
| Trials365, LLC Shreveport, Louisiana | |
| UC Irvine Health Orange, California | |
| UC San Diego Moores Cancer Center La Jolla, California | |
| USC/Norris Comprehensive Cancer Center Los Angeles, California | |
| University of Arkansas for Medical Sciences Little Rock, Arkansas | |
| University of California Los Angeles (UCLA) Santa Monica, California | |
| University of California, Davis Comprehensive Cancer Center Sacramento, California | |
| University of Chicago Medicine Chicago, Illinois | |
| University of Cincinnati Cancer Center Cincinnati, Ohio | |
| University of Colorado Aurora, Colorado | |
| University of Illinois Cancer Center Chicago, Illinois | |
| University of Iowa Iowa City, Iowa | |
| University of Massachusetts Chan Medical School Worcester, Massachusetts | |
| University of North Carolina at Chapel Hill Chapel Hill, North Carolina | |
| University of Rochester Medical Center Rochester, New York | |
| University of South Alabama Mitchell Cancer Institute Mobile, Alabama | |
| University of Texas Southwestern Medical Center Dallas, Texas | |
| University of Texas, MD Anderson Cancer Center Houston, Texas | |
| University of Virginia Health System Charlottesville, Virginia | |
| Universitätsklinikum Münster, Klinik für Frauenheilkunde und Geburtshilfe Münster, | |
| Universitätsklinikum Ulm, Frauenheilunde und Geburtshilfe Ulm, | |
| Vall d'Hebron Institute of Oncology (VHIO) Barcelona, | |
| Virginia Commonwealth University Richmond, Virginia | |
| West Penn Hospital Pittsburgh, Pennsylvania | |
| Women & Infants Hospital Providence, Rhode Island | - (oncologyresearch@wihri.org) |
| Yale Cancer Center New Haven, Connecticut |
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Boehringer Ingelheim - clintriage.rdg@boehringer-ingelheim.com
NCT05882058
Show full eligibility criteria
Hide eligibility criteria
Inclusion criteria:
• Male or female participants ≥18 years old and at least at the legal age of consent in countries where it is greater than 18 years at the time of signature of the informed consent form (ICF).
• Signed and dated written informed consent in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.
• Part 1: Histologically or cytologically confirmed, cancer of the following histologies: * Small cell lung cancer (SCLC) * Extra-pulmonary neuroendocrine carcinoma (epNEC) (except Merkel cell carcinoma (MCC), Medullary thyroid cancer (MTC) and Neuroendocrine prostate cancer (NEPC)) * Large cell neuroendocrine carcinoma (LCNEC) of the lung Patients with tumours with mixed histologies for any above type are eligible only if the neuroendocrine carcinoma/small tumour cells component is predominant and represents at least 50% of the overall tumour tissue. Patients must have progressed or recurred after standard of care therapy * SCLC: after at least two prior lines of therapy, including at least one platinum-based regimen; in countries where standard of care in first line therapy includes PD-L1 inhibitor treatment patients should have received the combination of platinum-based regimen plus PD-L1 inhibitor unless they have been unable to receive checkpoint inhibitor treatment. * Therapy includes PD-L1 inhibitor treatment; patients should have received the combination of platinum-based regimen plus PD-L1 inhibitor unless they have been unable to receive checkpoint inhibitor treatment. * epNEC/LCNEC: after at least one platinum-based regimen. Part 2 and part 3: Histologically or cytologically confirmed epNEC (except MCC, MTC and NEPC) with centrally assessed DLL3 high expression status. Patients must have progressed or recurred after at least one platinum-based regimen.
• Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.,
• Measurable lesions as defined per Response Evaluation Criteria In Solid Tumours (RECIST) v 1.1 within 21 days prior to the first dose of BI 764532.
• Part 1: Availability of archival tumour tissue sample Part 2 and part 3: Availability of archival formalin-fixed paraffin-embedded (FFPE) tumour tissue sample. Following specimens are not allowed: Fine Needle Aspiration (FNA), Cytology samples, decalcified bone samples.
• Adequate organ function as defined in the protocol.
• All toxicities related to previous anti-cancer therapies have resolved = Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 prior to trial treatment administration (except for alopecia, peripheral neuropathy, fatigue and endocrinopathies controlled by replacement therapy which must be = CTCAE Grade 2 and amenorrhea/menstrual disorders which can be any grade).
• Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use acceptable methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria and instructions on the duration of their use is provided in the participant information
• Only for Part 3, at the timepoint of Screening 02: * For Cycle 1, patients should be willing to stay within 1 hour driving distance for 48 hours after IMP administration and confirm availability of a caregiver for the same timeframe. * Patients should be considered suitable by the investigator to follow instructions applicable to the reduced monitoring cohort, such as taking their temperature and administration of oral medication at home if needed. Exclusion criteria:
• Untreated or symptomatic brain metastases. (Part 2 and part 3: identified during the mandatory assessment by brain MRI within 21 days before first trial drug administration.) Participants with treated, stable brain metastases are eligible provided they meet the following criteria: * Radiotherapy or surgery for brain metastases was completed at least 2 weeks prior to the first administration of BI 764532. * Patient is off steroids for at least 7 days (physiologic doses of steroids are permitted), and the patient is off anti-epileptic drugs for at least 7 days or on stable doses of anti-epileptic drugs for malignant central nervous system (CNS) disease.
• Presence of leptomeningeal disease or, part 2 and part 3: epidural disease including spinal cord compression.
• Part 1: Active/previous history of interstitial lung disease or non-infectious pneumonitis (any grade). Part 2 and part 3: Active/previous history of interstitial lung disease, pulmonary fibrosis, organizing pneumonia or non-infectious pneumonitis (any grade). Patients with a history of therapy-related pneumonitis that is considered clinically resolved are eligible.
• Participants who experienced severe, life-threatening immune-mediated adverse events or infusion-related reactions including those that lead to permanent discontinuation while on treatment with immuno-oncology agents.
• Prior anti-cancer therapy: * Patients who have been treated with any other anti-cancer drug within 4 weeks or within 5 half-life periods (whichever is shorter) prior to first administration of BI 764532. * Patients who have been treated with extensive field radiotherapy including whole brain irradiation within 2 weeks prior to first administration of BI 764532.
• Previous treatment with Delta-like ligand 3 (DLL3)-targeting T cell engagers or cell therapies.
• Diagnosis of immunodeficiency or systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of BI 764532. Physiological replacement of steroids is allowed.
• Unresolved toxicity from prior anti-tumour therapy, defined in the inclusion criteria. Further exclusion criteria apply.
• Male or female participants ≥18 years old and at least at the legal age of consent in countries where it is greater than 18 years at the time of signature of the informed consent form (ICF).
• Signed and dated written informed consent in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.
• Part 1: Histologically or cytologically confirmed, cancer of the following histologies: * Small cell lung cancer (SCLC) * Extra-pulmonary neuroendocrine carcinoma (epNEC) (except Merkel cell carcinoma (MCC), Medullary thyroid cancer (MTC) and Neuroendocrine prostate cancer (NEPC)) * Large cell neuroendocrine carcinoma (LCNEC) of the lung Patients with tumours with mixed histologies for any above type are eligible only if the neuroendocrine carcinoma/small tumour cells component is predominant and represents at least 50% of the overall tumour tissue. Patients must have progressed or recurred after standard of care therapy * SCLC: after at least two prior lines of therapy, including at least one platinum-based regimen; in countries where standard of care in first line therapy includes PD-L1 inhibitor treatment patients should have received the combination of platinum-based regimen plus PD-L1 inhibitor unless they have been unable to receive checkpoint inhibitor treatment. * Therapy includes PD-L1 inhibitor treatment; patients should have received the combination of platinum-based regimen plus PD-L1 inhibitor unless they have been unable to receive checkpoint inhibitor treatment. * epNEC/LCNEC: after at least one platinum-based regimen. Part 2 and part 3: Histologically or cytologically confirmed epNEC (except MCC, MTC and NEPC) with centrally assessed DLL3 high expression status. Patients must have progressed or recurred after at least one platinum-based regimen.
• Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.,
• Measurable lesions as defined per Response Evaluation Criteria In Solid Tumours (RECIST) v 1.1 within 21 days prior to the first dose of BI 764532.
• Part 1: Availability of archival tumour tissue sample Part 2 and part 3: Availability of archival formalin-fixed paraffin-embedded (FFPE) tumour tissue sample. Following specimens are not allowed: Fine Needle Aspiration (FNA), Cytology samples, decalcified bone samples.
• Adequate organ function as defined in the protocol.
• All toxicities related to previous anti-cancer therapies have resolved = Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 prior to trial treatment administration (except for alopecia, peripheral neuropathy, fatigue and endocrinopathies controlled by replacement therapy which must be = CTCAE Grade 2 and amenorrhea/menstrual disorders which can be any grade).
• Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use acceptable methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria and instructions on the duration of their use is provided in the participant information
• Only for Part 3, at the timepoint of Screening 02: * For Cycle 1, patients should be willing to stay within 1 hour driving distance for 48 hours after IMP administration and confirm availability of a caregiver for the same timeframe. * Patients should be considered suitable by the investigator to follow instructions applicable to the reduced monitoring cohort, such as taking their temperature and administration of oral medication at home if needed. Exclusion criteria:
• Untreated or symptomatic brain metastases. (Part 2 and part 3: identified during the mandatory assessment by brain MRI within 21 days before first trial drug administration.) Participants with treated, stable brain metastases are eligible provided they meet the following criteria: * Radiotherapy or surgery for brain metastases was completed at least 2 weeks prior to the first administration of BI 764532. * Patient is off steroids for at least 7 days (physiologic doses of steroids are permitted), and the patient is off anti-epileptic drugs for at least 7 days or on stable doses of anti-epileptic drugs for malignant central nervous system (CNS) disease.
• Presence of leptomeningeal disease or, part 2 and part 3: epidural disease including spinal cord compression.
• Part 1: Active/previous history of interstitial lung disease or non-infectious pneumonitis (any grade). Part 2 and part 3: Active/previous history of interstitial lung disease, pulmonary fibrosis, organizing pneumonia or non-infectious pneumonitis (any grade). Patients with a history of therapy-related pneumonitis that is considered clinically resolved are eligible.
• Participants who experienced severe, life-threatening immune-mediated adverse events or infusion-related reactions including those that lead to permanent discontinuation while on treatment with immuno-oncology agents.
• Prior anti-cancer therapy: * Patients who have been treated with any other anti-cancer drug within 4 weeks or within 5 half-life periods (whichever is shorter) prior to first administration of BI 764532. * Patients who have been treated with extensive field radiotherapy including whole brain irradiation within 2 weeks prior to first administration of BI 764532.
• Previous treatment with Delta-like ligand 3 (DLL3)-targeting T cell engagers or cell therapies.
• Diagnosis of immunodeficiency or systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of BI 764532. Physiological replacement of steroids is allowed.
• Unresolved toxicity from prior anti-tumour therapy, defined in the inclusion criteria. Further exclusion criteria apply.
DRUG: BI 764532, dose 1, DRUG: BI 764532, dose 2, DEVICE: Ventana DLL3 RxDx assay
Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
I'm interested
Share via email
Show 59 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| 960 Hospital of the Chinese People's Liberation Army Jinan, | Boehringer Ingelheim - (china@bitrialsupport.com) |
| Aichi Cancer Center Hospital Nagoya, | Boehringer Ingelheim - (nippon@bitrialsupport.com) |
| Asan Medical Center Seoul, | |
| Asklepios Fachkliniken München-Gauting Gauting, | |
| Chang Gung Memorial Hospital, Linkou Taoyuan, | |
| Dana-Farber Cancer Institute Boston, Massachusetts | |
| Evangelische Lungenklinik Berlin Berlin, | |
| Freeman Hospital High Heaton, | Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com) |
| H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| HOP Civil Strasbourg, | |
| HOP Intercommunal Créteil, | |
| Hopital Cochin Paris, | |
| Hospital CUF Descobertas-Lisboa-69316 Lisbon, | |
| Hospital Clinico Universitario de Valencia Valencia, | |
| Hospital Cuf porto Porto, | |
| Hospital Del Mar Barcelona, | |
| Hospital Universitari Vall d'Hebron Barcelona, | Boehringer Ingelheim - (espana@bitrialsupport.com) |
| Hospital Universitario 12 de Octubre Madrid, | Boehringer Ingelheim - (espana@bitrialsupport.com) |
| Hospital Universitario Virgen de la Victoria Málaga, | Boehringer Ingelheim - (espana@bitrialsupport.com) |
| Indiana University Indianapolis, Indiana | |
| Infirmary Cancer Care Mobile, Alabama | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Japanese Foundation for Cancer Research Kōtō City, | Boehringer Ingelheim - (nippon@bitrialsupport.com) |
| Kindai University Hospital Sakai, | Boehringer Ingelheim - (nippon@bitrialsupport.com) |
| Laura & Isaac Perlmutter Cancer Center at NYU Langone Health New York, New York | |
| Leicester Royal Infirmary Leicester, Leicestershire | Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com) |
| LungenClinic Grosshansdorf GmbH Großhansdorf, | |
| MHAT Heart and Brain Pleven, | |
| Mayo Clinic Cancer Center Jacksonville, Florida | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Mayo Clinic, Rochester Rochester, Minnesota | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Mayo Clinic-Arizona Phoenix, Arizona | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Montefiore Medical Center The Bronx, New York | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Multiprofile Hospital For Active Treatment-Uni Hospital Ltd. Panagyurishte, | |
| NCKUH Tainan, | |
| National Cancer Center Hospital Tokyo, | Boehringer Ingelheim - (nippon@bitrialsupport.com) |
| National Cancer Center Hospital East Kashiwa, | Boehringer Ingelheim - (nippon@bitrialsupport.com) |
| Osaka International Cancer Institute Osaka, | Boehringer Ingelheim - (nippon@bitrialsupport.com) |
| Qilu Hospital, Shangdong University Jinan, | Boehringer Ingelheim - (china@bitrialsupport.com) |
| Samsung Medical Center Seoul, | |
| Sendai Kousei Hospital Miyagi, | |
| Severance Hospital Seoul, | Boehringer Ingelheim - (namhan@bitrialsupport.com) |
| Shanghai Chest Hospital Shanghai, | Boehringer Ingelheim - (china@bitrialsupport.com) |
| Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine Hangzhou, | Boehringer Ingelheim - (china@bitrialsupport.com) |
| Taipei Veterans General Hospital Taipei, | |
| The Christie Hospital Manchester, | Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com) |
| The Second Affiliated Hospital to Nanchang University Nanchang, | Boehringer Ingelheim - (china@bitrialsupport.com) |
| UZ Leuven Leuven, | Boehringer Ingelheim - (belgique@bitrialsupport.com) |
| Universitair Ziekenhuis Gent Ghent, | Boehringer Ingelheim - (belgique@bitrialsupport.com) |
| University College Hospital London, | Boehringer Ingelheim - (unitedkingdom@bitrialsupport.com) |
| University of California San Francisco San Francisco, California | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| University of Kansas Cancer Center Kansas City, Kansas | |
| University of Kentucky Medical Center Lexington, Kentucky | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| University of Maryland School of Medicine Baltimore, Maryland | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| University of Miami Miami, Florida | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Universitätsklinikum Carl Gustav Carus Dresden Dresden, | Boehringer Ingelheim - (deutschland@bitrialsupport.com) |
| Universitätsklinikum Erlangen Erlangen, | Boehringer Ingelheim - (deutschland@bitrialsupport.com) |
| Universitätsmedizin der Johannes Gutenberg-Universität Mainz Mainz, | Boehringer Ingelheim - (deutschland@bitrialsupport.com) |
| Valkyrie Clinical Trials Los Angeles, California | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| Virginia Commonwealth University Health- Adult Outpatient Pavilion Richmond, Virginia | Boehringer Ingelheim - (unitedstates@bitrialsupport.com) |
| West China Hospital, Sichuan University Chengdu, | Boehringer Ingelheim - (china@bitrialsupport.com) |
ALS/MND Natural History Study Data Repository
Natalia Tarasenko - ntarasenko@mgh.harvard.edu
NCT05966038
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* A clinical diagnosis of El Escorial of suspected, possible, probable, or definite ALS or
* Other motor neuron disorders, including but not limited to Spinal-Bulbar Muscular Atrophy (SBMA, Kennedy's disease), Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA), and Progressive Bulbar Palsy (PBP)
Exclusion Criteria:
* Disease does not meet criteria for any motor neuron disorder ALS, PLS, MND (Motor Neurone DIsease), Kennedy Disease, PMA - Progressive Muscular Atrophy, PBP - Progressive Bulbar Palsy
I'm interested
Share via email
Show 18 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Centro Clinico NEMO Milano Milan, | Monica Montuori - (monica.montuori@centrocliniconemo.it) |
| Hadassah Medical Organization Jerusalem, | Michal Zabari - (michalza@hadassah.org.il) |
| Henry Ford Health System Novi, Michigan | Anne Vallis - (avallis1@hfhs.org) |
| Istituti Clinici Scientifici Maugeri SpA Milan, | Camilla Garrè - (camilla.garre@icsmaugeri.it) |
| Kaiser Permanente Fresno, California | Chris Greer - (chris.x.lindgren@kp.org) |
| Lahey Clinic Burlington, Massachusetts | Sorieba Fofanah - (Sorieba.Fofanah@lahey.org) Melo Catia - (catia.s.melo@lahey.org) |
| Loma Linda University Health Loma Linda, California | |
| Northwestern University Chicago, Illinois | Emma Schmidt - (emma.schmidt@northwestern.edu) |
| Providence ALS Clinic Portland, Oregon | Tyler Regan - (tyler.regan@providence.org) |
| Saint Louis University St Louis, Missouri | Katie Forsman - (katie.forsman@health.slu.edu) |
| Tel Aviv Medical Center Tel Aviv, | Beatrice Abramovich - (beatricen@tlvmc.gov.il) |
| Temple University Lewis Katz School of Medicine Philadelphia, Pennsylvania | John Furey - (john.furey0001@temple.edu) |
| Thomas Jefferson University Philadelphia, Pennsylvania | Gemma Krautzel - (Gemma.Krautzel@jefferson.edu) |
| Trinity Health Michigan Grand Rapids, Michigan | Nicolina Evola - (nicolina.evola@trinity-health.org) Katherine Schwass - (Katherine.Schwass@trinity-health.org) |
| University of Florida Gainesville, Florida | Jennifer Steshyn - (Jennifer.Steshyn@neurology.ufl.edu) |
| University of Minnesota Minneapolis, Minnesota | Valerie Ferment - (ferm0016@umn.edu) |
| University of Pittsburgh Pittsburgh, Pennsylvania | Helen Ismail - (ismailhh@upmc.edu) |
| Virginia Commonwealth University Richmond, Virginia | Demetrius Carter - (Demetrius.R.Carter@vcuhealth.org) |
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
ctrrecruit@vcu.edu
NCT06500455
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Pathologically (histologically or cytologically) proven diagnosis of one of the following solid tumor malignancies within 5 years prior to registration:
* Non-small cell lung cancer
* Melanoma
* Breast cancer
* Renal cell carcinoma
* Gastrointestinal cancer
* If the original histologic proof of malignancy is greater than 5 years, then more recent pathologic confirmation (e.g., from a systemic site or brain metastasis) or unequivocal imaging confirmation of extracranial metastatic disease (e.g. CT of the chest/abdomen/pelvis, positron emission tomography \[PET\]/CT, etc.) is required
* Patients must have at least 1 and up to 8 total intact brain metastases detected on a contrast-enhanced MRI performed ≤ 21 days prior to registration
* At least 1 of the up to 8 lesions must be a study eligible lesion, defined as lesion with a maximum diameter as measured on any orthogonal plane (axial, sagittal, coronal) of ≥ 1.0 cm and ≤ 3.0 cm
* All brain metastases must be located outside of the brainstem and ≥ 5 mm from the optic nerves or optic chiasm and ≤ 3.0 cm in maximum dimension
* Note: brainstem metastases per the MRI within 21 days of registration are an exclusion criterion; however, if the MRI used for treatment planning performed within 7 days of SRS/FSRS reveals a brainstem metastasis, the patient remains eligible if the patient is considered an appropriate radiosurgery candidate per the local investigator
* Patients must have a diagnosis-specific graded prognostic assessment ≥ 1.5
* No more than 2 lesions planned for resection if clinically indicated
* No known leptomeningeal disease (LMD)
* Note: For the purposes of exclusion, LMD is a clinical diagnosis, defined as positive cerebrospinal fluid (CSF) cytology and/or unequivocal radiologic or clinical evidence of leptomeningeal involvement. Patients with leptomeningeal symptoms in the setting of leptomeningeal enhancement by imaging (MRI) would be considered to have LMD even in the absence of positive CSF cytology. In contrast, an asymptomatic or minimally symptomatic patient with mild or nonspecific leptomeningeal enhancement (MRI) would not be considered to have LMD. In that patient, CSF sampling is not required to formally exclude LMD, but can be performed at the investigator's discretion based on level of clinical suspicion
* Age ≥ 18 years
* Karnofsky performance status (KPS) ≥ 60
* Negative urine or serum pregnancy test (in persons of childbearing potential) within 14 days prior to registration. Childbearing potential is defined as any person who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal
* No prior radiotherapy to the brain (partial or whole brain irradiation, SRS, FSRS, or prophylactic cranial irradiation \[PCI\])
* New York Heart Association Functional Classification II or better (NYHA Functional Classification III/IV are not eligible) (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification)
* No active infection currently requiring intravenous (IV) antibiotic management
* No hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
* No chronic obstructive pulmonary disease exacerbation or other acute respiratory illness precluding study therapy PROCEDURE: Computed Tomography, RADIATION: Fractionated Stereotactic Radiation Therapy, PROCEDURE: Magnetic Resonance Imaging, RADIATION: Stereotactic Radiosurgery
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
I'm interested
Share via email
Show 270 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Aspirus Cancer Care - James Beck Cancer Center Rhinelander, Wisconsin | Site Public Contact - (Beth.Knetter@aspirus.org) |
| Aspirus Cancer Care - Stevens Point Stevens Point, Wisconsin | Site Public Contact - (Beth.Knetter@aspirus.org) |
| Aspirus Cancer Care - Wisconsin Rapids Wisconsin Rapids, Wisconsin | |
| Aspirus Regional Cancer Center Wausau, Wisconsin | |
| Banner University Medical Center - Tucson Tucson, Arizona | Site Public Contact - (UACC-IIT@uacc.arizona.edu) |
| Baptist Health Hardin Elizabethtown, Kentucky | |
| Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Houston, Texas | Site Public Contact - (burton@bcm.edu) |
| Beacon Hospital Dublin, Co Dublin | |
| Boca Raton Regional Hospital Boca Raton, Florida | |
| CHUM - Centre Hospitalier de l'Universite de Montreal Montreal, Quebec | Site Public Contact - (info.cr.chum@ssss.gouv.qc.ca) |
| Cancer Care Center of O'Fallon O'Fallon, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Cancer Care Specialists of Illinois - Decatur Decatur, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Cancer Care and Hematology-Fort Collins Fort Collins, Colorado | Site Public Contact - (Roster@nrgoncology.org) |
| Carle Cancer Center Urbana, Illinois | Site Public Contact - (Research@carle.com) |
| Carle Physician Group-Effingham Effingham, Illinois | Site Public Contact - (Research@carle.com) |
| Carle Physician Group-Mattoon/Charleston Mattoon, Illinois | Site Public Contact - (Research@carle.com) |
| Carle at The Riverfront Danville, Illinois | Site Public Contact - (Research@Carle.com) |
| Case Western Reserve University Cleveland, Ohio | Site Public Contact - (CTUReferral@UHhospitals.org) |
| Castle Medical Center Kailua, Hawaii | |
| Cedars-Sinai Medical Center Los Angeles, California | Site Public Contact - (Cancer.trial.info@cshs.org) |
| Central Maryland Radiation Oncology in Howard County Columbia, Maryland | |
| Centralia Oncology Clinic Centralia, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Chambersburg Hospital Chambersburg, Pennsylvania | Site Public Contact - (Roster@nrgoncology.org) |
| City of Hope Antelope Valley Lancaster, California | Site Public Contact - (becomingapatient@coh.org) |
| City of Hope Comprehensive Cancer Center Duarte, California | Site Public Contact - (becomingapatient@coh.org) |
| City of Hope Corona Corona, California | Site Public Contact - (becomingapatient@coh.org) |
| City of Hope South Bay Torrance, California | |
| City of Hope South Pasadena South Pasadena, California | Site Public Contact - (becomingapatient@coh.org) |
| City of Hope Upland Upland, California | Site Public Contact - (becomingapatient@coh.org) |
| City of Hope at Irvine Lennar Irvine, California | |
| Clackamas Radiation Oncology Center Clackamas, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| Coborn Cancer Center at Saint Cloud Hospital Saint Cloud, Minnesota | Site Public Contact - (coborncancercenter@centracare.com) |
| Community Medical Center Toms River, New Jersey | Site Public Contact - (Lennette.Gonzales@rwjbh.org) |
| Cork Radiation Oncology Associates Limited Cork, | |
| Cork University Hospital Cork, | |
| Crossroads Cancer Center Effingham, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Decatur Memorial Hospital Decatur, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Delaware Health Center-Grady Cancer Center Delaware, Ohio | Site Public Contact - (Jennifer.Sexton@ohiohealth.com) |
| Edward Hospital/Cancer Center Naperville, Illinois | |
| Elmhurst Memorial Hospital Elmhurst, Illinois | Site Public Contact - (Jrohde@emhc.org) |
| Emory Saint Joseph's Hospital Atlanta, Georgia | |
| Emory University Hospital Midtown Atlanta, Georgia | |
| Emory University Hospital/Winship Cancer Institute Atlanta, Georgia | |
| Fairview Clinics and Surgery Center Maple Grove Maple Grove, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Goshen Center for Cancer Care Goshen, Indiana | Site Public Contact - (cccois@goshenhealth.com) |
| Grady Memorial Hospital Delaware, Ohio | Site Public Contact - (Jennifer.Sexton@ohiohealth.com) |
| Grant Medical Center Columbus, Ohio | Site Public Contact - (Jennifer.Sexton@ohiohealth.com) |
| Gundersen Lutheran Medical Center La Crosse, Wisconsin | Site Public Contact - (cancerctr@gundersenhealth.org) |
| HSHS Saint Elizabeth's Hospital O'Fallon, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Hartford Hospital Hartford, Connecticut | |
| Hawaii Cancer Care - Westridge ‘Aiea, Hawaii | Site Public Contact - (info@hawaiicancercare.com) |
| Hawaii Cancer Care Inc - Waterfront Plaza Honolulu, Hawaii | Site Public Contact - (i.webster@hawaiicancercare.com) |
| Hennepin County Medical Center Minneapolis, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Henry Ford Cancer Institute-Downriver Brownstown, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Henry Ford Health Providence Novi Hospital Novi, Michigan | Site Public Contact - (kfife3@hfhs.org) |
| Henry Ford Hospital Detroit, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Henry Ford Macomb Hospital-Clinton Township Clinton Township, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Henry Ford West Bloomfield Hospital West Bloomfield, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Huntsman Cancer Institute/University of Utah Salt Lake City, Utah | |
| Indu and Raj Soin Medical Center Beavercreek, Ohio | Site Public Contact - (clinical.trials@daytonncorp.org) |
| Jefferson Cherry Hill Hospital Cherry Hill, New Jersey | Site Public Contact - (ONCTrialNow@jefferson.edu) |
| Jefferson Torresdale Hospital Philadelphia, Pennsylvania | Site Public Contact - (ONCTrialNow@jefferson.edu) |
| Jersey Shore Medical Center Neptune City, New Jersey | |
| John Muir Medical Center-Walnut Creek Walnut Creek, California | |
| Kaiser Permanente Los Angeles Medical Center Los Angeles, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente-Anaheim Anaheim, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente-Bellflower Bellflower, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente-Ontario Ontario, California | Site Public Contact - (clinical.trials@kp.org) |
| Kapiolani Medical Center for Women and Children Honolulu, Hawaii | |
| Kettering Medical Center Kettering, Ohio | Site Public Contact - (clinical.trials@daytonncorp.org) |
| Langlade Hospital and Cancer Center Antigo, Wisconsin | Site Public Contact - (Juli.Alford@aspirus.org) |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, New York | Site Public Contact - (CancerTrials@nyulangone.org) |
| Legacy Cancer Institute Medical Oncology and Day Treatment Vancouver, Washington | Site Public Contact - (oncologyresearch@lhs.org) |
| Legacy Good Samaritan Hospital and Medical Center Portland, Oregon | Site Public Contact - (cancer@lhs.org) |
| Legacy Meridian Park Hospital Tualatin, Oregon | |
| Legacy Mount Hood Medical Center Gresham, Oregon | |
| Legacy Salmon Creek Hospital Vancouver, Washington | |
| Lenox Hill Hospital New York, New York | |
| Loyola University Medical Center Maywood, Illinois | |
| MD Anderson West Houston Houston, Texas | Site Public Contact - (askmdanderson@mdanderson.org) |
| MD Anderson in Sugar Land Sugar Land, Texas | Site Public Contact - (askmdanderson@mdanderson.org) |
| MD Anderson in The Woodlands Conroe, Texas | Site Public Contact - (askmdanderson@mdanderson.org) |
| MU Health - University Hospital/Ellis Fischel Cancer Center Columbia, Missouri | |
| MaineHealth Cancer Care Center of York County Sanford, Maine | |
| MaineHealth Maine Medical Center - Portland Portland, Maine | Site Public Contact - (clinicalresearch@mainehealth.org) |
| MaineHealth Maine Medical Center- Scarborough Scarborough, Maine | Site Public Contact - (clinicalresearch@mainehealth.org) |
| Manhattan Eye Ear and Throat Hospital New York, New York | |
| Mary Greeley Medical Center Ames, Iowa | |
| Maryland Proton Treatment Center Baltimore, Maryland | Site Public Contact - (info@mdproton.com) |
| McFarland Clinic - Ames Ames, Iowa | Site Public Contact - (ksoder@mcfarlandclinic.com) |
| Medical Center of the Rockies Loveland, Colorado | |
| Medical College of Wisconsin Milwaukee, Wisconsin | |
| Memorial Hermann Texas Medical Center Houston, Texas | |
| Memorial Hospital East Shiloh, Illinois | Site Public Contact - (dschwab@wustl.edu) |
| Memorial Hospital North Colorado Springs, Colorado | |
| Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey | |
| Memorial Sloan Kettering Bergen Montvale, New Jersey | |
| Memorial Sloan Kettering Cancer Center New York, New York | |
| Memorial Sloan Kettering Commack Commack, New York | |
| Memorial Sloan Kettering Monmouth Middletown, New Jersey | |
| Memorial Sloan Kettering Nassau Uniondale, New York | |
| Memorial Sloan Kettering Westchester Harrison, New York | |
| Mercy Hospital Fort Smith Fort Smith, Arkansas | |
| Mercy Hospital Springfield Springfield, Missouri | |
| Miami Cancer Institute Miami, Florida | |
| Minnesota Oncology Hematology PA-Chaska Chaska, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Moffitt Cancer Center Tampa, Florida | Site Public Contact - (ClinicalTrials@moffitt.org) |
| Moffitt Cancer Center - McKinley Campus Tampa, Florida | Site Public Contact - (ClinicalTrials@moffitt.org) |
| Moffitt Cancer Center at Wesley Chapel Wesley Chapel, Florida | Site Public Contact - (ClinicalTrials@moffitt.org) |
| Moffitt Cancer Center-International Plaza Tampa, Florida | Site Public Contact - (ClinicalTrials@moffitt.org) |
| Montefiore Medical Center - Moses Campus The Bronx, New York | Site Public Contact - (eskwak@montefiore.org) |
| Montefiore Medical Center-Einstein Campus The Bronx, New York | Site Public Contact - (eskwak@montefiore.org) |
| Montefiore Medical Center-Weiler Hospital The Bronx, New York | Site Public Contact - (eskwak@montefiore.org) |
| Monticello Cancer Center Monticello, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Mount Sinai Chelsea New York, New York | Site Public Contact - (CCTO@mssm.edu) |
| Mount Sinai Hospital New York, New York | Site Public Contact - (CCTO@mssm.edu) |
| Mount Sinai South Nassau Oceanside, New York | Site Public Contact - (crsu@mssm.edu) |
| Mount Sinai West New York, New York | Site Public Contact - (CCTO@mssm.edu) |
| MyMichigan Medical Center Saginaw Saginaw, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| MyMichigan Medical Center Tawas Tawas City, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| NRG Oncology Philadelphia, Pennsylvania | Rupesh R. Kotecha - (rupeshk@baptisthealth.net) |
| NYP/Weill Cornell Medical Center New York, New York | |
| NYU Langone Hospital - Brooklyn Brooklyn, New York | Site Public Contact - (david.wallach@nyulangone.org) |
| NYU Langone Hospital - Long Island Mineola, New York | Site Public Contact - (cancertrials@nyulangone.org) |
| Nebraska Medicine-Bellevue Bellevue, Nebraska | Site Public Contact - (unmcrsa@unmc.edu) |
| Nebraska Medicine-Village Pointe Omaha, Nebraska | |
| New York-Presbyterian/Brooklyn Methodist Hospital Brooklyn, New York | Site Public Contact - (Adg9003@nyp.org) |
| Newark Beth Israel Medical Center Newark, New Jersey | Site Public Contact - (Christine.Kosmides@rwjbh.org) |
| Northeast Radiation Oncology Center Dunmore, Pennsylvania | |
| Northwell Health/Center for Advanced Medicine Lake Success, New York | |
| Northwest Cancer Center - Crown Point Crown Point, Indiana | Site Public Contact - (CancerResearch@powershealth.org) |
| Northwest Cancer Center - Hobart Hobart, Indiana | |
| Northwest Cancer Center - Valparaiso Valparaiso, Indiana | Site Public Contact - (CancerResearch@COMHS.org) |
| Northwest Oncology LLC Dyer, Indiana | |
| Northwestern Medicine Cancer Center Warrenville Warrenville, Illinois | Site Public Contact - (Donald.Smith3@nm.org) |
| Northwestern Medicine Orland Park Orland Park, Illinois | Site Public Contact - (nctnprogram_rhlccc@northwestern.edu) |
| Northwestern University Chicago, Illinois | Site Public Contact - (cancer@northwestern.edu) |
| Norton Brownsboro Hospital and Medical Campus Louisville, Kentucky | Site Public Contact - (Roster@nrgoncology.org) |
| Ohio State University Comprehensive Cancer Center Columbus, Ohio | Site Public Contact - (Jamesline@osumc.edu) |
| Owensboro Health Mitchell Memorial Cancer Center Owensboro, Kentucky | Site Public Contact - (vanissa.sorrels@owensborohealth.org) |
| Pamela Youde Nethersole Eastern Hospital Hong Kong, | |
| Parkland Health Center - Farmington Farmington, Missouri | |
| Penn State Milton S Hershey Medical Center Hershey, Pennsylvania | Site Public Contact - (CTO@hmc.psu.edu) |
| Piedmont Hospital Atlanta, Georgia | Site Public Contact - (ORS@piedmont.org) |
| Poudre Valley Hospital Fort Collins, Colorado | |
| Providence Medical Foundation - Santa Rosa Santa Rosa, California | |
| Providence Portland Medical Center Portland, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| Providence Queen of The Valley Napa, California | |
| Providence Saint Vincent Medical Center Portland, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| Queen's Cancer Cenrer - POB I Honolulu, Hawaii | |
| Queen's Cancer Center - Kuakini Honolulu, Hawaii | |
| Queen's Medical Center Honolulu, Hawaii | |
| Reading Hospital West Reading, Pennsylvania | |
| Renown Regional Medical Center Reno, Nevada | Site Public Contact - (research@sncrf.org) |
| Ridgeview Medical Center Waconia, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Riverside Methodist Hospital Columbus, Ohio | Site Public Contact - (Jennifer.Sexton@ohiohealth.com) |
| Robert Wood Johnson University Hospital Somerset Somerville, New Jersey | Site Public Contact - (Siby.Varughese@rwjbh.org) |
| Rush MD Anderson Cancer Center Chicago, Illinois | Site Public Contact - (Cancer_Studies@rush.edu) |
| Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey | |
| Rutgers New Jersey Medical School Newark, New Jersey | |
| SUNY Upstate Medical Center-Community Campus Syracuse, New York | |
| Saint Barnabas Medical Center Livingston, New Jersey | Site Public Contact - (joanne.loeb@rwjbh.org) |
| Saint Elizabeth Youngstown Hospital Youngstown, Ohio | Site Public Contact - (clinical.trials@daytonncorp.org) |
| Saint Francis Cancer Center Greenville, South Carolina | Site Public Contact - (Heather_Rich@bshsi.org) |
| Saint Francis Hospital Federal Way, Washington | Site Public Contact - (Heather_Rich@bshsi.org) |
| Saint Luke's Cancer Center - Allentown Allentown, Pennsylvania | |
| Saint Luke's Hospital - Monroe Campus Stroudsburg, Pennsylvania | Site Public Contact - (Roster@nrgoncology.org) |
| Saint Luke's Hospital - Upper Bucks Campus Quakertown, Pennsylvania | |
| Saint Luke's Hospital-Anderson Campus Easton, Pennsylvania | Site Public Contact - (Roster@nrgoncology.org) |
| Saint Luke's University Hospital-Bethlehem Campus Bethlehem, Pennsylvania | |
| Saint Lukes Hospital Dublin, Co Dublin | |
| Saint Mary Medical Center Hobart, Indiana | Site Public Contact - (CancerResearch@COMHS.org) |
| Sanford Broadway Medical Center Fargo, North Dakota | Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org) |
| Sanford Cancer Center Oncology Clinic Sioux Falls, South Dakota | Site Public Contact - (OncologyClinicTrialsSF@sanfordhealth.org) |
| Sanford Roger Maris Cancer Center Fargo, North Dakota | Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org) |
| Sanford USD Medical Center - Sioux Falls Sioux Falls, South Dakota | Site Public Contact - (OncologyClinicalTrialsSF@SanfordHealth.org) |
| Sidney Kimmel Cancer Center Washington Township Sewell, New Jersey | Site Public Contact - (ONCTrialNow@jefferson.edu) |
| Sinai Hospital of Baltimore Baltimore, Maryland | |
| Siteman Cancer Center at Christian Hospital St Louis, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| Siteman Cancer Center at Saint Peters Hospital City of Saint Peters, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| Siteman Cancer Center at West County Hospital Creve Coeur, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| Siteman Cancer Center-South County St Louis, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| Southern Illinois University School of Medicine Springfield, Illinois | |
| Springfield Clinic Springfield, Illinois | |
| Springfield Memorial Hospital Springfield, Illinois | Site Public Contact - (pallante.beth@mhsil.com) |
| Stanford Cancer Institute Palo Alto Palo Alto, California | Site Public Contact - (ccto-office@stanford.edu) |
| State University of New York Upstate Medical University Syracuse, New York | |
| Stony Brook University Medical Center Stony Brook, New York | |
| The Community Hospital Munster, Indiana | |
| The Hospital of Central Connecticut New Britain, Connecticut | |
| The James Graham Brown Cancer Center at University of Louisville Louisville, Kentucky | |
| The New York Hospital Medical Center of Queens Flushing, New York | Site Public Contact - (Roster@nrgoncology.org) |
| The Queen's Medical Center - West Oahu ‘Ewa Beach, Hawaii | Site Public Contact - (rohta@queens.org) |
| The Research Institute of the McGill University Health Centre (MUHC) Montreal, Quebec | Site Public Contact - (evelyn.ortega@muhc.mcgill.ca) |
| The University of Kansas Cancer Center - Olathe Olathe, Kansas | Site Public Contact - (OlatheCCResearch@kumc.edu) |
| The Valley Hospital - Luckow Pavilion Paramus, New Jersey | Site Public Contact - (clinicaltrialsresearch@valleyhealth.com) |
| ThedaCare Regional Cancer Center Appleton, Wisconsin | Site Public Contact - (ResearchDept@thedacare.org) |
| Thomas Jefferson University Hospital Philadelphia, Pennsylvania | Site Public Contact - (ONCTrialNow@jefferson.edu) |
| Trinity Health IHA Medical Group Hematology Oncology - Brighton Brighton, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus Ypsilanti, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| Trinity Health Saint Joseph Mercy Hospital Ann Arbor Ann Arbor, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| Trinity Health Saint Mary Mercy Livonia Hospital Livonia, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| UC Comprehensive Cancer Center at Silver Cross New Lenox, Illinois | Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu) |
| UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California | Site Public Contact - (ucstudy@uci.edu) |
| UC San Diego Health System - Encinitas Encinitas, California | |
| UC San Diego Medical Center - Hillcrest San Diego, California | Site Public Contact - (rhabbaba@health.ucsd.edu) |
| UC San Diego Moores Cancer Center La Jolla, California | Site Public Contact - (cancercto@ucsd.edu) |
| UCHealth Greeley Hospital Greeley, Colorado | Site Public Contact - (Roster@nrgoncology.org) |
| UCHealth Memorial Hospital Central Colorado Springs, Colorado | |
| UCHealth University of Colorado Hospital Aurora, Colorado | |
| UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California | Site Public Contact - (ucstudy@uci.edu) |
| UChicago Medicine Northwest Indiana Crown Point, Indiana | Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu) |
| UH Seidman Cancer Center at Lake Health Mentor Campus Mentor, Ohio | Site Public Contact - (CTUReferral@UHhospitals.org) |
| UH Seidman Cancer Center at UH Avon Health Center Avon, Ohio | |
| UM Baltimore Washington Medical Center/Tate Cancer Center Glen Burnie, Maryland | |
| UM Capital Region Medical Center Largo, Maryland | Site Public Contact - (Sarah.Larson@umm.edu) |
| UM Sylvester Comprehensive Cancer Center at Aventura Aventura, Florida | |
| UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida | |
| UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida | |
| UM Sylvester Comprehensive Cancer Center at Doral Doral, Florida | Site Public Contact - (kginnity@med.miami.edu) |
| UM Sylvester Comprehensive Cancer Center at Kendall Miami, Florida | |
| UM Sylvester Comprehensive Cancer Center at Plantation Plantation, Florida | |
| UM Upper Chesapeake Medical Center Bel Air, Maryland | |
| UPMC-Presbyterian Hospital Pittsburgh, Pennsylvania | |
| UPMC-Shadyside Hospital Pittsburgh, Pennsylvania | |
| UT MD Anderson - League City League City, Texas | Site Public Contact - (askmdanderson@mdanderson.org) |
| UT MD Anderson Cancer Center Houston, Texas | Site Public Contact - (askmdanderson@mdanderson.org) |
| University College Hospital Galway Galway, Co Galway | Site Public Contact - (info@cancercontrol.ie) |
| University of Arizona Cancer Center-North Campus Tucson, Arizona | Site Public Contact - (UACC-IIT@uacc.arizona.edu) |
| University of Arkansas for Medical Sciences Little Rock, Arkansas | |
| University of Chicago Comprehensive Cancer Center Chicago, Illinois | Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu) |
| University of Chicago Medicine-Orland Park Orland Park, Illinois | Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu) |
| University of Cincinnati Cancer Center-UC Medical Center Cincinnati, Ohio | Site Public Contact - (cancer@uchealth.com) |
| University of Cincinnati Cancer Center-West Chester West Chester, Ohio | Site Public Contact - (cancer@uchealth.com) |
| University of Hawaii Cancer Center Honolulu, Hawaii | |
| University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa | |
| University of Kansas Cancer Center Kansas City, Kansas | Site Public Contact - (KUCC_Navigation@kumc.edu) |
| University of Kansas Cancer Center-Overland Park Overland Park, Kansas | Site Public Contact - (KUCC_Navigation@kumc.edu) |
| University of Kentucky/Markey Cancer Center Lexington, Kentucky | |
| University of Maryland Shore Medical Center at Easton Easton, Maryland | Site Public Contact - (Christina.weisenborn@umm.edu) |
| University of Maryland/Greenebaum Cancer Center Baltimore, Maryland | |
| University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida | |
| University of Michigan Rogel Cancer Center Ann Arbor, Michigan | Site Public Contact - (CancerAnswerLine@med.umich.edu) |
| University of Minnesota/Masonic Cancer Center Minneapolis, Minnesota | |
| University of Mississippi Medical Center Jackson, Mississippi | |
| University of Nebraska Medical Center Omaha, Nebraska | Site Public Contact - (unmcrsa@unmc.edu) |
| University of New Mexico Cancer Center Albuquerque, New Mexico | Site Public Contact - (HSC-ClinicalTrialInfo@salud.unm.edu) |
| University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma | Site Public Contact - (ou-clinical-trials@ouhsc.edu) |
| University of Pennsylvania/Abramson Cancer Center Philadelphia, Pennsylvania | Site Public Contact - (PMCancerResearch@pennmedicine.upenn.edu) |
| University of Rochester Rochester, New York | |
| University of Texas Health Science Center at San Antonio San Antonio, Texas | Site Public Contact - (phoresearchoffice@uthscsa.edu) |
| University of Vermont Medical Center Burlington, Vermont | Site Public Contact - (rpo@uvm.edu) |
| University of Vermont and State Agricultural College Burlington, Vermont | Site Public Contact - (rpo@uvm.edu) |
| University of Virginia Cancer Center Charlottesville, Virginia | Site Public Contact - (uvacancertrials@hscmail.mcc.virginia.edu) |
| University of Wisconsin Carbone Cancer Center - Eastpark Medical Center Madison, Wisconsin | Site Public Contact - (clinicaltrials@cancer.wisc.edu) |
| University of Wisconsin Carbone Cancer Center - University Hospital Madison, Wisconsin | Site Public Contact - (clinicaltrials@cancer.wisc.edu) |
| UofL Health Medical Center Northeast Louisville, Kentucky | Site Public Contact - (ctoinfo@louisville.edu) |
| VCU Massey Comprehensive Cancer Center Richmond, Virginia | Site Public Contact - (CTOclinops@vcu.edu) |
| Valley Health System Ridgewood Campus Ridgewood, New Jersey | Site Public Contact - (clinicaltrialsresearch@valleyhealth.com) |
| Valley Medical Center Renton, Washington | Site Public Contact - (research@valleymed.org) |
| Vanderbilt Breast Center at One Hundred Oaks Nashville, Tennessee | |
| Vanderbilt University/Ingram Cancer Center Nashville, Tennessee | |
| Washington University School of Medicine St Louis, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| WellSpan Health-York Cancer Center York, Pennsylvania | |
| WellSpan Health-York Hospital York, Pennsylvania | |
| WellStar Cobb Hospital Austell, Georgia | Site Public Contact - (research@wellstar.org) |
| Wellstar Kennestone Hospital Marietta, Georgia | Site Public Contact - (research@wellstar.org) |
| Wilcox Memorial Hospital and Kauai Medical Clinic Lihue, Hawaii | |
| William E Kahlert Regional Cancer Center/Sinai Hospital Westminster, Maryland | |
| Women's Diagnostic Center - Munster Munster, Indiana | Site Public Contact - (mnicholson@comhs.org) |
Chest Drain Regular Flushing in Complicated Parapneumonic Effusions and Empyemas (RELIEF)
Samira Shojaee, MD, MPH - samira.shojaee@vumc.org
NCT06427538
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Patients with complicated parapneumonic pleural effusion and empyema requiring chest tube placement as standard of care for inpatient management of their pleural space infection with or without intrapleural tissue plasminogen activator and deoxyribonuclease therapy
* Age \> 18 years old.
Exclusion Criteria:
* Patients who have surgical tubes that can't accommodate a three-way stopcock.
* Study subject has any disease or condition that interferes with the safe completion of the study.
* Inability to provide informed consent.
* Inability to undergo a chest X-ray.
* If the managing clinician believes the chest tube will be placed for less than 24 hours.
* Patients with an indwelling pleural catheter (IPC) OTHER: Saline Flush
Empyema, Pleural, Pleural Infection
empyema, pleural infection, chest tube, saline flush
I'm interested
Share via email
Show 5 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Creighton University Omaha, Nebraska | Zachary S DePew, MD - (zachary.depew@commonspirit.org) |
| Henry Ford Detroit, Michigan | Labib Debiane, MD - (ldebian1@hfhs.org) |
| Mount Sinai New York, New York | Udit S Chaddha - (udit.chaddha@mssm.edu) |
| Vanderbilt University Medical Center Nashville, Tennessee | |
| Virginia Commonwealth University Richmond, Virginia | Danai Khemasuwan - (Danai.Khemasuwan@vcuhealth.org) |
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
ctrrecruit@vcu.edu
NCT05946213
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma of prostate cancer
* High-risk disease defined as having at least one or more of the following:
* cT3a-T3b by digital exam or imaging (American Joint Committee on Cancer \[AJCC\] 8th edition \[Ed.\]) Note: cT4 by imaging or on digital rectal exam is not allowed
* The patient's prostate specific antigen (PSA) value \> 20 ng/mL prior to starting androgen deprivation therapy (ADT) Note: Patients taking a 5-alpha reductase inhibitor (ex finasteride or dutasteride) are eligible The baseline PSA value should be doubled for PSAs taken while on 5-alpha reductase inhibitors
* Gleason Score of 8-10
* Pelvic node positive by conventional imaging with a short axis of at least 1.0 cm
* Prostate gland volume less than 100 cc prior to initiation of ADT as reported at time of biopsy or by separate measure with ultrasound or other imaging modalities including MRI or CT scan
* No definitive clinical or radiologic evidence of metastatic disease outside of the pelvic nodes (M1a, M1b or M1c) on conventional imaging (i.e. bone scan, CT scan, MRI); Negative prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is an acceptable substitute
* Age \>= 18
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
* No prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
* No prior radical prostatectomy
* No prior ablative or focal therapy to the prostate (including, but not limited to, transrectal or transurethral high-intensity focused ultrasound \[HIFU\], laser ablation, cryotherapy, irreversible electroporation \[IRE\], and vascular-targeted photodynamic therapy)
* Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation (both luteinizing hormone releasing hormone \[LHRH\] agonist and oral anti-androgen) is =\< 185 days prior to registration; Please note: PSA prior to the start of any ADT will be used to define disease
* No contraindication to prostate MRI (required for planning of radiotherapy in both arms)
* Patients enrolled in NRG-GU009 must be enrolled in NRG-GU013 prior to radiation therapy treatment planning and start of radiation therapy PROCEDURE: Biospecimen Collection, PROCEDURE: Bone Scan, PROCEDURE: Computed Tomography, RADIATION: External Beam Radiation Therapy, PROCEDURE: Magnetic Resonance Imaging, PROCEDURE: Positron Emission Tomography, OTHER: Quality-of-Life Assessment, OTHER: Questionnaire Administration, RADIATION: Stereotactic Body Radiation Therapy
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
I'm interested
Share via email
Show 413 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| AMG Crystal Lake - Oncology Crystal Lake, Illinois | Site Public Contact - (advocateresearch@advocate.com) |
| AMG Libertyville - Oncology Libertyville, Illinois | Site Public Contact - (advocateresearch@advocatehealth.com) |
| Abbott-Northwestern Hospital Minneapolis, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Adams Cancer Center Gettysburg, Pennsylvania | |
| Advocate Christ Medical Center Oak Lawn, Illinois | |
| Advocate Good Samaritan Hospital Downers Grove, Illinois | Site Public Contact - (Barbara.barhamand@advocatehealth.com) |
| Advocate Good Shepherd Hospital Barrington, Illinois | |
| Advocate High Tech Medical Park Palos Heights, Illinois | Site Public Contact - (ncorp@aah.org) |
| Advocate Illinois Masonic Medical Center Chicago, Illinois | |
| Advocate Lutheran General Hospital Park Ridge, Illinois | |
| Advocate Outpatient Center - Aurora Aurora, Illinois | Site Public Contact - (ncorp@aah.org) |
| Advocate Sherman Hospital Elgin, Illinois | |
| Advocate South Suburban Hospital Hazel Crest, Illinois | |
| Alton Memorial Hospital Alton, Illinois | |
| Altru Cancer Center Grand Forks, North Dakota | |
| American Fork Hospital / Huntsman Intermountain Cancer Center American Fork, Utah | Site Public Contact - (officeofresearch@imail.org) |
| Ascension Via Christi Hospitals Wichita Wichita, Kansas | |
| Aspirus Cancer Care - James Beck Cancer Center Rhinelander, Wisconsin | Site Public Contact - (Beth.Knetter@aspirus.org) |
| Aspirus Cancer Care - Stevens Point Stevens Point, Wisconsin | Site Public Contact - (Beth.Knetter@aspirus.org) |
| Aspirus Cancer Care - Wisconsin Rapids Wisconsin Rapids, Wisconsin | |
| Aspirus Regional Cancer Center Wausau, Wisconsin | |
| Atlantic Health Sciences Corporation-Saint John Regional Hospital Saint John, New Brunswick | |
| Augusta Health Center for Cancer and Blood Disorders Fishersville, Virginia | |
| Aultman Health Foundation Canton, Ohio | Site Public Contact - (ClinicalReserachDept@aultman.com) |
| Aurora Bay Area Medical Group-Marinette Marinette, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora BayCare Medical Center Green Bay, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora Cancer Care-Grafton Grafton, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora Cancer Care-Kenosha South Kenosha, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora Cancer Care-Milwaukee Milwaukee, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora Cancer Care-Milwaukee West Wauwatosa, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora Cancer Care-Racine Racine, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora Cancer Care-Southern Lakes VLCC Burlington, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora Health Care Germantown Health Center Germantown, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora Medical Center in Summit Summit, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora Saint Luke's Medical Center Milwaukee, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora Sinai Medical Center Milwaukee, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora West Allis Medical Center West Allis, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Baptist Health Hardin Elizabethtown, Kentucky | |
| Bay Pines VA Healthcare System Bay Pines, Florida | Site Public Contact - (vhabayresearch@va.gov) |
| Benefis Sletten Cancer Institute Great Falls, Montana | Site Public Contact - (mccinfo@mtcancer.org) |
| Billings Clinic Cancer Center Billings, Montana | Site Public Contact - (research@billingsclinic.org) |
| Bon Secours Cancer Institute at Reynolds Crossing Richmond, Virginia | Site Public Contact - (Anne_caramella@bshsi.org) |
| Bon Secours Memorial Regional Medical Center Mechanicsville, Virginia | Site Public Contact - (anne_carmellat@bshsi.org) |
| Bon Secours Saint Francis Medical Center Midlothian, Virginia | Site Public Contact - (anne_carmellat@bshsi.org) |
| Bon Secours Saint Mary's Hospital Richmond, Virginia | Site Public Contact - (anne_carmellat@bshsi.org) |
| Brigham and Women's Hospital Boston, Massachusetts | |
| Brooke Army Medical Center San Antonio, Texas | |
| CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ) Québec, Quebec | Site Public Contact - (rechclinique@crchuq.ulaval.ca) |
| CHUM - Centre Hospitalier de l'Universite de Montreal Montreal, Quebec | Site Public Contact - (info.cr.chum@ssss.gouv.qc.ca) |
| CIUSSSEMTL-Hopital Maisonneuve-Rosemont Montreal, Quebec | |
| Camden Clark Medical Center Parkersburg, West Virginia | Site Public Contact - (cancertrialsinfo@hsc.wvu.edu) |
| Cancer Care Center of O'Fallon O'Fallon, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Cancer Center of Western Wisconsin New Richmond, Wisconsin | Site Public Contact - (mmcorc@healthpartners.com) |
| Capital Health Medical Center-Hopewell Pennington, New Jersey | Site Public Contact - (clinicaltrials@capitalhealth.org) |
| Carle Cancer Center Urbana, Illinois | Site Public Contact - (Research@carle.com) |
| Carle Physician Group-Effingham Effingham, Illinois | Site Public Contact - (Research@carle.com) |
| Carle Physician Group-Mattoon/Charleston Mattoon, Illinois | Site Public Contact - (Research@carle.com) |
| Carle at The Riverfront Danville, Illinois | Site Public Contact - (Research@Carle.com) |
| Carlisle Regional Cancer Center Carlisle, Pennsylvania | Site Public Contact - (Roster@nrgoncology.org) |
| CarolinaEast Medical Center New Bern, North Carolina | Site Public Contact - (lharrison@carolinaeasthealth.com) |
| Case Western Reserve University Cleveland, Ohio | Site Public Contact - (CTUReferral@UHhospitals.org) |
| Castle Medical Center Kailua, Hawaii | |
| Cedars-Sinai Medical Center Los Angeles, California | Site Public Contact - (Cancer.trial.info@cshs.org) |
| Central Maryland Radiation Oncology in Howard County Columbia, Maryland | |
| Central Vermont Medical Center/National Life Cancer Treatment Berlin Corners, Vermont | |
| Centre Hospitalier Universitaire de Sherbrooke-Fleurimont Sherbrooke, Quebec | Site Public Contact - (crcinformation.chus@ssss.gouv.qc.ca) |
| Chambersburg Hospital Chambersburg, Pennsylvania | Site Public Contact - (Roster@nrgoncology.org) |
| Chelsea Hospital Chelsea, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| Christiana Care Health System-Concord Health Center Chadds Ford, Pennsylvania | Site Public Contact - (lbarone@christianacare.org) |
| Christiana Care Health System-Wilmington Hospital Wilmington, Delaware | Site Public Contact - (lbarone@christianacare.org) |
| Clackamas Radiation Oncology Center Clackamas, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| Cleveland Clinic Akron General Akron, Ohio | Site Public Contact - (CancerAnswer@ccf.org) |
| Cleveland Clinic Cancer Center Independence Independence, Ohio | Site Public Contact - (TaussigResearch@ccf.org) |
| Cleveland Clinic Cancer Center Mansfield Mansfield, Ohio | Site Public Contact - (TaussigResearch@ccf.org) |
| Cleveland Clinic Cancer Center Strongsville Strongsville, Ohio | Site Public Contact - (TaussigResearch@ccf.org) |
| Cleveland Clinic Cancer Center/Fairview Hospital Cleveland, Ohio | Site Public Contact - (TaussigResearch@ccf.org) |
| Cleveland Clinic Foundation Cleveland, Ohio | Site Public Contact - (TaussigResearch@ccf.org) |
| Cleveland Clinic Mercy Hospital Canton, Ohio | |
| Cleveland Clinic Wooster Family Health and Surgery Center Wooster, Ohio | Site Public Contact - (TaussigResearch@ccf.org) |
| Community Medical Center Toms River, New Jersey | Site Public Contact - (Lennette.Gonzales@rwjbh.org) |
| Condell Memorial Hospital Libertyville, Illinois | Site Public Contact - (advocateresearch@advocatehealth.com) |
| Corewell Health Beaumont Troy Hospital Troy, Michigan | |
| Corewell Health Dearborn Hospital Dearborn, Michigan | |
| Corewell Health Grand Rapids Hospitals - Butterworth Hospital Grand Rapids, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center Saint Joseph, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Corewell Health Lakeland Hospitals - Niles Hospital Niles, Michigan | |
| Corewell Health Lakeland Hospitals - Saint Joseph Hospital Saint Joseph, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Corewell Health William Beaumont University Hospital Royal Oak, Michigan | |
| Crossroads Cancer Center Effingham, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Dana-Farber Cancer Institute Boston, Massachusetts | |
| Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Milford, Massachusetts | |
| Dana-Farber/Brigham and Women's Cancer Center at South Shore South Weymouth, Massachusetts | |
| Dartmouth Cancer Center - North Saint Johnsbury, Vermont | Site Public Contact - (cancer.research.nurse@hitchcock.org) |
| Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center Lebanon, New Hampshire | Site Public Contact - (cancer.research.nurse@dartmouth.edu) |
| Decatur Memorial Hospital Decatur, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Delaware Health Center-Grady Cancer Center Delaware, Ohio | Site Public Contact - (Jennifer.Sexton@ohiohealth.com) |
| Doctors Hospital Columbus, Ohio | Site Public Contact - (Jennifer.Sexton@ohiohealth.com) |
| Drexel Town Square Health Center Oak Creek, Wisconsin | |
| Dublin Methodist Hospital Dublin, Ohio | Site Public Contact - (Jennifer.Sexton@ohiohealth.com) |
| Duluth Clinic Ashland Ashland, Wisconsin | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Durham VA Medical Center Durham, North Carolina | Site Public Contact - (VHADURcancertrials@va.gov) |
| Edward Hospital/Cancer Center Naperville, Illinois | |
| Edwards Comprehensive Cancer Center Huntington, West Virginia | Site Public Contact - (Christina.Cole@chhi.org) |
| Elmhurst Memorial Hospital Elmhurst, Illinois | Site Public Contact - (Jrohde@emhc.org) |
| Emory Decatur Hospital Decatur, Georgia | Site Public Contact - (clinicaltrialsoncology@dekalbmedical.org) |
| Emory Proton Therapy Center Atlanta, Georgia | Site Public Contact - (allyson.anderson@emory.edu) |
| Emory Saint Joseph's Hospital Atlanta, Georgia | |
| Emory University Hospital Midtown Atlanta, Georgia | |
| Emory University Hospital/Winship Cancer Institute Atlanta, Georgia | |
| Ephrata Cancer Center Ephrata, Pennsylvania | |
| Essentia Health - Deer River Clinic Deer River, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health Cancer Center Duluth, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health Hibbing Clinic Hibbing, Minnesota | |
| Essentia Health Saint Joseph's Medical Center Brainerd, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health Saint Mary's Hospital - Superior Superior, Wisconsin | |
| Essentia Health Saint Mary's Medical Center Duluth, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health Sandstone Sandstone, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health Virginia Clinic Virginia, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health-Hayward Clinic Hayward, Wisconsin | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health-Spooner Clinic Spooner, Wisconsin | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| FHCC at Northwest Hospital Seattle, Washington | |
| Fairview Southdale Hospital Edina, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Farmington Health Center Farmington, Utah | Site Public Contact - (cancerinfo@hci.utah.edu) |
| Fred Hutchinson Cancer Center Seattle, Washington | |
| Fresno Cancer Center Fresno, California | Site Public Contact - (Kpoct@kp.org) |
| Froedtert Menomonee Falls Hospital Menomonee Falls, Wisconsin | |
| Froedtert West Bend Hospital/Kraemer Cancer Center West Bend, Wisconsin | |
| Geisinger Cancer Services-Pottsville Pottsville, Pennsylvania | Site Public Contact - (HemonCCTrials@geisinger.edu) |
| Geisinger Medical Center Danville, Pennsylvania | Site Public Contact - (HemonCCTrials@geisinger.edu) |
| Geisinger Medical Oncology-Lewisburg Lewisburg, Pennsylvania | Site Public Contact - (HemonCCTrials@geisinger.edu) |
| Geisinger Wyoming Valley/Henry Cancer Center Wilkes-Barre, Pennsylvania | Site Public Contact - (HemonCCTrials@geisinger.edu) |
| Genesys Hurley Cancer Institute Flint, Michigan | Site Public Contact - (wstrong@ghci.org) |
| George Washington University Medical Center Washington D.C., District of Columbia | |
| Gibbs Cancer Center-Gaffney Gaffney, South Carolina | Site Public Contact - (kmertz-rivera@gibbscc.org) |
| Gibbs Cancer Center-Pelham Greer, South Carolina | Site Public Contact - (kmertz-rivera@gibbscc.org) |
| Goshen Center for Cancer Care Goshen, Indiana | Site Public Contact - (cccois@goshenhealth.com) |
| Grady Health System Atlanta, Georgia | |
| Grady Memorial Hospital Delaware, Ohio | Site Public Contact - (Jennifer.Sexton@ohiohealth.com) |
| Grant Medical Center Columbus, Ohio | Site Public Contact - (Jennifer.Sexton@ohiohealth.com) |
| HSHS Saint Elizabeth's Hospital O'Fallon, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Hawaii Cancer Care - Westridge ‘Aiea, Hawaii | Site Public Contact - (info@hawaiicancercare.com) |
| Hawaii Cancer Care Inc - Waterfront Plaza Honolulu, Hawaii | Site Public Contact - (i.webster@hawaiicancercare.com) |
| Helen F Graham Cancer Center Newark, Delaware | Site Public Contact - (lbarone@christianacare.org) |
| Henry Ford Cancer Institute-Downriver Brownstown, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Henry Ford Hospital Detroit, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Henry Ford Macomb Hospital-Clinton Township Clinton Township, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Henry Ford West Bloomfield Hospital West Bloomfield, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Hi-Line Sletten Cancer Center Havre, Montana | Site Public Contact - (Roster@nrgoncology.org) |
| Highland Hospital Rochester, New York | |
| Hillcrest Hospital Cancer Center Mayfield Heights, Ohio | Site Public Contact - (TaussigResearch@ccf.org) |
| Huntsman Cancer Institute/University of Utah Salt Lake City, Utah | Site Public Contact - (cancerinfo@hci.utah.edu) |
| Hurley Medical Center Flint, Michigan | Site Public Contact - (wstrong@ghci.org) |
| Illinois CancerCare-Bloomington Bloomington, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Carthage Carthage, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Galesburg Galesburg, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Kewanee Clinic Kewanee, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Macomb Macomb, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Ottawa Clinic Ottawa, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Pekin Pekin, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Peru Peru, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Princeton Princeton, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Intermountain Medical Center Murray, Utah | Site Public Contact - (officeofresearch@imail.org) |
| Jersey City Medical Center Jersey City, New Jersey | Site Public Contact - (Roster@nrgoncology.org) |
| Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland | Site Public Contact - (jhcccro@jhmi.edu) |
| Jupiter Medical Center Jupiter, Florida | Site Public Contact - (clinicaltrials@jupitermed.com) |
| Kaiser Permanente Cancer Treatment Center South San Francisco, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente Downtown Commons Sacramento, California | Site Public Contact - (kpoct@kp.org) |
| Kaiser Permanente Dublin Dublin, California | |
| Kaiser Permanente Fresno Orchard Plaza Fresno, California | |
| Kaiser Permanente Medical Center - Santa Clara Santa Clara, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente Medical Center-Vacaville Vacaville, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente Northwest Portland, Oregon | Site Public Contact - (information@kpchr.org) |
| Kaiser Permanente Oakland-Broadway Oakland, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente San Leandro San Leandro, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente- Marshall Medical Offices Redwood City, California | |
| Kaiser Permanente- Modesto MOB II Modesto, California | |
| Kaiser Permanente-Deer Valley Medical Center Antioch, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Fremont Fremont, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Fresno Fresno, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Modesto Modesto, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Oakland Oakland, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Rancho Cordova Cancer Center Rancho Cordova, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Richmond Richmond, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Roseville Roseville, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-San Francisco San Francisco, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Santa Rosa Santa Rosa, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Santa Teresa-San Jose San Jose, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-South Sacramento Sacramento, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-South San Francisco South San Francisco, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Stockton Stockton, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Vallejo Vallejo, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Walnut Creek Walnut Creek, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser San Rafael-Gallinas San Rafael, California | Site Public Contact - (Kpoct@kp.org) |
| Kantonsspital Aarau Aarau, | |
| Kapiolani Medical Center for Women and Children Honolulu, Hawaii | |
| LDS Hospital Salt Lake City, Utah | Site Public Contact - (officeofresearch@imail.org) |
| Lakeview Hospital Stillwater, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Langlade Hospital and Cancer Center Antigo, Wisconsin | Site Public Contact - (Juli.Alford@aspirus.org) |
| Lawrence Memorial Hospital Lawrence, Kansas | Site Public Contact - (Stephanie.Norris@LMH.ORG) |
| Lenox Hill Hospital New York, New York | |
| Lewis and Faye Manderson Cancer Center Tuscaloosa, Alabama | |
| Logan Regional Hospital Logan, Utah | Site Public Contact - (officeofresearch@imail.org) |
| Louis Stokes Cleveland VA Medical Center Cleveland, Ohio | Site Public Contact - (holly.henry@va.gov) |
| MD Anderson West Houston Houston, Texas | Site Public Contact - (askmdanderson@mdanderson.org) |
| MD Anderson in Sugar Land Sugar Land, Texas | Site Public Contact - (askmdanderson@mdanderson.org) |
| MD Anderson in The Woodlands Conroe, Texas | Site Public Contact - (askmdanderson@mdanderson.org) |
| MaineHealth Cancer Care Center of York County Sanford, Maine | |
| MaineHealth Coastal Cancer Treatment Center Bath, Maine | Site Public Contact - (Roster@nrgoncology.org) |
| MaineHealth Maine Medical Center - Portland Portland, Maine | Site Public Contact - (clinicalresearch@mainehealth.org) |
| MaineHealth Maine Medical Center- Scarborough Scarborough, Maine | Site Public Contact - (clinicalresearch@mainehealth.org) |
| Manhattan Eye Ear and Throat Hospital New York, New York | |
| Mary Bird Perkins Cancer Center Baton Rouge, Louisiana | Site Public Contact - (clinicalresearch@marybird.com) |
| Mary Bird Perkins Cancer Center - Gonzales Gonzales, Louisiana | Site Public Contact - (clinicalresearch@marybird.com) |
| Maryland Proton Treatment Center Baltimore, Maryland | Site Public Contact - (info@mdproton.com) |
| McFarland Clinic - Ames Ames, Iowa | Site Public Contact - (ksoder@mcfarlandclinic.com) |
| McKay-Dee Hospital Center Ogden, Utah | Site Public Contact - (officeofresearch@imail.org) |
| McLeod Regional Medical Center Florence, South Carolina | Site Public Contact - (dorie.sturgill@mcleodhealth.org) |
| Medical College of Wisconsin Milwaukee, Wisconsin | |
| Medical Oncology Hematology Consultants PA Newark, Delaware | Site Public Contact - (lbarone@christianacare.org) |
| Memorial Hospital East Shiloh, Illinois | Site Public Contact - (dschwab@wustl.edu) |
| Memorial Hospital North Colorado Springs, Colorado | |
| Mercy Clinic-Rolla-Cancer and Hematology Rolla, Missouri | |
| Mercy Hospital Coon Rapids, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Mercy Hospital Saint Louis St Louis, Missouri | |
| Mercy Hospital Springfield Springfield, Missouri | |
| MetroHealth Medical Center Cleveland, Ohio | Site Public Contact - (ababal@metrohealth.org) |
| Miller-Dwan Hospital Duluth, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Minnesota Oncology Hematology PA-Chaska Chaska, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Missouri Baptist Medical Center St Louis, Missouri | |
| Moffitt Cancer Center Tampa, Florida | Site Public Contact - (ClinicalTrials@moffitt.org) |
| Moffitt Cancer Center - McKinley Campus Tampa, Florida | Site Public Contact - (ClinicalTrials@moffitt.org) |
| Moffitt Cancer Center at SouthShore Ruskin, Florida | Site Public Contact - (ClinicalTrials@moffitt.org) |
| Moffitt Cancer Center at Wesley Chapel Wesley Chapel, Florida | Site Public Contact - (ClinicalTrials@moffitt.org) |
| Moffitt Cancer Center-International Plaza Tampa, Florida | Site Public Contact - (ClinicalTrials@moffitt.org) |
| Monmouth Medical Center Long Branch, New Jersey | Site Public Contact - (mary.danish@rwjbh.org) |
| Mount Sinai Comprehensive Cancer Center at Aventura Aventura, Florida | Site Public Contact - (yenrique@msmc.com) |
| Mount Sinai Medical Center New York, New York | Site Public Contact - (Yvonne.Enriquez@msmc.com) |
| Munson Medical Center Traverse City, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| MyMichigan Medical Center Saginaw Saginaw, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| Nebraska Medicine-Bellevue Bellevue, Nebraska | Site Public Contact - (unmcrsa@unmc.edu) |
| Nebraska Medicine-Village Pointe Omaha, Nebraska | |
| New York-Presbyterian/Brooklyn Methodist Hospital Brooklyn, New York | Site Public Contact - (Adg9003@nyp.org) |
| Newark Beth Israel Medical Center Newark, New Jersey | Site Public Contact - (Christine.Kosmides@rwjbh.org) |
| North Coast Cancer Care Sandusky, Ohio | Site Public Contact - (TaussigResearch@ccf.org) |
| Northern Westchester Hospital Mount Kisco, New York | Site Public Contact - (AMellor@northwell.edu) |
| Northwell Health Cancer Institute at Huntington Greenlawn, New York | |
| Northwell Health Imbert Cancer Center Bay Shore, New York | |
| Northwell Health Physicians Partners Radiation Medicine at Queens Forest Hills, New York | |
| Northwell Health/Center for Advanced Medicine Lake Success, New York | |
| Northwest Wisconsin Cancer Center Ashland, Wisconsin | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Northwestern Medicine Cancer Center Delnor Geneva, Illinois | Site Public Contact - (Donald.Smith3@nm.org) |
| Northwestern Medicine Cancer Center Kishwaukee DeKalb, Illinois | Site Public Contact - (Donald.Smith3@nm.org) |
| Northwestern Medicine Cancer Center Warrenville Warrenville, Illinois | Site Public Contact - (Donald.Smith3@nm.org) |
| Northwestern Medicine Oak Brook Oak Brook, Illinois | Site Public Contact - (nctnprogram_rhlccc@northwestern.edu) |
| Northwestern University Chicago, Illinois | Site Public Contact - (cancer@northwestern.edu) |
| Noyes Memorial Hospital/Myers Cancer Center Dansville, New York | Site Public Contact - (WCICTOresearch@urmc.rochester.edu) |
| OSF Saint Francis Medical Center Peoria, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Odette Cancer Centre- Sunnybrook Health Sciences Centre Toronto, Ontario | |
| Ohio State University Comprehensive Cancer Center Columbus, Ohio | Site Public Contact - (Jamesline@osumc.edu) |
| OhioHealth Mansfield Hospital Mansfield, Ohio | Site Public Contact - (Jennifer.Sexton@ohiohealth.com) |
| OhioHealth Marion General Hospital Marion, Ohio | Site Public Contact - (Jennifer.Sexton@ohiohealth.com) |
| Ottawa Hospital and Cancer Center-General Campus Ottawa, Ontario | |
| Pali Momi Medical Center ‘Aiea, Hawaii | |
| Pamela Youde Nethersole Eastern Hospital Hong Kong, | |
| Park Nicollet Clinic - Saint Louis Park Saint Louis Park, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| PeaceHealth Saint Joseph Medical Center Bellingham, Washington | Site Public Contact - (achapman1@peacehealth.org) |
| Penn State Milton S Hershey Medical Center Hershey, Pennsylvania | Site Public Contact - (CTO@hmc.psu.edu) |
| Phelps Health Delbert Day Cancer Institute Rolla, Missouri | Site Public Contact - (research@phelpshealth.org) |
| Phelps Memorial Hospital Center Sleepy Hollow, New York | |
| ProMedica Flower Hospital Sylvania, Ohio | Site Public Contact - (PCIOncResearch@promedica.org) |
| ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital Toledo, Ohio | Site Public Contact - (PCIOncResearch@promedica.org) |
| Providence Portland Medical Center Portland, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| Providence Saint Vincent Medical Center Portland, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| Queen's Cancer Cenrer - POB I Honolulu, Hawaii | |
| Queen's Cancer Center - Kuakini Honolulu, Hawaii | |
| Queen's Medical Center Honolulu, Hawaii | |
| Reading Hospital West Reading, Pennsylvania | |
| Regions Hospital Saint Paul, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Ridgeview Medical Center Waconia, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Riverside Methodist Hospital Columbus, Ohio | Site Public Contact - (Jennifer.Sexton@ohiohealth.com) |
| Riverton Hospital Riverton, Utah | Site Public Contact - (officeofresearch@imail.org) |
| Rocky Mountain Cancer Centers-Penrose Colorado Springs, Colorado | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Rohnert Park Cancer Center Rohnert Park, California | Site Public Contact - (Kpoct@kp.org) |
| Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey | |
| Rutgers New Jersey Medical School Newark, New Jersey | |
| SMC Center for Hematology Oncology Union Union, South Carolina | Site Public Contact - (kmertz-rivera@gibbscc.org) |
| Saint Barnabas Medical Center Livingston, New Jersey | Site Public Contact - (joanne.loeb@rwjbh.org) |
| Saint Charles Health System Bend, Oregon | Site Public Contact - (nosall@stcharleshealthcare.org) |
| Saint Francis Medical Center Cape Girardeau, Missouri | Site Public Contact - (sfmc@sfmc.net) |
| Saint George Regional Medical Center St. George, Utah | Site Public Contact - (officeofresearch@imail.org) |
| Saint Joseph Hospital Nashua, New Hampshire | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Joseph Hospital East Lexington, Kentucky | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Joseph Radiation Oncology Resource Center Lexington, Kentucky | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Luke's Hospital of Duluth Duluth, Minnesota | Site Public Contact - (kdean@slhduluth.com) |
| Saint Vincent Hospital Cancer Center Green Bay Green Bay, Wisconsin | Site Public Contact - (WI_research_admin@hshs.org) |
| Saint Vincent Hospital Cancer Center at Sheboygan Sheboygan, Wisconsin | Site Public Contact - (wi_research_admin@hshs.org) |
| Saint Vincent Hospital Cancer Center at Sturgeon Bay Sturgeon Bay, Wisconsin | Site Public Contact - (wi_research_admin@hshs.org) |
| Sandra L Maxwell Cancer Center Cedar City, Utah | Site Public Contact - (officeofresearch@imail.org) |
| Sands Cancer Center Canandaigua, New York | |
| Sanford Joe Lueken Cancer Center Bemidji, Minnesota | Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org) |
| Sanford Roger Maris Cancer Center Fargo, North Dakota | Site Public Contact - (OncologyClinicalTrialsFargo@sanfordhealth.org) |
| Sanford USD Medical Center - Sioux Falls Sioux Falls, South Dakota | Site Public Contact - (OncologyClinicalTrialsSF@SanfordHealth.org) |
| Sechler Family Cancer Center Lebanon, Pennsylvania | Site Public Contact - (doxenberg@wellspan.org) |
| Self Regional Healthcare Greenwood, South Carolina | Site Public Contact - (nmcgaha@selfregional.org) |
| Sheboygan Physicians Group Sheboygan, Wisconsin | Site Public Contact - (wi_research_admin@hshs.org) |
| Siteman Cancer Center at Christian Hospital St Louis, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| Siteman Cancer Center at Saint Peters Hospital City of Saint Peters, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| Siteman Cancer Center at West County Hospital Creve Coeur, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| Siteman Cancer Center-South County St Louis, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| South Sacramento Cancer Center Sacramento, California | Site Public Contact - (Kpoct@kp.org) |
| Southern Illinois University School of Medicine Springfield, Illinois | |
| Spartanburg Medical Center Spartanburg, South Carolina | Site Public Contact - (kmertz-rivera@gibbscc.org) |
| Springfield Memorial Hospital Springfield, Illinois | Site Public Contact - (pallante.beth@mhsil.com) |
| State University of New York Upstate Medical University Syracuse, New York | |
| Stony Brook University Medical Center Stony Brook, New York | |
| Straub Clinic and Hospital Honolulu, Hawaii | |
| The Cancer Center of Hawaii-Liliha Honolulu, Hawaii | |
| The James Graham Brown Cancer Center at University of Louisville Louisville, Kentucky | |
| The Kirklin Clinic at Acton Road Birmingham, Alabama | Site Public Contact - (tmyrick@uab.edu) |
| The New York Hospital Medical Center of Queens Flushing, New York | Site Public Contact - (Roster@nrgoncology.org) |
| The Permanente Medical Group-Roseville Radiation Oncology Roseville, California | Site Public Contact - (Kpoct@kp.org) |
| The Queen's Medical Center - West Oahu ‘Ewa Beach, Hawaii | Site Public Contact - (rohta@queens.org) |
| The Research Institute of the McGill University Health Centre (MUHC) Montreal, Quebec | Site Public Contact - (evelyn.ortega@muhc.mcgill.ca) |
| The University of Kansas Cancer Center - Olathe Olathe, Kansas | Site Public Contact - (OlatheCCResearch@kumc.edu) |
| The Valley Hospital - Luckow Pavilion Paramus, New Jersey | Site Public Contact - (clinicaltrialsresearch@valleyhealth.com) |
| Torrance Memorial Physician Network - Cancer Care Torrance, California | Site Public Contact - (courtney.steeneken@tmphysicians.com) |
| Tower Cancer Research Foundation Beverly Hills, California | Site Public Contact - (towercancerresearch@toweroncology.com) |
| Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus Elizabeth, New Jersey | |
| Trinity Health Medical Center - Brighton Brighton, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| Trinity Health Medical Center - Canton Canton, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| Trinity Health Saint Joseph Mercy Hospital Ann Arbor Ann Arbor, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| Trinity Health Saint Mary Mercy Livonia Hospital Livonia, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California | Site Public Contact - (ucstudy@uci.edu) |
| UCHealth Highlands Ranch Hospital Highlands Ranch, Colorado | |
| UCHealth Memorial Hospital Central Colorado Springs, Colorado | |
| UCHealth University of Colorado Hospital Aurora, Colorado | |
| UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California | Site Public Contact - (ucstudy@uci.edu) |
| UH Seidman Cancer Center at Lake Health Mentor Campus Mentor, Ohio | Site Public Contact - (CTUReferral@UHhospitals.org) |
| UH Seidman Cancer Center at UH Avon Health Center Avon, Ohio | |
| UHHS-Chagrin Highlands Medical Center Beachwood, Ohio | Site Public Contact - (CTUReferral@UHhospitals.org) |
| UM Baltimore Washington Medical Center/Tate Cancer Center Glen Burnie, Maryland | |
| UM Capital Region Medical Center Largo, Maryland | Site Public Contact - (Sarah.Larson@umm.edu) |
| UM Saint Joseph Medical Center Towson, Maryland | Site Public Contact - (Jeanmarie.downing@umm.edu) |
| UM Upper Chesapeake Medical Center Bel Air, Maryland | |
| UPMC Cancer Center - Monroeville Monroeville, Pennsylvania | Site Public Contact - (Roster@nrgoncology.org) |
| UPMC Cancer Center at UPMC Horizon Farrell, Pennsylvania | Site Public Contact - (Roster@nrgoncology.org) |
| UPMC Cancer Centers - Arnold Palmer Pavilion Greensburg, Pennsylvania | |
| UPMC Hillman Cancer Center Erie Erie, Pennsylvania | Site Public Contact - (ClinicalResearchServices@upmc.edu) |
| UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion Mechanicsburg, Pennsylvania | Site Public Contact - (haneydl@upmc.edu) |
| UPMC Pinnacle Cancer Center/Community Osteopathic Campus Harrisburg, Pennsylvania | Site Public Contact - (klitchfield@PINNACLEHEALTH.org) |
| UPMC-Heritage Valley Health System Beaver Beaver, Pennsylvania | Site Public Contact - (haneydl@upmc.edu) |
| UPMC-Magee Womens Hospital Pittsburgh, Pennsylvania | |
| UPMC-Passavant Hospital Pittsburgh, Pennsylvania | |
| UPMC-Saint Clair Hospital Cancer Center Pittsburgh, Pennsylvania | |
| UPMC-Saint Margaret Pittsburgh, Pennsylvania | |
| UPMC-Shadyside Hospital Pittsburgh, Pennsylvania | |
| UT MD Anderson - League City League City, Texas | Site Public Contact - (askmdanderson@mdanderson.org) |
| UT MD Anderson Cancer Center Houston, Texas | Site Public Contact - (askmdanderson@mdanderson.org) |
| United Hospital Saint Paul, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| University Health Network-Princess Margaret Hospital Toronto, Ontario | Site Public Contact - (clinical.trials@uhn.on.ca) |
| University Hospitals Parma Medical Center Parma, Ohio | Site Public Contact - (CTUReferral@UHhospitals.org) |
| University Hospitals Portage Medical Center Ravenna, Ohio | Site Public Contact - (CTUReferral@UHhospitals.org) |
| University of Alabama at Birmingham Cancer Center Birmingham, Alabama | Site Public Contact - (gingerreeves@uabmc.edu) |
| University of Arkansas for Medical Sciences Little Rock, Arkansas | |
| University of Hawaii Cancer Center Honolulu, Hawaii | |
| University of Illinois Chicago, Illinois | |
| University of Kansas Cancer Center Kansas City, Kansas | Site Public Contact - (KUCC_Navigation@kumc.edu) |
| University of Kansas Cancer Center - Lee's Summit Lee's Summit, Missouri | Site Public Contact - (KUCC_Navigation@kumc.edu) |
| University of Kansas Cancer Center - North Kansas City, Missouri | Site Public Contact - (KUCC_Navigation@kumc.edu) |
| University of Kansas Cancer Center-Overland Park Overland Park, Kansas | Site Public Contact - (KUCC_Navigation@kumc.edu) |
| University of Kansas Health System Saint Francis Campus Topeka, Kansas | |
| University of Kansas Hospital-Westwood Cancer Center Westwood, Kansas | Site Public Contact - (KUCC_Navigation@kumc.edu) |
| University of Maryland Shore Medical Center at Easton Easton, Maryland | Site Public Contact - (Christina.weisenborn@umm.edu) |
| University of Maryland/Greenebaum Cancer Center Baltimore, Maryland | |
| University of Michigan - Brighton Center for Specialty Care Brighton, Michigan | |
| University of Michigan Health - Sparrow Lansing Lansing, Michigan | Site Public Contact - (harsha.trivedi@umhsparrow.org) |
| University of Michigan Health - West Wyoming, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| University of Michigan Rogel Cancer Center Ann Arbor, Michigan | Site Public Contact - (CancerAnswerLine@med.umich.edu) |
| University of Nebraska Medical Center Omaha, Nebraska | Site Public Contact - (unmcrsa@unmc.edu) |
| University of New Mexico Cancer Center Albuquerque, New Mexico | Site Public Contact - (HSC-ClinicalTrialInfo@salud.unm.edu) |
| University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma | Site Public Contact - (ou-clinical-trials@ouhsc.edu) |
| University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania | |
| University of Rochester Rochester, New York | |
| University of Utah Sugarhouse Health Center Salt Lake City, Utah | Site Public Contact - (cancerinfo@hci.utah.edu) |
| University of Vermont Medical Center Burlington, Vermont | Site Public Contact - (rpo@uvm.edu) |
| University of Vermont and State Agricultural College Burlington, Vermont | Site Public Contact - (rpo@uvm.edu) |
| University of Washington Medical Center - Montlake Seattle, Washington | |
| University of Wisconsin Carbone Cancer Center - Eastpark Medical Center Madison, Wisconsin | Site Public Contact - (clinicaltrials@cancer.wisc.edu) |
| University of Wisconsin Carbone Cancer Center - Johnson Creek Johnson Creek, Wisconsin | Site Public Contact - (clinicaltrials@cancer.wisc.edu) |
| University of Wisconsin Carbone Cancer Center - University Hospital Madison, Wisconsin | Site Public Contact - (clinicaltrials@cancer.wisc.edu) |
| UofL Health Medical Center Northeast Louisville, Kentucky | Site Public Contact - (ctoinfo@louisville.edu) |
| Upstate Cancer Center Radiation Oncology at Oswego Oswego, New York | Site Public Contact - (BinghamE@upstate.edu) |
| Upstate Cancer Center at Hill Radiation Oncology Syracuse, New York | Site Public Contact - (BinghamE@upstate.edu) |
| Upstate Cancer Center at Oswego Oswego, New York | Site Public Contact - (McDowelE@upstate.edu) |
| Upstate Cancer Center at Verona Verona, New York | Site Public Contact - (McDowelE@upstate.edu) |
| Utah Valley Regional Medical Center Provo, Utah | Site Public Contact - (officeofresearch@imail.org) |
| VCU Massey Cancer Center at Hanover Medical Park Mechanicsville, Virginia | Site Public Contact - (CTOclinops@vcu.edu) |
| VCU Massey Cancer Center at Stony Point Richmond, Virginia | Site Public Contact - (ctoclinops@vcu.edu) |
| VCU Massey Comprehensive Cancer Center Richmond, Virginia | Site Public Contact - (CTOclinops@vcu.edu) |
| Veterans Administration Medical Center-Baltimore Baltimore, Maryland | |
| Vince Lombardi Cancer Clinic - Oshkosh Oshkosh, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Vince Lombardi Cancer Clinic-Sheboygan Sheboygan, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Vince Lombardi Cancer Clinic-Two Rivers Two Rivers, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Washington Hospital Fremont, California | |
| Washington University School of Medicine St Louis, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| WellSpan Health-York Cancer Center York, Pennsylvania | |
| WellSpan Health-York Hospital York, Pennsylvania | |
| West Virginia University Healthcare Morgantown, West Virginia | Site Public Contact - (cancertrialsinfo@hsc.wvu.edu) |
| Westchester Medical Center Valhalla, New York | Site Public Contact - (Roster@nrgoncology.org) |
| Wheeling Hospital/Schiffler Cancer Center Wheeling, West Virginia | |
| Wilcox Memorial Hospital and Kauai Medical Clinic Lihue, Hawaii | |
| Wilmot Cancer Institute at Webster Webster, New York | Site Public Contact - (WCICTOresearch@urmc.rochester.edu) |
| Zablocki Veterans Administration Medical Center Milwaukee, Wisconsin |
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Greg Durm, MD - gdurm@iu.edu
NCT04317534
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* The participant (or legally acceptable representative if applicable) must provide written informed consent for the study. The participant may also provide consent for future unspecified research samples. However, the participant may participate in the study without participating in the future unspecified research sample collection. NOTE: Initial informed consent will remain valid throughout the 12-week period between surgical resection and study registration unless, in the opinion of the treating investigator, the participant experiences a significant change in medical or mental status.
* Males and females age ≥ 18 years at the time of consent.
* ECOG Performance Status of 0-1 within 28 days prior to registration.
* Patients must have undergone complete surgical resection of their stage I NSCLC between 4-12 weeks prior to registration and have negative surgical margins (R0).
* NOTE: Both squamous and non-squamous histologies are allowed into the study. Cancers with a histology of "adenosquamous" are considered a type of adenocarcinoma and thus "non-squamous histology".
* NOTE: Staging will be according to the AJCC 8th edition.
* Pathological tumor size must be 1.0 - 4.0 cm in greatest dimension. NOTE: According to AJCC 8th edition, subjects with lepidic predominant adenocarcinoma should be staged based on their invasive tumor size and not their total tumor size (i.e., subjects with lepidic predominant tumors whose invasive tumor size is less than 1 cm are not eligible, even if their total tumor size is 1.0 cm or greater).
* Surgery for this lung cancer must be completed at least 28 days prior to registration.
* Baseline CT chest must be performed within 28 days of randomization to ensure no evidence of disease.
* Must have either previous NGS and PD-L1 results available using the Dako 22C3 antibody or have archival tissue of surgical specimen from current diagnosis available to perform analyses. PD-L1 results via the Dako 22C3 antibody will be performed per standard of care from a CLIA-accredited laboratory and are required for stratification. If NGS results are not available, subjects must be able to provide at least 10 x 10µm unstained and 1 x 4µm H\&E slides from current diagnosis for future NGS and/or other genetic analyses.
* Demonstrate adequate organ function as defined in the protocol; all screening labs to be obtained within 28 days prior to registration.
* Females of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to registration. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. For subjects randomized to the pembrolizumab arm: If there is \> 72 hours between the screening test and C1D1, another pregnancy test (urine or serum) must be performed and must be negative before the subject may start C1D1.
* NOTE: Females are considered of childbearing potential unless: they are postmenopausal; are surgically sterile; or they have a congenital or acquired condition that prevents childbearing. See Section 5.1.4 for definitions.
* NOTE: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
* A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
* Not a woman of childbearing potential (WOCBP) OR
* A WOCBP who is using a highly effective contraceptive method (failure rate of \<1% per year), or is abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) during the intervention period and for at least 120 days after the last dose of study drug. The investigator should evaluate the potential for contraceptive method failure (i.e., noncompliance, recently initiated) in relationship to the first dose of study drug. See contraceptive guidance in Section 5.1.4 of the protocol.
* Participants who are HBsAg positive are eligible if they have received HBV anti-viral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization. Note: Participants should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy after completion of study intervention.
Hepatitis B screening tests are not required unless:
* Known history of HBV infection
* As mandated by local health authority
* Participants with a history of HCV infection are eligible if HCV viral load is undetectable at screening. Note: Participants must have completed curative anti-viral therapy at least 4 weeks prior to randomization.
Hepatitis C screening tests are not required unless:
* Known history of HCV infection
* As mandated by local health authority
* HIV-infected participants are eligible but must have well-controlled HIV on anti-retroviral therapy (ART), defined as:
* Participants on ART must have a CD4+ T-cell count ≥350 cells/mm3 at screening.
* Participants on ART must have achieved and maintained virologic suppression defined as confirmed HIV RNA level below 50 or the LLOQ (below the limit of detection) using the locally available assay at the time of screening and for at least 12 weeks before screening.
* It is advised that participants must not have had any AIDS-defining opportunistic infections within the past 12 months before study entry (Day 1/randomization).
* Participants on ART must have been on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks before study entry (Day 1/randomization) and agree to continue ART throughout the study.
* Note: HIV screening testing is not required unless mandated by local health authority.
* As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study
Exclusion Criteria:
* Current lung cancer is \<1 cm or \> 4 cm in size or is stage II, III, or IV.
* Patients with tumors that are known to harbor actionable EGFR mutations.
* Prior chemotherapy, radiation therapy, or immunotherapy for the treatment of this lung cancer.
* Has a known active additional malignancy that is progressing or has required active treatment within the past 2 years. NOTE: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma in situ, cervical cancer in situ) that have undergone potentially curative therapy are not excluded. Participants with low-risk early-stage prostate cancer (T1-T2a, Gleason score ≤6, and PSA \<10 ng/mL) either treated with definitive intent or untreated in active surveillance with stable disease are not excluded.
* Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).
* Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed vaccines is allowed.
* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
* Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.
* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to randomization.
* Has had an allogenic tissue/solid organ transplant.
* Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
* Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
* Has an active infection requiring systemic therapy.
* Has active TB (Bacillus Tuberculosis) infection.
* HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment. DRUG: Pembrolizumab
NSCLC, Stage I
I'm interested
Share via email
Show 13 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana | Margaret Urich, RN - (muhrich@iu.edu) |
| Moffit Cancer Center Tampa, Florida | Mari Hardy - (marissa.hardy@moffitt.org) |
| Ohio State University Comprehensive Cancer Center Columbus, Ohio | Carly Pilcher - (Carly.Pilcher@osumc.edu) |
| Penn State Cancer Institute Hershey, Pennsylvania | Barbara Husic - (bhusic@pennstatehealth.psu.edu) |
| Providence Health & Services - Oregon Portland, Oregon | Kathleen Dronkowski, MSN, FNP - (kathleen.dronkowski@providence.org) |
| Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey | Karen Jackson - (jacksoka@cinj.rutgers.edu) |
| Univeristy of Wisconsin Madison, Wisconsin | Meghan Dykstra - (mndykstra@wisc.edu) |
| University of Illinois Cancer Center Chicago, Illinois | John Rosa - (johnrosa@uic.edu) |
| University of Iowa Hospitals and Clinics Iowa City, Iowa | Alisha Demsky - (alisha-demsky@uiowa.edu) |
| University of Minnesota Minneapolis, Minnesota | KiKi Price - (Price905@umn.edu) |
| University of Nebraska Medical Center Omaha, Nebraska | Kimberly Shields - (kimberly.shields@unmc.edu) |
| University of Virginia Health System Charlottesville, Virginia | Gracie Hockenberry - (mgt4n@virginia.edu) |
| Virginia Commonwealth University Richmond, Virginia | Carrie Donovan - (cdonovan2@vcu.edu) |
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
Takeda Contact - medinfoUS@takeda.com
NCT06562543
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
• Provide written (or electronic) informed consent.
• Male or female aged more than or equal to (≥)18 years.
• Presence of histologically and/or cytologically documented metastatic colorectal adenocarcinoma. Rat sarcoma virus (RAS) status for each participant must be documented.
• Have been previously treated with standard approved therapies: * Fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, * An anti-vascular endothelial growth factor (VEGF) biological therapy (e.g., bevacizumab, aflibercept, ramucirumab \[regorafenib is NOT an anti-VEGF biologic\]), and * If RAS wild-type and medically appropriate, an anti-epidermal growth factor receptor (EGFR) therapy (e.g., cetuximab, panitumumab). * If known microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) tumor and medically appropriate, a programmed cell death protein 1 (PD1) inhibitor.
• Self-identify as Black and/or African American or Hispanic and/or Latino or as both.
• Body weight ≥40 kilograms (kg).
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at screening.
• Have assessable disease according to RECIST version 1.1, assessed locally.
• In participants of childbearing potential, agreement to use highly effective form(s) of contraception, which results in a low failure rate (less than \[\<\]1 percent \[%\] per year) when used consistently and correctly, starting during the screening period, continuing throughout the entire trial period, and for 2 weeks after taking the last dose of the trial intervention. Such methods include oral (PO) hormonal contraception (combined estrogen/progestogen or progestogen-only) associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system (IUS), bilateral tubal ligation, vasectomized partner, or true sexual abstinence in line with the preferred and usual lifestyle of the participant. Those assigned male sex at birth must always use a condom.
Exclusion Criteria:
• Absolute neutrophil count (ANC) \<1.5 times 10\^9 per liter (10\^9/L), platelet count \<100 times 10\^9/L, or hemoglobin \<9.0 grams per deciliter (g/dL). Blood transfusion within 1 week prior to enrollment for the purpose of increasing the likelihood of eligibility is not allowed.
• Serum total bilirubin more than (\>)1.5 times the upper limit of normal range (ULN). Participants with previously documented Gilbert syndrome and bilirubin \<2 times ULN are eligible.
• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.5 times ULN in participants without hepatic metastases; ALT or AST \>5 times ULN in participants with hepatic metastases.
• Creatinine clearance \<30 milliliters per minute (mL/min). Creatinine clearance can either be measured in a 24-hour urine collection or estimated by the Cockcroft-Gault equation. Where available and appropriate, other formulae may be used to estimate clearance after consultation with the trial medical monitor.
• Urine dipstick or urinalysis with protein ≥2 positive or 24-hour urine protein ≥1.0 gram per 24 hours (g/24 hours). Participants with 1+ positive proteinuria must undergo a 24-hour urine collection to assess urine protein level.
• Uncontrolled hypertension, defined as systolic BP ≥140 millimeter of mercury (mmHg) and/or diastolic blood pressure (BP) ≥90 mmHg despite optimal medical management. The participant must have BP below both limits. Repeated assessments are permitted.
• International normalized ratio (INR) \>1.5 times ULN or activated partial thromboplastin time (aPTT) \>1.5 times ULN, unless the participant is currently receiving or intended to receive anticoagulants for prophylactic purposes.
• History of or active gastric/duodenal ulcer or ulcerative colitis, active hemorrhage of an unresected gastrointestinal tumor, history of perforation or fistulas, or any other condition that could, in the investigator's judgment, result in gastrointestinal hemorrhage or perforation within the 6 months prior to screening.
• History or presence of hemorrhage from any other site (e.g, hemoptysis or hematemesis) within 2 months prior to screening.
• History of a thromboembolic event, including deep vein thrombosis, pulmonary embolism, or arterial embolism within 6 months prior to screening.
• Stroke and/or transient ischemic attack within 12 months prior to screening.
• Clinically significant cardiovascular disease, including but not limited to, acute myocardial infarction or coronary artery bypass surgery within 6 months prior to enrollment, severe or unstable angina pectoris, New York Heart Association Class III/IV congestive heart failure, ventricular arrhythmias requiring treatment, or left ventricular ejection fraction \<50% by echocardiogram.
• QT interval, corrected using the Fridericia method (QTcF) \>480 milliseconds or any factors that increase the risk of QT interval, corrected based on the patient's heart rate (QTc) prolongation or risk of arrhythmic events such as hypokalemia, congenital long QT syndrome, or family history of long QT syndrome.
• Systemic antineoplastic therapies (except for that described in exclusion criterion no. 15) or any investigational therapy within 2 weeks prior to the first dose of the trial intervention, including chemotherapy, radical radiotherapy, hormonotherapy, biotherapy, and immunotherapy.
• Systemic small molecule targeted therapies (e.g., tyrosine kinase inhibitors \[TKIs\]) within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of the trial intervention.
• Palliative radiotherapy for bone metastasis/lesion within 2 weeks prior to the initiation of the trial intervention.
• Brachytherapy (i.e., implantation of radioactive seeds) within 60 days prior to the first dose of the trial intervention.
• Surgery or invasive procedure (i.e., a procedure that includes a biopsy; central venous catheter placement is allowed) within 14 days prior to the first dose of the trial intervention or unhealed surgical incision.
• Any unresolved toxicities from previous antitumor treatments greater than NCI CTCAE, version 5.0, Grade 1 (except for alopecia or neurotoxicity Grade less than or equal to \[≤\]2).
• Known human immunodeficiency virus infection.
• Known history of active viral hepatitis. For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load had to be undetectable on suppressive therapy, if indicated. Participants with hepatitis C virus (HCV) infection who are currently on treatment are eligible if they have an undetectable HCV viral load.
• Clinically uncontrolled active infection requiring intravenous (IV) antibiotics.
• Tumor invasion of a large vascular structure (e.g., pulmonary artery or superior or inferior vena cava).
• Those who are currently pregnant or lactating.
• Brain metastases and/or spinal cord compression untreated with surgery and/or radiotherapy, and without clinical imaging evidence of SD for 14 days or longer; participants requiring steroids within 4 weeks prior to the start of the trial intervention are to be excluded.
• Other malignancy, except for non-melanoma skin cancer, in situ cervical carcinoma, or bladder carcinoma (tumor in situ and T1) that had been adequately treated during the 5 years prior to screening. Participants with another primary malignancy that has been adequately treated may be included after consultation with the trial medical monitor.
• Inability to take medication PO, dysphagia, or an active gastric ulcer resulting from previous surgery (e.g., gastric bypass) or a severe gastrointestinal disease, or any other condition that investigators believe might affect absorption of the investigational medicinal product (IMP).
• Other disease, metabolic disorder, physical examination anomaly, abnormal laboratory result, or any other condition (e.g., current alcohol or drug abuse) that investigators suspect might prohibit use of the IMP, affect interpretation of trial results, or put the participant at undue risk of harm based on the investigator's assessment.
• Known hypersensitivity to fruquintinib or any of its inactive ingredients, including the azo dyes Tartrazine- Federal Food, Drug, and Cosmetic Act (FD\&C) Yellow 5 and Sunset yellow For Coloring Food (FCF)-FD\&C Yellow 6.
• Received prior fruquintinib.
• Live vaccine ≤28 days before the first dose of the trial intervention. Seasonal vaccines for influenza are generally inactivated vaccines and are allowed. Intranasal vaccines are live vaccines and are not allowed.
• Use of strong inducers of cytochrome P450 3A4 (CYP3A4) within 2 weeks before the first dose of the trial intervention.
DRUG: Fruquintinib
Colorectal Cancer
colorectal cancer, fruquintinib
I'm interested
Share via email
Show 45 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Albert Einstein College of Medicine The Bronx, New York | |
| BRCR Global Katy, Texas | |
| Baptist Health - Miami Cancer Institute Miami, Florida | |
| Baylor College of Medicine Houston, Texas | Site Contact - (karen.riggins@bcm.edu) |
| Boston Medical Center Boston, Massachusetts | |
| Capital Health Medical Center - Hopewell Pennington, New Jersey | Site Contact - (ALoaiza-Bonilla@capitalhealth.org) |
| Central Alabama Research Birmingham, Alabama | Site Contact - (kashraf@centralalabamaresearch.com) |
| Christiana Care Health Services Newark, Delaware | Site Contact - (jmisleh@cbg.org) |
| Columbia University New York, New York | |
| Emory University Atlanta, Georgia | Site Contact - (olatunji.alese@emory.edu) |
| Fox Chase Cancer Center | Philadelphia, PA Philadelphia, Pennsylvania | |
| Fundacion de Investigacion de Diego (FDI Clinical Research) San Juan, | |
| Hattiesburg Clinic Hattiesburg, Mississippi | Site Contact - (bo.hrom@hattiesburgclinic.com) |
| Hightower Clinical Research Oklahoma City, Oklahoma | |
| Hope and Healing Cancer Services Hinsdale, Illinois | Site Contact - (sgundala@hopenheal.care) |
| Indiana University Indianapolis, Indiana | Site Contact - (aalhader@iu.edu) |
| Ironwood Cancer and Research Centers Chandler, Arizona | Site Contact - (dharia@ironwoodcrc.com) |
| James J Peters Veterans Administration Medical Center - NAVREF The Bronx, New York | |
| Jefferson Health Abington, Pennsylvania | Site Contact - (Atrayee.BasuMallick@jefferson.edu) |
| Medical University of South Carolina Charleston, South Carolina | |
| Medstar Speciality Hospital Northwest, Washington | Site Contact - (marcus.s.noel@gunet.georgetown.edu) |
| Mercy Medical Center Springfield, Massachusetts | Site Contact - (pledakis@mdmercy.com) |
| Midwest Oncology Associates - Kansas City Kansas City, Missouri | Site Contact - (jaswinder.singh@amrllc.com) |
| Oncology Consultants - Memorial City Location Houston, Texas | Site Contact - (jpeguero@OncologyConsultants.com) |
| Our Lady of the Lake Physician Group - LSU Health Baton Rouge Oncology Baton Rouge, Louisiana | Site Contact - (stagg.patrick@yahoo.com) |
| PIH Health Whittier Hospital Downey, California | Site Contact - (Andrew.Pham@pihhealth.org) |
| Renovatio Clinical The Woodlands, Texas | Site Contact - (mary.crow@renovatioclinical.com) |
| Renovatio Clinical The Woodlands, Texas | Site Contact - (jonathan.lu@renovatioclinical.com) |
| SSM Health St. Louis DePaul Hospital St Louis, Missouri | Site Contact - (brian.smith@ssmhealth.com) |
| Saint Luke's Cancer Institute Kansas City, Missouri | |
| Tranquil Research Webster, Texas | Site Contact - (drknecht@cls.health) |
| UC Irvine Medical Center - Chao Family Comprehensive Cancer Orange, Virginia | Site Contact - (fdayyani@uci.edu) |
| University of Alabama at Birmingham Birmingham, Alabama | Site Contact - (ggupta@uabmc.edu) |
| University of Arizona Tucson, Arizona | Site Contact - (ajscott@arizona.edu) |
| University of California San Diego San Diego, California | Site Contact - (gbotta@ucsd.edu) |
| University of Florida Gainesville, Florida | |
| University of Miami Miami, Florida | |
| University of Southern California Los Angeles, California | Site Contact - (algaze@usc.edu) |
| University of Tennessee -- Memphis Memphis, Tennessee | Site Contact - (schokshi@uthsc.edu) |
| University of Texas Southwestern Medical Center Dallas, Texas | Site Contact - (Nilesh.Verma@UTSouthwestern.edu) |
| Vanderbilt University Medical Center Nashville, Tennessee | Site Contact - (brooke.d.looney@vumc.org) |
| Virginia Commonwealth University Richmond, Virginia | Site Contact - (khalid.matin@vcuhealth.org) |
| Washington University School of Medicine St Louis, Missouri | Site Contact - (nikolaos@wustl.edu) |
| Willis Knighton Cancer Center Shreveport, Louisiana | Site Contact - (jfeagin@wkhs.com) |
| Zangmeister Cancer Center Columbus, Ohio | Site Contact - (smikhail@zangcenter.com) |
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)
Clinical Trials Office - clinical@aveooncology.com
NCT06064877
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Male or female and ≥ 18 years of age
* Histologically and/or cytologically confirmed primary diagnosis of R/M HNSCC
* Participants with oropharyngeal cancer will be required to have proof of p16 negative status submitted on the basis of a pathology report
* At least 1 measurable lesion by contrast CT or MRI scan according to RECIST v.1.1. Such lesions must not have been previously irradiated; if the measurable lesion(s) has been irradiated, clear progression must be documented
* Participants must have failed prior therapy with an anti-PD-1/PD-L1 ICI and with platinum-based chemotherapy administered in combination or sequentially, in either the locally advanced or R/M setting. Failure of prior treatment may be due to progression of disease or intolerance to treatment
* Patient's tumor must be considered inoperable and incurable
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with a life expectancy of at least 12 weeks
* For women of childbearing potential (WOCBP), documentation of negative serum pregnancy test within 30 days of randomization
* For WOCBP and male participants whose sexual partners are of childbearing potential, agreement to use an effective method of contraception during the study and for at least 5 months after the last dose of study treatment. Birth control methods which may be considered highly effective include methods that achieve a failure rate of less than 1% per year when used consistently and correctly.
* Ability to give written informed consent and comply with protocol requirements
* Patients with feeding tubes are eligible for the study.
* Archived tissue sample must be submitted to the Sponsor-designated laboratory within 60 days of randomization for c-Met analysis (if a tissue sample is not available, a fresh biopsy may be required prior to enrollment)
Exclusion Criteria:
* Participants who have received \> 2 prior lines of anticancer therapy or prior treatment with cetuximab/alternative EGFR inhibitors for the treatment of R/M HNSCC
* History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agent or cetuximab
* Known or suspected untreated and uncontrolled brain metastases or leptomeningeal carcinomatosis Note: Participants with locally treated brain metastases are eligible provided 2 weeks have elapsed since local therapy. Participants are allowed to continue steroid taper during the start of study treatment.
* Prior treatment with any other investigational drug or biologic agent or radiation therapy before a washout has been completed (must be completed prior to randomization):
• 2 weeks (14 days) or 5 half-lives, whichever is shorter, for chemotherapeutic agents, small molecules, and checkpoint inhibitors
• 3 weeks (21 days) or 5 half-lives, whichever is shorter, for antibody-drug conjugates
• 4 weeks (28 days) for cell therapies
• 2 weeks (14 days) for radiation therapy * Any unresolved and significant toxicity (National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI-CTCAE\] version 5.0) Grade 2 or greater from previous anticancer therapy (including radiation therapy), other than alopecia * Significant cardiovascular disease, including: Cardiac failure New York Heart Association class III or IV; Myocardial infarction, severe or unstable angina within 6 months prior to randomization; History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) * Any other medical condition or psychiatric condition that, in the opinion of the Investigator, might interfere with the participant's involvement in the study or interfere with the interpretation of study results * History of prior malignancy within 2 years prior to randomization (except for adequately treated non-melanoma skin cancer, carcinoma in situ of the breast or cervix, superficial bladder cancer, or early-stage prostate cancer, without evidence of recurrence; participants may or may not be on maintenance therapy) * Participants who are positive for hepatitis B virus (HBV) or hepatitis C virus (HCV) with indication of acute or chronic hepatitis (as defined in protocol) * Radiographic evidence (historical or at screening) of interstitial lung disease or idiopathic pulmonary fibrosis * Female participants who are pregnant or breastfeeding A full list of inclusion and exclusion criteria can be found in the protocol.
BIOLOGICAL: Ficlatuzumab, BIOLOGICAL: Cetuximab, OTHER: Placebo
Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Recurrent, Metastatic, HPV-negative, Head and Neck, Squamous Cell Carcinoma
I'm interested
Share via email
Show 112 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| AOU Careggi Florence, Tuscany | |
| AdventHealth Medical Group Oncology & Hematology at Orlando Orlando, Florida | |
| Ajou University Hospital Suwon, Gyeonggi-do | |
| Antoni van Leeuwenhoek Amsterdam, | |
| Assistance Publique Hopitaux de Marseille (APHM)-Hôpital La Timone Marseille, | |
| Azienda Ospedaliera Universitaria Maggiore Della Carita Novara Novara, | |
| Banner MD Anderson Cancer Center Gilbert, Arizona | |
| CHU Liege Liège, | |
| CHU Universite Catholique de Louvain Namur, | |
| Centre Leon Berard Lyon, | |
| Centrul radioterapie Amethyst Cluj-Napoca Floreşti, | |
| Centrum Onkologii im. Prof. F. Lukaszczyka w Bydgoszczy Bydgoszcz, | |
| Chang Gung Memorial Hospital - Kaohsiung Kaohsiung Niao Sung Dist, Kaohsiung | |
| Chang Gung Memorial Hospital - Linkou Taoyuan City, | |
| Changhua Christian Hospital Changhua, | |
| Charite-Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK) - Medizinische Klinik mit Schwerpunkt Haematologie, Onkologie und Tumorimmunologie Berlin, | |
| China Medical University Hospital (CMUH) Taichung, | |
| City Hospital Nottingham Nottingham, | |
| Clinique Pasteur - Lanroze- Centre Finistérien de Radiothérapie et d'Oncologie Brest, | |
| Cross Cancer Institute Edmonton, Alberta | |
| Dana Farber Cancer Institute Boston, Massachusetts | |
| Emory University Atlanta, Georgia | |
| Fakultni nemocnice Brno Brno-Bohunice, | |
| Fakultni nemocnice Bulovka Prague, | |
| Fakultni nemocnice Kralovske Vinohrady Prague, | |
| Fakultni nemocnice Olomouc Olomouc, | |
| Fondazione IRCCS - Istituto Nazionale Tumori - Oncologia Milan, | |
| Fondazione Policlinico Universitario Agostino Gemelli Irccs Rome, | |
| Fox Chase Cancer Center Philadelphia, Pennsylvania | |
| Grupo Hospital de Madrid (HM) - Hospital Universitario Madrid Sanchinarro - Centro Integral Oncologico Clara Campal (CIOCC) Madrid, | |
| Hospital Clinico Universitario de Valencia (CHUV) Valencia, | |
| Hospital Quironsalud Malaga Málaga, | |
| Hospital Universitario La Paz Madrid, | |
| Hospital Universitario Marqués de Valdecilla Santander, | |
| Hospital Universitario Vinalopo Alicante, | |
| Hospital Universitario de Torrejón Torrejón de Ardoz, | |
| Hospital universitario Jerez Cadiz, | |
| Hôpital Privé des Côtes d'Armor Plérin, | |
| IRCCS - ICS Maugeri Pavia, | |
| IRCCS Istituto Clinico Humanitas - Cancer center Milan, | |
| IRCCS Istituto Scienze Neurologiche Bologna, | |
| IRCCS Ospedale San Raffaele Milano Milan, | |
| Institut Catala d'Oncologia (ICO) - Hospitalet Barcelona, | |
| Institut Catala d'Oncologia - Hospital Duran i Reynals Badalona, | |
| Institut Curie Paris, | |
| Institut Gustave Roussy Villejuif, | |
| Institute for Oncology Vojvodina Kamenitz, | |
| Institute of Oncology and Radiology of Serbia Belgrade, | |
| Istituto Oncologico Veneto Padua, | |
| Josa Andras Oktatokorhaz Nyíregyháza, | |
| Keimyung University Dongsan Hospital Daegu, | |
| Korea University Anam Hospital Seoul, | |
| Ludwig-Maximilians University Munich, | |
| MD Anderson Cancer Center Houston, Texas | |
| MaineHealth Institute for Research South Portland, Maine | |
| Manhattan Eye, Ear & Throat Hospital New York, New York | |
| Mary Bird Perkins Cancer Center Baton Rouge, Louisiana | |
| Masaryk Memorial Cancer Institute Brno, | |
| Massachusetts General Hospital Boston, Massachusetts | |
| McGill University Health Centre (MUHC) Montreal, Quebec | |
| Medical College of Wisconsin - Froedtert Hospital Cancer Center Milwaukee, Wisconsin | |
| Medical University of South Carolina (MUSC) Charleston, South Carolina | |
| Medisprof Cancer Center Cluj-Napoca, | |
| Moffitt Cancer Center Tampa, Florida | |
| Montefiore Medical Center The Bronx, New York | |
| NHS Grampian - Aberdeen Royal Infirmary Aberdeen, | |
| National Cheng-Kung University Hospital Tainan, | |
| National Research Institute of Oncology Gliwice, | |
| National Taiwan University Hospital Taipei, | |
| Northwell Health Cancer Institute Lake Success, New York | |
| Ohio State University, James Cancer Hospital and Solove Research Institute Columbus, Ohio | |
| Oncology Consultants Houston, Texas | |
| Orszagos Onkologiai Intezet Budapest, | |
| Petz Aladar Country Teaching Hospital Győr, | |
| Princess Alexandra Hospital Woolloongabba, Queensland | |
| Princess Margaret Cancer Center - University Health Network Toronto, | |
| Pôle Santé Léonard de Vinci Chambray-lès-Tours, | |
| Radboud University Medical Center Nijmegen, | |
| Samsung Medical Center Seoul, | |
| Sarah Cannon Research Institute Denver, Colorado | |
| Seoul National University Hospital Seoul, | |
| Severance Hospital, Yonsei University Health System Seoul, | |
| Siteman Cancer Center - Washington University St Louis, Missouri | |
| St George Hospital Sydney, | |
| St. John of God Murdoch Hospital Murdoch, Western Australia | |
| St. Vincent's Hospital Darlinghurst, New South Wales | |
| Szent Lázár Megyei Kórház Salgótarján, | |
| Taipei Veterans General Hospital Taipei, | |
| The Catholic University of Korea, Eunpyeong St. Mary's Hospital Seoul, | |
| The George Washington University Washington D.C., District of Columbia | |
| The Ottawa Hospital Cancer Centre Ottawa, Ontario | |
| The Royal Marden Hospital, Surrey Sutton, | |
| The Royal Marsden NHS Foundation Trust London, | |
| The University of Arizona Cancer Center Tucson, Arizona | |
| Tom Baker Cancer Centre (Alberta Health Services) Calgary, Alberta | |
| Torbay Hospital Torquay, | |
| UNIVERSITÄTSKLINIKUM FREIBURG, Klinik für Innere Medizin I, Schwerpunkt Hämatologie, Onkologie und Stammzelltransplantation Freiburg im Breisgau, | |
| UOMI Cancer Center-Clinica Tres Torres Barcelona, | |
| Universita degli Studi di Pavia - Fondazione IRCCS Policlinico San Matteo Pavia, | |
| University Clinical Center Kragujevac Kragujevac, | |
| University Hospital Newark, New Jersey | |
| University of California Los Angeles Los Angeles, California | |
| University of Cincinnati - UC Health Barrett Cancer Center Cincinnati, Ohio | |
| University of Illinois Cancer Center Chicago, Illinois | |
| University of Kansas Cancer Center Kansas City, Kansas | |
| University of Maryland Baltimore, Maryland | |
| University of Pecs - Oncology Pécs, | |
| University of Pittsburgh Medical Center - Hillman Cancer Center Pittsburgh, Pennsylvania | |
| VCU Massey Cancer Center Richmond, Virginia | |
| Vall d'Hebron Institut d'Oncologia (VHIO) Barcelona, | |
| Vitaz-Sint-Niklaas Moerland Sint-Niklaas, | |
| Yale School of Medicine - Smilow Cancer Hospital New Haven, Connecticut |
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Gilead Clinical Study Information Center - GileadClinicalTrials@gilead.com
NCT05633654
Show full eligibility criteria
Hide eligibility criteria
Key
Inclusion Criteria:
* Age \> 18 years, with residual invasive triple negative breast cancer (TNBC) in the breast or lymph nodes after neoadjuvant therapy and surgery:
* TNBC criteria for the study is defined as estrogen receptor (ER) and progesterone receptor (PR) ≤ 10%, human epidermal growth factor receptor 2 (HER2)-negative per American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) guidelines (immunohistochemistry (IHC) and/or in situ hybridization (ISH)).
* Adequate excision and surgical removal of all clinically evident of disease in the breast and/or lymph nodes and have adequately recovered from surgery.
* Submission of both pre-neoadjuvant treatment diagnostic biopsy and resected residual invasive disease tissue.
* Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
* Individuals must have received appropriate radiotherapy aligned with local/institutional practice and have recovered prior to starting study treatment.
* Adequate organ function.
Key Exclusion Criteria:
* Stage IV (metastatic) breast cancer as well as history of any prior (ipsi- or contralateral) invasive breast cancer.
* Prior treatment with another stimulatory or coinhibitory T-cell receptor agent (eg, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), OX-40, cluster of differentiation 137 (CD137), prior treatment with any HER2-directed agent, prior endocrine therapy for \> 4 weeks or planned concurrent endocrine therapy while receiving on-study treatment.
* Evidence of recurrent disease following preoperative therapy and surgery.
* Prior treatment with topoisomerase 1 inhibitors or antibody-drug conjugates (ADCs) containing a topoisomerase inhibitor.
* Individuals with germline breast cancer gene (BRCA) mutations.
* Myocardial infarction or unstable angina pectoris within 6 months of enrollment or history of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias or Left ventricular ejection fraction (LVEF) of \< 50%
* Active serious infections requiring anti-microbial therapy.
Note: Other protocol defined Inclusion/Exclusion criteria may apply. DRUG: Sacituzumab govitecan-hziy (SG), DRUG: Pembrolizumab, DRUG: Capecitabine
Triple Negative Breast Cancer
AFT-65, GBG 119, NSABP B-63, OptimICE-RD
I'm interested
Share via email
Show 356 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| AMO Clinic - Rio Vermelho Salvador, | |
| AOU Città della Salute e della Scienza di Torino Torino, | |
| AOU Modena Modena, | |
| AZ Delta vzw Roeselare, West-Vlaanderen | |
| Alabama Oncology Birmingham, Alabama | |
| Albert-Schweitzer-Campus 1, Building A1, Münster, | |
| Alta Bates Summit Medical Center Berkeley, California | |
| Althaia Xarxa Assistencial de Manresa Manresa, | |
| Am Klinikum 1 Jena, | |
| American Oncology Partners of Maryland, PA Bethesda, Maryland | |
| Anita Stewart Oncology Center Columbus, Ohio | |
| Arizona Oncology Associates Tucson, Arizona | |
| Arnold-Heller-Str. 3 Haus C Kiel, | |
| Asan Medical Center Seoul, | |
| Asante Rogue Regional Medical Center Medford, Oregon | |
| Ascension Grosse Pointe Woods, Michigan | |
| Ascension Providence Hospital Southfield Cancer Center Southfield, Michigan | |
| Ascension St. Francis Reiman Cancer Center Franklin, Wisconsin | |
| Asst Papa Giovanni XXIII Bergamo, Lombardy | |
| Atrium Health Wake Forest Baptist Winston-Salem, North Carolina | |
| Av. Brigadeiro Luís Antônio 733, loja 8 São Paulo, | |
| Av. Ipiranga 6690 Porto Alegre, | |
| Av. Miguel Castro, 1355, Nossa Senhora de Nazaré, Natal/RN Natal, | |
| Av. Milton Santos, 123 - Ondina, Salvador - BA, , Brasil Salvador, | |
| Av. Soledad, 569, sala 1103, Três Figueiras, CEP 90470-340 Porto Alegre, | |
| Avera Cancer Institute Sioux Falls, South Dakota | |
| Azienda Ospedaliera Universitaria Careggi Florence, Tuscany | |
| Ballad Health Cancer Care - Kingsport Kingsport, Tennessee | |
| Baptist Clinical Research Institute St Louis, Missouri | |
| Barts Health NHS Trust London, | |
| Baystate Medical Center Inc. Springfield, Massachusetts | |
| Beaumont Hospital Dublin, Co Dublin | |
| Beethovenstrasse 20 Wiesbaden, | |
| Bei der Marienkirche 6 Mühlhausen, | |
| Bendigo Health Bendigo, Victoria | |
| Beth Israel Deaconess Medical Center Boston, Massachusetts | |
| Biedermannstrasse 84 Leipzig, | |
| Bon Secours Cancer Institute at St. Francis Midlothian, Virginia | |
| Böheimstr. 37 Stuttgart, | |
| CHU Amiens Picardie Amiens, | |
| CHU de Limoges Limoges, | |
| CHU de Nimes Nîmes, | |
| CHU de Poitiers, 2 Rue de la Milétrie Poitiers, | |
| CIPE Centro Internacional de Pesquisa; A.C. Camargo Cancer Center São Paulo, | |
| Cairns Hospital Cairns, | |
| Calwerstrasse 7 Tübingen, | |
| Cancer Care & Hematology Specialists Reno, Nevada | |
| Cancer Care Associates of York York, Pennsylvania | |
| Cancer Care Centers of Brevard, Inc Palm Bay, Florida | |
| Cancer Center Of Kansas Wichita, Kansas | |
| Cancer Research SA Adelaide, South Australia | |
| Cancer Specialists of North Florida Jacksonville, Florida | |
| Cancer and Hematology Centers of Western Michigan Grand Rapids, Michigan | |
| Carle Cancer Center Urbana, Illinois | |
| Cedars-Sinai Cancer at Beverly Hills Los Angeles, California | |
| Center for Biomedical Research, LLC Knoxville, Tennessee | |
| Centre Eugene Marquis Rennes, | |
| Centre d'Oncologie de Gentilly Nancy, | |
| Charlottenstraße 72 Potsdam, | |
| Chirec Delta Hospital Brussels, | |
| City of Hope (Duarte) San Francisco, California | |
| Clearview Cancer Institute Huntsville, Alabama | |
| Cleveland Clinic Florida, Martin North Hospital Stuart, Florida | |
| Clinical Research Alliance Westbury, New York | |
| Clinique CHC MontLégia Liège, | |
| Clinique Ste Anne Strasbourg_Oncologie Liberale Strasbourg, | |
| Clinique Victor Hugo Le Mans, | |
| Clínica Universidad de Navarra - Madrid Pamplona, | |
| Columbus NCORP Columbus, Ohio | |
| Community Cancer Institute Clovis, California | |
| Compassionate Cancer Care Medical Group - Inc Fountain Valley, California | |
| Comprehensive Cancer Centers of Nevada Las Vegas, Nevada | |
| Cone Health Medical Group (Moses Cone Health System) Greensboro, North Carolina | |
| Consorcio Hospitalario Provincial de Castellon Castellon, | |
| Cork University Hospital Cork, | |
| Dana Farber Cancer Institute Boston, Massachusetts | |
| Dana Farber Cancer Institute @ Milford Regional Hospital Milford, Massachusetts | |
| Dana-Farber Cancer Institude at Merrimack Valley Methuen, Massachusetts | |
| Dana-Farber Cancer Institute @Foxborough Foxborough, Massachusetts | |
| Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) in Clinical Affiliation with South Shore Hospital South Weymouth, Massachusetts | |
| Duke Cancer Institute Durham, North Carolina | |
| East Carolina University Health Medical Center Greenville, North Carolina | |
| East and North Hertfordshire NHS Trust Northwood, | |
| Edgar-von-Gierke-Straße 2 Karlsruhe, | |
| Edward H. Kaplan MD & Associates - Hematology/Oncology of the North Shore Skokie, Illinois | |
| Edward Hospital Naperville, Illinois | |
| Elisabeth Krankenhaus Brustzentrum Kassel, | |
| Elisabethenstr. 19, 88212 Ravensburg Ravensburg, | |
| Emad Ibrahim, MD, INC Redlands, California | |
| Fachärztezentrum Langen Langen, | |
| Fetscherstraße ,74 Dresden, | |
| Fiona Stanley Hospital Murdoch, Western Australia | |
| FirstHealth Outpatient Cancer Center Pinehurst, North Carolina | |
| Fondazione Policlinico Universitario Agostino Gemelli Irccs Rome, | |
| Fondazione Policlinico Universitario Campus Bio-Medico di Roma Rome, | |
| Franciscan Health Indianapolis Indianapolis, Indiana | |
| Franciscan Health Munster Munster, Indiana | |
| Gangnam Severance Hospital Seoul, | |
| Good Samaritan Hospital Corvallis, Oregon | |
| Gotenstraße 6-8 Frankfurt am Main, | |
| Greater Baltimore Medical Center Baltimore, Maryland | |
| Guthrie Clinical Research Sayre, Pennsylvania | |
| Guy's Hospital Great Maze Pond, | |
| H. León León, | |
| HSHS Saint Mary's Hospital Medical Center - Green Bay Green Bay, Wisconsin | |
| HU Marqués de Valdecilla Santander, | |
| Harsefelderstraße 8 Stade, | |
| Helios University Hospital University Witten/Herdecke Wuppertal, | |
| Hematology Oncology Associates of Central New York, PC East Syracuse, New York | |
| Hendrick Health System Abilene, Texas | |
| Henricistraße 92, 45136 Essen, Germany Essen, | |
| Henry Ford Health System Novi, Michigan | |
| Hoag Memorial Hospital Presbyterian Newport Beach, California | |
| Hohe Weide 17b Hamburg, | |
| Hopital Prive Jean Mermoz Lyon, | |
| Hopital Privé des Côtes d'Armor - Centre CARIO-HPCA Plérin, | |
| Hosp. Mat-Inf. Carlos Haya Málaga, | |
| Hospital Arnau de Vilanova Lleida, | |
| Hospital Beata María Ana Madrid, | |
| Hospital Clinic de Barcelona Barcelona, | |
| Hospital Clinico Universitario de Valencia Valencia, | |
| Hospital Clinico Universitario de Valencia Valencia, | |
| Hospital Clinico Universitario de Valladolid Valladolid, | |
| Hospital De La Santa Creu I Sant Pau Barcelona, | |
| Hospital Del Mar Barcelona, | |
| Hospital Donostia Donostia / San Sebastian, | |
| Hospital Galdakao Galdakao, | |
| Hospital General Univers Murcia, | |
| Hospital General Universitario Gregorio Marañon Madrid, | |
| Hospital General Universitario de Elche Elche, Alicante | |
| Hospital Parc Tauli Sabadell, | |
| Hospital Quironsalud Sagrado Corazón Seville, | |
| Hospital Reina Sofia Córdoba, | |
| Hospital Universitari Sant Joan de Reus Reus, | |
| Hospital Universitario Clínico San Cecilio Granada, | |
| Hospital Universitario Morales Meseguer Murcia, | |
| Hospital Universitario San Pedro de Alcantara Cáceres, | |
| Hospital Universitario Virgen Macarena Seville, | |
| Hospital Universitario Virgen de la Victoria Málaga, | |
| Hospital Universitario Virgen de las Nieves Granada, | |
| Hospital Universitario de Canarias Santa Cruz de Tenerife, | |
| Hospital Universitario de Fuenlabrada Fuenlabrada, | |
| Hospital Universitario de Jaen Jaén, | |
| Hospital Universitary of Cruces Barakaldo, | |
| Hospital de Toledo Toledo, | |
| Hugstetter Str. 55 Freiburg im Breisgau, | |
| Hull University Teaching Hospitals NHS Trust Cottingham, | |
| Humanitas Istituto Clinico Catanese Misterbianco, | |
| Hunterdon Medical Center Flemington, New Jersey | |
| Huntsman Cancer Institute Salt Lake City, Utah | |
| Husenerstr. 81 Paderborn, | |
| Hämato-Onkologische Praxis im Medicum Bremen, | |
| Hämatologie-Onkologie im Zentrum MVZ GmbH Augsburg, | |
| ICO Badalona - Hospital Germans Trias I Pujol Badalona, | |
| IRCCS AOM Ospedale Policlinico San Martino Genova, | |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna Bologna, | |
| IRCCS Fondazione G. Pascale Naples, | |
| IRCCS Istituto Tumori "Giovanni Paolo II" Bari, | |
| IU Health Arnett Hospital Lafayette, Indiana | |
| InVO - Institut für Versorgungsforschung in der Onkologie GbR / Praxis für Hämatologie und Onkologie Koblenz, | |
| Inova Fairfax Hospital Falls Church, Virginia | |
| Institut de Cancérologie de l'Ouest (ICO) - St Herblain Loire Atlantique, | |
| Instituto Santa Joana Recife de Ensino e Pesquisa Recife, | |
| Investigative Clinical Research of Indiana, LLC Indianapolis, Indiana | |
| Isabel la Catolica nº 1-3 Zaragoza, | |
| Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) 'Dino Amadori? IRCCS Meldola, | |
| James M Stockman Cancer Institute Frederick, Maryland | |
| Jessa Ziekenhuis Hasselt, | |
| Joe Arrington Cancer Research and Treatment Center Lubbock, Texas | |
| Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland | |
| Josef-Albers-Str.70 Bottrop, | |
| Jupiter Medical Center Jupiter, Florida | |
| Kinghorn Cancer Centre Darlinghurst, New South Wales | |
| Klinikum Esslingen Esslingen am Neckar, | |
| Klinikum Worms Frauenklinik Worms, | |
| Kootenai Health Coeur d'Alene, Idaho | |
| Korea University Anam Hospital Seoul, | |
| Kostara Gyn. Oncology Clinic Research UG Düsseldorf, | |
| Kyungpook National University Chilgok Hospital Daegu, | |
| L'Hôpital Privé du Confluent Nantes, | |
| Lake Macquarie Private Hospital Gateshead, New South Wales | |
| Lancaster General Health Lancaster, Pennsylvania | |
| Lankenau Medical Center Wynnewood, Pennsylvania | |
| Laura and Isaac Perlmutter Cancer Canter New York, New York | |
| Liebigstraße 20 Leipzig, | |
| Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina | |
| Lipson Cancer Institute - Linden Oaks Rochester, New York | |
| Los Angeles Cancer Network Glendale, California | |
| Lutherplatz 40 Krefeld, | |
| MD Anderson Cancer Center Houston, Texas | |
| MVZ II der Niels Stensen Kliniken Georgsmarienhütte, | |
| Macarthur Cancer Therapy Centre, Campbelltown Hospital Campbelltown, New South Wales | |
| Marienplatz 2 Witten, | |
| Martiiano de Carvalho 965 São Paulo, | |
| Mary Bird Perkins Cancer Center Baton Rouge, Louisiana | |
| Mary Lanning Healthcare - Morrison Cancer Center Hastings, Nebraska | |
| Massachusetts General Hospital Boston, Massachusetts | |
| Mater Misericordiae University Hospital Dublin, Co Dublin | |
| Mayo Clinic Florida Jacksonville, Florida | |
| Mayo Clinic Hospital Phoenix, Arizona | |
| Mayo Clinic Rochester Rochester, Minnesota | |
| MedStar Georgetown University Hospital Washington D.C., District of Columbia | |
| Medical Oncology Associates Kingston, Pennsylvania | |
| Medical Oncology Unit. A Coruña University Hospital A Coruña, | |
| Medical University of South Carolina Charleston, South Carolina | |
| Medstar Washington Hospital Center Washington D.C., District of Columbia | |
| Memorial Healthcare System Hollywood, Florida | |
| Mercy Health Paducah, Kentucky | |
| Mercy Hospital Coon Rapids, Minnesota | |
| Mercy Medical Center Springfield, Massachusetts | |
| Metro Minnesota Community Oncology Saint Louis Park, Minnesota | |
| Midland Florida Clinical Research Center, L Orange City, Florida | |
| Minnesota Oncology Hematology, PA Maplewood, Minnesota | |
| Mission Cancer & Blood - John Stoddard Cancer Center Des Moines, Iowa | |
| Monash Medical Centre Clayton, | |
| Montefiore Medical Center The Bronx, New York | |
| Monument Health Cancer Care Institute Rapid City, South Dakota | |
| Moorkamp 2-6 Hamburg, | |
| Morton Plant Hospital - Bay Care Clearwater, Florida | |
| Mount Sinai Comprehensive Cancer Center Miami Beach, Florida | |
| MultiCare Regional Cancer Center - Tacoma Puyallup, Washington | |
| Munckelstrasse 27 Gelsenkirchen, | |
| Möllendorffstr. 52, 10367 Berlin 2. Behandlungsstandort: Markt 2-3, 13597 Berlin Berlin, | |
| Nebraska Methodist Hospital (change from Chi Health Bergan Mercy) Omaha, Nebraska | |
| New England Cancer Specialists Westbrook, Maine | |
| New York Cancer and Blood Specialists New York, New York | |
| New York Oncology Hematology (NYOH) Amsterdam, New York | |
| NorthShore University Healthsystem Evanston, Illinois | |
| Northside Hospital Atlanta, Georgia | |
| Northwell Health Lake Success, New York | |
| Northwest Georgia Oncology Centers, PC Marietta, Georgia | |
| Northwest Medical Specialties, PLLC Tacoma, Washington | |
| Northwestern Medicine Chicago, Illinois | |
| Norton Healthcare, Inc. Louisville, Kentucky | |
| Norwalk Hospital Norwalk, Connecticut | |
| Novant Health Cancer Institute - Elizabeth (Breast) Charlotte, North Carolina | |
| Ohio Health Research Institute Columbus, Ohio | |
| Ohio State University CRS Columbus, Ohio | |
| Oncology Hematology Care, Inc. Cincinnati, Ohio | |
| Oncology Hematology West - Methodist Omaha, Nebraska | |
| Oncology and Hematology Associates of Southwest Virginia, Inc Wytheville, Virginia | |
| Oncopole Claudius Regaud - IUCT-O Toulouse, | |
| Oncosite Ijuí, | |
| Oregon Health & Science University Portland, Oregon | |
| Orlando Health Orlando, Florida | |
| Ospedale Santa Chiara Trento, | |
| Overlook Medical Center Summit, New Jersey | |
| PIH Health Whittier Hospital Downey, California | |
| Palo Verde Hematology Oncology Glendale, Arizona | |
| Pearlman Cancer Center Valdosta, Georgia | |
| Piedmont Cancer Institute Atlanta, Georgia | |
| Port Macquarie Base Hospital Port Macquarie, New South Wales | |
| Princess Alexandra Hospital Woolloongabba, Queensland | |
| Prittwitzstr. 43 Ulm, | |
| Providence Cancer Institute - Oncology Clinical Trials Portland, Oregon | |
| Providence Health Providence, Rhode Island | |
| Providence Regional Cancer System Lacey, Washington | |
| Pôle Santé Léonard De Vinci - ROC37 Chambray-lès-Tours, | |
| R. Aderbal Ramos da Silva, 148 - Centro, Itajaí - SC, 88300-000, Brasil Itajaí, | |
| Rahel-Straus-Straße 10 Oldenburg, | |
| Reading Hospital and Medical Center West Reading, Pennsylvania | |
| Regional Cancer Care Associates LLC East Brunswick, New Jersey | |
| Roswell Park Cancer Institute Buffalo, New York | |
| Royal Marsden Hospital London, | |
| Rua Gardênia, 710, Edifício Prime, 4º andar, Bairro Jóquei, Teresina - PI, CEP 60449-200 Teresina, | |
| Rua Myltho Anselmo da Silva, 870 - Mercês, Curitiba - PR, CEP 80510-130 Curitiba, | |
| Rua Professor Annes Dias, 295 - Centro Histórico, Porto Alegre - RS, , Brasil Porto Alegre, | |
| Rush University Medical Center Chicago, Illinois | |
| Rutgers Health New Brunswick, New Jersey | |
| SUNY Upstate Medical University Syracuse, New York | |
| Sacred Heart Medical Oncology Group Pensacola, Florida | |
| Saint Luke's University Hospital Bethlehem, Pennsylvania | |
| Samaritan Hospital Corvallis, Oregon | |
| Samsung Medical Center Seoul, | |
| San Juan Oncology Associates Farmington, New Mexico | |
| Sansum Clinic Santa Barbara, California | |
| Schierghoferstrasse 1 Traunstrein, | |
| Schwanebecker Chaussee 50 Berlin, | |
| Seoul National University Bundang Hospital Seongnam-si, | |
| Seoul National University Hospital Seoul, | |
| Severance Hospital Seoul, | |
| Sinai Hospital of Baltimore, Inc. Baltimore, Maryland | |
| Soonchunhyang University Cheonan Hospital Chungcheongnam-do, | |
| Southeastern Regional Medical Center, Inc. dba City of Hope Atlanta Newnan, Georgia | |
| Spartanburg Medical Center Spartanburg, South Carolina | |
| Springfield Clinic LLP Springfield, Illinois | |
| St James's Hospital Dublin, | |
| St Lukes Mountain States Tumor Institute Boise, Idaho | |
| St. Agnes Hospital Baltimore, Maryland | |
| St. Charles Health System, Inc. DBA St. Charles Medical Center Bend, Oregon | |
| St. Elisabeth Krankenhaus GmbH Cologne, | |
| St. Johannes Hospital Dortmund, | |
| St. Joseph's Hospital Tucson, Arizona | |
| St. de Habitações Individuais Sul QI 15 - Lago Sul, Brasília - DF, Brasil Brasília, | |
| St.-Juergen-Str. 1 Bremen, | |
| Stamford Hospital Stamford, Connecticut | |
| Starkenburgring 66, 63069 Offenbach Offenbach, | |
| Stockton Hematology Oncology Medical Group Stockton, California | |
| Stony Brook Medicine Stony Brook, New York | |
| Straße des Friedens 122 Gera, | |
| Studien GbR Braunschweig Braunschweig, | |
| Summit Medical Group, P.A. Florham Park, New Jersey | |
| Sutter Institute for Medical Research Sacramento, California | |
| Sylvester Comprehensive Cancer Center Miami, Florida | |
| Südring 81 Rostock, | |
| Taunton and Somerset Nhs Foundation Trust Taunton, | |
| Taxisstrasse 3 Munich, | |
| Teutoburger Str. 60 Bielefeld, | |
| Texas Oncology Pearland, Texas | |
| Texas Oncology Pearland, Texas | |
| Texas Oncology Pearland, Texas | |
| The Catholic University of Korea, Seoul St. Mary's Hospital Seoul, | |
| The Christie NHS Foundation Trust Manchester, Lancashire | |
| The Clatterbridge Cancer Centre NHS Foundation Trust Liverpool, | |
| ThedaCare Regional Cancer Center Appleton, Wisconsin | |
| Toledo Clinic Cancer Center Toledo, Ohio | |
| Trinity Health St. Joseph Mercy Ann Arbor Ypsilanti, Michigan | |
| UCSF Medical Center San Francisco, California | |
| UNC Nash Cancer Center Rocky Mount, North Carolina | |
| UNC REX Cancer Center Raleigh, North Carolina | |
| UPMC Magee-Womens Hospital Pittsburgh, Pennsylvania | |
| USC Norris Comprehensive Cancer Center Los Angeles, California | |
| UZ Leuven Leuven, | |
| Universitatsklinikum Mannheim Mannheim, | |
| University Cancer & Blood Center, LLC. Athens, Georgia | |
| University Hospital Limerick Limerick, | |
| University Hospitals Birmingham NHS Foundation Trust Birmingham, | |
| University Medical Center New Orleans New Orleans, Louisiana | |
| University of Chicago Medical Center Chicago, Illinois | |
| University of Colorado Cancer Center Aurora, Colorado | |
| University of Florida Gainesville, Florida | |
| University of Illinois Chicago, Illinois | |
| University of Iowa Hospitals and Clinics Iowa City, Iowa | |
| University of Kentucky Lexington, Kentucky | |
| University of Massachusetts Worcester Worcester, Massachusetts | |
| University of Minnesota Medical Center, Fairview Minneapolis, Minnesota | |
| University of New Mexico Albuquerque, New Mexico | |
| University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma | |
| University of Pennsylvania Abramson Cancer Center Philadelphia, Pennsylvania | |
| University of Tennessee Knoxville, Tennessee | |
| University of Virginia Charlottesville, Virginia | |
| University of Washington Seattle, Washington | |
| University of Wisconsin Madison, Wisconsin | |
| Universitätsstraße, 21-23 Erlangen, | |
| Virginia Commonwealth University Medical Center Richmond, Virginia | |
| Virginia Piper Cancer Center (Allina Health) Minneapolis, Minnesota | |
| Washington University School of Medicine St Louis, Missouri | |
| West Suburban Medical Center- River Forest River Forest, Illinois | |
| West Virginia University Hospital Morgantown, West Virginia | |
| Weston Hospital Weston, Florida | |
| White Plains Hospital Physician Associates White Plains, New York | |
| Willamette Valley Cancer Institute and Research Center Eugene, Oregon | |
| William Beaumont Hospital Royal Oak, Michigan | |
| Wismarsche Strasse 393-397 Schwerin, | |
| York Teaching Hospital NHS Foundation Trust York, | |
| Ziekenhuls aan de Stroom vzw (ZAS vzw), ZAS Augustinus Wilrijk, |
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment (ASCENDE-SBRT)
Wendy Parulekar - wparulekar@ctg.queensu.ca
NCT06235697
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Histologically confirmed adenocarcinoma of the prostate diagnosed within the last 9 months
* Participants with unfavourable risk prostate cancer are eligible according to the following NCCN classification guidelines (Version 4.2022 - May 10, 2022):
• Unfavourable-intermediate risk - has one or more of the following:
* 2 or 3 Intermediate Risk Factors (IRFs): cT2b-cT2c, Gleason 7 (grade group 2 or 3), and/or PSA 10-20 ng/ml;
* Gleason 4+3 (grade group 3)
* \> 50% biopsy cores positive
• High risk - has one of the following:
* cT3a
* Gleason 8-10 (grade group 4 or 5)
* PSA \> 20 ng/ml
• Very-high risk - has at least one of the following:
* cT3b-cT4
* Primary Gleason pattern 5
* 2 or 3 high risk features: cT3a, Gleason 8-10 (grade group 4 or 5), and/or PSA \> 20 ng/ml
* \> 4 cores with Gleason 8-10 (grade group 4 or 5)
* ECOG performance status of 0, 1 or 2
* Participants must be ≥ 18 years of age
* Judged to be medically fit for brachytherapy
* Participant is able (i.e. sufficiently fluent) and willing to complete the quality of life and/or health utility questionnaires in either English, French or Spanish
* Participants consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each participant must sign a consent form prior to enrollment in the trial to document their willingness to participate
* Participants must be accessible for treatment and follow-up. Investigators must assure themselves the participants enrolled on this trial will be available for complete documentation of the treatment, adverse events, and follow-up
* In accordance with CCTG policy, protocol treatment is to begin within 12 weeks of participant enrollment
* Participants must be willing to take precautions to prevent pregnancy while on study
* ADT (LHRH agonists, antagonists, or anti-androgens) for prostate cancer is permitted for up to 30 days before study enrollment
* 5-alpha reductase inhibitors (5-ARI) are allowed, but baseline PSA will be corrected if 5-ARI use occurs within 6 months of enrollment
* Participants may NOT have received other therapies including chemotherapy, PARPi, radioligand or other investigational drugs for prostate cancer
* Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
* Urinary function defined as International Prostate Symptom Score (IPSS) \< 20. Alpha blockers are allowed to treat baseline urinary function
* HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
Exclusion Criteria:
* Prior pelvic radiotherapy
* Contraindication to radical prostate radiotherapy (e.g. connective tissue disease or inflammatory bowel disease)
* Anticoagulation medication (if unsafe to discontinue for gold seed insertion or brachytherapy implant) and/or prior or current bleeding diathesis
* Prior steam vaporization (Rezum), transurethral resection of the prostate (TURP), prostatectomy (simple or radical), or any ablative therapy to the prostate (cryotherapy, HIFU, TULSA, focal laser ablation, photodynamic therapy)
* Prostate volume \> 60cc before start of androgen deprivation therapy
* Anatomy that would preclude precise brachytherapy implant (such as arch interference or large median lobe)
* Evidence of castrate resistance (defined as a rising PSA \> 3.0 ng/ml while testosterone is \< 3.0 nmol/l)
* Hip prosthesis (unilateral hip replacement is allowed if dose constrains can be reasonably achieved. RADIATION: Radiation, RADIATION: Radiation SBRT only, DRUG: ADT
Prostate Cancer
I'm interested
Share via email
Show 57 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Allegheny General Hospital Pittsburgh, Pennsylvania | |
| Billings Clinic Cancer Center Billings, Montana | Site Public Contact - (research@billingsclinic.org) |
| Bon Secours Cancer Institute at Reynolds Crossing Richmond, Virginia | Site Public Contact - (Anne_caramella@bshsi.org) |
| Bon Secours Saint Francis Medical Center Midlothian, Virginia | Site Public Contact - (anne_carmellat@bshsi.org) |
| CHUM - Centre Hospitalier de l'Universite de Montreal Montreal, Quebec | Site Public Contact - (info.cr.chum@ssss.gouv.qc.ca) |
| Doctor H. Bliss Murphy Cancer Centre St. John's, Newfoundland and Labrador | |
| Forbes Hospital Monroeville, Pennsylvania | |
| Jefferson Hospital Jefferson Hills, Pennsylvania | Site Public Contact - (ddefazio@wpahs.org) |
| Jewish General Hospital Montreal, Quebec | |
| Kaiser Permanente Cancer Treatment Center South San Francisco, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente Downtown Commons Sacramento, California | Site Public Contact - (kpoct@kp.org) |
| Kaiser Permanente Dublin Dublin, California | |
| Kaiser Permanente Fresno Orchard Plaza Fresno, California | |
| Kaiser Permanente Medical Center - Santa Clara Santa Clara, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente Medical Center-Vacaville Vacaville, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente Oakland-Broadway Oakland, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente San Leandro San Leandro, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente- Marshall Medical Offices Redwood City, California | |
| Kaiser Permanente-Deer Valley Medical Center Antioch, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Fremont Fremont, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Fresno Fresno, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Modesto Modesto, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Oakland Oakland, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Richmond Richmond, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Roseville Roseville, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-San Francisco San Francisco, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Santa Rosa Santa Rosa, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Santa Teresa-San Jose San Jose, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-South Sacramento Sacramento, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-South San Francisco South San Francisco, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Stockton Stockton, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Vallejo Vallejo, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser Permanente-Walnut Creek Walnut Creek, California | Site Public Contact - (Kpoct@kp.org) |
| Kaiser San Rafael-Gallinas San Rafael, California | Site Public Contact - (Kpoct@kp.org) |
| Kingston Health Sciences Centre Kingston, Ontario | Site Public Contact - (cc-clinicaltrials@kgh.kari.net) |
| Lakeridge Health Oshawa Oshawa, Ontario | |
| Lenox Hill Hospital New York, New York | |
| London Regional Cancer Program London, Ontario | |
| Manhattan Eye Ear and Throat Hospital New York, New York | |
| Memorial Hospital East Shiloh, Illinois | Site Public Contact - (dschwab@wustl.edu) |
| Northwell Health/Center for Advanced Medicine Lake Success, New York | |
| Odette Cancer Centre- Sunnybrook Health Sciences Centre Toronto, Ontario | |
| Rohnert Park Cancer Center Rohnert Park, California | Site Public Contact - (Kpoct@kp.org) |
| Royal Victoria Regional Health Centre Barrie, Ontario | |
| Saint Vincent Hospital Erie, Pennsylvania | |
| Siteman Cancer Center at Christian Hospital St Louis, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| Siteman Cancer Center at Saint Peters Hospital City of Saint Peters, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| Siteman Cancer Center at West County Hospital Creve Coeur, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| Siteman Cancer Center-South County St Louis, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| The Permanente Medical Group-Roseville Radiation Oncology Roseville, California | Site Public Contact - (Kpoct@kp.org) |
| Trillium Health Partners - Credit Valley Hospital Mississauga, Ontario | |
| University Health Network-Princess Margaret Hospital Toronto, Ontario | Site Public Contact - (clinical.trials@uhn.on.ca) |
| VCU Massey Comprehensive Cancer Center Richmond, Virginia | Site Public Contact - (CTOclinops@vcu.edu) |
| Washington University School of Medicine St Louis, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| Waterloo Regional Health Network Kitchener, Ontario | Site Public Contact - (research@wrhn.ca) |
| West Penn Hospital Pittsburgh, Pennsylvania | |
| Wexford Health and Wellness Pavilion Wexford, Pennsylvania | Site Public Contact - (Dawnmarie.DeFazio@ahn.org) |
PREVENT ALL ALS Study
ALL ALS Patient Navigator - info@all-als.org
NCT06581861
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
• Age 18 years or older
• Capable of providing informed consent
• Willing to follow study procedures
• First-degree relative of a known carrier of any ALS causative gene1 (regardless of whether ALS or FTD has actually been symptomatic in the family) OR First-degree relative of an individual with ALS and/or FTD in a family with a "compelling family history" of ALS/FTD, regardless of whether genetic testing has occurred in symptomatic family members. A "compelling family history" is defined as a pedigree with at least 2 close relatives who had ALS or FTD, with at least one of those family members having had ALS.
• Access to a smartphone, computer, or tablet, and internet (need not be in the home - access to a public library or other available computer with internet connection is sufficient)
Exclusion Criteria:
• Evidence of neurological signs or symptoms concerning for ALS of FTD, at the discretion of the site investigator which will be communicated to the applicant along with referral for appropriate clinical follow-up.
• Significant cognitive impairment, clinical dementia, or unstable psychiatric illness, including psychosis, active suicidal ideation, suicide attempt, or untreated major depression \<= 90 days (about 3 months) of screening, which in the opinion of the Investigator would interfere with the study procedures
• Clinically significant, unstable medical condition (e.g., cardiovascular instability, systemic infection, untreated thyroid dysfunction, malignant and potentially progressive cancer) that would render the participant unlikely to be able to complete 12 months of follow-up, according to Investigator's judgment Exclusion Criteria for Participants Undergoing Optional Lumbar Puncture
• Medically unable to undergo lumbar puncture (LP) as determined by the site investigator (i.e., bleeding disorder, a skin infection at or near the LP site, known or suspected intracranial or intraspinal tumor or other cause of increased intracranial pressure).
• Allergy to Lidocaine or other local anesthetic agents.
• Use of anticoagulant medication or antiplatelet medications (aside from aspirin 81 mg) that cannot be safely withheld prior to lumbar puncture.
• Blood dyscrasia, abnormal bleeding diathesis, or the use of dialysis for renal failure.
• Current pregnancy based on participant self-report
• Clinical judgement of the site investigator that the participant would be unable to undergo multiple lumbar punctures. Inclusion Criteria for Genetic Testing Results Sub-study
• Age 18 years of age or older
• Capable of providing informed consent
• Willing to follow study procedures
• Currently enrolled in the PREVENT ALS Study
Amyotrophic Lateral Sclerosis
ALS, Amyotrophic Lateral Sclerosis, Biomarker, Observational, at-risk
I'm interested
Share via email
Show 32 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Barrow Neurological Institute Phoenix, Arizona | Christopher Shiver - (fulton.research@dignityhealth.org) |
| CHALS-CCT, University of Puerto Rico, Medical Sciences Campus San Juan, Puerto Rico | Frances M Aponte - (frances.aponte2@upr.edu) |
| Columbia University New York, New York | Ben Hoover - (bnh2119@cumc.columbia.edu) |
| Dartmouth Hitchcock Medical Center Lebanon, New Hampshire | Kathleen Sullivan - (DHALLALS@Hitchcock.org) |
| Duke University Durham, North Carolina | - (alsresearch@dm.duke.edu) |
| Georgetown University Washington D.C., District of Columbia | Cassandra Holmes - (cassie.holmes@georgetown.edu) |
| Henry Ford Health Detroit, Michigan | Maria Stotland - (mstotla1@hfhs.org) |
| Hospital for Special Care New Britain, Connecticut | Sabine Lebel-Hardenac - (shardenack@hfsc.org) |
| Indiana University Indianapolis, Indiana | Angela Micheels - (amicheel@iu.edu) |
| John Hopkins University Baltimore, Maryland | Colleen Kane - (Ckane13@jh.edu) |
| Massachusetts General Brigham Boston, Massachusetts | Anika Allen - (mghpreventallals@mgb.org) |
| Mayo Clinic Rochester, Minnesota | Jeffery Gainer - (gainer.jeffery@mayo.edu) Jany Dagher - (dagher.jany@mayo.edu) |
| Nih/Ninds Bethseda, Maryland | Katelyn Porter - (katelyn.porter@nih.gov) |
| Northwestern University Chicago, Illinois | Aeryn Hopwood - (aeryn.hopwood@northwestern.edu) |
| Ohio State University Columbus, Ohio | Alexander Michael - (alsresearch@osumc.edu) |
| Penn State Health Hershey, Pennsylvania | Michele Hare - (nervemuscle@pennstatehealth.psu.edu) |
| Providence ALS Center Portland, Oregon | Kimberly Perry - (kimberly.perry2@providence.org) |
| Saint Alphonsus Regional Medical Center Boise, Idaho | Helena Snider - (neuro.research@saintalphonsus.org) |
| Temple University Philadelphia, Pennsylvania | John Furey - (tuf40109@temple.edu) |
| Texas Neurology Dallas, Texas | Reham Azab - (razab@texasneurology.com) |
| University of Alabama Birmingham Birmingham, Alabama | Melanie Benge - (melaniebenge@uabmc.edu) |
| University of California Irvine Irvine, California | Rosa Gonzalez - (rosaig1@hs.uci.edu) |
| University of California San Diego San Diego, California | Gil Gutierrez - (grg005@health.ucsd.edu) |
| University of California, San Francisco San Francisco, California | Hannah George - (hannah.george@ucsf.edu) |
| University of Colorado Anschutz Medical Campus Aurora, Colorado | Alexis Shepardson - (neuroresearch@cuanschutz.edu) |
| University of Michigan Ann Arbor, Michigan | Caroline Piecuch - (carolinp@med.umich.edu) |
| University of Minnesota Minneapolis, Minnesota | Claire Mavis - (mavis009@umn.edu) Mia Freiberg - (freib052@umn.edu) |
| University of Nebraska Medical Center Omaha, Nebraska | Veronica Alonso - (valonso@unmc.edu) Nathan McKain - (nmckain@unmc.edu) |
| University of Utah Salt Lake City, Utah | Scott Redlin - (scott.redlin@utah.edu) |
| University of Washington Seattle, Washington | Lila Brisk - (lbrisk@uw.edu) |
| Virginia Commonwealth University Richmond, Virginia | Demetrius Carter - (demetrius.r.carter@vcuhealth.org) |
| Washington University St Louis, Missouri | Jesse Markway - (als@wustl.edu) |
Automated Robotic TCD in Traumatic Brain Injury (ART-TBI)
Shraddha Mainali, MD - shraddha.mainali@vcuhealth.org
NCT05848297
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Adults ≥18
* Blunt TBI with Glasgow Coma Score (GCS) ≤8
* Injury within 72 hours
* Adequate TCD windows
* Ability to obtain informed consent from a Legally Authorized Representative (LAR)
Exclusion Criteria:
* Catastrophic brain injury with grim prognosis (e.g.: GCS 3 with bilateral mid-position pupil)
* C- spine fracture with evidence of spinal cord injury
* Severe skull or scalp injury precluding device placement
* Planned decompressive hemicraniectomy
* Continuous fever for \>6 hours at the time of enrollment (despite treatment)
* Lack of TCD window DEVICE: Transcranial Doppler ultrasonography (TCD)
Brain Injuries, Traumatic
I'm interested
Share via email
Show 3 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| University of California, Davis Sacramento, California | Jeffrey Robert Vitt, MD - (jrvitt@ucdavis.edu) |
| Virginia Commonwealth University Richmond, Virginia | Shraddha Mainali, MD - (Shraddha.Mainali@vcuhealth.org) |
| Wake Forest University Winston-Salem, North Carolina | Aarti Sarwal, MD - (asarwal@wakehealth.edu) |
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation (REACT-AF)
Anna Baranova - anna.baranova2@vcuhealth.org
NCT05836987
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
• 22-85 years of age.
• English speaking participants. Spanish-only speakers may be included in the future at select sites appropriately translated.
• History of non-permanent atrial fibrillation.
• CHA2DS2-VASC score of 1-4 for men and 2-4 for women without prior stroke or Transient Ischemic Attack (TIA), The CHA2DS2-VASc score is a point-based system used to stratify the risk of stroke in Atrial Fibrillation (AF) patients. The acronym CHA2DS2-VASc stands for congestive heart failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74 and sex category (female). Congestive heart failure defined as: The presence of signs and symptoms of either right (elevated central venous pressure, hepatomegaly, dependent edema) or left ventricular failure (exertional dyspnea, cough, fatigue, orthopnea, paroxysmal nocturnal dyspnea, cardiac enlargement, rales, gallop rhythm, pulmonary venous congestion) or both, confirmed by non-invasive or invasive measurements demonstrating objective evidence of cardiac dysfunction and/or ejection fraction \< 40%.
• The participant is on a DOAC at the time of screening and willing to stay on DOAC for duration of study.
• Willing and able to comply with the protocol, including: * Possession of a smart watch-compatible smart phone (iPhone that supports the latest shipping iOS) with a cellular service plan * Be willing to wear the smart watch for the suggested minimum of 14 hours a day * Expected to be within cellular service range at least 80% of the time
• Willing and able to discontinue DOAC
• The participant is willing and able to provide informed consent.
Exclusion Criteria:
• Valvular or permanent atrial fibrillation.
• Current treatment with warfarin and unwilling or unable to take a DOAC.
• The participant is a woman who is pregnant or nursing.
• The participant is being treated with chronic aspirin, another anti-platelet agent, or chronic NSAIDS outside of current medical guidelines (e.g., primary stroke prevention in patients with atrial fibrillation, primary prevention of cardiovascular events, pain relief, fever, gout) and is unwilling or unable to discontinue use for the study duration.
• Existing cardiac rhythm device or indication for a permanent pacemaker, Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy (CRT) device or planned insertable cardiac monitor. Insertable cardiac monitors are permitted unless they are being used to guide anticoagulation treatment.
• Known or suspected symptomatic or asymptomatic atrial fibrillation lasting ≥ 1 hour/month over the last 3 months.
• Any documented single AF episode lasting ≥ 1 hour on standard of care or study-provided external cardiac monitor of \> 6 days duration performed within 45 days prior to randomization. Shorter monitoring durations may be acceptable for inclusion at the discretion of the site PI based on the totality of monitoring data and approval of the study PI.
• Ablation for AF within the last 2 months.
• Prior or anticipated left atrial appendage occlusion or ligation.
• Mechanical prosthetic valve(s) or severe valve disease.
• Hypertrophic cardiomyopathy.
• Participant needs DOAC for reasons other than preventing stroke or arterial embolism resulting from AF (i.e., preventing Deep Vein Thrombosis (DVT) or PE) or needs permanent OAC (i.e., congenital heart defects, prosthetic heart valve).
• Participants deemed high risk for non-cardioembolic stroke (i.e., significant carotid artery disease defined as stenosis \> 75%) based on the investigator's discretion.
• The participant is enrolled, has participated within the last 30 days, or is planning to participate in a concurrent drug and/or device study during the course of this clinical trial. Co-enrollment in concurrent trials is only allowed with documented pre-approval from the study manager; there is no concern that co-enrollment could confound the results of this trial.
• The participant has a tattoo, birthmark, or surgical scar over the dorsal wrist area on the ipsilateral side that the AFSW may be worn.
• The participant has a tremor on their ipsilateral side that the AFSW may be worn.
• Any concomitant condition that, in the investigator's opinion, would not allow safe participation in the study (e.g., drug addiction, alcohol abuse).
• Known hypersensitivity or contraindication to direct oral anticoagulants.
• Documented prior stroke (ischemic or hemorrhagic) or transient ischemic attack.
• Reversible causes of AF (e.g., cardiac surgery, pulmonary embolism, untreated hyperthyroidism). AF ablation does not constitute reversible AF.
• \> 5% burden of premature atrial or ventricular depolarizations on pre-enrollment cardiac monitoring.
• History of atrial flutter that has not been treated with ablation (participants in atrial flutter and have been ablated are eligible for enrollment).
• Stage 4 or 5 chronic kidney disease.
• Conditions associated with an increased risk of bleeding: * Major surgery in the previous month * Planned surgery or intervention in the next three months that would require cessation of anticoagulation \> 2 weeks. * History of intracranial, intraocular, spinal, retroperitoneal, or atraumatic intra- articular bleeding * Gastrointestinal hemorrhage within the past year unless the cause has been permanently eliminated (e.g., by surgery) * Symptomatic or endoscopically documented gastroduodenal ulcer disease in the previous 30 days * Hemorrhagic disorder or bleeding diathesis * Need for anticoagulant treatment for disorders other than AF * Uncontrolled hypertension (Systolic Blood Pressure \>180 mmHg and/or Diastolic Blood Pressure \>100 mmHg)
DEVICE: AFSW Guided DOAC, DRUG: Continuous DOAC therapy
Atrial Fibrillation
Atrial Fibrillation, Anticoagulation, AF-sensing Smart Watch, Ischemic Stroke, Systemic Embolism
I'm interested
Share via email
Show 93 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Advanced Heart and Vascular Institute of Hunterdon Flemington, New Jersey | Alexis Bellafiore - (abellafiore@ahvi-nj.com) Jessica Senatore - (jsenatore@ahvi-nj.com) |
| Alexian Brothers Health System Elk Grove Village, Illinois | Michelle Garcia - (michelle.garcia5@ascension.org) Jeanine Pilat - (jeanine.pilat@ascension.org) |
| Allegheny Singer Research Institute Pittsburgh, Pennsylvania | Caitlin Phalunas - (caitlin.phalunas@ahn.org) Elizabeth Belden - (elizabeth.belden@ahn.org) |
| Ascension St. Vincent Indianapolis, Indiana | Regina Margiotti - (regina.margiotti@ascension.org) Ann Renick - (anne.renick@ascension.org) |
| BMC - Brighton Boston, Massachusetts | Rina Vaquerano - (rina.vaquerano@steward.org) |
| Banner University Phoenix, Arizona | Herisse Sabulao - (herisse.sabulao@bannerhealth.com) Raeven Maxwell - (raeven.maxwell@bannerhealth.com) |
| BayCare Health Systems Clearwater, Florida | Karen Herring - (karen.herring@baycare.org) |
| Baycare Health Systems Clearwater Winter Haven, Florida | Amanda Steadham - (Amanda.Steadham@baycare.org) Lynda Argenzio - (lynda.argenzio@baycare.org) |
| Baylor College of Medicine Houston, Texas | Stephen Harold - (harold@bcm.edu) |
| Beth Israel Deaconess Medical Center Boston, Massachusetts | Jenifer M Kaufman - (jmkaufma@bidmc.harvard.edu) Patricia Tyler - (ptyler@bidmc.harvard.edu) |
| Boston Medical Center Boston, Massachusetts | Laura Gavrilles - (laura.gavrilles@bmc.org) |
| Brigham and Women's Hospital Boston, Massachusetts | Daniela Hincapie Tabres - (dhincapietabares@bwh.harvard.edu) Obadah Aloum - (OALOUM@BWH.HARVARD.EDU) |
| Cardiology Consultants of Philadelphia Paoli, Pennsylvania | Hope Bernhardy - (hopeb@ccpdocs.com) |
| Cleveland Clinic Florida Weston, Florida | |
| Columbia University Medical Center New York, New York | Raghd Ahmed - (ria2120@cumc.columbia.edu) |
| Corewell Health (Former Spectrum Health) Grand Rapids, Michigan | Lisa Van Loo - (lisa.vanloo@spectrumhealth.org) Jose Gavina - (jose.gavina@corewellhealth.org) |
| Emory University Atlanta, Georgia | Thomas Preiser - (tpreise@emory.edu) |
| Essentia Health The Duluth Clinic Duluth, Minnesota | |
| Georgia Arrhythmia Consultants and Research Institute Warner Robins, Georgia | Heather Maschenik - (hmaschenik@gacri.com) |
| Hackensack Meridian Health Hackensack, New Jersey | Patricia Arakelian - (Patricia.Arakelian@hmhn.org) |
| Hennepin Healthcare Research Institute Minneapolis, Minnesota | Sahil Thummar - (sthummar@bermancenter.org) |
| Henry Ford Health Detroit, Michigan | Briita Wanhala - (bwanhal1@hfhs.org) Danielle Delmotte - (ddelmot2@hfhs.org) |
| Houston Methodist Hospital Houston, Texas | Chinwe Ngumezi - (ccngumezi@houstonmethodist.org) |
| James River Cardiology Richmond, Virginia | Janet Barrett - (Janet.Barrett@alignedcardio.com) |
| Johns Hopkins Univeristy Baltimore, Maryland | Michele Martucci - (mmill148@jhmi.edu) Natalie Horstman - (nhorstm3@jhu.edu) |
| Kaiser Permanente Fresno, California | Annie Lei - (Annie.X.Lei@kp.org) Quyen Chau - (Quyen.X.Chau@kp.org) |
| Lahey Hospital & Medical Center Burlington, Massachusetts | Jean Byrne - (jean.byrne@lahey.org) |
| Loyola University Chicago Chicago, Illinois | Nancy Schoenecker - (nschoenecker@luc.edu) Jean Del Priore - (jdelpri@luc.edu) |
| MUSC Health Heart and Vascular Columbia, South Carolina | Jacqueline Sheriod-Scott - (sheriods@musc.edu) |
| Maine Medical Partners MaineHealth Cardiology Scarborough, Maine | Hilary Curtis - (hilary.curtis@mainehealth.org) Brenda Galsgow - (brenda.glasgow@mainehealth.org) |
| Mass General Hospital Boston, Massachusetts | Kristen Steinmetz - (ksteinmetz@mgh.harvard.edu) |
| Mayo Clinic Rochester, Minnesota | Pamela Wong - (WongLucio.Pamela@mayo.edu) |
| Medical College of Wisconsin Froedtert Hospital Milwaukee, Wisconsin | Debbi Hoff - (dhoff@mcw.edu) |
| Medical Faculty Associates George Washington University Washington D.C., District of Columbia | |
| Medical University of South Carolina Charleston, South Carolina | Krista Szymanski - (szymankr@musc.edu) |
| Midwest Cardiovascular Institute Naperville, Illinois | Josilyn Klimek - (Josilyn.Klimek@cardio.com) |
| Minneapolis Heart Institute Foundation Minneapolis, Minnesota | Andrew Garner - (andrew.garner@allina.com) Julianne Feola - (julianne.feola@allina.com) |
| NYU Langone Health New York, New York | Mollie Machado - (mollie.machado@nyulangone.org) |
| NewYork Presbyterian - Queens Queens, New York | Jackson Ng - (jan9044@nyp.org) |
| NorthShore University Healthsystem Evanston, Illinois | Marisa Durante - (mdurante@northshore.org) |
| Northwestern University Chicago, Illinois | CTU Regulatory Team - (cturegulatoryteam@nm.org) |
| Ohio State University Medical Center Columbus, Ohio | Adrianne Miller - (adrianne.miller3@osumc.edu) Kalyn Ferguson - (kalyn.ferguson@osumc.edu) |
| OhioHealth Research Institute Columbus, Ohio | Reem Bekheet - (reem.bekheet@ohiohealth.com) |
| Penn State Health Medical Group Berks Cardiology Wyomissing, Pennsylvania | Emese Futchko - (efutchko@pennstatehealth.psu.edu) Michelle Feltenberger - (mfeltenberger@pennstatehealth.psu.edu) |
| Presbyterian Healthcare Services Albuquerque, New Mexico | |
| Rhode Island Hospital Providence, Rhode Island | Kelly Franchetti - (kfranchetti@brownhealth.org) |
| Rush University Medical Center Chicago, Illinois | Nusrat Jahan - (nusrat_jahan@rush.edu) Christine Radochonski - (Christine_Radochonski@rush.edu) |
| Rutgers, the State University of New Jersey Piscataway, New Jersey | Glaucia Dos Santos-Vaccaro - (gd301@rwjms.rutgers.edu) |
| Sarasota Memorial Health Care System Sarasota, Florida | Jennifer Jordan - (Jennifer-Jordan@smh.com) Colleen Lindner - (Colleen-Lindner@smh.com) |
| Scripps Health San Diego, California | Janet Lawrence - (Lawrence.Janet@scrippshealth.org) |
| South Denver Cardiology Associates, P.C. Littleton, Colorado | Kathrin Siegel - (ksiegel@southdenver.com) |
| St. Elizabeth's Medical Center Washington D.C., District of Columbia | Rina Vaquerano - (rina.vaquerano@steward.org) |
| St. Joseph Medical Center Tacoma Tacoma, Washington | Boyoung Moore - (boyoung.moore@vmfh.org) |
| Stanford University Stanford, California | Diona Gjermeni, MD - (gjermeni@stanford.edu) |
| Staten Island University Hospital-Northwell Health Staten Island, New York | Alexandra Pantea - (apantea@northwell.edu) |
| Stony Brook University Stony Brook, New York | Melanie Rooney - (melanie.rooney@stonybrookmedicine.edu) Michelle Xikis - (Michele.xikis@stonybrookmedicine.edu) |
| Texas Cardiac Arrhythmia Research Foundation Austin, Texas | Deb Cardinal - (dscardinal@austinheartbeat.com) |
| The Lindner Center for Research and Education at The Christ Hospital Cincinnati, Ohio | Anne Voorhorst - (anne.voorhorst@thechristhospital.com) Rebecca Harper - (RebeccaM.Harper@thechristhospital.com) |
| The Valley Hospital, Inc. Ridgewood, New Jersey | RoseMarie Hroncich - (rhronci@valleyhealth.com) |
| Thomas Jefferson University Philadelphia, Pennsylvania | Ashley Borgella - (ashley.borgella@jefferson.edu) |
| Trinity Health Grand Rapids/Mercy Health Grand Rapids, Michigan | Melissa Brown-Culbertson - (melissa.brown-culbertson@trinity-health.org) Nicolina Evola - (Nicolina.evola@trinity-health.org) |
| Trinity Health Michigan Heart - Ann Arbor Ypsilanti, Michigan | Autumn Howe - (ahowe@michiganheart.com) |
| Tufts Medical Center Boston, Massachusetts | Juan Carlos Collado Falcon - (Juan.Carlos.Collado.Falcon@tuftsmedicine.org) Abena Adwetewa-Badu - (Abena.Adwetewa-Badu@tuftsmedicine.org) |
| UC Davis Health Sacramento, California | Edward Lingayo - (lingayo@health.ucdavis.edu) |
| UMass Chan Medical School Worcester, Massachusetts | |
| University Health Truman Medical Center Kansas City, Missouri | |
| University at Buffalo Buffalo, New York | Courtney Bishop - (cabishop@buffalo.edu) Cassandra Davern - (cadavern@buffalo.edu) |
| University of California Los Angeles (UCLA Health) Los Angeles, California | Monserrath Campos - (monserrathcampos@mednet.ucla.edu) |
| University of Chicago Chicago, Illinois | Shahram Sarrafi - (ssarrafi1@uchicagomedicine.org) Kie Ng - (kie@bsd.uchicago.edu) |
| University of Cincinnati College of Medicine Cincinnati, Ohio | Elias Shamieh - (shamiees@ucmail.uc.edu) |
| University of Colorado Aurora, Colorado | Megan Collett - (megan.collett@uchealth.org) |
| University of Florida Gainesville, Florida | Walter Erikson - (erikson.walter@medicine.ufl.edu) Vanessa Scheuble - (vanessa.scheuble@medicine.ufl.edu) |
| University of Illinois Chicago Chicago, Illinois | Muriel Chen - (yining@uic.edu) |
| University of Iowa Hospitals and Clinics Iowa City, Iowa | Trisha Elliott - (trisha-elliott@uiowa.edu) |
| University of Miami - Leonard S. Miller SOM Miami, Florida | Carmen Maria Baez-Garcia - (cbaezgarcia@med.miami.edu) |
| University of Minnesota Minneapolis, Minnesota | Julie Dicken - (dicke022@umn.edu) Maddy Chopp - (Chopp015@umn.edu) |
| University of New Mexico Health Sciences Center Albuquerque, New Mexico | Elvia Padilla - (EPadillaMendez@salud.unm.edu) Noela Garcia-Soberanez - (NGarciaSoberanez@salud.unm.edu) |
| University of North Carolina Chapel Hill, North Carolina | Meghan Allen - (meghme@med.unc.edu) Elias Wen - (elias_wen@med.unc.edu) |
| University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma | Kylie Ricci - (kylie-ricci@ouhsc.edu) Aurora Vera - (aurora-vera@ouhsc.edu) |
| University of Southern California - Keck School of Medicine Los Angeles, California | Rohit Varma - (RohitVarma.Penmetsa@med.usc.edu) Stephanie Chao - (Stephanie.Chao@med.usc.edu) |
| University of Texas Health Science Center at Houston Houston, Texas | Mary Pierce - (mary.h.pierce@uth.tmc.edu) Vickie Ramirez - (vickie.m.ramirez@uth.tmc.edu) |
| University of Texas Southwestern Medical Center Dallas, Texas | Vukile Mlambo - (vukile.mlambo@utsouthwestern.edu) |
| University of Utah Salt Lake City, Utah | Andy Rivera - (andy.rivera@hsc.utah.edu) |
| University of Virginia Charlottesville, Virginia | Cathy Roy - (cjp6t@virginia.edu) |
| University of Wisconsin Madison, Wisconsin | Karen Olson - (kjolson@medicine.wisc.edu) Emma Rolf - (erolf@medicine.wisc.edu) |
| Virginia Commonwealth University Richmond, Virginia | Anya Baranova - (Anna.Baranova2@vcuhealth.org) |
| Wake Forest Baptist Health Winston-Salem, North Carolina | Keishia Rodriguez - (kyrodrig@wakehealth.edu) Mohammed Mostafa - (mmostafa@wakehealth.edu) |
| Washington University School of Medicine St Louis, Missouri | Kyle Smith - (kyle.smith1@wustl.edu) Sharon Heuerman - (sheuerman@wustl.edu) |
| Weill Medical College of Cornell University New York, New York | Dolores Reynolds - (dtr2001@med.cornell.edu) |
| Westchester Medical Center Valhalla, New York | Allyson Pulsoni - (allyson.pulsoni@wmchealth.org) Erida Castro-Rivas - (Erida.Castro@wmchealth.org) |
| White Plains Hospital White Plains, New York | Aileen Ferrick - (aferrick@wphospital.org) Uloma Ijomah - (uijomah@wphospital.org) |
| William Beaumont Hospital Royal Oak, Michigan | Lisa Carney - (lisa.carney2@corewellhealth.org) |
| Wooster Community Hospital Wooster, Ohio | Erica Stahl - (estahl@wchosp.org) |
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR)
Oana Danciu, MD - ocdanciu@uic.edu
NCT05467891
Show full eligibility criteria
Hide eligibility criteria
Eligibility Criteria to Collect Optional Correlative Blood and Tissue at Local Recurrence
* Written informed consent (stage I) and HIPAA authorization for release of personal health information obtained prior to performing any study-specific procedures. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
* Male or female age ≥ 18 years at the time of consent.
* Patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer based on the most recently analyzed tissue sample and all tested by local laboratory.
* Patient has HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test is required by local laboratory testing and based on the most recently analyzed tissue sample. If there is insufficient tissue from the most recently collected sample, earlier tissue may be used on a case-by-case basis if permission is granted by the sponsor investigator.
* Patient has locoregional recurrence of breast cancer: locoregional recurrence is defined as invasive recurrence in the ipsilateral breast, axilla, regional nodes, or chest wall.
Inclusion Criteria for Treatment Phase:
Subject must meet all of the following applicable inclusion criteria to participate in this study:
* Written informed consent (stage II/ main consent) and HIPAA authorization for release of personal health information obtained prior to performing any study-specific screening procedures. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
* Male or female age ≥ 18 years at the time of consent. NOTE: Both pre- and post-menopausal women are eligible. Post-menopausal status is defined as:
* Prior bilateral oophorectomy
* Age ≥60
* Age \<60 and amenorrhea for the last 12 or more months(in the absence of chemotherapy, tamoxifen, toremifen, or ovarian suppression) and FSH and estradiol in the postmenopausal range per local normal range.
* ECOG Performance Status of 0-1 within 28 days prior to registration.
* If patient is receiving tamoxifen or toremifene, a washout period of 5 half-lives (i.e. 35 days) prior to registration is required (during that period the participant can take AI).
* Patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer based on the most recently analyzed tissue sample and all tested by local laboratory.
* Patient has HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test is required by local laboratory testing and based on the most recently analyzed tissue sample. If there is insufficient tissue from the most recently collected sample, earlier tissue may be used on a case-by-case basis if permission is granted by the sponsor investigator.
* Patients have had adequate local treatment for locoregional recurrence (LRR) of breast cancer.
* Locoregional recurrence is defined as recurrence in the ipsilateral breast, axilla, regional lymph nodes, or chest wall.
* Local treatment is defined as either surgery, radiation therapy, or a combination of both if indicated.
* Adequate local therapy is surgery with negative microscopic margins. Radiation therapy is mandated for patients with microscopically involved margins and recommended for all patients who had not received radiotherapy as part of their primary treatment.
* Patients who have distant metastatic disease will not be eligible.
* Prior treatment with neoadjuvant and adjuvant chemotherapy and ET is allowed.
* Patients must enroll within 6 months of the last local treatment, either local surgery or radiation; or systemic chemotherapy (if patient is receiving chemotherapy), whichever occurred last. Chemotherapy after local therapy is allowed. ET for recurrent disease is allowed for up to 12 months prior to enrollment.
* Patient has no contraindication to the adjuvant ET in the trial and is planned to be treated or continue treatment with ET.
* Demonstrate adequate organ function as defined below; all screening labs to be obtained within 28 days prior to registration.
* Hematological
* Absolute Neutrophil Count (ANC): ≥ 1.5 x 109/L
* Platelets: ≥ 100 x 109/L
* Hemoglobin (Hgb): ≥ 9.0 g/dL
* Renal
---Estimated glomerular filtration rate (eGFR): ≥ 30 mL/min/1.73m2 according to the Modification of Diet in Renal Disease (MDRD) formula
* Hepatic
* Bilirubin: ≤ upper limit of normal (ULN) except for patients with Gilbert's syndrome who may only be included if the total bilirubin is ≤ 3.0 × ULN or direct bilirubin ≤ 1.5 × ULN
* Aspartate aminotransferase (AST): ≤ 2.5 × ULN except for patients with liver metastasis, who are only included if the AST is \< 5 × ULN
* Alanine aminotransferase (ALT): ≤ 2.5 × ULN except for patients with liver metastasis, who are only included if the ALT is \< 5 × ULN
* Coagulation
---International Normalized Ratio (INR) : ≤ 1.5 × ULN (unless is receiving anticoagulants and the INR is within the therapeutic range of intended use for that anticoagulant within 7 days prior to the first dose of study drug)
* Electrolytes ---Potassium, Magnesium, and Total Calcium (corrected for serum albumin): Within normal limits or corrected to within normal limits with supplements.
* Standard 12-lead ECG values defined as
* QTcF interval at screening \< 450 msec (QT interval using Fridericia's correction)
* Resting heart rate 50-90 bpm (determined from the ECG)
* Females of childbearing potential who are sexually active with a male able to father a child must have a negative pregnancy test (serum or urine) within 14 days prior to registration and must be willing to use a highly effective method of contraception that does not contain estrogen and/or progesterone. See the protocol for definition of childbearing potential.
* As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study.
* Ability to swallow and retain oral medication.
Exclusion Criteria for Treatment Phase:
Subjects meeting any of the criteria below may not participate in the study:
* Patient with a known hypersensitivity to any of the excipients of ribociclib.
* Patient who has received prior CDK4/6 inhibitor for recurrent disease. Patients who received a CDK4/6 inhibitor in the adjuvant setting may participate if they have been off therapy for at least 1 year prior to diagnosis of recurrent disease.
* Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects.
* Pregnant or breastfeeding or planning to become pregnant during the trial (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
* Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen are not eligible for this trial.
* Patients with distant metastases of breast cancer beyond regional lymph nodes as defined by AJCC (8th edition).
* Treatment with any investigational drug within 30 days prior to registration or participation in any other type of medical research judged not to be scientifically or medically compatible with this study. Enrollment or planned enrollment in another study that does not involve an investigational drug will be allowed at the discretion of the treating investigator.
* Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., uncontrolled ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
* Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol: (e.g., chronic pancreatitis, chronic active hepatitis, HIV, active untreated or uncontrolled fungal, bacterial or viral infections, etc.). Testing to be done at investigator's discretion.
* Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality, including any of the following:
* History of documented myocardial infarction (MI), angina pectoris, symptomatic pericarditis, or coronary artery bypass graft (CABG) within 6 months prior to study entry
* Documented cardiomyopathy
* History of Left Ventricular Ejection Fraction (LVEF) \< 50%
* Long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:
* Risk factors for Torsades de Pointe (TdP) including uncorrected hypocalcemia, hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia
* Concomitant medication(s) with a known risk to prolong the QT interval and/or known to cause Torsades de Pointe that cannot be discontinued or replaced by safe alternative medication (e.g., within 5 half-lives or 7 days prior to starting study drug)
* Inability to determine the QTcF interval
* Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g., bifascicular block, Mobitz type II and third-degree AV block)
* Systolic Blood Pressure (SBP) \>160 or \<90 mmHg
* Patient is currently receiving any of the following substances and cannot be discontinued 7 days prior to Cycle 1 Day 1:
* Concomitant medications, herbal supplements, and/or fruits (e.g., grapefruit, pummelos, star fruit, Seville oranges) and their juices that are strong inducers or inhibitors of CYP3A4/5,
* Medications that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5.
* Patient is currently receiving or has received systemic corticosteroids ≤ 2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment. Note: The following uses of corticosteroids are permitted: a short duration (\<5 days) of systemic corticosteroids; any duration of topical applications (e.g. for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular).
* Patient with an uncontrolled psychiatric condition that, in the investigator's judgment, may cause unacceptable safety risks, impede research integrity and compliance, or interfere with the objectives of the study.
DRUG: Ribociclib, DRUG: Fulvestrant, DRUG: Anastrozole, DRUG: Letrozole, DRUG: Exemestane
Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
I'm interested
Share via email
Show 21 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Georgetown University Washington D.C., District of Columbia | Julie Castle - (bickmorj@georgetown.edu) |
| Medical University of South Carolina Charleston, South Carolina | Alex M Jones - (joalex@musc.edu) |
| New York University Clinical Cancer Center New York, New York | Manju P Rajan - (pamela.rajan@nyulangone.org) |
| Ohio State University Comprehensive Cancer Center Columbus, Ohio | Emily Viall - (Emily.Viall@osumc.edu) |
| Orlando Health Cancer Institute Orlando, Florida | |
| Parkview Research Center Fort Wayne, Indiana | Kari Schultz - (kari.schultz@parkview.com) |
| Penn State Cancer Institute Hershey, Pennsylvania | Monali Vasekar, MD - (Penn-CTO@pennstatehealth.psu.edu) |
| Providence Portland Medical Center Portland, Oregon | Staci Mellinger, RN - (canrsrchstudies@providence.org) |
| Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey | Yue Wang, MD, PhD - (yw670@cinj.rutgers.edu) |
| Tufts Medical Center Boston, Massachusetts | Larkin De Laria - (larkin.delaria@tuftsmedicine.org) |
| University of Alabama at Birmingham Birmingham, Alabama | Kyndall Thomas - (kyndallrthomas@uabmc.edu) |
| University of Arizona Tucson, Arizona | Letticia Gillis - (lgillis@arizona.edu) |
| University of Illinois Cancer Center Chicago, Illinois | Erin Vidra - (evidra@uic.edu) |
| University of Iowa Hospitals and Clinics Iowa City, Iowa | Katie Carius - (katie-carius@uiowa.edu) |
| University of Michigan Health System Ann Arbor, Michigan | Cancer Answer Line - (canceranswerline@med.umich.edu) |
| University of Michigan Health-West Wyoming, Michigan | |
| University of Nebraska Medical Center Omaha, Nebraska | Shelly Aust - (shelly.aust@unmc.edu) |
| University of New Mexico Comprehensive Cancer Center Albuquerque, New Mexico | Bernard Tawfik, MD - (BTawfik@salud.unm.edu) |
| University of Virginia Health System Charlottesville, Virginia | Olena Glushakova - (oyg2n@uvahealth.org) |
| University of Wisconsin Madison, Wisconsin | Danae Wolff - (danae.wolff@wisc.edu) |
| Virginia Commonwealth University Richmond, Virginia | Lindsey Gwaltney - (masseyctbrst@vcu.edu) |
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
ctrrecruit@vcu.edu
NCT05711667
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* \>= 2 years and \< 18 years at the time of enrollment
* Weight must be \>= 6 kg at the time of enrollment
* Planned allogeneic HCT (bone marrow, peripheral blood stem cell, or cord blood transplant)
* Patient must be CMV sero-positive (i.e., recipient CMV immunoglobulin G positive)
* Note: If a patient has hypogammaglobulinemia but has previously been documented as CMV sero-positive, that is acceptable for study inclusion. For all patients already confirmed to be CMV IgG seropositive, repeat testing is not required within 7 days prior to enrollment. However, the laboratory data determining eligibility must be available in the patient's medical/research record for verification
* Patient is eligible for entry only if it is feasible for plasma CMV PCR testing to be sent and resulted within the protocol mandated time period
* Reminder: To limit the likelihood of positive plasma CMV PCR post-enrollment and prior to start of study treatment period, it is recommended that patient enrollment proceed after patients start their transplant preparative regimen
* Patient must have a performance status corresponding to Lansky/Karnofsky scores \> 50
* Note: Use Lansky for patients =\< 16 years of age and Karnofsky for patients \> 16 years of age. For further reference, see performance status scales scoring under the standard sections for protocols among protocol reference materials provided on the Children's Oncology Group (COG) member website: https://members.childrensoncologygroup.org/prot/reference\_materials.asp
* Estimated glomerular filtration rate \> 10 mL/min/1.73 m\^2 and not receiving dialysis
* Direct bilirubin =\< 2 mg/dL and serum glutamate-pyruvate transaminase (SPGT) (alanine transaminase \[ALT\]) =\<10 x upper limit of normal (ULN) for age
* Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
Exclusion Criteria:
* Expected inability to tolerate oral formulation of letermovir
* Hypersensitivity to letermovir or any component of the formulation
* History of CMV end organ disease within 6 months (180 days) prior to enrollment
* Note: CMV end organ disease based on proposed definitions by Ljungman et al. and inclusive of proven, probable or possible disease
* Receipt of prior allogeneic HCT within one year of study enrollment
* Planned prophylactic administration of other anti-CMV medications or cellular products during the study, including:
* High dose acyclovir (defined as doses \>= 1500 mg/m\^2 IV or \>= 3200 mg oral (patients \>= 40 kg) or \>= 2400 mg/m\^2 (patients \< 40 kg) per day)
* High dose valacyclovir (defined as doses \>= 3000 mg/day in patients \> 20 kg)
* Foscarnet
* Ganciclovir
* Valganciclovir
* CMV-directed cytotoxic T lymphocytes
* Planned receipt of the following contraindicated medications during the study treatment period; contraindicated medications must be discontinued at least 14 days prior to Day +1
* Contraindicated medications for all patients:
* Pimozide
* Ergot alkaloids
* Contraindicated medications for patients planned to receive cyclosporine:
* Bosentan
* Pitavastatin
* Simvastatin
* Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted in certain animal reproduction studies with letermovir. A pregnancy test is required for female patients of childbearing potential
* Lactating females who plan to breastfeed their infants
* Sexually active female patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their letermovir treatment and through at least 4 weeks after the last dose of letermovir.
* Note: No contraception measures are needed specifically during letermovir treatment for male trial participants who have pregnant or non-pregnant female partner(s) of reproductive potential. Contraception measures may be required for other aspects of the HCT procedure.
* All patients and/or their parents or legal guardians must sign a written informed consent
* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met PROCEDURE: Biospecimen Collection, DRUG: Letermovir
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
I'm interested
Share via email
Show 29 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Alfred I duPont Hospital for Children Wilmington, Delaware | Site Public Contact - (Allison.bruce@nemours.org) |
| Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Houston, Texas | Site Public Contact - (burton@bcm.edu) |
| Children's Hospital Colorado Aurora, Colorado | Site Public Contact - (josh.b.gordon@nsmtp.kp.org) |
| Children's Hospital New Orleans New Orleans, Louisiana | |
| Children's Hospital of Alabama Birmingham, Alabama | Site Public Contact - (oncologyresearch@peds.uab.edu) |
| Children's Hospital of Michigan Detroit, Michigan | Site Public Contact - (helpdesk@childrensoncologygroup.org) |
| Children's Hospital of Philadelphia Philadelphia, Pennsylvania | Site Public Contact - (CancerTrials@email.chop.edu) |
| Children's Mercy Hospitals and Clinics Kansas City, Missouri | Site Public Contact - (COGResearchGroup@cmh.edu) |
| Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital Grand Rapids, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland | Site Public Contact - (jhcccro@jhmi.edu) |
| Kapiolani Medical Center for Women and Children Honolulu, Hawaii | |
| Medical City Dallas Hospital Dallas, Texas | |
| Methodist Children's Hospital of South Texas San Antonio, Texas | Site Public Contact - (Vinod.GidvaniDiaz@hcahealthcare.com) |
| Nemours Children's Clinic-Jacksonville Jacksonville, Florida | Site Public Contact - (Allison.bruce@nemours.org) |
| Nicklaus Children's Hospital Miami, Florida | |
| Norton Children's Hospital Louisville, Kentucky | Site Public Contact - (CancerResource@nortonhealthcare.org) |
| Primary Children's Hospital Salt Lake City, Utah | |
| Riley Hospital for Children Indianapolis, Indiana | |
| Saint Jude Children's Research Hospital Memphis, Tennessee | |
| The Children's Hospital at TriStar Centennial Nashville, Tennessee | |
| UCSF Benioff Children's Hospital Oakland Oakland, California | Site Public Contact - (PedOncRschOAK@ucsf.edu) |
| UCSF Medical Center-Mission Bay San Francisco, California | Site Public Contact - (cancertrials@ucsf.edu) |
| UT Southwestern/Simmons Cancer Center-Dallas Dallas, Texas | Site Public Contact - (canceranswerline@UTSouthwestern.edu) |
| University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa | |
| University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma | Site Public Contact - (ou-clinical-trials@ouhsc.edu) |
| University of Wisconsin Carbone Cancer Center - University Hospital Madison, Wisconsin | Site Public Contact - (clinicaltrials@cancer.wisc.edu) |
| VCU Massey Comprehensive Cancer Center Richmond, Virginia | Site Public Contact - (CTOclinops@vcu.edu) |
| Vanderbilt University/Ingram Cancer Center Nashville, Tennessee | |
| Washington University School of Medicine St Louis, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
Olena Boyarska - olena.boyarska@seattlechildrens.org
NCT06504589
Show full eligibility criteria
Hide eligibility criteria
Consent
A. Written informed consent (and assent when applicable) obtained from participant or participant's legal guardian
B. Is willing and able to adhere to the study visit schedule and other protocol requirements
Demographics
A. ≥ 12 years of age at Visit 1
Medical History
A. For persons of child-bearing potential: must not be pregnant at Visit 1 or plan to get pregnant during the 12-month study period
Disease History
A. Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:
* Sweat chloride ≥ 60 mEq/liter by quantitative pilocarpine iontophoresis test (QPIT)
* Two well-characterized disease-causing pathogenic variants in the CFTR gene
or
* One well-characterized disease-causing mutation and a second CFTR variant (with variable or uncharacterized disease-causing potential) and sweat ≥ 30 mmol/liter with permission of the study sponsor-investigators
B. Clinically stable with no significant changes in health status within the 28 days prior to and including Visit 1
C. Does not have a history of lung transplantation
Concomitant Medications
A. Not genetically eligible for a CFTR modulator according to product label indications and/or No use of CFTR modulator for 28 days prior to Visit 1 with no intent to start or restart during the study period
B. No use of an investigational drug within 90 days prior to and including Visit 1
C. Not currently participating in an interventional drug or device trial. Participation in long-term safety follow-up studies (without redosing) and/or behavioral intervention trials is allowed.
D. No initiation of new chronic therapy (e.g., ibuprofen, azithromycin, inhaled tobramycin, Cayston®) within 28 days prior to and including Visit 1
E. No acute use of antibiotics (oral, inhaled or IV) or acute use of systemic corticosteroids for respiratory tract symptoms within 28 days prior to and including Visit 1
Cystic Fibrosis
ineligible and/or not taking CFTR modulators, People with CF
I'm interested
Share via email
Show 68 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Adult Cystic Fibrosis Center at the University of Utah Salt Lake City, Utah | Kristyn Packer - (kristyn.packer@hsc.utah.edu) |
| Atrium Health Wake Forest Baptist Winston-Salem, North Carolina | Anna Pippins - (apippins@wakehealth.edu) |
| Augusta University Augusta, Georgia | Heidi Stapp - (hstapp@augusta.edu) |
| Baylor College of Medicine Houston, Texas | Tracy Mosely - (tlmosely@texaschildrens.org) |
| Billings Clinic Billings, Montana | Jerimiah Lysinger - (JLysinger@billingsclinic.org) |
| Boston Children's Hospital Boston, Massachusetts | Robert Fowler - (Robert.fowler@childrens.harvard.edu) |
| Central Florida Pulmonary Group Altamonte Springs, Florida | Desiree Serr - (dserr@cfpulmonary.com) |
| Children's Healthcare of Atlanta and Emory University Atlanta, Georgia | Ashleigh Streby - (ashleigh.streby@emory.edu) |
| Children's Hospital Colorado Aurora, Colorado | Mary Cross - (mary.cross@childrenscolorado.org) |
| Children's Hospital of Philadelphia Philadelphia, Pennsylvania | Erin Donnelly - (Donnellye4@email.chop.edu) |
| Childrens Hospital Los Angeles Los Angeles, California | Carmen Reyes - (mareyes@chla.usc.edu) |
| Cincinnati Children's Hospital Medical Center Cincinnati, Ohio | Kelly Thornton - (Kelly.Thornton@cchmc.org) |
| Cleveland Clinic Cystic Fibrosis Program Cleveland, Ohio | Dave Weaver - (weaverd@ccf.org) |
| Cohen Children's Medical Center of New York New Hyde, New York | Susan Galvin - (sgalvin@northwell.edu) |
| Columbia University Cystic Fibrosis Program New York, New York | Emily DiMango - (ead3@cumc.columbia.edu) |
| Cook Children's Medical Center Fort Worth, Texas | Anna Reyes - (anna.reyes@cookchildrens.org) |
| Corewell Health Helen DeVos Grand Rapids, Michigan | Alicia Castillo Bahena - (alicia.castillobahena@corewellhealth.org) |
| Dayton Children's Hospital Dayton, Ohio | Amy Jones - (Jonesa11@childrensdayton.org) |
| Dell Children's Medical Center of Central Texas Austin, Texas | Kristina "Tina" Adrean - (Kadrean@ascension.org) |
| Hershey Medical Center Pennsylvania State University Hershey, Pennsylvania | Diane M Kitch - (dkitch@pennstatehealth.psu.edu) |
| Inova L.J. Murphy Pediatric CF Program Fairfax, Virginia | Colleen Mann - (colleen.mann@inova.org) |
| John Hopkins Hospital Baltimore, Maryland | Jeanne Pinto - (jpinto4@jh.edu) |
| Massachusetts General Hospital Boston, Massachusetts | Margot Hardcastle - (mhardcastle@mgh.harvard.edu) |
| Medical University of South Carolina Charleston, South Carolina | Ashley Warden - (jonesash@musc.edu) |
| Morristown Medical Center Morristown, New Jersey | Debra Connolly - (Debra.Connolly@atlantichealth.org) |
| National Jewish Health Denver, Colorado | Alix Wilson - (wilsona@njhealth.org) |
| Nationwide Children's Hospital Columbus, Ohio | Diana Gilmore - (Diana.Gilmore@nationwidechildrens.org) |
| New York Medical College at Westchester Medical Center Valhalla, New York | Zachary Messer - (Zachary_Messer@nymc.edu) |
| Northwestern University Chicago, Illinois | Rachel Nelson - (rachel.nelson@northwestern.edu) |
| Oregon Health & Sciences University Portland, Oregon | Jenna Bucher - (bucherj@ohsu.edu) |
| Phoenix Children's Hospital Phoenix, Arizona | Natalia Argel - (Nargel@phoenixchildrens.com) |
| Prisma Health Children's Hospital - Midlands Columbia, South Carolina | Veronica Lipscomb - (Veronica.Lipscomb@PrismaHealth.org) |
| Providence Medical Group, Cystic Fibrosis Clinic Spokane, Washington | Joan Milton - (joan.milton@providence.org) |
| Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center Cleveland, Ohio | Primary RC & Participant Contact General Contact - (RainbowCFResearch@UHhospitals.org) |
| Riley Hospital for Children Indianapolis, Indiana | Lisa Bendy - (lbendy@iupui.edu) |
| Saint Luke's Cystic Fibrosis Center of Idaho Boise, Idaho | Lejla Godusevic - (godusevl@slhs.org) |
| Seattle Children's Hospital Seattle, Washington | Sharon McNamara - (sharon.mcnamara@seattlechildrens.org) |
| Stanford University Medical Center Palo Alto, California | Jacquelyn Spano - (jmzirbes@stanford.edu) |
| Tampa General Hospital Tampa, Florida | Andrew Marino - (armarino@usf.edu) |
| The Children's Hospital Alabama, University of Alabama at Birmingham Birmingham, Alabama | Kathryn Monroe - (kathrynmonroe@uabmc.edu) |
| The Cystic Fibrosis Center of Western New York Buffalo, New York | Julianne Hergenroder - (jhergenroder@upa.chob.edu) |
| The Minnesota Cystic Fibrosis Center Minneapolis, Minnesota | CF Trials Contact University of Minnesota, Participant Contact - (cftrials@umn.edu) |
| Tucson Cystic Fibrosis Center Tucson, Arizona | Elizabeth Ryan - (elizabethryan@email.arizona.edu) |
| Tulane University New Orleans, Louisiana | Adrienne Savant - (asavant1@tulane.edu) |
| University of Arkansas for Medical Sciences Little Rock, Arkansas | Kathleen Hicks - (HicksKathleenT@uams.edu) |
| University of California San Diego San Diego, California | Jenna Mielke - (jmielke@health.ucsd.edu) |
| University of California, San Francisco - Adult Center San Francisco, California | Courtney Moreno - (Courtney.Moreno@ucsf.edu) |
| University of California, San Francisco - Peds Center San Francisco, California | Ngoc Ly - (Ngoc.Ly@ucsf.edu) |
| University of Florida Gainesville, Florida | Chrystal Bailey - (Cbailey1@peds.ufl.edu) |
| University of Kansas Medical Center Kansas City, Kansas | Lawrence Scott - (lscott2@kumc.edu) |
| University of Kentucky Lexington, Kentucky | Chase Whitaker - (chase.whitaker@uky.edu) |
| University of Massachusetts Memorial Health Care Worcester, Massachusetts | Jaclyn Longtine - (Jaclyn.Longtine@umassmed.edu) |
| University of Miami Miami, Florida | Ylber (Ivan) Whitaker - (yiw2@miami.edu) |
| University of Michigan, Michigan Medicine Ann Arbor, Michigan | Dawn Kruse - (dmkruse@med.umich.edu) |
| University of Nebraska Medical Center Omaha, Nebraska | Michel Veit - (michel.veit@unmc.edu) |
| University of North Carolina at Chapel Hill Chapel Hill, North Carolina | Julie Goudy - (julie_goudy@med.unc.edu) |
| University of Pennsylvania Philadelphia, Pennsylvania | Melissa Molter - (melissa.molter@pennmedicine.upenn.edu) |
| University of Pittsburgh Medical Center Pittsburgh, Pennsylvania | Adrienne DeRicco - (adrienne.dericco2@upmc.edu) |
| University of Rochester Medical Center Strong Memorial Rochester, New York | Barb Johnson - (Barbara_Johnson@URMC.Rochester.edu) |
| University of Texas Southwestern Dallas, Texas | Ashley Keller - (Ashley.Keller@UTSouthwestern.edu) |
| University of Texas Southwestern / Children's Health Dallas, Texas | Keianna Brown - (Keianna.brown@utsouthwestern.edu) |
| University of Washington Medical Center Seattle, Washington | Lauren Bartlett - (lrejman@uw.edu) |
| University of Wisconsin Madison, Wisconsin | Melanie Nelson - (mnelson@pediatrics.wisc.edu) |
| Vanderbilt University Medical Center Nashville, Tennessee | Brijesh Patel - (brijesh.patel@vumc.org) |
| Virginia Commonwealth University Richmond, Virginia | Akilah Pierre-Louis - (akilah.pierrelouis1@vcuhealth.org) |
| Washington University School of Medicine St Louis, Missouri | Irma Bauer - (irmabauer@wustl.edu) |
| Wayne State University Harper University Hospital Detroit, Michigan | Debra Driscoll - (ddriscol@med.wayne.edu) |
| West Virginia University - Morgantown Morgantown, West Virginia | Tammy Clark - (tclark@hsc.wvu.edu) |
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
ctrrecruit@vcu.edu
NCT05040360
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Participants must have a histologic diagnosis of well-differentiated pancreatic neuroendocrine tumor (pNET) that was resected between 14 and 120 days prior to registration. Participants must have a scan within 90 days prior to registration without evidence of metastatic disease. Acceptable scans are multiphase computed tomography (CT) abdomen, magnetic resonance imaging (MRI) with intravenous (IV) contrast of the abdomen, or positron emission tomography (PET)-CT DOTATATE imaging if the DOTATATE PET-CT included IV iodine contrast for the CT portion of the exam
* Resection must have been an R0 or R1 per treating investigator's assessment and/or pathology report
* Ki-67 testing, which is considered part of standard of care in the pathology report, must have been performed between 14 and 90 days prior to registration and the result must be \>= 3% and =\< 55%. Treating investigators are encouraged to contact the S2104 Study Chairs and/or the study pathology chair with questions. If more than one Ki-67 is reported (e.g., primary tumor versus lymph node or metastatic site), the highest one should be considered for the study eligibility criteria
* Participants with localized resected pNETS must have a Zaidi score of \>= 3 derived by the following factors and points:
* 1 point; symptomatic tumor defined as one of the following:
* Gastrointestinal bleed
* Jaundice
* Gastrointestinal obstruction
* Pain from primary tumor prior to surgical resection
* Pancreatitis
* 2 points; primary pancreas tumor size \> 2 cm
* 1 point; Ki-67 3% to 20%
* 1 point; lymph node positivity = 1
* 6 points; Ki-67 21% to 55%
* Participants may have received resection/ablation of liver oligo-metastatic disease (up to 5 liver metastases) at the time of well-differentiated pNET resection
* Participants must have recovered from effects of surgery as determined by the treating investigator
* Participants must be \>= 18 years old
* Participants must have Zubrod performance status of 0-2
* Participants must have a complete medical history and physical exam within 28 days prior to registration
* Leukocytes \>= 3 x 10\^3/uL (within 28 days prior to registration)
* Absolute neutrophil count \>= 1.5 x 10\^3/uL (within 28 days prior to registration)
* Platelets \>= 100 x 10\^3/uL (within 28 days prior to registration)
* Total bilirubin =\< institutional upper limit of normal (ULN) unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin =\< 5 x institutional ULN (within 28 days prior to registration)
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3 x institutional ULN (within 28 days prior to registration)
* Serum creatinine =\< 1.5 x institutional ULN (within 28 days prior to registration)
* Calculated creatinine clearance \>= 50 ml/min (within 28 days prior to registration)
* Participants must be able to swallow pills
* Participants must be able to tolerate CT or magnetic resonance (MR) imaging including contrast agents as required for their treatment and the protocol
* No other active malignancy or history of prior malignancy is allowed, except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the participant is currently in complete remission, or any other cancer from which the participant has been disease free for two years
* Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines
Exclusion Criteria:
* Participants must not have unresected or unablated metastatic disease
* Participants must not have clinically apparent central nervous system metastases or carcinomatous meningitis
* Participants must not have received prior neoadjuvant therapy for treatment of pancreatic neuroendocrine tumor. Use of somatostatin analogs prior to surgery is permitted
* Participants must not have received somatostatin analogs after surgery
* Participants must not be planning to receive warfarin while on protocol treatment. Other anticoagulants are allowed
* Participants must not have history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or capecitabine
* Participants must not have known absorption issues that would limit the ability to absorb study agents
* Participants must not have had an arterial thromboembolic event, unstable angina, or myocardial infarction within 12 months prior to registration
* Participants must not have active or uncontrolled infection
* Participants must not have serious medical or psychiatric illness that could affect study participation in the judgement of the treating investigator
* Participants must not be pregnant due to the possibility of harm to the fetus. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen DRUG: Capecitabine, DRUG: Temozolomide
Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8, Stage III Pancreatic Neuroendocrine Tumor AJCC v8
I'm interested
Share via email
Show 448 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Abbott-Northwestern Hospital Minneapolis, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| AdventHealth Littleton Littleton, Colorado | |
| AdventHealth Parker Parker, Colorado | |
| AdventHealth Porter Denver, Colorado | |
| Alaska Breast Care and Surgery LLC Anchorage, Alaska | Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org) |
| Alaska Oncology and Hematology LLC Anchorage, Alaska | Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org) |
| Alaska Women's Cancer Care Anchorage, Alaska | Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org) |
| Alegent Health Bergan Mercy Medical Center Omaha, Nebraska | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Alegent Health Immanuel Medical Center Omaha, Nebraska | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Alegent Health Lakeside Hospital Omaha, Nebraska | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Alegent Health Mercy Hospital Council Bluffs, Iowa | |
| Allegiance Health Jackson, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Alliance for Childhood Diseases/Cure 4 the Kids Foundation Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Anchorage Associates in Radiation Medicine Anchorage, Alaska | Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org) |
| Anchorage Oncology Centre Anchorage, Alaska | |
| Anchorage Radiation Therapy Center Anchorage, Alaska | |
| Ann M Wierman MD LTD Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Atrium Medical Center-Middletown Regional Hospital Franklin, Ohio | Site Public Contact - (clinical.trials@daytonncorp.org) |
| BASS Medical Group - Lennon Walnut Creek, California | |
| Banner MD Anderson Cancer Center Gilbert, Arizona | |
| Banner University Medical Center - Tucson Tucson, Arizona | Site Public Contact - (UACC-IIT@uacc.arizona.edu) |
| Baptist Memorial Hospital and Cancer Center-Collierville Collierville, Tennessee | Site Public Contact - (BCCclintrials@bmhcc.org) |
| Baptist Memorial Hospital and Cancer Center-Desoto Southhaven, Mississippi | Site Public Contact - (BCCclintrials@bmhcc.org) |
| Baptist Memorial Hospital and Cancer Center-Memphis Memphis, Tennessee | Site Public Contact - (BCCclintrials@bmhcc.org) |
| Baptist Memorial Hospital and Cancer Center-Oxford Oxford, Mississippi | Site Public Contact - (BCCclintrials@bmhcc.org) |
| Bay Area Breast Surgeons Inc Emeryville, California | |
| Bay Area Hospital Coos Bay, Oregon | Site Public Contact - (cherie.cox@bayareahospital.org) |
| Bay Area Tumor Institute Oakland, California | |
| Benefis Sletten Cancer Institute Great Falls, Montana | Site Public Contact - (mccinfo@mtcancer.org) |
| Bethesda North Hospital Cincinnati, Ohio | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Billings Clinic Cancer Center Billings, Montana | Site Public Contact - (research@billingsclinic.org) |
| Billings Clinic-Cody Cody, Wyoming | Site Public Contact - (research@billingsclinic.org) |
| Boulder Community Foothills Hospital Boulder, Colorado | |
| Bozeman Health Deaconess Hospital Bozeman, Montana | Site Public Contact - (mccinfo@mtcancer.org) |
| CARTI Cancer center Little Rock, Arkansas | Site Public Contact - (Research@CARTI.com) |
| CHI Health Good Samaritan Kearney, Nebraska | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| CHI Health Saint Francis Grand Island, Nebraska | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Cambridge Medical Center Cambridge, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Cancer Care Northwest - Spokane South Spokane, Washington | Site Public Contact - (research@ccnw.net) |
| Cancer Care Northwest-North Spokane Spokane, Washington | Site Public Contact - (research@ccnw.net) |
| Cancer Care Northwest-Valley Spokane, Washington | Site Public Contact - (research@ccnw.net) |
| Cancer Center at Saint Joseph's Phoenix, Arizona | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Cancer Center of Colorado at Sloan's Lake Denver, Colorado | |
| Cancer Center of Western Wisconsin New Richmond, Wisconsin | Site Public Contact - (mmcorc@healthpartners.com) |
| Cancer and Blood Specialists-Henderson Henderson, Nevada | Site Public Contact - (research@sncrf.org) |
| Carle Cancer Center Urbana, Illinois | Site Public Contact - (Research@carle.com) |
| Carle Physician Group-Effingham Effingham, Illinois | Site Public Contact - (Research@carle.com) |
| Carle Physician Group-Mattoon/Charleston Mattoon, Illinois | Site Public Contact - (Research@carle.com) |
| Carle at The Riverfront Danville, Illinois | Site Public Contact - (Research@Carle.com) |
| Carson Tahoe Regional Medical Center Carson City, Nevada | Site Public Contact - (research@sncrf.org) |
| Case Western Reserve University Cleveland, Ohio | Site Public Contact - (CTUReferral@UHhospitals.org) |
| Cedars Sinai Medical Center Los Angeles, California | |
| Central Care Cancer Center - Bolivar Bolivar, Missouri | Site Public Contact - (aroland@kccop.org) |
| Central Care Cancer Center - Garden City Garden City, Kansas | Site Public Contact - (aroland@kccop.org) |
| Central Care Cancer Center - Great Bend Great Bend, Kansas | Site Public Contact - (aroland@kccop.org) |
| Clackamas Radiation Oncology Center Clackamas, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| Colorado Blood Cancer Institute Denver, Colorado | |
| CommonSpirit Cancer Center Mercy Durango, Colorado | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Commonwealth Cancer Center-Corbin Corbin, Kentucky | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Community Hospital of Anaconda Anaconda, Montana | Site Public Contact - (mccinfo@mtcancer.org) |
| Community Medical Center Toms River, New Jersey | Site Public Contact - (mccinfo@mtcancer.org) |
| Comprehensive Cancer Centers of Nevada Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Comprehensive Cancer Centers of Nevada - Central Valley Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Comprehensive Cancer Centers of Nevada - Henderson Henderson, Nevada | Site Public Contact - (research@sncrf.org) |
| Comprehensive Cancer Centers of Nevada - Northwest Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Comprehensive Cancer Centers of Nevada - Town Center Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Comprehensive Cancer Centers of Nevada-Horizon Ridge Henderson, Nevada | Site Public Contact - (research@sncrf.org) |
| Comprehensive Cancer Centers of Nevada-Southeast Henderson Henderson, Nevada | Site Public Contact - (research@sncrf.org) |
| Comprehensive Cancer Centers of Nevada-Summerlin Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Contra Costa Regional Medical Center Martinez, California | |
| Cox Cancer Center Branson Branson, Missouri | |
| CoxHealth South Hospital Springfield, Missouri | |
| Creighton University Medical Center Omaha, Nebraska | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Dartmouth Cancer Center - North Saint Johnsbury, Vermont | Site Public Contact - (cancer.research.nurse@hitchcock.org) |
| Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center Lebanon, New Hampshire | Site Public Contact - (cancer.research.nurse@dartmouth.edu) |
| Duluth Clinic Ashland Ashland, Wisconsin | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| East Jefferson General Hospital Metairie, Louisiana | Site Public Contact - (emede1@lsuhsc.edu) |
| Emory Decatur Hospital Decatur, Georgia | Site Public Contact - (clinicaltrialsoncology@dekalbmedical.org) |
| Emory Saint Joseph's Hospital Atlanta, Georgia | |
| Emory University Hospital Midtown Atlanta, Georgia | |
| Emory University Hospital/Winship Cancer Institute Atlanta, Georgia | |
| Epic Care Cyberknife Center Walnut Creek, California | |
| Epic Care Partners in Cancer Care Emeryville, California | |
| Epic Care-Dublin Dublin, California | |
| Essentia Health - Baxter Clinic Baxter, Minnesota | |
| Essentia Health - Deer River Clinic Deer River, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health - Ely Clinic Ely, Minnesota | |
| Essentia Health - Fosston Fosston, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health - International Falls Clinic International Falls, Minnesota | |
| Essentia Health - Jamestown Clinic Jamestown, North Dakota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health - Moose Lake Clinic Moose Lake, Minnesota | |
| Essentia Health - Park Rapids Park Rapids, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health - Saint Joseph's Crosslake Clinic Crosslake, Minnesota | |
| Essentia Health - Saint Joseph's Pequot Lakes Clinic Pequot Lakes, Minnesota | |
| Essentia Health - Saint Joseph's Pine River Clinic Pine River, Minnesota | |
| Essentia Health - Saint Joseph's Staples Clinic Staples, Minnesota | |
| Essentia Health Cancer Center Duluth, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health Cancer Center-South University Clinic Fargo, North Dakota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health Hibbing Clinic Hibbing, Minnesota | |
| Essentia Health Saint Joseph's Medical Center Brainerd, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health Saint Mary's - Detroit Lakes Clinic Detroit Lakes, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health Saint Mary's Hospital - Superior Superior, Wisconsin | |
| Essentia Health Saint Mary's Medical Center Duluth, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health Sandstone Sandstone, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health Virginia Clinic Virginia, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health-Hayward Clinic Hayward, Wisconsin | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health-Spooner Clinic Spooner, Wisconsin | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Fairbanks Memorial Hospital Fairbanks, Alaska | |
| Fairview Clinics and Surgery Center Maple Grove Maple Grove, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Fairview Lakes Medical Center Wyoming, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Fairview Northland Medical Center Princeton, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Fairview Southdale Hospital Edina, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Farmington Health Center Farmington, Utah | Site Public Contact - (cancerinfo@hci.utah.edu) |
| Flaget Memorial Hospital Bardstown, Kentucky | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Franciscan Research Center-Northwest Medical Plaza Tacoma, Washington | |
| Fred Hutchinson Cancer Center Seattle, Washington | |
| Freeman Health System Joplin, Missouri | Site Public Contact - (LJCrockett@freemanhealth.com) |
| George Washington University Medical Center Washington D.C., District of Columbia | |
| Good Samaritan Hospital - Cancer Centers of Colorado Lafayette, Colorado | Site Public Contact - (peaksresearch@imail.org) |
| Good Samaritan Hospital - Cincinnati Cincinnati, Ohio | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Great Falls Clinic Great Falls, Montana | Site Public Contact - (mccinfo@mtcancer.org) |
| Greater Regional Medical Center Creston, Iowa | |
| Gundersen Lutheran Medical Center La Crosse, Wisconsin | Site Public Contact - (cancerctr@gundersenhealth.org) |
| Health Partners Inc Minneapolis, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Heartland Regional Medical Center Saint Joseph, Missouri | Site Public Contact - (Trisha.England2@mymlc.com) |
| Hennepin County Medical Center Minneapolis, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Henry Ford Cancer Institute-Downriver Brownstown, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Henry Ford Hematology Oncology - Hayes Clinton Township, Michigan | Site Public Contact - (tpearce1@hfhs.org) |
| Henry Ford Hospital Detroit, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Henry Ford Macomb Hospital-Clinton Township Clinton Township, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Henry Ford Medical Center-Columbus Novi, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Henry Ford Medical Center-Fairlane Dearborn, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Henry Ford West Bloomfield Hospital West Bloomfield, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Henry Ford Wyandotte Hospital Wyandotte, Michigan | Site Public Contact - (nhay@hfhs.org) |
| Hi-Line Sletten Cancer Center Havre, Montana | Site Public Contact - (protocols@swog.org) |
| Highline Medical Center-Main Campus Burien, Washington | |
| Hope Cancer Care of Nevada Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Hope Cancer Care of Nevada-Pahrump Pahrump, Nevada | Site Public Contact - (research@sncrf.org) |
| Hospital de Clinicas Dr Manuel Quintela Montevideo, | |
| Huntsman Cancer Institute/University of Utah Salt Lake City, Utah | Site Public Contact - (cancerinfo@hci.utah.edu) |
| Idaho Urologic Institute-Meridian Meridian, Idaho | |
| Instituto Nacional De Cancerologia de Mexico Mexico City, Tlalpan | |
| Intermountain Health Lutheran Hospital Wheat Ridge, Colorado | Site Public Contact - (peaksresearch@imail.org) |
| Intermountain Health West End Clinic Billings, Montana | |
| Jefferson Healthcare Port Townsend, Washington | |
| Jewish Hospital Louisville, Kentucky | |
| Jewish Hospital Medical Center South Shepherdsville, Kentucky | |
| Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland | Site Public Contact - (jhcccro@jhmi.edu) |
| Kadlec Clinic Hematology and Oncology Kennewick, Washington | Site Public Contact - (research@kadlecmed.org) |
| Katmai Oncology Group Anchorage, Alaska | Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org) |
| Keck Medical Center of USC Pasadena Pasadena, California | |
| Keck Medicine of USC Buena Park Buena Park, California | |
| Keck Medicine of USC Huntington Beach Huntington Beach, California | Site Public Contact - (karenn@pacshoresoncology.com) |
| Keck Medicine of USC Koreatown Los Angeles, California | |
| Kingman Regional Medical Center Kingman, Arizona | Site Public Contact - (research@sncrf.org) |
| Kootenai Clinic Cancer Services - Post Falls Post Falls, Idaho | Site Public Contact - (mccinfo@mtcancer.org) |
| Kootenai Clinic Cancer Services - Sandpoint Sandpoint, Idaho | Site Public Contact - (mccinfo@mtcancer.org) |
| Kootenai Health - Coeur d'Alene Coeur d'Alene, Idaho | Site Public Contact - (mccinfo@mtcancer.org) |
| Lake Region Healthcare Corporation-Cancer Care Fergus Falls, Minnesota | |
| Lake Regional Hospital Osage Beach, Missouri | Site Public Contact - (clinicaltrials@lakeregional.com) |
| Lakeview Hospital Stillwater, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Las Vegas Cancer Center-Henderson Henderson, Nevada | |
| Las Vegas Cancer Center-Medical Center Las Vegas, Nevada | |
| Las Vegas Prostate Cancer Center Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Las Vegas Urology - Cathedral Rock Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Las Vegas Urology - Green Valley Henderson, Nevada | Site Public Contact - (research@sncrf.org) |
| Las Vegas Urology - Pebble Henderson, Nevada | Site Public Contact - (research@sncrf.org) |
| Las Vegas Urology - Pecos Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Las Vegas Urology - Smoke Ranch Las Vegas, Nevada | Site Public Contact - (research@smcrf.org) |
| Las Vegas Urology - Sunset Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Logan Health Medical Center Kalispell, Montana | Site Public Contact - (mccinfo@mtcancer.org) |
| Longmont United Hospital Longmont, Colorado | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Los Angeles General Medical Center Los Angeles, California | Site Public Contact - (uscnorrisinfo@med.usc.edu) |
| Marshfield Medical Center - Minocqua Minocqua, Wisconsin | Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org) |
| Marshfield Medical Center - Weston Weston, Wisconsin | Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org) |
| Marshfield Medical Center-EC Cancer Center Eau Claire, Wisconsin | Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org) |
| Marshfield Medical Center-Marshfield Marshfield, Wisconsin | Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org) |
| Marshfield Medical Center-Rice Lake Rice Lake, Wisconsin | Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org) |
| Marshfield Medical Center-River Region at Stevens Point Stevens Point, Wisconsin | Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org) |
| Mary Greeley Medical Center Ames, Iowa | |
| Mayo Clinic Hospital in Arizona Phoenix, Arizona | |
| Mayo Clinic in Rochester Rochester, Minnesota | |
| McFarland Clinic - Ames Ames, Iowa | Site Public Contact - (ksoder@mcfarlandclinic.com) |
| McFarland Clinic - Boone Boone, Iowa | |
| McFarland Clinic - Jefferson Jefferson, Iowa | |
| McFarland Clinic - Marshalltown Marshalltown, Iowa | |
| McFarland Clinic - Trinity Cancer Center Fort Dodge, Iowa | |
| Medical University of South Carolina Charleston, South Carolina | Site Public Contact - (hcc-clinical-trials@musc.edu) |
| Memorial Hospital East Shiloh, Illinois | Site Public Contact - (dschwab@wustl.edu) |
| Mercy Cancer Center Merced, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Mercy Cancer Center - Cape Girardeau Cape Girardeau, Missouri | |
| Mercy Cancer Center - Carmichael Carmichael, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Mercy Cancer Center - Elk Grove Elk Grove, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Mercy Cancer Center - Rocklin Rocklin, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Mercy Cancer Center - Sacramento Sacramento, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Mercy Cancer Center-West Lakes Clive, Iowa | |
| Mercy Clinic-Rolla-Cancer and Hematology Rolla, Missouri | |
| Mercy Health - Paducah Cancer Center Paducah, Kentucky | |
| Mercy Hospital Coon Rapids, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Mercy Hospital Fort Smith Fort Smith, Arkansas | |
| Mercy Hospital Joplin Joplin, Missouri | Site Public Contact - (esmeralda.carrillo@mercy.net) |
| Mercy Hospital Oklahoma City Oklahoma City, Oklahoma | |
| Mercy Hospital Pittsburg Pittsburg, Kansas | |
| Mercy Hospital Saint Louis St Louis, Missouri | |
| Mercy Hospital South St Louis, Missouri | Site Public Contact - (Danielle.Werle@mercy.net) |
| Mercy Hospital Springfield Springfield, Missouri | |
| Mercy Hospital Washington Washington, Missouri | |
| Mercy Infusion Center - Chippewa St Louis, Missouri | |
| Mercy Medical Center Springfield, Massachusetts | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Mercy Medical Center Springfield, Massachusetts | Site Public Contact - (acline@mdmercy.com) |
| Mercy Medical Center - Des Moines Des Moines, Iowa | |
| Mercy Medical Center-West Lakes West Des Moines, Iowa | |
| Mercy Oncology and Hematology - Clayton-Clarkson Ballwin, Missouri | |
| Mercy San Juan Medical Center Carmichael, California | Site Public Contact - (OncologyResearch@DignityHealth.org) |
| Miami Valley Cancer Care and Infusion Greenville, Ohio | |
| Miami Valley Hospital Dayton, Ohio | Site Public Contact - (clinical.trials@daytonncorp.org) |
| Miami Valley Hospital North Dayton, Ohio | Site Public Contact - (clinical.trials@daytonncorp.org) |
| Miami Valley Hospital South Centerville, Ohio | Site Public Contact - (clinical.trials@daytonncorp.org) |
| Midlands Community Hospital Papillion, Nebraska | |
| Miller-Dwan Hospital Duluth, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Minnesota Oncology - Burnsville Burnsville, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Minnesota Oncology Hematology PA-Maplewood Maplewood, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Minnesota Oncology Hematology PA-Woodbury Woodbury, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Mission Hope Medical Oncology - Arroyo Grande Arroyo Grande, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Mission Hope Medical Oncology - Santa Maria Santa Maria, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Moffitt Cancer Center Tampa, Florida | Site Public Contact - (ClinicalTrials@moffitt.org) |
| Moffitt Cancer Center - McKinley Campus Tampa, Florida | Site Public Contact - (ClinicalTrials@moffitt.org) |
| Moffitt Cancer Center-International Plaza Tampa, Florida | Site Public Contact - (ClinicalTrials@moffitt.org) |
| Montefiore Medical Center-Einstein Campus The Bronx, New York | Site Public Contact - (eskwak@montefiore.org) |
| Monticello Cancer Center Monticello, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Mountain Blue Cancer Care Center - Swedish Englewood, Colorado | |
| National Jewish Health-Main Campus Denver, Colorado | Site Public Contact - (glicht@co-cancerresearch.org) |
| National Jewish Health-Northern Hematology Oncology Thornton, Colorado | Site Public Contact - (glicht@co-cancerresearch.org) |
| National Jewish Health-Western Hematology Oncology Golden, Colorado | Site Public Contact - (glicht@co-cancerresearch.org) |
| Nebraska Cancer Specialists/Oncology Hematology West PC Grand Island, Nebraska | |
| New Ulm Medical Center New Ulm, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| North Memorial Medical Health Center Robbinsdale, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| North Star Lodge Cancer Center at Yakima Valley Memorial Hospital Yakima, Washington | Site Public Contact - (Memorial-ClinicalTrials@yvmh.org) |
| Northwest Wisconsin Cancer Center Ashland, Wisconsin | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Northwestern Medicine Cancer Center Delnor Geneva, Illinois | Site Public Contact - (Donald.Smith3@nm.org) |
| Northwestern Medicine Cancer Center Kishwaukee DeKalb, Illinois | Site Public Contact - (Donald.Smith3@nm.org) |
| Northwestern Medicine Cancer Center Warrenville Warrenville, Illinois | Site Public Contact - (Donald.Smith3@nm.org) |
| Northwestern Medicine Glenview Outpatient Center Glenview, Illinois | |
| Northwestern Medicine Grayslake Outpatient Center Grayslake, Illinois | |
| Northwestern Medicine Lake Forest Hospital Lake Forest, Illinois | Site Public Contact - (cancertrials@northwestern.edu) |
| Northwestern Medicine Orland Park Orland Park, Illinois | Site Public Contact - (nctnprogram_rhlccc@northwestern.edu) |
| Northwestern University Chicago, Illinois | Site Public Contact - (cancer@northwestern.edu) |
| OSF Saint Anthony's Health Center Alton, Illinois | |
| Ohio State University Comprehensive Cancer Center Columbus, Ohio | Site Public Contact - (Jamesline@osumc.edu) |
| Oncology Las Vegas - Henderson Henderson, Nevada | Site Public Contact - (research@sncrf.org) |
| Oncology Las Vegas - Tenaya Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| OptumCare Cancer Care at Charleston Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| OptumCare Cancer Care at Fort Apache Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| OptumCare Cancer Care at MountainView Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| OptumCare Cancer Care at Seven Hills Henderson, Nevada | Site Public Contact - (research@sncrf.org) |
| Oregon Health and Science University Portland, Oregon | Site Public Contact - (trials@ohsu.edu) |
| Overlake Medical Center Bellevue, Washington | |
| PCR Oncology Arroyo Grande, California | Site Public Contact - (research@sncrf.org) |
| Pacific Central Coast Health Center-San Luis Obispo San Luis Obispo, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Park Nicollet Clinic - Saint Louis Park Saint Louis Park, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| PeaceHealth Saint John Medical Center Longview, Washington | Site Public Contact - (kmakin-bond@peacehealth.org) |
| PeaceHealth Saint Joseph Medical Center Bellingham, Washington | |
| PeaceHealth Southwest Medical Center Vancouver, Washington | Site Public Contact - (kmakin-bond@peacehealth.org) |
| PeaceHealth United General Medical Center Sedro-Woolley, Washington | Site Public Contact - (rcrompton@peacehealth.org) |
| Penrose-Saint Francis Healthcare Colorado Springs, Colorado | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Phelps Health Delbert Day Cancer Institute Rolla, Missouri | Site Public Contact - (research@phelpshealth.org) |
| Premier Blood and Cancer Center Dayton, Ohio | |
| Presbyterian - Saint Lukes Medical Center - Health One Denver, Colorado | |
| Prisma Health Cancer Institute - Butternut Greenville, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| Prisma Health Cancer Institute - Easley Easley, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| Prisma Health Cancer Institute - Eastside Greenville, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| Prisma Health Cancer Institute - Faris Greenville, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| Prisma Health Cancer Institute - Greer Greer, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| Prisma Health Cancer Institute - Seneca Seneca, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| Prisma Health Cancer Institute - Spartanburg Boiling Springs, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| Prisma Health Greenville Memorial Hospital Greenville, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| Providence Alaska Medical Center Anchorage, Alaska | Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org) |
| Providence Cancer Institute Clackamas Clinic Clackamas, Oregon | |
| Providence Hood River Memorial Hospital Hood River, Oregon | Site Public Contact - (canrsrchstudies@provdience.org) |
| Providence Medical Foundation - Santa Rosa Santa Rosa, California | |
| Providence Newberg Medical Center Newberg, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| Providence Portland Medical Center Portland, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| Providence Queen of The Valley Napa, California | |
| Providence Regional Cancer Partnership Everett, Washington | Site Public Contact - (marilyn.birchman@providence.org) |
| Providence Regional Cancer System-Aberdeen Aberdeen, Washington | Site Public Contact - (deidre.dillon@providence.org) |
| Providence Regional Cancer System-Centralia Centralia, Washington | Site Public Contact - (deidre.dillon@providence.org) |
| Providence Regional Cancer System-Lacey Lacey, Washington | Site Public Contact - (deidre.dillon@providence.org) |
| Providence Regional Cancer System-Shelton Shelton, Washington | |
| Providence Regional Cancer System-Yelm Yelm, Washington | |
| Providence Saint Joseph Medical Center/Disney Family Cancer Center Burbank, California | Site Public Contact - (Najee.Boucher@providence.org) |
| Providence Saint Mary Regional Cancer Center Walla Walla, Washington | Site Public Contact - (Cheryl.Dodd@providence.org) |
| Providence Saint Vincent Medical Center Portland, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| Providence Santa Rosa Memorial Hospital Santa Rosa, California | |
| Providence Willamette Falls Medical Center Oregon City, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| Radiation Oncology Associates Reno, Nevada | Site Public Contact - (research@sncrf.org) |
| Radiation Oncology Centers of Nevada Central Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Radiation Oncology Centers of Nevada Southeast Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Regional Cancer Center-Lee Memorial Health System Fort Myers, Florida | Site Public Contact - (protocols@swog.org) |
| Regions Hospital Saint Paul, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Renown Regional Medical Center Reno, Nevada | Site Public Contact - (research@sncrf.org) |
| Rice Memorial Hospital Willmar, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Ridgeview Medical Center Waconia, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Riverwood Healthcare Center Aitkin, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Rocky Mountain Cancer Centers - Centennial Centennial, Colorado | |
| Rocky Mountain Cancer Centers - Swedish Englewood, Colorado | |
| Rocky Mountain Cancer Centers-Aurora Aurora, Colorado | |
| Rocky Mountain Cancer Centers-Boulder Boulder, Colorado | |
| Rocky Mountain Cancer Centers-Lakewood Lakewood, Colorado | |
| Rocky Mountain Cancer Centers-Littleton Littleton, Colorado | |
| Rocky Mountain Cancer Centers-Longmont Longmont, Colorado | |
| Rocky Mountain Cancer Centers-Midtown Denver, Colorado | |
| Rocky Mountain Cancer Centers-Penrose Colorado Springs, Colorado | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Rocky Mountain Cancer Centers-Rose Denver, Colorado | |
| Rocky Mountain Cancer Centers-Sky Ridge Lone Tree, Colorado | |
| Rocky Mountain Cancer Centers-Thornton Thornton, Colorado | |
| Rush-Copley Healthcare Center Yorkville, Illinois | Site Public Contact - (Cancer.Research@rushcopley.com) |
| Rush-Copley Medical Center Aurora, Illinois | Site Public Contact - (RCMC_Cancer_Research@rush.edu) |
| SSM Health Good Samaritan Mount Vernon, Illinois | Site Public Contact - (gayla.hall@ssmhealth.com) |
| SUNY Upstate Medical Center-Community Campus Syracuse, New York | |
| Saint Alphonsus Cancer Care Center-Baker City Baker City, Oregon | |
| Saint Alphonsus Cancer Care Center-Boise Boise, Idaho | |
| Saint Alphonsus Cancer Care Center-Caldwell Caldwell, Idaho | |
| Saint Alphonsus Cancer Care Center-Nampa Nampa, Idaho | |
| Saint Alphonsus Cancer Care Center-Ontario Ontario, Oregon | |
| Saint Anthony Hospital Lakewood, Colorado | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Anthony North Hospital Westminster, Colorado | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Charles Health System Bend, Oregon | Site Public Contact - (nosall@stcharleshealthcare.org) |
| Saint Charles Health System-Redmond Redmond, Oregon | |
| Saint Clare Hospital Lakewood, Washington | |
| Saint Elizabeth Hospital Enumclaw, Washington | |
| Saint Elizabeth Regional Medical Center Lincoln, Nebraska | |
| Saint Francis Cancer Center Greenville, South Carolina | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Francis Hospital Federal Way, Washington | |
| Saint Francis Regional Medical Center Shakopee, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Saint James Community Hospital and Cancer Treatment Center Butte, Montana | |
| Saint John's Hospital - Healtheast Maplewood, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Saint Joseph Hospital Nashua, New Hampshire | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Joseph Hospital - Cancer Centers of Colorado Denver, Colorado | |
| Saint Joseph Hospital East Lexington, Kentucky | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Joseph London London, Kentucky | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Joseph Mount Sterling Mount Sterling, Kentucky | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Joseph Radiation Oncology Resource Center Lexington, Kentucky | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Joseph Regional Cancer Center Bryan, Texas | |
| Saint Joseph's Medical Center Stockton, California | |
| Saint Luke's Cancer Institute - Boise Boise, Idaho | Site Public Contact - (eslinget@slhs.org) |
| Saint Luke's Cancer Institute - Fruitland Fruitland, Idaho | Site Public Contact - (eslinget@slhs.org) |
| Saint Luke's Cancer Institute - Meridian Meridian, Idaho | Site Public Contact - (eslinget@slhs.org) |
| Saint Luke's Cancer Institute - Nampa Nampa, Idaho | Site Public Contact - (eslinget@slhs.org) |
| Saint Luke's Cancer Institute - Twin Falls Twin Falls, Idaho | Site Public Contact - (eslinget@slhs.org) |
| Saint Mary Corwin Medical Center Pueblo, Colorado | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Mary's Hospital Centralia, Illinois | Site Public Contact - (protocols@swog.org) |
| Saint Mary's Hospital and Regional Medical Center Grand Junction, Colorado | Site Public Contact - (ccrp@co-cancerresearch.org) |
| Saint Mary's Regional Medical Center Reno, Nevada | Site Public Contact - (research@sncrf.org) |
| Saint Michael Cancer Center Silverdale, Washington | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Patrick Hospital - Community Hospital Missoula, Montana | Site Public Contact - (amy.hanneman@providence.org) |
| Saint Vincent Frontier Cancer Center Billings, Montana | |
| Saint Vincent Healthcare Billings, Montana | Site Public Contact - (mccinfo@mtcancer.org) |
| Saints Mary and Elizabeth Hospital Louisville, Kentucky | |
| Schulze Family Foundation Cancer Clinic - Bonita Health Center Bonita Springs, Florida | Site Public Contact - (RCCR@leehealth.org) |
| Siteman Cancer Center at Christian Hospital St Louis, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| Siteman Cancer Center at Saint Peters Hospital City of Saint Peters, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| Siteman Cancer Center at West County Hospital Creve Coeur, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| Siteman Cancer Center-South County St Louis, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| Skagit Regional Health Cancer Care Center Mount Vernon, Washington | Site Public Contact - (rcccclinicalresearch@skagitvalleyhospital.org) |
| Smilow Cancer Hospital Care Center - Guilford Guilford, Connecticut | Site Public Contact - (canceranswers@yale.edu) |
| Smilow Cancer Hospital Care Center - Waterford Waterford, Connecticut | Site Public Contact - (canceranswers@yale.edu) |
| Smilow Cancer Hospital Care Center - Westerly Westerly, Rhode Island | Site Public Contact - (canceranswers@yale.edu) |
| Smilow Cancer Hospital Care Center at Glastonbury Glastonbury, Connecticut | Site Public Contact - (canceranswers@yale.edu) |
| Smilow Cancer Hospital Care Center at Greenwich Greenwich, Connecticut | Site Public Contact - (canceranswers@yale.edu) |
| Smilow Cancer Hospital Care Center at Saint Francis Hartford, Connecticut | Site Public Contact - (canceranswers@yale.edu) |
| Smilow Cancer Hospital Care Center-Fairfield Fairfield, Connecticut | Site Public Contact - (canceranswers@yale.edu) |
| Smilow Cancer Hospital Care Center-Trumbull Trumbull, Connecticut | Site Public Contact - (canceranswers@yale.edu) |
| Smilow Cancer Hospital-Derby Care Center Derby, Connecticut | Site Public Contact - (canceranswers@yale.edu) |
| Smilow Cancer Hospital-Orange Care Center Orange, Connecticut | Site Public Contact - (canceranswers@yale.edu) |
| Smilow Cancer Hospital-Torrington Care Center Torrington, Connecticut | Site Public Contact - (canceranswers@yale.edu) |
| Smilow Cancer Hospital-Waterbury Care Center Waterbury, Connecticut | Site Public Contact - (canceranswers@yale.edu) |
| State University of New York Upstate Medical University Syracuse, New York | |
| Stony Brook University Medical Center Stony Brook, New York | |
| Summerlin Hospital Medical Center Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Sunrise Hospital and Medical Center Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Swedish Cancer Institute-Edmonds Edmonds, Washington | Site Public Contact - (PCRC-NCORP@Swedish.org) |
| Swedish Cancer Institute-Issaquah Issaquah, Washington | Site Public Contact - (PCRC-NCORP@Swedish.org) |
| Swedish Medical Center-Ballard Campus Seattle, Washington | Site Public Contact - (PCRC-NCORP@Swedish.org) |
| Swedish Medical Center-Cherry Hill Seattle, Washington | Site Public Contact - (PCRC-NCORP@Swedish.org) |
| Swedish Medical Center-First Hill Seattle, Washington | Site Public Contact - (PCRC-NCORP@Swedish.org) |
| Tamarack Health Hayward Medical Center Hayward, Wisconsin | |
| Tampa General Hospital Tampa, Florida | Site Public Contact - (syapchanyk@tgh.org) |
| The Carle Foundation Hospital Urbana, Illinois | Site Public Contact - (Research@carle.com) |
| The Melanoma and Skin Cancer Institute Englewood, Colorado | |
| The Women's Imaging Center Denver, Colorado | |
| Torrance Memorial Physician Network - Cancer Care Torrance, California | Site Public Contact - (courtney.steeneken@tmphysicians.com) |
| Tower Cancer Research Foundation Beverly Hills, California | Site Public Contact - (towercancerresearch@toweroncology.com) |
| TriHealth Cancer Institute-Anderson Cincinnati, Ohio | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| TriHealth Cancer Institute-Westside Cincinnati, Ohio | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| UC Comprehensive Cancer Center at Silver Cross New Lenox, Illinois | Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu) |
| UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California | Site Public Contact - (ucstudy@uci.edu) |
| UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California | Site Public Contact - (ucstudy@uci.edu) |
| UF Health Cancer Institute - Gainesville Gainesville, Florida | |
| UH Seidman Cancer Center at Saint John Medical Center Westlake, Ohio | Site Public Contact - (CTUReferral@UHhospitals.org) |
| UH Seidman Cancer Center at UH Avon Health Center Avon, Ohio | |
| UHHS-Chagrin Highlands Medical Center Beachwood, Ohio | Site Public Contact - (CTUReferral@UHhospitals.org) |
| UI Health Care Mission Cancer and Blood - Laurel Clinic Des Moines, Iowa | |
| UI Health Care Mission Cancer and Blood - West Des Moines Clinic Clive, Iowa | |
| UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida | |
| UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida | |
| UM Sylvester Comprehensive Cancer Center at Kendall Miami, Florida | |
| UM Sylvester Comprehensive Cancer Center at Plantation Plantation, Florida | |
| USC / Norris Comprehensive Cancer Center Los Angeles, California | |
| USC Norris Oncology/Hematology-Newport Beach Newport Beach, California | |
| UW Health Carbone Cancer Center Rockford Rockford, Illinois | Site Public Contact - (lkline@uwhealth.org) |
| United Hospital Saint Paul, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| University Cancer Center Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| University Cancer Specialists - Alcoa Alcoa, Tennessee | Site Public Contact - (bherbert@utmck.edu) |
| University Medical Center of Southern Nevada Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| University of Arizona Cancer Center-North Campus Tucson, Arizona | Site Public Contact - (UACC-IIT@uacc.arizona.edu) |
| University of Chicago Comprehensive Cancer Center Chicago, Illinois | Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu) |
| University of Chicago Medicine-Orland Park Orland Park, Illinois | Site Public Contact - (cancerclinicaltrials@bsd.uchicago.edu) |
| University of Cincinnati Cancer Center-UC Medical Center Cincinnati, Ohio | Site Public Contact - (cancer@uchealth.com) |
| University of Cincinnati Cancer Center-West Chester West Chester, Ohio | Site Public Contact - (cancer@uchealth.com) |
| University of Illinois Chicago, Illinois | |
| University of Kentucky/Markey Cancer Center Lexington, Kentucky | |
| University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida | |
| University of Miami Sylvester Comprehensive Cancer Center at Sole Mia North Miami, Florida | Site Public Contact - (kginnity@med.miami.edu) |
| University of Michigan - Brighton Center for Specialty Care Brighton, Michigan | |
| University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan | Site Public Contact - (slusserb@med.umich.edu) |
| University of New Mexico Cancer Center Albuquerque, New Mexico | Site Public Contact - (HSC-ClinicalTrialInfo@salud.unm.edu) |
| University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma | Site Public Contact - (ou-clinical-trials@ouhsc.edu) |
| University of Pennsylvania/Abramson Cancer Center Philadelphia, Pennsylvania | Site Public Contact - (PMCancerResearch@pennmedicine.upenn.edu) |
| University of Tennessee - Knoxville Knoxville, Tennessee | |
| University of Utah Sugarhouse Health Center Salt Lake City, Utah | Site Public Contact - (cancerinfo@hci.utah.edu) |
| University of Vermont Medical Center Burlington, Vermont | Site Public Contact - (rpo@uvm.edu) |
| University of Vermont and State Agricultural College Burlington, Vermont | Site Public Contact - (rpo@uvm.edu) |
| University of Washington Medical Center - Montlake Seattle, Washington | |
| UofL Health Medical Center Northeast Louisville, Kentucky | |
| Upper Valley Medical Center Troy, Ohio | Site Public Contact - (clinical.trials@daytonncorp.org) |
| Upstate Cancer Center at Oswego Oswego, New York | Site Public Contact - (McDowelE@upstate.edu) |
| Upstate Cancer Center at Verona Verona, New York | Site Public Contact - (McDowelE@upstate.edu) |
| Urology Specialists of Nevada - Central Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Urology Specialists of Nevada - Green Valley Henderson, Nevada | Site Public Contact - (research@sncrf.org) |
| Urology Specialists of Nevada - Northwest Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Urology Specialists of Nevada - Southwest Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| VCU Massey Cancer Center at Stony Point Richmond, Virginia | Site Public Contact - (ctoclinops@vcu.edu) |
| VCU Massey Comprehensive Cancer Center Richmond, Virginia | Site Public Contact - (CTOclinops@vcu.edu) |
| Valley Medical Center Renton, Washington | Site Public Contact - (research@valleymed.org) |
| Washington University School of Medicine St Louis, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| Woodland Memorial Hospital Woodland, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Yale University New Haven, Connecticut | Site Public Contact - (canceranswers@yale.edu) |
| Yale-New Haven Hospital North Haven Medical Center North Haven, Connecticut | Site Public Contact - (canceranswers@yale.edu) |
Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer
Massey IIT Research Operations - masseyepd@vcu.edu
NCT06728072
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Diagnosis of stage IV colorectal cancer
* Measurable disease by Response evaluation criteria in solid tumors (RECIST) 1.1 criteria
* Planned first-line treatment with a 5FU-based doublet chemotherapy regimen for colon cancer, specifics of the regimen at the discretion of the treating physician Note: Patients who have received adjuvant therapy \>6 months prior are eligible
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2
* Absolute neutrophil count (ANC) ≥1,500 cells/μL
* Platelet count ≥100,000 cells/μL
* Hemoglobin ≥8 g/dL Note: The use of transfusion or other intervention to achieve hemoglobin ≥8 g/dL is acceptable.
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × upper limit of normal (ULN) Note: Patients with documented liver metastases: AST and ALT ≤5 × ULN
* Serum creatinine ≤1.5 x ULN or calculated creatinine clearance ≥40 mL/min using the Cockcroft-Gault equation: (140 - age) × body weight/plasma creatinine × 72 (× 0.85 if female)
* Radiographically measurable disease by RECIST 1.1
* Nonpregnant and not actively breastfeeding
* Sexually active patients of childbearing potential and their partners must agree to use medically acceptable form of contraception, per treating investigator, throughout the study Patients should continue to use medically acceptable methods of contraception after study treatment ends, following the guidance for their specific chemotherapy regimen.
Childbearing potential excludes:
Age \> 50 years and naturally amenorrhoeic for \> 1 year OR previous hysterectomy or bilateral salpingo-oophorectomy
* Patients on a pre-existing daily aspirin regimen may participate in the study without interrupting this regimen.
* Patients with a contraindication to aspirin may participate in the study. These patients will not be required to take aspirin as part of the study treatment.
Exclusion Criteria:
* Total colectomy
* Diagnosed with Cockayne Syndrome
* Using disulfiram, tizanidine, or theophylline and unable to stop taking these medications for the length of the microbiome modulation therapy
* On methotrexate doses of 15 mg/week or more
* History of allergic reaction to ciprofloxacin, metronidazole, or aspirin
* Fuss course of antibiotics in the 30 days before chemotherapy start Note: Full course is defined as ≥5 doses with an intent to treat a defined infection. Use of antibiotics intended for prophylaxis at the time of surgery is allowed
* Corrected QT interval (QTc) \>480 on baseline ECG
* Diagnosed with a malabsorptive syndrome
* Inability to swallow tablets DRUG: Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirin
Colorectal Cancer, CRC
Colorectal Cancer, CRC
I'm interested
Share via email
Show 2 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Virginia Cancer Institute (VCI) Richmond, Virginia | Sue Moore, MSN, CNS - (smoore@vacancer.com) |
| Virginia Commonwealth University Richmond, Virginia | Massey CTO GI Team - (masseygi@vcu.edu) |
A Single-session Intervention Adaptation of the Habit Framework for the Prevention of Eating Disorders
Courtney Breiner - breinerc@vcu.edu
NCT06861608
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* EAT-26 score ≥ 20 ( EAT-26, participants will meet the "referral criteria" which includes a score of 20 or more or meeting frequency criteria on bingeing, purging, laxative/diuretic use, and/or exercise.)
* English-language fluency, self-reported3
* Access to a phone, tablet, or computer
Exclusion Criteria:
* Failure to correctly complete one of the attention checks in the survey prior to the intervention
* Failure to correctly complete both anagram tasks in the survey prior to the intervention
* Completion of the screening survey or pre-intervention surveys in an improbably fast time BEHAVIORAL: Screening Questionnaire, BEHAVIORAL: Pre-Intervention Questionnaires (~10 minutes), BEHAVIORAL: SSI (Single-session intervention (~30 minutes) Active arm, BEHAVIORAL: SSI (Single-session intervention (~30 minutes) control arm, BEHAVIORAL: End-of-Intervention Questionnaires (~5 minutes)
Eating Disorder Not Otherwise Specified
prevention of eating disorders
I'm interested
Share via email
Show 1 location
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Virginia Commonwealth University Richmond, Virginia | Courtney Breiner - (breinerc@vcu.edu) |
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Jayadev Sureddi, CBCC CRO - jayadev.sureddi@cbcc.global
NCT06425926
Show full eligibility criteria
Hide eligibility criteria
Key
Inclusion Criteria:
* Written informed consent
* Cytologically or histologically confirmed locally advanced or metastatic solid tumor that has progressed on standard therapy or for which no standard therapy exist; or be intolerant of standard therapy
* Have not received an experimental drug within 4 weeks or 5 half-lives (whichever is shorter) of study drug treatment or already be enrolled in a clinical study
* ECOG performance status 0-1
* Laboratory and ECG assessments within 28 days of enrollment including acceptable cardiac, renal, and hepatic functions
* Agree to baseline core needle biopsy or archival (within 12 months of screening) tumor submission; Note: Participants whose only site(s) of disease are in areas considered moderate or high risk for biopsy complications may be enrolled without a fresh biopsy upon Sponsor approval.
* Non pregnant participants; female participants of child bearing potential with non-sterile partners agree to use an effective form of contraception from the time of first dose of study drug (or 14 days prior to first dose for oral contraception) until 7 months after the last dose of study drug. Effective forms of contraception include hormonal (injection or oral), double barrier method, or intrauterine device. Non-sterile male participants with sexual partners of childbearing potential agree to use a barrier contraception method and agree to not donate sperm from the time of first dose of study drug until 4 months after the last dose of study drug.
* Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Phase 1 Expansion Cohorts Specific Inclusion Criteria (in addition to above inclusion criteria):
* NSCLC: Participants must have locally advanced/unresectable or metastatic NSCLC. Participants must have received no more than 3 prior lines of therapy in the advanced/metastatic setting.
* TNBC: Participants must have locally advanced unresectable, recurrent, or metastatic TNBC. Participants must have received no more than 3 prior lines of therapy in the advanced/metastatic setting.
* Ovarian Cancer: Participants must have locally advanced unresectable, recurrent, or metastatic ovarian cancer. Participants must have platinum-resistant ovarian cancer defined as disease recurrence or within 6 months after the last administration of platinum-based chemotherapy. Participants must have received no more than 1 line of therapy after development of platinum resistance. Maintenance treatment with Poly(ADP-ribose) polymerase inhibitors (PARPi) or bevacizumab are not counted as separate lines of therapy.
* Tumors with AKT3 mutation/amplification: Participants must have a locally advanced unresectable, recurrent, or metastatic solid malignancy. Participants with known AKT3 mutation/amplification based on next generation sequencing (NGS) performed per local standard of care.
Phase 2 Specific Inclusion Criteria (in addition to above inclusion criteria):
* Have confirmed unresectable Stage III or metastatic Stage IV cutaneous melanoma, NSCLC, or RCC that has radiographically progressed (as confirmed by imaging assessed by the Investigator) on an approved single-agent or combination anti-PD-1 therapy
* Must have received the anti-PD-1 therapy containing regimen as the latest line of treatment and be eligible to restart or to continue anti-PD-1 therapy in combination with GIM-531
* BRAF wild-type melanoma or RCC: Participants must have received no more than 2 prior lines of therapy in the advanced/metastatic setting
* BRAF (V600) mutant melanoma or NSCLC: Participants must have received no more than 3 prior lines of therapy in the advanced/metastatic setting.
Key Exclusion Criteria:
* Ongoing \>Grade 1 toxicity from prior therapy according to Common Terminology Criteria for Adverse Events v5.0 (Note: Grade 2 alopecia and Grade 2 sensory neuropathy are not exclusionary)
* Has known leptomeningeal disease, spinal cord compression, or brain metastases, except participants with the following:
* Brain metastases that have been treated and are clinically stable for at least 4 weeks prior to the first administration of study drug; Note: Participants receiving steroids for brain metastases must be either off steroids or on a stable, or decreasing dose, of \<10 mg daily of prednisone (or equivalent) in order to be eligible for enrollment; and
* No ongoing neurological symptoms related to the anatomic location of the brain metastases.
Note: Neurological symptoms that are considered sequelae to treatment for brain metastases are allowed.
* Has known structural cardiac disease
* Has known serious arrythmia, serious dysrhythmia, history of long QT syndrome, or clinically relevant cardiac conduction abnormalities
* Has an active autoimmune disease that has required systemic treatment in the past 12 months (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
* At time of screening, is receiving systemic steroid therapy (greater than or equal to 10 mg/day of prednisone or equivalent) or is taking any immunosuppressive therapy; Note: Use of topical, inhaled, nasal, or ophthalmic steroids is allowed.
* Has active and clinically significant bacterial, fungal, or viral infection, including known hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)
* Has a history of, or currently has, an acquired or primary (congenital) immunodeficiency;
* Has had prior anti-cancer treatment with chemotherapeutic agents or immune modulating agents within \<4 weeks or 5 half-lives, whichever is shorter, prior to the first dose of study drug.
* Has received a live vaccine within 30 days of first dose of study drug;
* Has had or has planned major surgery within 2 weeks of the first dose of study drug;
* Inability to swallow an oral dose of a medication (eg, oral capsules)
* Is taking medications that are considered strong inducers or inhibitors of CYP2C8 or CYP3A4/5, P-glycoprotein (P-gp), breast cancer resistant protein (BCRP), or sensitive substrates of P-gp and BCRP (Appendix C) that cannot be discontinued at least 1 week prior to first dose of study drug and for the duration of the study.
* Is taking drugs that modify gastric pH, such as proton-pump inhibitors (PPIs) or H2 blockers. Antacids such as calcium carbonate or aluminum hydroxide-based products are permitted. DRUG: GIM-531, DRUG: Anti-PD-1 monoclonal antibody
Melanoma Stage IV, Solid Tumor
PD-1 resistance, PD-1 resistant/refractory, AKT3
I'm interested
Share via email
Show 11 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Comprehensive Blood and Cancer Center Bakersfield, California | Nicole Ward - (nward@cbccusa.com) |
| HonorHealth Research Institute Scottsdale, Arizona | Andrew Islas - (anislas@honorhealth.com) |
| Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana Billings, Montana | Matt Adler - (matt.adler@imail.org) |
| Massachusetts General Hospital Boston, Massachusetts | Ryan Sullivan, MD - (RSULLIVAN7@mgh.harvard.edu) |
| Providence Medical Foundation Santa Rosa, California | Kendall Karp - (kendall.karp@providence.org) |
| Tennessee Oncology, PLLC Nashville, Tennessee | |
| The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate Los Angeles, California | Navid Hafez, MD - (nhafez@theangelesclinic.org) Saba Mukarram - (smukarram@theangelesclinic.org) |
| UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California | Sonia Contreras Martinez - (Sonia.ContrerasMartinez@ucsf.edu) |
| University of Cincinnati Cancer Center Cincinnati, Ohio | |
| Virginia Commonwealth University Richmond, Virginia | - (masseysiit@vcu.edu) |
| Weill Cornell Medicine - New York Presbyterian Hospital New York, New York |
Left vs Left Randomized Clinical Trial
Mihail G Chelu, MD, PhD - leftvsleft@bcm.edu
NCT05650658
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Men and women 18 years of age or older.
* A LVEF ≤ 50% within 6 months prior to enrollment.
* Resting QRS duration ≥130 ms as evidenced by a historical 12-lead ECG prior to enrollment OR anticipated right ventricular pacing \>40% OR device in place with right ventricular pacing \> 40%.
* Are optimized on HF guideline directed medical therapy according to current HF published guidelines OR patient's physician will make an effort to start all guideline-directed medical therapy and titrate doses up as permitted by the participant clinical status and co-morbidities prior to implantation procedure.
Exclusion Criteria:
* Women who are pregnant, lactating, or plan to become pregnant during the course of the trial.
* Participants with angiographic evidence of coronary disease who are candidates for coronary revascularization and are likely to undergo coronary artery bypass graft surgery or percutaneous coronary, intervention in the next three (3) months.
* Enzyme-positive myocardial infarction within the past three (3) months prior to enrollment.
* Coronary artery bypass graft surgery or percutaneous coronary intervention (balloon and/or stent angioplasty) within the past three (3) months prior to enrollment.
* Reversible non-ischemic cardiomyopathy (e.g., acute viral myocarditis).
* Participants with Chagas disease, cardiac sarcoidosis or amyloidosis.
* Expected to receive left ventricular assist device or heart transplantation within 6 months.
* Participants with primary severe valvular disease (e.g., aortic stenosis).
* Have a life expectancy of less than 12 months.
* Participants with irreversible brain damage from preexisting cerebral disease.
* Participants with a contrast dye allergy unable or unwilling to undergo pretreatment with steroids and/or diphenhydramine.
* Participants participating in any other interventional cardiovascular clinical trial.
* Participants who would be unable to comply with the study's follow-up visit schedule; or
* Participants who had any prior unsuccessful attempt at implantation of biventricular pacing (BiVP), His Bundle Pacing (HBP), or Left Bundle Branch Pacing (LBBP) device. DEVICE: His/LBBP, DEVICE: BiVP
Heart Failure, Heart Failure With Reduced Ejection Fraction, AV Block, LBBB, RBBB, Intraventricular Conduction Delay, Pacing-Induced Cardiomyopathy
I'm interested
Share via email
Show 71 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Allegheny-Singer Research Institute Pittsburgh, Pennsylvania | Minesh Lathia - (minesh.lathia@ahn.org) |
| Baptist Health Louisville Louisville, Kentucky | Karin Cryan - (karin.cryan@BHSI.COM) |
| Baylor College of Medicine Houston, Texas | Stephen Harold - (harold@bcm.edu) |
| Beth Israel Deaconess Medical Center Boston, Massachusetts | Henry Xie - (hxie1@bidmc.harvard.edu) |
| CIS Clinical Research Corporation Naperville, Illinois | |
| CIUSSS de l'Estrie - CHUS Saint-Jean-sur-Richelieu, Quebec | Marie-Claude Grenier - (marie-claude.grenier.ciussse-chus@ssss.gouv.qc.ca) |
| Cleveland Clinic Cleveland, Ohio | Raquel Rozich - (Rozichr@ccf.org) |
| Cleveland Clinic Florida Weston, Florida | Maria Gomez Mejia - (MEJIAGM@ccf.org) |
| Columbia University Medical Center/New York-Presbyterian Hospital (CUMC/NYPH) New York, New York | Alicha Daniel - (aad2223@cumc.columbia.edu) |
| Florida Heart and Vascular, LLC dba Florida Heart Rhythm Specialist, PLLC South Pasadena, Florida | Adryanna Alban - (adryanna.alban@flahrs.com) |
| Geisinger Commonwealth School of Medicine Scranton, Pennsylvania | |
| HMH Hospitals Corporation Hackensack, New Jersey | Stephanie Lynes - (stephanie.lynes@hmhn.org) |
| Hamilton Health Sciences (HHS) Hamilton, Ontario | Kiran Qamar - (qamarulisl@HHSC.CA) |
| Hartford Hospital Hartford, Connecticut | Saskia Campbell - (Saskia.Campbell@hhchealth.org) |
| Heart Rhythm Solutions Davie, Florida | Daniela Rodriguez - (Daniela@heartrhythmsolutions.com) |
| Icahn School of Medicine at Mount Sinai New York, New York | Ugur Gurol - (Ugur.Gurol@mountsinai.org) |
| Inova Heart and Vascular Institute Falls Church, Virginia | Tracy Plummer - (tracy.plummer@inova.org) |
| Lehigh Valley Hospital Inc. Allentown, Pennsylvania | Traci L Eichelberger - (Traci.Eichelberger@jefferson.edu) |
| Lovelace Medical Center Albuquerque, New Mexico | |
| MH Mission Hospital LLLP- Asheville Cardiology Associates Asheville, North Carolina | Olivia Lim - (olivia.lim@hcahealthcare.com) |
| Massachusetts General Hospital Boston, Massachusetts | Chris Azzam - (cazzam@MGH.HARVARD.EDU) |
| Mayo Clinic Rochester, Minnesota | Axe M Ahmed - (Ahmed.Abdimajid@mayo.edu) |
| Mazankowski Alberta Heart Institute/University of Alberta Edmonton, Alberta | Lee-Ann Langkaas - (Lee-Ann.Langkaas@albertahealthservices.ca) |
| Medical University of South Carolina (MUSC) Charleston, South Carolina | Olivia Washington - (washoliv@musc.edu) |
| Mercy Gilbert & Chandler Regional Medical Centers, Gilbert AZ Gilbert, Arizona | Jacqueline Killian - (jacqueline.killian@commonspirit.org) |
| Montreal Heart Institute Montreal, Quebec | François François - (Francois.Lemarbre@icm-mhi.org) |
| Mount Sinai Medical Center of Florida, Inc. Miami Beach, Florida | Giselle Cortez - (Giselle.CortezVargas@msmc.com) |
| Newark Beth Israel Medical Center Newark, New Jersey | Patricia Policastro - (Patricia.Policastro@rwjbh.org) |
| Newmarket Electrophysiology Research Group Inc. (NERG) Newmarket, Ontario | Lynn Nyman - (lnyman@southlake.ca) |
| Northwestern University Chicago, Illinois | Katrina Martin - (katrina.martin@nm.org) |
| Nova Scotia Health Authority Halifax, Nova Scotia | Stephanie Hobbs - (Stephanie.hobbs@nshealth.ca) |
| Novant Health Charlotte, North Carolina | |
| Oregon Health & Science University Portland, Oregon | Liz Cannard - (cannarde@ohsu.edu) |
| Penn Medicine Lancaster General Lancaster, Pennsylvania | Andrew Hershey - (Andrew.Hershey@pennmedicine.upenn.edu) |
| Prisma Health-Upstate Greenville, South Carolina | Prisma Health-Upstate Shrum - (ann.shrum@prismahealth.org) |
| Research Institute of the McGill University Health Centre (RI-MUHC) - MUHC, Montreal General Hospital Montreal, | |
| Rush University Chicago, Illinois | |
| Sentara Healthcare Newport News, Virginia | |
| South Denver Cardiology Associates Littleton, Colorado | Kathrin Siegel - (ksiegel@southdenver.com) |
| St. Luke's University Health Network Bethlehem, Pennsylvania | Kyle McFadden - (Kyle.McFadden@sluhn.org) |
| St. Mark's Hospital Salt Lake City, Utah | Pragyna Gundaboina - (Pragyna.Gundaboina@HCAhealthcare.com) |
| Sunnybrook Research Institute Toronto, Ontario | Ambreen Syeda - (ambreen.syeda@sunnybrook.ca) |
| Texas Health Research & Education Institute Arlington, Texas | Rebecca Wade - (rebeccawade@texashealth.org) |
| The Christ Hospital Cincinnati, Ohio | Susanne Pasley - (Susanne.Pasley@thechristhospital.com) |
| The MetroHealth System Cleveland, Ohio | Pete Leo - (pleo@metrohealth.org) |
| The Valley Hospital, Inc. Ridgewood, New Jersey | Lauren Tedeschi - (ltedesc2@Valleyhealth.com) |
| Thomas Jefferson University Hospital Philadelphia, Pennsylvania | |
| Trustees of Indiana University Indianapolis, Indiana | Molly Stearns - (mstearns2@IUHEALTH.ORG) |
| University of Arizona College of Medicine- Phoenix Tucson, Arizona | Raeven Maxwell - (Raeven.Maxwell@bannerhealth.com) |
| University of Arkansas for Medical Sciences (UAMS) Little Rock, Arkansas | Urvashi Kalola - (ukalola@uams.edu) |
| University of British Columbia Vancouver, British Columbia | Munyura Yannick - (yannick.munyura@ubc.ca) |
| University of Calgary Calgary, | |
| University of California San Diego San Diego, California | Jesus Gil - (jegil@health.ucsd.edu) |
| University of Chicago Chicago, Illinois | |
| University of Colorado (Anschutz Medical Campus) Denver, Colorado | Tanner Bloks - (tanner.bloks@cuanschutz.edu) |
| University of Florida Jacksonville Jacksonville, Florida | Latonya Been - (latonya.been@ufhealth.org) |
| University of North Carolina Chapel Hill, North Carolina | Elias Wen - (emwen@email.unc.edu) |
| University of Ottawa Heart Institute Ottawa, Ontario | Maitreya PATEL - (MaPatel@ottawaheart.ca) |
| University of Pennsylvania Philadelphia, Pennsylvania | Mary Gnap - (Mary.Gnap@pennmedicine.upenn.edu) |
| University of Pittsburg Pittsburgh, Pennsylvania | Sherry Pellegrino - (pellegrinosl@upmc.edu) |
| University of South Florida Tampa, Florida | Jacky He - (jackyhe@usf.edu) |
| University of Vermont Burlington, Vermont | Sonja Baden - (Sonja.Baden@uvmhealth.org) |
| University of Virginia Health System Charlottesville, Virginia | |
| University of Washington Seattle, Washington | Adele Stefanowicz - (amstef99@uw.edu) |
| Université Laval Québec, | Marina Sanchez - (marina.sanchez.1@ulaval.ca) |
| Victoria Cardiac Arrhythmia Trials (VCAT) Inc. Victoria, British Columbia | Matthew Coxon - (mcoxon@catrials.org) |
| Virginia Commonwealth University Richmond, Virginia | |
| Virtua Health Camden, New Jersey | Marisa Brown - (Mbrown3@virtua.org) |
| Waterloo Wellington Cardiovascular Research Institute (WWCRI) - St. Mary's General Hospital Kitchener, | |
| Weill Cornell Medicine New York, New York | Penn Collins - (gpc4001@med.cornell.edu) |
| Yale University New Haven, Connecticut | Meg Leiss - (Margaret.leiss@yale.edu) |
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Socorro Portella, MD - clinicaltrials@cariboubio.com
NCT04637763
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Age greater than or equal to 18 at the time of enrollment
* Documented diagnosis of relapsed or refractory non-Hodgkin lymphoma after prior standard of care
* Eastern Cooperative Oncology Group performance status 0 or 1
* Adequate hematologic, renal, liver, cardiac and pulmonary organ function
Exclusion Criteria:
* Prior therapy with an anti-CD19 targeting agent
* Active or chronic graft versus host disease requiring therapy
* Prior allogeneic stem cell transplantation
* Central nervous system (CNS) lymphoma, prior CNS malignancy
* Prior seizure disorder, cerebrovascular ischemia, dementia, cerebellar disease or autoimmune disease with CNS involvement.
* Primary immunodeficiency
* Current or expected need for systemic corticosteroid therapy
* Current thyroid disorder. Hypothyroidism controlled with stable hormone replacement is permitted
* Other malignancy within 2 years of study entry, except curatively treated malignancies or malignancies with low risk of recurrence
* Unwillingness to follow extended safety monitoring GENETIC: CB-010, DRUG: Cyclophosphamide, DRUG: Fludarabine
Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma
I'm interested
Share via email
Show 38 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Advent Health Orlando, Florida | Kristen Wing - (Kristen.Wing@adventhealth.org) |
| Atlantic Health System Morristown, New Jersey | Amanda Hall - (Amandamaria.hall@atlantichealth.org) Salome Greene - (salome.geene@atlantichealth.org) |
| Banner MD Anderson Cancer Center Gilbert, Arizona | Tracy Kliner - (tracy.kliner@bannerhealth.com) |
| Baylor Charles A. Sammons Cancer Center Dallas, Texas | Tarah Satterfield - (Tarah.Satterfield@BSWHealth.org) |
| Bone and Marrow Transplant Group of Georgia Atlanta, Georgia | Melhem Solh, MD - (msolh@bmtga.com) |
| Chao Family Comprehensive Cancer Center/University of California Irvine Orange, California | Blake Johnson - (blakej@hs.uci.edu) |
| Epworth Healthcare Richmond, Victoria | Dr Costas Yannakou - (costas.yannakou@epworth.org.au) Dr Connie Barlas - (connie.barlas@epworth.org.au) |
| Georgia Cancer Center at Augusta University Augusta, Georgia | Kelly Jenkins - (kejenkins@augusta.edu) |
| Hackensack Medical Center Hackensack, New Jersey | Elizabeth McCarthy - (elizabethl.mccarthy@hmhn.org) |
| Hadassah Medical Center Jerusalem, | Nurit Ben Shmuel - (nuritb@hadassah.org.il) |
| Holden Comprehensive Cancer Center at the University of Iowa Iowa City, Iowa | Umar Farooq - (umar-farooq@uiowa.edu) |
| HonorHealth Phoenix, Arizona | Research Nurse Navigator - (clinicaltrials@honorhealth.com) |
| Huntsman Cancer Institute at the University of Utah Salt Lake City, Utah | Erin Peterson - (erin.peterson@hci.utah.edu) |
| MD Anderson Cancer Center Houston, Texas | Ly Dsouza - (ldsouza@mdanderson.org) |
| Medical College of Wisconsin Milwaukee, Wisconsin | Roisin McAndrew - (rmcandrew@mcw.edu) |
| Montefiore Medical Center The Bronx, New York | Joel Victor - (jovictor@montefiore.org) |
| NYU Langone Health New York, New York | MARK BOND - (Mark.Bond@nyulangone.org) |
| Norton Cancer Institute Louisville, Kentucky | Tabby Thomas - (StudyStartup@NCIResearch.org) |
| Ohio State University James Cancer Hospital Columbus, Ohio | |
| Oncology Hematology Care Cincinnati, Ohio | Eric Clayton - (Eric.Clayton@usoncology.com) |
| Oregon Health & Science University Portland, Oregon | Richard Maziarz, MD - (MAZIARZR@ohsu.edu) |
| Rabin Medical Center Petah Tikva, | Miri Pinhasov - (miripi@clalit.org.il) |
| Royal Perth Hospital Perth, Western Australia | Megan Margaria - (megan.margaria@health.wa.gov.au) Lisa Forsyth - (lisa.forsyth@health.wa.gov.au) |
| Swedish Cancer Institute Seattle, Washington | |
| Tel Aviv Medical Center Tel Aviv, | Sandrine Harari-Csillag - (sandrinehc@tlvmc.gov.il) |
| The Sheba Fund for Health Services and Research (R.A.) Tel HaShomer, | Kira Lozinsky - (kira.lozinsky@sheba.health.gov.il) |
| Tufts Medical Center Boston, Massachusetts | LaToya Marshall - (latoya.marshall@tuftsmedicine.org) |
| University of Alabama at Birmingham Birmingham, Alabama | |
| University of Arizona Cancer Center Tucson, Arizona | Francois Chu - (fchu@arizona.edu) |
| University of Arkansas Little Rock, Arkansas | Dr. Cesar Gentille Sanchez - (cgentille@uams.edu) |
| University of California San Diego Moores Cancer Center La Jolla, California | Michelle Padilla - (mlp002@health.ucsd.edu) |
| University of Kentucky Markey Cancer Lexington, Kentucky | Yvonne Taul - (Yvonne.Taul@uky.edu) |
| University of Pennsylvania Philadelphia, Pennsylvania | Sunita Nasta - (Sunita.Nasta@pennmedicine.upenn.edu) Michael McNicholas - (Michael.McNicholas@pennmedicine.upenn.edu) |
| University of Southern California, Norris Comprehensive Cancer Center Los Angeles, California | Christine Duran - (Duran_c@med.usc.edu) |
| Vanderbilt University Medical Center Nashville, Tennessee | Dr. Olalekan Oluwole - (olalekan.oluwole@vanderbilt.edu) |
| Virginia Commonwealth University (VCU) Richmond, Virginia | Kristin Lantis - (kllantis@vcu.edu) |
| Virginia Oncology Associates Hampton, Virginia | Karen McClain - (Karen.mcclain@usoncology.com) |
| Westmead Hospital Westmead, | Dr Kenneth Micklethwaite - (ken.micklethwaite@health.nsw.gov.au) Gillian Huang - (gillian.huang@health.nsw.gov.au) |
Patient-reported Outcomes of Donor Site Healing Using Different Palatal Protection Techniques
Rafael Amorim Cavalcanti de Siqueira - amorimcavalr@vcu.edu
NCT06892496
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* At least 18 years of age
* Healthy or Mild controlled systemic diseases with no functional limitations (ASA I or ASA II)
* Sites with 1 to 3 teeth or implants requiring soft-tissue grafting
* Minimum palatal thickness of 2 mm
* Willing to participate and sign an informed consent
Exclusion Criteria:
* Patients with systemic conditions that could impair wound healing (i.e. diabetes, immunosuppressive, chemotherapy, etc.)
* Pregnant patients
* Patients with bleeding disorders or taking anticoagulants
* Smokers
* Patients with a history of palatal graft harvesting OTHER: Visual Analog scale (VAS) questionnaire, OTHER: Vacuum-formed retainer (VFR) technique, OTHER: 3-D printed acrylic resin stent (3DS) technique, OTHER: Flowable resin composite stent (FRC) technique, OTHER: Photographs of the patient's palate, OTHER: Measuring graft dimensions, OTHER: Chairside Polymer Stent
Mucosal Erosion, Gingival Recession
soft tissue graft, pain, wound healing, CPS: Chairside polymer stent
I'm interested
Share via email
Show 1 location
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Virginia Commonwealth University Richmond, Virginia | Rafael Amorim Cavalcanti de Siqueira - (amorimcavalr@vcu.edu) Anamika Khosla - (khoslaar@vcu.edu) |
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
BMS Study Connect Contact Center www.BMSStudyConnect.com - Clinical.Trials@bms.com
NCT04094610
Show full eligibility criteria
Hide eligibility criteria
Key
• Documented genetic ROS1 point mutation, fusion, or amplification or NTRK1-3 fusion as identified by local testing in a Clinical Laboratory Improvement Amendments (CLIA) laboratory in the US or equivalently accredited diagnostic lab outside the United States (US) is required.
• Phase 1: Age \<12 years; Phase 2: Age 12- 25 years
• Prior cytotoxic chemotherapy is allowed.
• Prior immunotherapy is allowed.
• Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Grade less than or equal to 1.
• All subjects must have measurable disease by RECIST v1.1 or Response Assessment in Neuro-Oncology (RANO) criteria at time of enrollment.
• Subjects with a primary CNS tumor or CNS metastases must be neurologically stable on a stable or decreasing dose of steroids for at least 7 days prior to enrollment.
• Subjects must have a Lansky (\< 16 years) or Karnofsky (≥ 16 years) score of at least 50.
• Life expectancy greater than or equal to 12 weeks, in the investigator's opinion.
• Adequate hematologic, renal and hepatic function. Phase 2
• Cohort Specific
• Subjects in Cohorts 1 and 2 must have prospectively confirmed measurable disease by BICR prior to enrollment. Key Exclusion Criteria (Phase 1 and Phase 2):
• Subjects with neuroblastoma with only bone marrow disease evaluable by bone marrow aspiration only.
• Major surgery within 14 days (2 weeks) of start of repotrectinib treatment. Central venous access (Broviac, Mediport, etc.) placement does not meet criteria for major surgery.
• Known active infections requiring ongoing treatment (bacterial, fungal, viral including HIV positivity).
• Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact drug absorption.
• Any of the following cardiac criteria: * Mean resting corrected QT interval (ECG interval measured from the onset of the QRS complex to the end of the T wave) for heart rate (QTc) \> 480 msec obtained from three ECGs, using the screening clinic ECG machine-derived QTc value * Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval \> 250 msec) * Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication known to prolong the QT interval
• Peripheral neuropathy of CTCAE ≥grade 2.
• Subjects being treated with or anticipating the need for treatment with strong CYP3A4 inhibitors or inducers.
• Any potential allergies to repotrectinib and/or its excipients.
Inclusion Criteria:
• Documented genetic ROS1 point mutation, fusion, or amplification or NTRK1-3 fusion as identified by local testing in a Clinical Laboratory Improvement Amendments (CLIA) laboratory in the US or equivalently accredited diagnostic lab outside the United States (US) is required.
• Phase 1: Age \<12 years; Phase 2: Age 12- 25 years
• Prior cytotoxic chemotherapy is allowed.
• Prior immunotherapy is allowed.
• Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Grade less than or equal to 1.
• All subjects must have measurable disease by RECIST v1.1 or Response Assessment in Neuro-Oncology (RANO) criteria at time of enrollment.
• Subjects with a primary CNS tumor or CNS metastases must be neurologically stable on a stable or decreasing dose of steroids for at least 7 days prior to enrollment.
• Subjects must have a Lansky (\< 16 years) or Karnofsky (≥ 16 years) score of at least 50.
• Life expectancy greater than or equal to 12 weeks, in the investigator's opinion.
• Adequate hematologic, renal and hepatic function. Phase 2
Inclusion Criteria:
• Cohort Specific
Inclusion Criteria:
* Cohort 1: Subjects with NTRK fusion gene positive (NTRK+) advanced solid tumors (including primary CNS tumors), that are tropomyosin receptor kinase (TRK) TKI naïve;
* Cohort 2: subjects with NTRK+ advanced solid tumors (including primary CNS tumors), that are TRK TKI pre-treated;
* Cohort 3: subjects with advanced solid tumors with ROS1 gene fusions or other ROS1 aberrations (including amplifications and point mutations) with measurable disease.
• Subjects in Cohorts 1 and 2 must have prospectively confirmed measurable disease by BICR prior to enrollment. Key Exclusion Criteria (Phase 1 and Phase 2):
• Subjects with neuroblastoma with only bone marrow disease evaluable by bone marrow aspiration only.
• Major surgery within 14 days (2 weeks) of start of repotrectinib treatment. Central venous access (Broviac, Mediport, etc.) placement does not meet criteria for major surgery.
• Known active infections requiring ongoing treatment (bacterial, fungal, viral including HIV positivity).
• Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact drug absorption.
• Any of the following cardiac criteria: * Mean resting corrected QT interval (ECG interval measured from the onset of the QRS complex to the end of the T wave) for heart rate (QTc) \> 480 msec obtained from three ECGs, using the screening clinic ECG machine-derived QTc value * Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval \> 250 msec) * Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication known to prolong the QT interval
• Peripheral neuropathy of CTCAE ≥grade 2.
• Subjects being treated with or anticipating the need for treatment with strong CYP3A4 inhibitors or inducers.
• Any potential allergies to repotrectinib and/or its excipients.
DRUG: Oral repotrectinib (TPX-0005)
Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
ALK, ROS1, NTRK1-3, Primary CNS tumor, anaplastic large cell lymphoma, metastatic solid tumor, advanced solid tumor, sarcoma, infantile fibrosarcoma, glioblastoma, soft tissue schwannoma, solitary fibrous tumor, glioma, inflammatory myofibroblastic tumor, pediatric
I'm interested
Share via email
Show 68 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| Alder Hey Children's NHS Foundation Trust Liverpool, England | |
| Asan Medical Center Seoul, | |
| Baylor College of Medicine Houston, Texas | |
| Centre Hospitalier Universitaire d'Angers Angers, | |
| Centre Hospitalier Universitaire de Bordeaux - Groupe Hospitalier Pellegrin Bordeaux, | |
| Children's Health Queensland Hospital and Health Service South Brisbane, Queensland | |
| Children's Healthcare of Atlanta - Egleston Hospital Atlanta, Georgia | |
| Children's Hospital Colorado - Anschutz Medical Campus Aurora, Colorado | |
| Children's Hospital Los Angeles Los Angeles, California | |
| Children's Hospital Of Eastern Ontario Ottawa, Ontario | |
| Children's Hospital of Philadelphia-Center for Childhood Cancer Research Philadelphia, Pennsylvania | |
| Children's Hospital of Richmond at VCU Richmond, Virginia | |
| Clinica Universidad de Navarra Madrid, | |
| Clinica Universidad de Navarra Madrid, | |
| Dana Farber Cancer Institute. Boston, Massachusetts | |
| Fondazione IRCCS - Istituto Nazionale dei Tumori Milan, | |
| Great Ormond Street Hospital for Children NHS Foundation Trust London, | |
| HM Sanchinarro University Hospital Madrid, | |
| Hospital Infantil Universitario Nino Jesus Madrid, | |
| Hospital Sant Joan de Deu Barcelona, | |
| Hospital Universitari Vall d'Hebron Barcelona, | |
| Hospital Universitario Virgen del Rocio Seville, | |
| Hospital Universitario y Politécnico La Fe Valencia, | |
| Hôpitaux Universitaires de Marseille Timone Marseille, | |
| Institut Gustave-Roussy Villejuif, FR | |
| Institut d Hematologie et d Oncologie Pediatriques Lyon, | |
| KK Women's and Children's Hospital Singapore, | |
| Levine Children's Hospital- Pediatric Neuro-Oncology Charlotte, North Carolina | |
| Local Institution - 2102 New York, New York | |
| Local Institution - 2104 Houston, Texas | |
| Local Institution - 2105 Orlando, Florida | |
| Local Institution - 2110 New Brunswick, New Jersey | |
| Local Institution - 2112 Cleveland, Ohio | |
| Local Institution - 2114 Hershey, Pennsylvania | |
| Local Institution - 2120 Orlando, Florida | |
| Local Institution - 4302 Rome, | |
| Local Institution - 4403 Birmingham, | |
| Local Institution - 6103 Westmead, New South Wales | |
| Local Institution - 6104 Randwick, New South Wales | |
| Local Institution - 6105 Barcelona, | |
| Local Institution - 6106 Madrid, | |
| Local Institution - 6107 Valencia, | |
| Local Institution - 6108 Villejuif, | |
| Local Institution - 6109 Paris, | |
| Local Institution - 6110 Marseille, | |
| Local Institution - 6111 Lyon, Rhone | |
| Local Institution - 6112 Nantes, | |
| Local Institution - 6113 Padua, | |
| Local Institution - 6114 Torino, | |
| Local Institution - 6303 Seoul, Seodaemun-gu | |
| Local Institution - 6304 Seoul, | |
| Maine Medical Center Portland, Maine | |
| National Taiwan University Hospital Taipei, | |
| National University Hospital Singapore, | |
| Perth Childrens Hospital Nedlands, Western Australia | |
| Rigshospitalet - Glostrup Copenhagen, | |
| Royal Hosp. for Children Glasgow, | |
| Seoul National University Hospital Seoul, | |
| St Justine Hospital Montreal, Quebec | |
| St. Jude Children's Research Hospital Memphis, Tennessee | |
| Stollery Children's Hospital Edmonton, Alberta | |
| Taipei Medical University Hospital Taipei, | |
| The Royal Marsden NHS Foundation Trust London, | |
| The University of Texas Southwestern Medical Center - Harold C Simmons Comprehensive Cancer Center Dallas, Texas | |
| University Hospital of Wales Cardiff, | |
| University of Calgary Calgary, | |
| University of California at Los Angeles Los Angeles, California | |
| Washington University School of Medicine in St. Louis St Louis, Missouri |
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
ctrrecruit@vcu.edu
NCT02523014
Show full eligibility criteria
Hide eligibility criteria
* Documentation of disease:
* Histologic documentation: histologically proven intracranial meningioma as documented by central pathology review
* Molecular documentation: Presence of SMO, PTCH1, NF2, CDKN2A, AKT1, PIK3CA, PTEN mutations, CDKN2A copy number loss, CDK4, CDK6, CCND1, CCND2, CCND3, or CCNE1 copy number gain in tumor sample as documented specifically by the central laboratory, regardless of whether prior genotype testing outside of the central laboratory was performed
* Progressive OR residual disease, as defined by the following:
* Residual measurable disease: residual measurable disease immediately after surgery without requirement for progression; for grade I disease, progression pre-operatively needs to be documented, with an increase in size of the measurable primary lesion on imaging by 25% or more (bidirectional area); the change must occur between scans separated by no more than 25 months; for patients with SMO/PTCH1 mutations enrolling to receive vismodegib, the change can occur between scans separated by up to 25 months; residual measurable disease will be defined by bidimensionally measurable lesions with clearly defined margins by MRI scans, with a minimum diameter of 10 mm in both dimensions
* Progressive measurable disease: progression defined as an increase in size of the measurable primary lesion on imaging by 25% or more (bidirectional area); the change must occur between scans separated by no more than 25 months
* Post radiation patients: patients with measurable and progressive meningioma who have received radiation are potentially eligible, but need to show evidence of progressive disease after completion of radiation; if the progressive meningioma lesion has been radiated, at least 24 weeks must have elapsed from completion of radiation to registration; if the progressive lesion is outside of the radiation field, then an interval of at least 2 weeks must have elapsed from completion of radiation to registration
* Measurable disease: measurable disease is defined by a bidimensionally measurable main lesion on MRI or computed tomography (CT) images (MRI preferred) with clearly defined margins and a minimum diameter of 10 mm in both dimensions; multifocal disease is allowed
* Prior treatment
* Prior medical therapy is allowed but not required
* No limit on number of prior therapies
* No chemotherapy, or other investigational agents within 28 days prior to registration
* No other concurrent investigational agents or other meningioma-directed therapy (chemotherapy, radiation) while on study; additionally, no cases of nitrosourea or mitomycin C within 6 weeks prior to registration
* For patients treated with external beam radiation, interstitial brachytherapy or radiosurgery, an interval \> 4 weeks must have elapsed from completion of radiation therapy to registration; if the progressive lesion is outside of the radiation field, then an interval of at least 2 weeks must have elapsed from completion of radiation to registration
* Steroid dosing stable for at least 4 days
* Recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or less toxicity from other agents with exception of alopecia and fatigue
* No craniotomy 28 days prior to and after registration
* Not pregnant and not nursing:
\* A female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
* For patients with NF2/CDKN2A/AKT1/PIK3CA/PTEN mutation, CKDN2A copy number loss, or CDK4/CDK6/CCND1/CCND2/CCND3/CCNE1 copy number gain: Age \>= 18 years
* For patients with SMO/PTCH1 mutation: Age \>= 30 years
* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
* Patient history:
* Patients with history of neurofibromatosis (NF) may have other stable central nervous system (CNS) tumors (schwannoma, acoustic neuroma or ependymoma) if lesions have been stable for 6 months
* No metastatic meningiomas (as defined by extracranial meningiomas outside of CNS) allowed; spinal meningiomas are allowed
* No history of allergic reactions attributed to compounds of similar or biologic composition to assigned study drug
* No known active hepatitis B or C
* No current Child Pugh class B or C liver disease
* No uncontrolled gastric ulcer disease (grade 3 gastric ulcer disease within 28 days of registration)
* No uncontrolled hypertension defined as blood pressure (BP) \> 140/90
* No abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within 28 days prior to registration
* No major surgery within 28 days prior to registration for any patients with AKT1/PIK3CA/PTEN mutations receiving capivasertib
* For patients going on to receive capivasertib (i.e. enrolled after Update #08)
* Patients should not have any of the following cardiac criteria:
* Any clinically important abnormalities in rhythm, conduction, or morphology of resting electrocardiogram (EKG) (e.g., complete left bundle branch block, third degree heart block)
* Any factors that increase the risk of corrected QT (QTc) prolongation or risk of arrhythmic events such as heart failure, hypokalemia, potential for Torsade de Pointes, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age, or any concomitant medication known to prolong the QT interval
* Experience any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure New York Heart Association (NYHA) class \>= II
* Uncontrolled hypertension (systolic blood pressure \[SBP\] \< 90 mmHg and/or diastolic blood pressure \[DBP\] \< 50 mmHg)
* Cardiac ejection fraction outside institutional range of normal or \< 50% (whichever is higher) as measured by echocardiogram (or multigated acquisition \[MUGA\] scan if an echocardiogram can't be performed or is inconclusive); left ventricular ejection fraction (LVEF) below lower limit of normal for site
* Patients should not have any of the following criteria:
* With the exception of alopecia, any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of registration
* Hemoglobin \< 9 g/dL (\< 5.59 mmol/L); note: any blood transfusion must be \>= 14 days prior to the determination of a hemoglobin \>= 9 g/dL (\>= 5.59 mmol/L)
* Proteinuria 3+ on dipstick analysis or \> 500 mg/24 hours
* Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of capivasertib
* History of hypersensitivity to active or inactive excipients of capivasertib or drugs with a similar chemical structure or class to capivasertib
* Current disease or condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
* Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
* Previous allogeneic bone marrow transplant
* Known immunodeficiency syndrome
* Concomitant medications (only regarding NF2/CDKN2A/CDK4/CDK6/CCND1/CCND2/CCND3/CCNE1/AKT1/PIK3CA/PTEN genetic alterations):
* Chronic concomitant treatment with strong inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors must discontinue the drug for 14 days prior to registration on the study for patients with NF2 mutation enrolled to GSK2256098, as well as for patients with AKT1/PIK3CA/PTEN mutations enrolled to capivasertib
* For NF2 patients going on to receive GSK2256098 and for patients with AKT1/PIK3CA/PTEN mutations enrolled to capivasertib: concomitant treatment with strong CYP3A4 inducers or CYP2D6 substrates is not allowed; patients must discontinue the drug 14 days prior to registration
* For NF2 patients going on to receive abemaciclib: avoid concomitant use of CYP3A inducers and strong CYP3A inhibitors; use caution with coadministered moderate or weak CYP3A inhibitors
* Diabetic status:
* For patients with NF2 or SMO/PTCH1 mutations: No uncontrolled diabetes defined as a known diabetic with HBA1C \> 7.5 OR fasting glucose \> 140 mg/dL.
* For patients with AKT1/PIK3CA/PTEN mutations:
* Glycosylated hemoglobin (HbA1C) \< 8.0% (63.9 mmol/mol)
* No type 1 diabetes mellitus
* No requirement for insulin for routine diabetic management and control
* No requirement for more than two oral hypoglycemic medications for routine diabetic management and control
* Patients with a pre-existing diagnosis of type 2 diabetes mellitus must have fasting glucose \< 9.3 mmol/L (167mg/dL); fasting is defined as no caloric intake for at least 8 hours
* Patients without a pre-existing diagnosis of type 2 diabetes mellitus must have fasting glucose =\< 7.0 mmol/L (126 mg/dL); fasting is defined as no caloric intake for at least 8 hours
* Absolute neutrophil count (ANC) \>= 1,500/mm\^3
* Platelet count \>= 100,000/mm\^3
* Creatinine OR =\< 1.5 mg/dl x upper limit of normal (ULN) OR calculated (calc.) creatinine clearance \> 50 mL/min
* Urine protein:creatinine ratio (UPC) =\< 45 mg/mmol
* Total bilirubin =\< 1.5 x upper limit of normal (ULN); except in case of Gilbert's disease
* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 2.5 x ULN
* Sodium, potassium, total calcium (corrected for serum albumin) \& phosphorus within normal limits per institutional guidelines
* QTcF \< 450 msec (QT calculated using Fridericia formula)
* Mean resting heart rate (determined from EKG) 50-100 beats per minute (BMP) (must be obtained from 12-lead EKG defined by a triplicate EKG for patients assigned to the capivasertib arm; patients assigned to all other arms will require a single EKG
* No uncontrolled medical comorbidities per investigator discretion (e.g. interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, history of major surgical resection involving the stomach or small bowel, or pre-existing Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea)
* ADDITIONAL REGISTRATION ELIGIBILITY CRITERIA FOR ABEMACICLIB ARM: Hemoglobin \>= 8 g/dL
\* Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator; initial treatment must not begin earlier than the day after the erythrocyte transfusion
* ADDITIONAL REGISTRATION ELIGIBILITY CRITERIA FOR ABEMACICLIB ARM: Prior Treatment
* Patients who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events \[CTCAE\] grade =\< 1) from the acute effects of chemotherapy except for residual alopecia or grade 2 peripheral neuropathy prior to registration; a washout period of at least 28 days is required between last chemotherapy dose and registration (provided the patient did not receive radiotherapy)
* Patients who received adjuvant radiotherapy must have completed and fully recovered from the acute effects of radiotherapy; a washout period of at least 28 days is required between end of radiotherapy and registration
* ADDITIONAL REGISTRATION ELIGIBILITY CRITERIA FOR ABEMACICLIB ARM: No active bacterial infection (requiring intravenous \[IV\] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C \[for example, hepatitis B surface antigen positive\]); screening is not required for enrollment in the absence of symptoms
* ADDITIONAL REGISTRATION ELIGIBILITY CRITERIA FOR ABEMACICLIB ARM: No personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest
DRUG: Vismodegib, DRUG: FAK Inhibitor GSK2256098, DRUG: Capivasertib, DRUG: Abemaciclib
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
I'm interested
Share via email
Show 783 locations
Study Locations
Hide all locations
| Location | Contacts |
|---|---|
| AMG Crystal Lake - Oncology Crystal Lake, Illinois | Site Public Contact - (advocateresearch@advocate.com) |
| AMG Libertyville - Oncology Libertyville, Illinois | Site Public Contact - (advocateresearch@advocatehealth.com) |
| Abbott-Northwestern Hospital Minneapolis, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Adena Regional Medical Center Chillicothe, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Advanced Breast Care Center PLLC Warren, Michigan | |
| AdventHealth Hendersonville Hendersonville, North Carolina | |
| AdventHealth Infusion Center Asheville Asheville, North Carolina | |
| AdventHealth Littleton Littleton, Colorado | |
| AdventHealth Parker Parker, Colorado | |
| AdventHealth Porter Denver, Colorado | |
| Advocate Christ Medical Center Oak Lawn, Illinois | |
| Advocate Good Samaritan Hospital Downers Grove, Illinois | Site Public Contact - (Barbara.barhamand@advocatehealth.com) |
| Advocate Good Shepherd Hospital Barrington, Illinois | |
| Advocate High Tech Medical Park Palos Heights, Illinois | Site Public Contact - (ncorp@aah.org) |
| Advocate Illinois Masonic Medical Center Chicago, Illinois | |
| Advocate Lutheran General Hospital Park Ridge, Illinois | |
| Advocate Outpatient Center - Oak Lawn Oak Lawn, Illinois | Site Public Contact - (ncorp@aah.org) |
| Advocate Sherman Hospital Elgin, Illinois | |
| Advocate South Suburban Hospital Hazel Crest, Illinois | |
| Alaska Breast Care and Surgery LLC Anchorage, Alaska | Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org) |
| Alaska Oncology and Hematology LLC Anchorage, Alaska | Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org) |
| Alaska Women's Cancer Care Anchorage, Alaska | Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org) |
| Alegent Health Bergan Mercy Medical Center Omaha, Nebraska | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Alegent Health Immanuel Medical Center Omaha, Nebraska | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Alegent Health Lakeside Hospital Omaha, Nebraska | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Alegent Health Mercy Hospital Council Bluffs, Iowa | |
| Allegiance Health Jackson, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Alliance for Childhood Diseases/Cure 4 the Kids Foundation Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Alta Bates Summit Medical Center-Herrick Campus Berkeley, California | |
| Anchorage Associates in Radiation Medicine Anchorage, Alaska | Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org) |
| Anchorage Oncology Centre Anchorage, Alaska | |
| Anchorage Radiation Therapy Center Anchorage, Alaska | |
| Ann M Wierman MD LTD Las Vegas, Nevada | |
| Arizona Oncology Services Foundation Scottsdale, Arizona | |
| Armes Family Cancer Center Findlay, Ohio | |
| Ascension Via Christi Hospitals Wichita Wichita, Kansas | |
| Aspirus Cancer Care - Stevens Point Stevens Point, Wisconsin | |
| Associates In Womens Health Wichita, Kansas | |
| Atrium Medical Center-Middletown Regional Hospital Franklin, Ohio | |
| Aurora Bay Area Medical Group-Marinette Marinette, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora BayCare Medical Center Green Bay, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora Cancer Care-Grafton Grafton, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora Cancer Care-Kenosha South Kenosha, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora Cancer Care-Milwaukee Milwaukee, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora Cancer Care-Milwaukee West Wauwatosa, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora Cancer Care-Racine Racine, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora Cancer Care-Southern Lakes VLCC Burlington, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora Cancer Care-Waukesha Waukesha, Wisconsin | |
| Aurora Health Care Germantown Health Center Germantown, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora Health Center-Fond du Lac Fond du Lac, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora Medical Center in Summit Summit, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora Saint Luke's Medical Center Milwaukee, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora Saint Luke's South Shore Cudahy, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora Sinai Medical Center Milwaukee, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Aurora West Allis Medical Center West Allis, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Barnes-Jewish Hospital St Louis, Missouri | |
| Bay Area Hospital Coos Bay, Oregon | Site Public Contact - (cherie.cox@bayareahospital.org) |
| Beacon Kalamazoo Kalamazoo, Michigan | |
| Beacon Kalamazoo Cancer Center Kalamazoo, Michigan | |
| Benefis Helena Specialty Center Helena, Montana | Site Public Contact - (mccinfo@mtcancer.org) |
| Benefis Sletten Cancer Institute Great Falls, Montana | Site Public Contact - (mccinfo@mtcancer.org) |
| Bethesda North Hospital Cincinnati, Ohio | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Bhadresh Nayak MD PC-Sterling Heights Sterling Heights, Michigan | |
| Big Horn Basin Cancer Center Cody, Wyoming | |
| Billings Clinic Cancer Center Billings, Montana | Site Public Contact - (research@billingsclinic.org) |
| Billings Clinic-Cody Cody, Wyoming | Site Public Contact - (research@billingsclinic.org) |
| Blanchard Valley Hospital Findlay, Ohio | |
| Boca Raton Regional Hospital Boca Raton, Florida | |
| Bozeman Health Deaconess Hospital Bozeman, Montana | Site Public Contact - (mccinfo@mtcancer.org) |
| Bronson Battle Creek Battle Creek, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Bronson Methodist Hospital Kalamazoo, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| CARTI Cancer center Little Rock, Arkansas | Site Public Contact - (Research@CARTI.com) |
| CHI Health Good Samaritan Kearney, Nebraska | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| CHI Health Saint Francis Grand Island, Nebraska | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| CHI Saint Vincent Cancer Center Hot Springs Hot Springs, Arkansas | |
| California Pacific Medical Center-Pacific Campus San Francisco, California | |
| Cambridge Medical Center Cambridge, Minnesota | |
| Camden Clark Medical Center Parkersburg, West Virginia | |
| Cancer Care Center at Island Hospital Anacortes, Washington | |
| Cancer Care Center of O'Fallon O'Fallon, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Cancer Care Northwest - Spokane South Spokane, Washington | Site Public Contact - (research@ccnw.net) |
| Cancer Care Northwest-North Spokane Spokane, Washington | Site Public Contact - (research@ccnw.net) |
| Cancer Care Northwest-Valley Spokane, Washington | Site Public Contact - (research@ccnw.net) |
| Cancer Care Specialists of Illinois - Decatur Decatur, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Cancer Center at Saint Joseph's Phoenix, Arizona | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Cancer Center of Kansas - Chanute Chanute, Kansas | |
| Cancer Center of Kansas - Dodge City Dodge City, Kansas | |
| Cancer Center of Kansas - El Dorado El Dorado, Kansas | |
| Cancer Center of Kansas - Fort Scott Fort Scott, Kansas | |
| Cancer Center of Kansas - McPherson McPherson, Kansas | |
| Cancer Center of Kansas - Newton Newton, Kansas | |
| Cancer Center of Kansas - Parsons Parsons, Kansas | |
| Cancer Center of Kansas - Pratt Pratt, Kansas | |
| Cancer Center of Kansas - Salina Salina, Kansas | |
| Cancer Center of Kansas - Wellington Wellington, Kansas | |
| Cancer Center of Kansas - Wichita Wichita, Kansas | |
| Cancer Center of Kansas - Winfield Winfield, Kansas | |
| Cancer Center of Kansas-Independence Independence, Kansas | |
| Cancer Center of Kansas-Kingman Kingman, Kansas | |
| Cancer Center of Kansas-Liberal Liberal, Kansas | |
| Cancer Center of Kansas-Manhattan Manhattan, Kansas | |
| Cancer Center of Kansas-Wichita Medical Arts Tower Wichita, Kansas | |
| Cancer Center of Western Wisconsin New Richmond, Wisconsin | Site Public Contact - (mmcorc@healthpartners.com) |
| Cancer Hematology Centers - Flint Flint, Michigan | Site Public Contact - (wstrong@ghci.org) |
| Cancer Therapy and Integrative Medicine Las Vegas, Nevada | |
| Cancer and Blood Specialists-Henderson Henderson, Nevada | |
| Cancer and Blood Specialists-Shadow Las Vegas, Nevada | |
| Cancer and Blood Specialists-Tenaya Las Vegas, Nevada | |
| Cancer and Hematology Centers of Western Michigan - Norton Shores Norton Shores, Michigan | |
| Carle Cancer Center Urbana, Illinois | Site Public Contact - (Research@carle.com) |
| Carle Physician Group-Effingham Effingham, Illinois | Site Public Contact - (Research@carle.com) |
| Carle Physician Group-Mattoon/Charleston Mattoon, Illinois | Site Public Contact - (Research@carle.com) |
| Carle at The Riverfront Danville, Illinois | Site Public Contact - (Research@Carle.com) |
| Caro Cancer Center Caro, Michigan | |
| Carson Tahoe Regional Medical Center Carson City, Nevada | Site Public Contact - (research@sncrf.org) |
| Case Western Reserve University Cleveland, Ohio | Site Public Contact - (CTUReferral@UHhospitals.org) |
| Cedars-Sinai Medical Center Los Angeles, California | Site Public Contact - (Cancer.trial.info@cshs.org) |
| Centerpoint Medical Center LLC Independence, Missouri | |
| Central Care Cancer Center - Bolivar Bolivar, Missouri | |
| Central Care Cancer Center - Great Bend Great Bend, Kansas | Site Public Contact - (aroland@kccop.org) |
| Central Illinois Hematology Oncology Center Springfield, Illinois | |
| Central Vermont Medical Center/National Life Cancer Treatment Berlin Corners, Vermont | |
| Centralia Oncology Clinic Centralia, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Chelsea Hospital Chelsea, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| Clackamas Radiation Oncology Center Clackamas, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| Cleveland Clinic Foundation Cleveland, Ohio | Site Public Contact - (TaussigResearch@ccf.org) |
| Clinton Memorial Hospital/Foster J Boyd Regional Cancer Center Wilmington, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Columbus Oncology and Hematology Associates Dublin, Ohio | |
| Columbus Oncology and Hematology Associates Inc Columbus, Ohio | |
| CommonSpirit Cancer Center Mercy Durango, Colorado | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| CommonSpirit Saint Anthony Hospital Cancer Center Lakewood, Colorado | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| CommonSpirit Saint Joseph Hospital - Bardstown Bardstown, Kentucky | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| CommonSpirit Saint Joseph Hospital - Lexington Lexington, Kentucky | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| CommonSpirit Saint Joseph Hospital London London, Kentucky | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| CommonSpirit Saint Joseph Hospital Mount Sterling Mount Sterling, Kentucky | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| CommonSpirit Saint Joseph Medical Center - East Lexington Lexington, Kentucky | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Commonwealth Cancer Center-Corbin Corbin, Kentucky | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Community Medical Center Toms River, New Jersey | Site Public Contact - (mccinfo@mtcancer.org) |
| Community Medical Center Toms River, New Jersey | |
| Comprehensive Cancer Centers of Nevada Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Comprehensive Cancer Centers of Nevada - Central Valley Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Comprehensive Cancer Centers of Nevada - Henderson Henderson, Nevada | Site Public Contact - (research@sncrf.org) |
| Comprehensive Cancer Centers of Nevada - Northwest Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Comprehensive Cancer Centers of Nevada - Town Center Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Comprehensive Cancer Centers of Nevada-Horizon Ridge Henderson, Nevada | Site Public Contact - (research@sncrf.org) |
| Comprehensive Cancer Centers of Nevada-Southeast Henderson Henderson, Nevada | Site Public Contact - (research@sncrf.org) |
| Comprehensive Cancer Centers of Nevada-Summerlin Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Condell Memorial Hospital Libertyville, Illinois | Site Public Contact - (advocateresearch@advocatehealth.com) |
| Corewell Health Dearborn Hospital Dearborn, Michigan | |
| Corewell Health Grand Rapids Hospitals - Butterworth Hospital Grand Rapids, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital Grand Rapids, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center Saint Joseph, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Corewell Health Lakeland Hospitals - Niles Hospital Niles, Michigan | |
| Corewell Health Lakeland Hospitals - Saint Joseph Hospital Saint Joseph, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Corewell Health Reed City Hospital Reed City, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Cox Cancer Center Branson Branson, Missouri | |
| CoxHealth South Hospital Springfield, Missouri | |
| Crossroads Cancer Center Effingham, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Dana-Farber Cancer Institute Boston, Massachusetts | |
| Dartmouth Cancer Center - North Saint Johnsbury, Vermont | Site Public Contact - (cancer.research.nurse@hitchcock.org) |
| Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center Lebanon, New Hampshire | Site Public Contact - (cancer.research.nurse@dartmouth.edu) |
| Dayton Physician LLC - Englewood Dayton, Ohio | |
| Dayton Physicians LLC - Troy Troy, Ohio | |
| Dayton Physicians LLC-Atrium Franklin, Ohio | |
| Dayton Physicians LLC-Miami Valley South Centerville, Ohio | |
| Dayton Physicians LLC-Signal Point Middletown, Ohio | |
| Dayton Physicians LLC-Wayne Greenville, Ohio | |
| Dayton Physicians LLC-Wilson Sidney, Ohio | |
| Decatur Memorial Hospital Decatur, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Delaware Health Center-Grady Cancer Center Delaware, Ohio | |
| Delaware Radiation Oncology Delaware, Ohio | |
| Dell Seton Medical Center at The University of Texas Austin, Texas | |
| Desert West Surgery Las Vegas, Nevada | |
| Doctors Hospital Columbus, Ohio | |
| Duluth Clinic Ashland Ashland, Wisconsin | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| East Carolina University Greenville, North Carolina | |
| Eden Hospital Medical Center Castro Valley, California | |
| Emory University Hospital Midtown Atlanta, Georgia | |
| Emory University Hospital/Winship Cancer Institute Atlanta, Georgia | |
| Essentia Health - Baxter Clinic Baxter, Minnesota | |
| Essentia Health - Deer River Clinic Deer River, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health - Ely Clinic Ely, Minnesota | |
| Essentia Health - Fosston Fosston, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health - International Falls Clinic International Falls, Minnesota | |
| Essentia Health - Jamestown Clinic Jamestown, North Dakota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health - Moose Lake Clinic Moose Lake, Minnesota | |
| Essentia Health - Park Rapids Park Rapids, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health - Saint Joseph's Crosslake Clinic Crosslake, Minnesota | |
| Essentia Health - Saint Joseph's Pequot Lakes Clinic Pequot Lakes, Minnesota | |
| Essentia Health - Saint Joseph's Pine River Clinic Pine River, Minnesota | |
| Essentia Health - Saint Joseph's Staples Clinic Staples, Minnesota | |
| Essentia Health Cancer Center Duluth, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health Cancer Center-South University Clinic Fargo, North Dakota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health Hibbing Clinic Hibbing, Minnesota | |
| Essentia Health Saint Joseph's Medical Center Brainerd, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health Saint Mary's - Detroit Lakes Clinic Detroit Lakes, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health Saint Mary's Medical Center Duluth, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health Sandstone Sandstone, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Essentia Health Virginia Clinic Virginia, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Fairbanks Memorial Hospital Fairbanks, Alaska | Site Public Contact - (Veronica.Stevenson@foundationhealth.org) |
| Fairfield Medical Center Lancaster, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Fairview Clinics and Surgery Center Maple Grove Maple Grove, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Fairview Lakes Medical Center Wyoming, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Fairview Northland Medical Center Princeton, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Fairview Ridges Hospital Burnsville, Minnesota | |
| Fairview Southdale Hospital Edina, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Farmington Health Center Farmington, Utah | |
| First Dayton Cancer Care Kettering, Ohio | |
| Franciscan Research Center-Northwest Medical Plaza Tacoma, Washington | |
| Fred and Pamela Buffett Cancer Center - Kearney Kearney, Nebraska | |
| Freeman Health System Joplin, Missouri | Site Public Contact - (LJCrockett@freemanhealth.com) |
| Geisinger Cancer Services-Pottsville Pottsville, Pennsylvania | |
| Geisinger Medical Center Danville, Pennsylvania | |
| Geisinger Medical Center-Cancer Center Hazleton Hazleton, Pennsylvania | |
| Geisinger Medical Group State College, Pennsylvania | |
| Geisinger Medical Oncology-Lewisburg Lewisburg, Pennsylvania | |
| Geisinger Medical Oncology-Selinsgrove Selinsgrove, Pennsylvania | |
| Geisinger Wyoming Valley/Henry Cancer Center Wilkes-Barre, Pennsylvania | |
| Genesee Hematology Oncology PC Flint, Michigan | Site Public Contact - (wstrong@ghci.org) |
| Genesis Healthcare System Cancer Care Center Zanesville, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Genesys Hurley Cancer Institute Flint, Michigan | Site Public Contact - (wstrong@ghci.org) |
| Gibbs Cancer Center-Gaffney Gaffney, South Carolina | |
| Gibbs Cancer Center-Pelham Greer, South Carolina | |
| Glens Falls Hospital Glens Falls, New York | |
| Good Samaritan Hospital - Cincinnati Cincinnati, Ohio | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Good Samaritan Hospital - Dayton Dayton, Ohio | |
| Grady Health System Atlanta, Georgia | |
| Grady Memorial Hospital Delaware, Ohio | |
| Grand Valley Oncology Grand Junction, Colorado | |
| Grant Medical Center Columbus, Ohio | |
| Greater Dayton Cancer Center Kettering, Ohio | |
| Greater Regional Medical Center Creston, Iowa | |
| Greenville Health System Cancer Institute-Andrews Greenville, South Carolina | |
| Gundersen Lutheran Medical Center La Crosse, Wisconsin | |
| HSHS Saint Elizabeth's Hospital O'Fallon, Illinois | Site Public Contact - (morganthaler.jodi@mhsil.com) |
| Hackensack University Medical Center Hackensack, New Jersey | |
| Harrison HealthPartners Hematology and Oncology-Poulsbo Poulsbo, Washington | |
| Health Partners Inc Minneapolis, Minnesota | |
| HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills Las Vegas, Nevada | |
| HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway Las Vegas, Nevada | |
| HealthCare Partners Medical Group Oncology/Hematology-San Martin Las Vegas, Nevada | |
| HealthCare Partners Medical Group Oncology/Hematology-Tenaya Las Vegas, Nevada | |
| Heartland Regional Medical Center Saint Joseph, Missouri | Site Public Contact - (Trisha.England2@mymlc.com) |
| Hematology Oncology Consultants-Clarkston Clarkston, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| Hematology and Oncology Consultants PC Omaha, Nebraska | |
| Hennepin County Medical Center Minneapolis, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Henry Ford Cancer Institute-Downriver Brownstown, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Henry Ford Health Saint John Hospital Detroit, Michigan | Site Public Contact - (Kkeenan1@hfhs.org) |
| Henry Ford Health Warren Hospital Warren, Michigan | Site Public Contact - (kforman1@hfhs.org) |
| Henry Ford Hospital Detroit, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Henry Ford Macomb Health Center - Shelby Township Shelby, Michigan | |
| Henry Ford Macomb Hospital-Clinton Township Clinton Township, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Henry Ford Madison Heights Hospital - Breast Warren, Michigan | Site Public Contact - (kforman1@hfhs.org) |
| Henry Ford Medical Center-Columbus Novi, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Henry Ford Medical Center-Fairlane Dearborn, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Henry Ford River District Hospital East China Township, Michigan | Site Public Contact - (kforman1@hfhs.org) |
| Henry Ford Rochester Hospital Rochester Hills, Michigan | |
| Henry Ford Saint John Hospital - Academic Grosse Pointe Woods, Michigan | Site Public Contact - (kforman1@hfhs.org) |
| Henry Ford Saint John Hospital - Breast Grosse Pointe Woods, Michigan | Site Public Contact - (karen.forman@ascension.org) |
| Henry Ford Saint John Hospital - Macomb Medical Macomb, Michigan | Site Public Contact - (kforman1@hfhs.org) |
| Henry Ford Saint John Hospital - Van Elslander Grosse Pointe Woods, Michigan | Site Public Contact - (kforman1@hfhs.org) |
| Henry Ford Warren Hospital - Breast Macomb Macomb, Michigan | Site Public Contact - (kforman1@hfhs.org) |
| Henry Ford Warren Hospital - GLCMS Warren, Michigan | Site Public Contact - (kforman1@hfhs.org) |
| Henry Ford West Bloomfield Hospital West Bloomfield, Michigan | Site Public Contact - (CTOResearch@hfhs.org) |
| Henry Ford Wyandotte Hospital Wyandotte, Michigan | Site Public Contact - (nhay@hfhs.org) |
| Hi-Line Sletten Cancer Center Havre, Montana | Site Public Contact - (protocols@AllianceNCTN.org) |
| Highline Medical Center-Main Campus Burien, Washington | |
| Holy Cross Hospital Silver Spring, Maryland | Site Public Contact - (eileen.georgi@holy-cross.com) |
| Hope Cancer Care of Nevada Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Hope Cancer Care of Nevada-Pahrump Pahrump, Nevada | Site Public Contact - (research@sncrf.org) |
| Hope Cancer Center Pontiac, Michigan | |
| Hope Cancer Clinic Livonia, Michigan | |
| Huntsman Cancer Institute/University of Utah Salt Lake City, Utah | |
| Hurley Medical Center Flint, Michigan | Site Public Contact - (wstrong@ghci.org) |
| Huron Gastroenterology PC Ypsilanti, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| Idaho Urologic Institute-Meridian Meridian, Idaho | Site Public Contact - (stephanie.couch@stjoeshealth.org) |
| Illinois CancerCare - Washington Washington, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Bloomington Bloomington, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Canton Canton, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Carthage Carthage, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Dixon Dixon, Illinois | |
| Illinois CancerCare-Eureka Eureka, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Galesburg Galesburg, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Kewanee Clinic Kewanee, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Macomb Macomb, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Ottawa Clinic Ottawa, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Pekin Pekin, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Peoria Peoria, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Peru Peru, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Illinois CancerCare-Princeton Princeton, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Indu and Raj Soin Medical Center Beavercreek, Ohio | |
| Inova Fairfax Hospital Falls Church, Virginia | |
| Inova Schar Cancer Institute Fairfax, Virginia | Site Public Contact - (Stephanie.VanBebber@inova.org) |
| Jersey Shore Medical Center Neptune City, New Jersey | |
| Jewish Hospital Louisville, Kentucky | |
| Jewish Hospital Medical Center South Shepherdsville, Kentucky | |
| Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland | Site Public Contact - (jhcccro@jhmi.edu) |
| Kadlec Clinic Hematology and Oncology Kennewick, Washington | Site Public Contact - (research@kadlecmed.org) |
| Kaiser Permanente Los Angeles Medical Center Los Angeles, California | Site Public Contact - (clinical.trials@kp.org) |
| Kaiser Permanente Medical Center - Santa Clara Santa Clara, California | |
| Kaiser Permanente Medical Center-Vacaville Vacaville, California | |
| Kaiser Permanente Moanalua Medical Center Honolulu, Hawaii | |
| Kaiser Permanente Sacramento Medical Center Sacramento, California | |
| Kaiser Permanente San Leandro San Leandro, California | |
| Kaiser Permanente Washington Seattle, Washington | |
| Kaiser Permanente-Deer Valley Medical Center Antioch, California | |
| Kaiser Permanente-Fremont Fremont, California | |
| Kaiser Permanente-Fresno Fresno, California | |
| Kaiser Permanente-Modesto Modesto, California | |
| Kaiser Permanente-Oakland Oakland, California | |
| Kaiser Permanente-Redwood City Redwood City, California | |
| Kaiser Permanente-Richmond Richmond, California | |
| Kaiser Permanente-Roseville Roseville, California | |
| Kaiser Permanente-San Francisco San Francisco, California | |
| Kaiser Permanente-San Rafael San Rafael, California | |
| Kaiser Permanente-Santa Rosa Santa Rosa, California | |
| Kaiser Permanente-Santa Teresa-San Jose San Jose, California | |
| Kaiser Permanente-South Sacramento Sacramento, California | |
| Kaiser Permanente-South San Francisco South San Francisco, California | |
| Kaiser Permanente-Stockton Stockton, California | |
| Kaiser Permanente-Vallejo Vallejo, California | |
| Kaiser Permanente-Walnut Creek Walnut Creek, California | |
| Kaiser San Rafael-Gallinas San Rafael, California | |
| Kansas Institute of Medicine Cancer and Blood Center Lenexa, Kansas | |
| Katmai Oncology Group Anchorage, Alaska | Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org) |
| Keck Medical Center of USC Pasadena Pasadena, California | |
| Kettering Medical Center Kettering, Ohio | |
| Kingman Regional Medical Center Kingman, Arizona | Site Public Contact - (research@sncrf.org) |
| Knox Community Hospital Mount Vernon, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Kootenai Clinic Cancer Services - Post Falls Post Falls, Idaho | Site Public Contact - (mccinfo@mtcancer.org) |
| Kootenai Clinic Cancer Services - Sandpoint Sandpoint, Idaho | Site Public Contact - (mccinfo@mtcancer.org) |
| Kootenai Health - Coeur d'Alene Coeur d'Alene, Idaho | Site Public Contact - (mccinfo@mtcancer.org) |
| Lake Huron Medical Center Port Huron, Michigan | |
| Lake Region Healthcare Corporation-Cancer Care Fergus Falls, Minnesota | |
| Lake Regional Hospital Osage Beach, Missouri | Site Public Contact - (clinicaltrials@lakeregional.com) |
| Lakeview Hospital Stillwater, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Las Vegas Cancer Center-Henderson Henderson, Nevada | |
| Las Vegas Cancer Center-Medical Center Las Vegas, Nevada | |
| Las Vegas Prostate Cancer Center Las Vegas, Nevada | |
| Las Vegas Urology - Cathedral Rock Las Vegas, Nevada | |
| Las Vegas Urology - Green Valley Henderson, Nevada | |
| Las Vegas Urology - Pebble Henderson, Nevada | |
| Las Vegas Urology - Pecos Las Vegas, Nevada | |
| Las Vegas Urology - Smoke Ranch Las Vegas, Nevada | |
| Las Vegas Urology - Sunset Las Vegas, Nevada | |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, New York | Site Public Contact - (CancerTrials@nyulangone.org) |
| Lawrence Memorial Hospital Lawrence, Kansas | |
| Lehigh Valley Hospital - Muhlenberg Bethlehem, Pennsylvania | Site Public Contact - (Morgan_M.Horton@lvhn.org) |
| Lehigh Valley Hospital-Cedar Crest Allentown, Pennsylvania | Site Public Contact - (Morgan_M.Horton@lvhn.org) |
| Lehigh Valley Hospital-Hazleton Hazleton, Pennsylvania | Site Public Contact - (Morgan_M.Horton@lvhn.org) |
| Lenox Hill Hospital New York, New York | |
| Lewistown Hospital Lewistown, Pennsylvania | |
| Liberty Hospital Liberty, Missouri | |
| Licking Memorial Hospital Newark, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Logan Health Medical Center Kalispell, Montana | Site Public Contact - (mccinfo@mtcancer.org) |
| Longmont United Hospital Longmont, Colorado | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Los Angeles General Medical Center Los Angeles, California | |
| Louisiana State University Health Science Center New Orleans, Louisiana | |
| MU Health Care Goldschmidt Cancer Center Jefferson City, Missouri | |
| Macomb Hematology Oncology PC Warren, Michigan | |
| Marietta Memorial Hospital Marietta, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Marshfield Clinic Cancer Center at Sacred Heart Eau Claire, Wisconsin | |
| Marshfield Clinic-Chippewa Center Chippewa Falls, Wisconsin | Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org) |
| Marshfield Clinic-Wausau Center Wausau, Wisconsin | Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org) |
| Marshfield Medical Center - Minocqua Minocqua, Wisconsin | Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org) |
| Marshfield Medical Center - Weston Weston, Wisconsin | Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org) |
| Marshfield Medical Center-EC Cancer Center Eau Claire, Wisconsin | Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org) |
| Marshfield Medical Center-Marshfield Marshfield, Wisconsin | Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org) |
| Marshfield Medical Center-Rice Lake Rice Lake, Wisconsin | Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org) |
| Marshfield Medical Center-River Region at Stevens Point Stevens Point, Wisconsin | Site Public Contact - (oncology.clinical.trials@marshfieldresearch.org) |
| Mary Greeley Medical Center Ames, Iowa | |
| Massachusetts General Hospital Cancer Center Boston, Massachusetts | |
| Mayo Clinic in Arizona Scottsdale, Arizona | |
| Mayo Clinic in Florida Jacksonville, Florida | |
| Mayo Clinic in Rochester Rochester, Minnesota | |
| McFarland Clinic - Ames Ames, Iowa | |
| McFarland Clinic - Boone Boone, Iowa | |
| McFarland Clinic - Jefferson Jefferson, Iowa | |
| McFarland Clinic - Marshalltown Marshalltown, Iowa | |
| McFarland Clinic - Trinity Cancer Center Fort Dodge, Iowa | |
| Medical College of Wisconsin Milwaukee, Wisconsin | |
| Medical University of South Carolina Charleston, South Carolina | |
| Memorial GYN Plus Ooltewah, Tennessee | |
| Memorial Health University Medical Center Savannah, Georgia | |
| Memorial Hermann Northeast Hospital Humble, Texas | Site Public Contact - (ctsucontact@westat.com) |
| Memorial Hermann Texas Medical Center Houston, Texas | |
| Memorial Hermann The Woodlands Hospital The Woodlands, Texas | Site Public Contact - (ctsucontact@westat.com) |
| Memorial Hospital Marysville, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Memorial Hospital Marysville, Ohio | |
| Memorial Hospital West Pembroke Pines, Florida | |
| Memorial Hospital of Carbondale Carbondale, Illinois | Site Public Contact - (clinical.research@sih.net) |
| Memorial Hospital of Laramie County Cheyenne, Wyoming | Site Public Contact - (protocols@AllianceNCTN.org) |
| Memorial Hospital of South Bend South Bend, Indiana | |
| Memorial Medical Center Modesto, California | |
| Memorial Regional Cancer Center Day Road Mishawaka, Indiana | |
| Memorial Regional Hospital/Joe DiMaggio Children's Hospital Hollywood, Florida | Site Public Contact - (OHR@mhs.net) |
| Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey | |
| Memorial Sloan Kettering Bergen Montvale, New Jersey | |
| Memorial Sloan Kettering Cancer Center New York, New York | |
| Memorial Sloan Kettering Commack Commack, New York | |
| Memorial Sloan Kettering Monmouth Middletown, New Jersey | |
| Memorial Sloan Kettering Nassau Uniondale, New York | |
| Memorial Sloan Kettering Westchester Harrison, New York | |
| Menorah Medical Center Overland Park, Kansas | |
| Mercy Cancer Center Merced, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Mercy Cancer Center - Cape Girardeau Cape Girardeau, Missouri | |
| Mercy Cancer Center - Carmichael Carmichael, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Mercy Cancer Center - Elk Grove Elk Grove, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Mercy Cancer Center - Rocklin Rocklin, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Mercy Cancer Center - Sacramento Sacramento, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Mercy Cancer Center-West Lakes Clive, Iowa | |
| Mercy Clinic-Rolla-Cancer and Hematology Rolla, Missouri | |
| Mercy Health - Perrysburg Hospital Perrysburg, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Mercy Health - Saint Anne Hospital Toledo, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Mercy Health - Saint Vincent Hospital Toledo, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Mercy Health Sylvania Radiation Oncology Center Toledo, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Mercy Hospital Coon Rapids, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Mercy Hospital Fort Smith Fort Smith, Arkansas | |
| Mercy Hospital Joplin Joplin, Missouri | Site Public Contact - (esmeralda.carrillo@mercy.net) |
| Mercy Hospital Oklahoma City Oklahoma City, Oklahoma | |
| Mercy Hospital Pittsburg Pittsburg, Kansas | |
| Mercy Hospital Saint Louis St Louis, Missouri | |
| Mercy Hospital South St Louis, Missouri | Site Public Contact - (Danielle.Werle@mercy.net) |
| Mercy Hospital Springfield Springfield, Missouri | |
| Mercy Hospital Washington Washington, Missouri | |
| Mercy Infusion Center - Chippewa St Louis, Missouri | |
| Mercy Medical Center Springfield, Massachusetts | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Mercy Medical Center - Des Moines Des Moines, Iowa | |
| Mercy Medical Center-West Lakes West Des Moines, Iowa | |
| Mercy Oncology and Hematology - Clayton-Clarkson Ballwin, Missouri | |
| Mercy San Juan Medical Center Carmichael, California | Site Public Contact - (ResearchInstituteInquiries@commonspirit.org) |
| Methodist Medical Center of Illinois Peoria, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| Miami Valley Hospital Dayton, Ohio | |
| Miami Valley Hospital North Dayton, Ohio | |
| Miami Valley Hospital South Centerville, Ohio | |
| Michigan Healthcare Professionals Pontiac Pontiac, Michigan | Site Public Contact - (Emily.Crofts@trinity-health.org) |
| Midlands Community Hospital Papillion, Nebraska | |
| Miller-Dwan Hospital Duluth, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Mills Health Center San Mateo, California | |
| Mills-Peninsula Medical Center Burlingame, California | |
| Minimally Invasive Surgery Hospital Lenexa, Kansas | |
| Minnesota Oncology - Burnsville Burnsville, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Minnesota Oncology - Coon Rapids Coon Rapids, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Minnesota Oncology - Edina Edina, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Minnesota Oncology - Maple Grove Maple Grove, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Minnesota Oncology Hematology PA-Chaska Chaska, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Minnesota Oncology Hematology PA-Maplewood Maplewood, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Minnesota Oncology Hematology PA-Woodbury Woodbury, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Mission Hope Medical Oncology - Arroyo Grande Arroyo Grande, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Mission Hope Medical Oncology - Santa Maria Santa Maria, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Missouri Baptist Medical Center St Louis, Missouri | |
| Missouri Baptist Sullivan Hospital Sullivan, Missouri | |
| Moffitt Cancer Center Tampa, Florida | |
| Montefiore Medical Center - Moses Campus The Bronx, New York | |
| Montefiore Medical Center-Einstein Campus The Bronx, New York | |
| Montefiore Medical Center-Weiler Hospital The Bronx, New York | |
| Monticello Cancer Center Monticello, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Mount Carmel East Hospital Columbus, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Mount Carmel Grove City Hospital Grove City, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Mount Carmel Health Center West Columbus, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Mount Carmel New Albany Surgical Hospital New Albany, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Mount Sinai Comprehensive Cancer Center at Aventura Aventura, Florida | |
| Mount Sinai Hospital New York, New York | |
| Mount Sinai Medical Center New York, New York | |
| Mountain Blue Cancer Care Center Golden, Colorado | |
| MultiCare Deaconess Cancer and Blood Specialty Center - Downtown Spokane, Washington | |
| MultiCare Deaconess Cancer and Blood Specialty Center - North Spokane, Washington | |
| MultiCare Deaconess Cancer and Blood Specialty Center - Valley Spokane Valley, Washington | |
| Munson Medical Center Traverse City, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| MyMichigan Medical Center Alpena Alpena, Michigan | Site Public Contact - (CVResearch@mymichigan.org) |
| MyMichigan Medical Center Gladwin Gladwin, Michigan | Site Public Contact - (CVResearch@mymichigan.org) |
| MyMichigan Medical Center Gratiot Alma, Michigan | Site Public Contact - (CVResearch@mymichigan.org) |
| MyMichigan Medical Center Midland Midland, Michigan | Site Public Contact - (CVResearch@mymichigan.org) |
| MyMichigan Medical Center Mount Pleasant Mount Pleasant, Michigan | Site Public Contact - (CVResearch@mymichigan.org) |
| MyMichigan Medical Center Saginaw Saginaw, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| MyMichigan Medical Center Tawas Tawas City, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York, New York | |
| NYP/Weill Cornell Medical Center New York, New York | |
| Nebraska Cancer Specialists/Oncology Hematology West PC Grand Island, Nebraska | |
| Nebraska Medicine-Bellevue Bellevue, Nebraska | |
| Nebraska Medicine-Village Pointe Omaha, Nebraska | |
| New Ulm Medical Center New Ulm, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Newark Radiation Oncology Newark, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Newland Medical Associates-Clarkston Clarkston, Michigan | |
| Newland Medical Associates-Pontiac Pontiac, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| North Memorial Medical Health Center Robbinsdale, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| North Shore University Hospital Manhasset, New York | |
| North Star Lodge Cancer Center at Yakima Valley Memorial Hospital Yakima, Washington | Site Public Contact - (Memorial-ClinicalTrials@yvmh.org) |
| Northwell Health/Center for Advanced Medicine Lake Success, New York | |
| Northwest Medical Specialties PLLC Tacoma, Washington | |
| Northwest Wisconsin Cancer Center Ashland, Wisconsin | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Northwestern Medicine Cancer Center Delnor Geneva, Illinois | |
| Northwestern Medicine Cancer Center Warrenville Warrenville, Illinois | |
| Northwestern Medicine Orland Park Orland Park, Illinois | |
| Northwestern University Chicago, Illinois | |
| Norton Brownsboro Hospital and Medical Campus Louisville, Kentucky | Site Public Contact - (ctsucontact@westat.com) |
| OSF Saint Anthony's Health Center Alton, Illinois | |
| OSF Saint Francis Medical Center Peoria, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| OSF Saint Francis Radiation Oncology at Pekin Pekin, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| OSF Saint Francis Radiation Oncology at Peoria Cancer Center Peoria, Illinois | Site Public Contact - (andersonj@illinoiscancercare.com) |
| OSF Saint Joseph Medical Center Bloomington, Illinois | |
| Ohio State University Comprehensive Cancer Center Columbus, Ohio | |
| OhioHealth Mansfield Hospital Mansfield, Ohio | |
| OhioHealth Marion General Hospital Marion, Ohio | |
| Oklahoma Cancer Specialists and Research Institute-Tulsa Tulsa, Oklahoma | |
| Olympic Medical Cancer Care Center Sequim, Washington | |
| Oncology Hematology Associates of Saginaw Valley PC Saginaw, Michigan | |
| Oncology Hematology Care Inc-Anderson Cincinnati, Ohio | |
| Oncology Hematology Care Inc-Blue Ash Cincinnati, Ohio | |
| Oncology Hematology Care Inc-Crestview Crestview Hills, Kentucky | |
| Oncology Hematology Care Inc-Eden Park Cincinnati, Ohio | |
| Oncology Hematology Care Inc-Healthplex Fairfield, Ohio | |
| Oncology Hematology Care Inc-Kenwood Cincinnati, Ohio | |
| Oncology Hematology Care Inc-Mercy West Cincinnati, Ohio | |
| Oncology Las Vegas - Henderson Henderson, Nevada | Site Public Contact - (research@sncrf.org) |
| Oncology Las Vegas - Tenaya Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| OptumCare Cancer Care at Charleston Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| OptumCare Cancer Care at Fort Apache Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| OptumCare Cancer Care at MountainView Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Orion Cancer Care Findlay, Ohio | |
| Overlake Medical Center Bellevue, Washington | |
| Overlook Hospital Summit, New Jersey | |
| PCR Oncology Arroyo Grande, California | Site Public Contact - (research@sncrf.org) |
| Pacific Central Coast Health Center-San Luis Obispo San Luis Obispo, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Pacific Gynecology Specialists Seattle, Washington | |
| Palo Alto Medical Foundation Health Care Palo Alto, California | |
| Palo Alto Medical Foundation-Camino Division Mountain View, California | |
| Palo Alto Medical Foundation-Fremont Fremont, California | |
| Palo Alto Medical Foundation-Gynecologic Oncology Mountain View, California | |
| Palo Alto Medical Foundation-Santa Cruz Santa Cruz, California | |
| Palo Alto Medical Foundation-Sunnyvale Sunnyvale, California | |
| Park Nicollet Clinic - Saint Louis Park Saint Louis Park, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Parkland Health Center - Farmington Farmington, Missouri | |
| Parkland Health Center-Bonne Terre Bonne Terre, Missouri | |
| Parkland Memorial Hospital Dallas, Texas | |
| PeaceHealth Saint John Medical Center Longview, Washington | Site Public Contact - (kmakin-bond@peacehealth.org) |
| PeaceHealth Saint Joseph Medical Center Bellingham, Washington | Site Public Contact - (achapman1@peacehealth.org) |
| PeaceHealth Southwest Medical Center Vancouver, Washington | Site Public Contact - (kmakin-bond@peacehealth.org) |
| PeaceHealth United General Medical Center Sedro-Woolley, Washington | Site Public Contact - (achapman1@peacehealth.org) |
| Peninsula Cancer Center Poulsbo, Washington | |
| Penn State Milton S Hershey Medical Center Hershey, Pennsylvania | Site Public Contact - (CTO@hmc.psu.edu) |
| Penrose-Saint Francis Healthcare Colorado Springs, Colorado | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Phelps Health Delbert Day Cancer Institute Rolla, Missouri | Site Public Contact - (research@phelpshealth.org) |
| Piedmont Hospital Atlanta, Georgia | Site Public Contact - (ORS@piedmont.org) |
| Pocono Medical Center East Stroudsburg, Pennsylvania | Site Public Contact - (Morgan_M.Horton@lvhn.org) |
| Prisma Health Cancer Institute - Butternut Greenville, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| Prisma Health Cancer Institute - Easley Easley, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| Prisma Health Cancer Institute - Eastside Greenville, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| Prisma Health Cancer Institute - Faris Greenville, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| Prisma Health Cancer Institute - Greer Greer, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| Prisma Health Cancer Institute - Seneca Seneca, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| Prisma Health Cancer Institute - Spartanburg Boiling Springs, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| Prisma Health Greenville Memorial Hospital Greenville, South Carolina | Site Public Contact - (Kim.Williams3@prismahealth.org) |
| ProHealth D N Greenwald Center Mukwonago, Wisconsin | |
| ProHealth Oconomowoc Memorial Hospital Oconomowoc, Wisconsin | |
| ProHealth Waukesha Memorial Hospital Waukesha, Wisconsin | |
| Providence Alaska Medical Center Anchorage, Alaska | Site Public Contact - (AKPAMC.OncologyResearchSupport@providence.org) |
| Providence Cancer Institute Clackamas Clinic Clackamas, Oregon | |
| Providence Hood River Memorial Hospital Hood River, Oregon | Site Public Contact - (canrsrchstudies@provdience.org) |
| Providence Newberg Medical Center Newberg, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| Providence Portland Medical Center Portland, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| Providence Regional Cancer Partnership Everett, Washington | Site Public Contact - (marilyn.birchman@providence.org) |
| Providence Regional Cancer System-Aberdeen Aberdeen, Washington | Site Public Contact - (deidre.dillon@providence.org) |
| Providence Regional Cancer System-Centralia Centralia, Washington | Site Public Contact - (deidre.dillon@providence.org) |
| Providence Regional Cancer System-Lacey Lacey, Washington | Site Public Contact - (deidre.dillon@providence.org) |
| Providence Regional Cancer System-Shelton Shelton, Washington | |
| Providence Regional Cancer System-Yelm Yelm, Washington | |
| Providence Saint Joseph Medical Center/Disney Family Cancer Center Burbank, California | Site Public Contact - (Najee.Boucher@providence.org) |
| Providence Saint Mary Regional Cancer Center Walla Walla, Washington | Site Public Contact - (Cheryl.Dodd@providence.org) |
| Providence Saint Vincent Medical Center Portland, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| Providence Willamette Falls Medical Center Oregon City, Oregon | Site Public Contact - (CanRsrchStudies@providence.org) |
| Pulmonary Medicine Center of Chattanooga-Hixson Hixson, Tennessee | |
| Radiation Oncology Associates Reno, Nevada | |
| Radiation Oncology Centers of Nevada Central Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Radiation Oncology Centers of Nevada Southeast Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Radiation Oncology of Northern Illinois Ottawa, Illinois | |
| Regions Hospital Saint Paul, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Reid Health Richmond, Indiana | |
| Renown Regional Medical Center Reno, Nevada | Site Public Contact - (Renown-CRD@renown.org) |
| Research Medical Center Kansas City, Missouri | |
| Rhode Island Hospital Providence, Rhode Island | |
| Rice Memorial Hospital Willmar, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Ridgeview Medical Center Waconia, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Riverside Methodist Hospital Columbus, Ohio | |
| Riverwood Healthcare Center Aitkin, Minnesota | Site Public Contact - (CancerTrials@EssentiaHealth.org) |
| Rocky Mountain Cancer Centers - Pueblo Pueblo, Colorado | |
| Rocky Mountain Cancer Centers-Lakewood Lakewood, Colorado | |
| Rocky Mountain Cancer Centers-Longmont Longmont, Colorado | |
| Rocky Mountain Cancer Centers-Parker Parker, Colorado | |
| Rocky Mountain Cancer Centers-Penrose Colorado Springs, Colorado | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Rocky Mountain Cancer Centers-Thornton Thornton, Colorado | |
| Rush MD Anderson Cancer Center Chicago, Illinois | Site Public Contact - (Cancer_Studies@rush.edu) |
| Rush MD Anderson Cancer Center at Rush Oak Park Oak Park, Illinois | Site Public Contact - (Cancer_Studies@rush.edu) |
| Rush-Copley Healthcare Center Yorkville, Illinois | Site Public Contact - (Cancer.Research@rushcopley.com) |
| Rush-Copley Medical Center Aurora, Illinois | Site Public Contact - (RCMC_Cancer_Research@rush.edu) |
| SIH Cancer Institute Carterville, Illinois | Site Public Contact - (clinical.research@sih.net) |
| SMC Center for Hematology Oncology Union Union, South Carolina | |
| SSM Health Good Samaritan Mount Vernon, Illinois | Site Public Contact - (gayla.hall@ssmhealth.com) |
| Saint Alphonsus Cancer Care Center-Baker City Baker City, Oregon | Site Public Contact - (mccinfo@mtcancer.org) |
| Saint Alphonsus Cancer Care Center-Boise Boise, Idaho | Site Public Contact - (stephanie.couch@stjoeshealth.org) |
| Saint Alphonsus Cancer Care Center-Caldwell Caldwell, Idaho | Site Public Contact - (stephanie.couch@stjoeshealth.org) |
| Saint Alphonsus Cancer Care Center-Nampa Nampa, Idaho | |
| Saint Alphonsus Cancer Care Center-Ontario Ontario, Oregon | Site Public Contact - (mccinfo@mtcancer.org) |
| Saint Ann's Hospital Westerville, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Saint Anthony North Hospital Westminster, Colorado | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Charles Health System Bend, Oregon | Site Public Contact - (nosall@stcharleshealthcare.org) |
| Saint Charles Health System-Redmond Redmond, Oregon | |
| Saint Clare Hospital Lakewood, Washington | |
| Saint Elizabeth Hospital Enumclaw, Washington | |
| Saint Elizabeth Regional Medical Center Lincoln, Nebraska | |
| Saint Francis Cancer Center Greenville, South Carolina | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Francis Hospital Federal Way, Washington | |
| Saint Francis Medical Center Cape Girardeau, Missouri | Site Public Contact - (sfmc@sfmc.net) |
| Saint Francis Regional Medical Center Shakopee, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Saint James Community Hospital and Cancer Treatment Center Butte, Montana | |
| Saint John's Hospital - Healtheast Maplewood, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| Saint Joseph Medical Center Hematology and Oncology - Silverdale Silverdale, Washington | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Joseph Radiation Oncology Resource Center Lexington, Kentucky | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Joseph Regional Cancer Center Bryan, Texas | |
| Saint Joseph's Hospital and Medical Center Phoenix, Arizona | |
| Saint Joseph's Medical Center Stockton, California | |
| Saint Luke's Cancer Institute - Boise Boise, Idaho | Site Public Contact - (eslinget@slhs.org) |
| Saint Luke's Cancer Institute - Fruitland Fruitland, Idaho | Site Public Contact - (eslinget@slhs.org) |
| Saint Luke's Cancer Institute - Meridian Meridian, Idaho | Site Public Contact - (eslinget@slhs.org) |
| Saint Luke's Cancer Institute - Nampa Nampa, Idaho | Site Public Contact - (eslinget@slhs.org) |
| Saint Luke's Cancer Institute - Twin Falls Twin Falls, Idaho | Site Public Contact - (eslinget@slhs.org) |
| Saint Luke's East - Lee's Summit Lee's Summit, Missouri | |
| Saint Luke's Hospital of Kansas City Kansas City, Missouri | |
| Saint Luke's South Hospital Overland Park, Kansas | |
| Saint Mary Corwin Medical Center Pueblo, Colorado | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Saint Mary's Hospital Centralia, Illinois | |
| Saint Mary's Oncology/Hematology Associates of Marlette Marlette, Michigan | |
| Saint Mary's Oncology/Hematology Associates of West Branch West Branch, Michigan | |
| Saint Mary's Regional Medical Center Reno, Nevada | Site Public Contact - (research@sncrf.org) |
| Saint Patrick Hospital - Community Hospital Missoula, Montana | Site Public Contact - (amy.hanneman@providence.org) |
| Saint Peter's Community Hospital Helena, Montana | |
| Saint Rita's Medical Center Lima, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Saint Vincent Healthcare Billings, Montana | |
| Sainte Genevieve County Memorial Hospital Sainte Genevieve, Missouri | |
| Saints Mary and Elizabeth Hospital Louisville, Kentucky | |
| Skagit Regional Health Cancer Care Center Mount Vernon, Washington | Site Public Contact - (rcccclinicalresearch@skagitvalleyhospital.org) |
| Smilow Cancer Hospital Care Center at Saint Francis Hartford, Connecticut | Site Public Contact - (canceranswers@yale.edu) |
| Smilow Cancer Hospital Care Center-Trumbull Trumbull, Connecticut | Site Public Contact - (canceranswers@yale.edu) |
| South Jordan Health Center South Jordan, Utah | |
| Southern Illinois University School of Medicine Springfield, Illinois | |
| Southern Ohio Medical Center Portsmouth, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Southwest Illinois Health Services LLP Swansea, Illinois | |
| Spartanburg Medical Center Spartanburg, South Carolina | |
| Springfield Clinic Springfield, Illinois | |
| Springfield Memorial Hospital Springfield, Illinois | Site Public Contact - (pallante.beth@mhsil.com) |
| Springfield Regional Cancer Center Springfield, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Springfield Regional Medical Center Springfield, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Strecker Cancer Center-Belpre Belpre, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Summerlin Hospital Medical Center Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Sunrise Hospital and Medical Center Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Sutter Auburn Faith Hospital Auburn, California | |
| Sutter Cancer Centers Radiation Oncology Services-Auburn Auburn, California | |
| Sutter Cancer Centers Radiation Oncology Services-Cameron Park Cameron Park, California | |
| Sutter Cancer Centers Radiation Oncology Services-Roseville Roseville, California | |
| Sutter Cancer Research Consortium Novato, California | |
| Sutter Davis Hospital Davis, California | |
| Sutter Medical Center Sacramento Sacramento, California | |
| Sutter Pacific Medical Foundation Santa Rosa, California | |
| Sutter Roseville Medical Center Roseville, California | |
| Sutter Solano Medical Center/Cancer Center Vallejo, California | |
| Swedish Cancer Institute-Edmonds Edmonds, Washington | Site Public Contact - (PCRC-NCORP@Swedish.org) |
| Swedish Cancer Institute-Issaquah Issaquah, Washington | Site Public Contact - (PCRC-NCORP@Swedish.org) |
| Swedish Medical Center-Ballard Campus Seattle, Washington | Site Public Contact - (PCRC-NCORP@Swedish.org) |
| Swedish Medical Center-Cherry Hill Seattle, Washington | Site Public Contact - (PCRC-NCORP@Swedish.org) |
| Swedish Medical Center-First Hill Seattle, Washington | Site Public Contact - (PCRC-NCORP@Swedish.org) |
| Tamarack Health Hayward Medical Center Hayward, Wisconsin | |
| Tampa General Hospital Tampa, Florida | Site Public Contact - (syapchanyk@tgh.org) |
| The Carle Foundation Hospital Urbana, Illinois | Site Public Contact - (Research@carle.com) |
| The Mark H Zangmeister Center Columbus, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |
| Torrance Memorial Medical Center Torrance, California | |
| Torrance Memorial Physician Network - Cancer Care Torrance, California | Site Public Contact - (courtney.steeneken@tmphysicians.com) |
| TriHealth Cancer Institute-Anderson Cincinnati, Ohio | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| TriHealth Cancer Institute-Westside Cincinnati, Ohio | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Trinity Health Grand Rapids Hospital Grand Rapids, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Trinity Health IHA Medical Group Hematology Oncology - Brighton Brighton, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| Trinity Health IHA Medical Group Hematology Oncology - Canton Canton, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital Chelsea, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus Ypsilanti, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| Trinity Health Medical Center - Brighton Brighton, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| Trinity Health Medical Center - Canton Canton, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| Trinity Health Muskegon Hospital Muskegon, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| Trinity Health Saint Joseph Mercy Hospital Ann Arbor Ann Arbor, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| Trinity Health Saint Joseph Mercy Oakland Hospital Pontiac, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| Trinity Health Saint Mary Mercy Livonia Hospital Livonia, Michigan | Site Public Contact - (MCRCwebsitecontactform@stjoeshealth.org) |
| Tufts Medical Center Boston, Massachusetts | |
| UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California | |
| UC San Diego Medical Center - Hillcrest San Diego, California | |
| UC San Diego Moores Cancer Center La Jolla, California | Site Public Contact - (cancercto@ucsd.edu) |
| UCHealth University of Colorado Hospital Aurora, Colorado | |
| UCSF Medical Center-Mission Bay San Francisco, California | |
| UCSF Medical Center-Parnassus San Francisco, California | |
| UF Health Cancer Institute - Gainesville Gainesville, Florida | |
| UI Health Care Mission Cancer and Blood - Ankeny Clinic Ankeny, Iowa | |
| UI Health Care Mission Cancer and Blood - Des Moines Clinic Des Moines, Iowa | |
| UI Health Care Mission Cancer and Blood - Laurel Clinic Des Moines, Iowa | |
| UI Health Care Mission Cancer and Blood - Waukee Clinic Waukee, Iowa | |
| UI Health Care Mission Cancer and Blood - West Des Moines Clinic Clive, Iowa | |
| UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida | |
| UM Sylvester Comprehensive Cancer Center at Plantation Plantation, Florida | |
| UMass Memorial Medical Center - University Campus Worcester, Massachusetts | |
| UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina | |
| UPMC Cancer Center at UPMC McKeesport McKeesport, Pennsylvania | |
| UPMC Cancer Center at UPMC Northwest Seneca, Pennsylvania | |
| UPMC Cancer Centers - Arnold Palmer Pavilion Greensburg, Pennsylvania | |
| UPMC Hillman Cancer Center Pittsburgh, Pennsylvania | |
| UPMC Hillman Cancer Center in Coraopolis Moon Township, Pennsylvania | |
| UPMC Jefferson Regional Radiation Oncology Pittsburgh, Pennsylvania | |
| UPMC Uniontown Hospital Radiation Oncology Uniontown, Pennsylvania | |
| UPMC Washington Hospital Radiation Oncology Washington, Pennsylvania | |
| UPMC-Heritage Valley Health System Beaver Beaver, Pennsylvania | |
| UPMC-Johnstown/John P. Murtha Regional Cancer Center Johnstown, Pennsylvania | |
| UPMC-Magee Womens Hospital Pittsburgh, Pennsylvania | |
| UPMC-Passavant Hospital Pittsburgh, Pennsylvania | |
| UPMC-Presbyterian Hospital Pittsburgh, Pennsylvania | |
| UPMC-Saint Clair Hospital Cancer Center Pittsburgh, Pennsylvania | |
| UPMC-Saint Margaret Pittsburgh, Pennsylvania | |
| UPMC-Shadyside Hospital Pittsburgh, Pennsylvania | |
| USC / Norris Comprehensive Cancer Center Los Angeles, California | |
| USC Norris Oncology/Hematology-Newport Beach Newport Beach, California | |
| UT MD Anderson Cancer Center Houston, Texas | Site Public Contact - (askmdanderson@mdanderson.org) |
| UT Southwestern/Simmons Cancer Center-Dallas Dallas, Texas | |
| UW Cancer Center at ProHealth Care Waukesha, Wisconsin | |
| United Hospital Saint Paul, Minnesota | Site Public Contact - (mmcorc@healthpartners.com) |
| United Hospital Center Bridgeport, West Virginia | |
| Unity Hospital Fridley, Minnesota | |
| University Cancer Center Las Vegas, Nevada | |
| University Medical Center New Orleans New Orleans, Louisiana | |
| University Medical Center of Southern Nevada Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| University of Alabama at Birmingham Cancer Center Birmingham, Alabama | |
| University of California Davis Comprehensive Cancer Center Sacramento, California | |
| University of Cincinnati Cancer Center-UC Medical Center Cincinnati, Ohio | Site Public Contact - (cancer@uchealth.com) |
| University of Cincinnati Cancer Center-West Chester West Chester, Ohio | Site Public Contact - (cancer@uchealth.com) |
| University of Illinois Chicago, Illinois | |
| University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa | |
| University of Kentucky/Markey Cancer Center Lexington, Kentucky | |
| University of Maryland/Greenebaum Cancer Center Baltimore, Maryland | |
| University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida | |
| University of Michigan Health - Sparrow Lansing Lansing, Michigan | Site Public Contact - (harsha.trivedi@umhsparrow.org) |
| University of Michigan Health - West Wyoming, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| University of Mississippi Medical Center Jackson, Mississippi | |
| University of Nebraska Medical Center Omaha, Nebraska | |
| University of New Mexico Cancer Center Albuquerque, New Mexico | Site Public Contact - (HSC-ClinicalTrialInfo@salud.unm.edu) |
| University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma | Site Public Contact - (ou-clinical-trials@ouhsc.edu) |
| University of Pennsylvania/Abramson Cancer Center Philadelphia, Pennsylvania | Site Public Contact - (PMCancerResearch@pennmedicine.upenn.edu) |
| University of Rochester Rochester, New York | |
| University of Texas Health Science Center at San Antonio San Antonio, Texas | |
| University of Vermont Medical Center Burlington, Vermont | Site Public Contact - (rpo@uvm.edu) |
| University of Vermont and State Agricultural College Burlington, Vermont | Site Public Contact - (rpo@uvm.edu) |
| University of Virginia Cancer Center Charlottesville, Virginia | Site Public Contact - (uvacancertrials@hscmail.mcc.virginia.edu) |
| University of Wisconsin Carbone Cancer Center - University Hospital Madison, Wisconsin | |
| UofL Health Medical Center Northeast Louisville, Kentucky | |
| Upper Valley Medical Center Troy, Ohio | |
| Urology Specialists of Nevada - Central Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Urology Specialists of Nevada - Green Valley Henderson, Nevada | Site Public Contact - (research@sncrf.org) |
| Urology Specialists of Nevada - Northwest Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| Urology Specialists of Nevada - Southwest Las Vegas, Nevada | Site Public Contact - (research@sncrf.org) |
| VCU Massey Comprehensive Cancer Center Richmond, Virginia | Site Public Contact - (CTOclinops@vcu.edu) |
| Valley Medical Center Renton, Washington | Site Public Contact - (research@valleymed.org) |
| Valley Radiation Oncology Peru, Illinois | |
| Vanderbilt Breast Center at One Hundred Oaks Nashville, Tennessee | |
| Vanderbilt University/Ingram Cancer Center Nashville, Tennessee | |
| Vanderbilt-Ingram Cancer Center Cool Springs Franklin, Tennessee | |
| Vince Lombardi Cancer Clinic - Oshkosh Oshkosh, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Vince Lombardi Cancer Clinic-Sheboygan Sheboygan, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| Vince Lombardi Cancer Clinic-Two Rivers Two Rivers, Wisconsin | Site Public Contact - (ncorp@aurora.org) |
| WVUH-Berkely Medical Center Martinsburg, West Virginia | |
| Wake Forest University Health Sciences Winston-Salem, North Carolina | |
| Walter Knox Memorial Hospital Emmett, Idaho | |
| Washington University School of Medicine St Louis, Missouri | Site Public Contact - (info@siteman.wustl.edu) |
| Wayne Hospital Greenville, Ohio | |
| Welch Cancer Center Sheridan, Wyoming | |
| West Jefferson Medical Center Marrero, Louisiana | |
| West Michigan Cancer Center Kalamazoo, Michigan | Site Public Contact - (crcwm-regulatory@crcwm.org) |
| West Virginia University Healthcare Morgantown, West Virginia | |
| Western Illinois Cancer Treatment Center Galesburg, Illinois | |
| Woodland Memorial Hospital Woodland, California | Site Public Contact - (ResearchInstituteInquiries@CommonSpirit.org) |
| Yale University New Haven, Connecticut | Site Public Contact - (canceranswers@yale.edu) |
| Zangmeister Center Grove City Grove City, Ohio | Site Public Contact - (Jeffh@columbusccop.org) |